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ABSTRACT 
 
The tumour vasculature is an attractive target for cancer therapy because tumour growth 
and spread depend on these structures for oxygen and nutrient supply. Anti-vasculature 
therapy aims to cause rapid and selective shutdown of the established tumour vasculature, 
leading to secondary tumour cell death. 
In this study, we propose to employ an Antibody Guided Enzyme Nitrile Therapy 
(AGENT) approach to selectively target extra-domain B fibronectin (B-FN), which is 
abundantly expressed in tumour vasculature. A recombinant fusion protein, composed of 
the humanised BC-1 single chain fragment (huBC1 scFv) fused with a re-engineered human 
cytosolic β–glucosidase (rehCβG) enzyme, was investigated to target this antigen and 
generate cytotoxic cyanide molecules specifically within tumour sites. Naturally-occurring 
human β-glucosidase (hCβG) cannot hydrolyse the cyanogenic glycoside linamarin, to any 
significant level, but was chosen as a suitable candidate for site-directed mutagenesis due to 
its homology with a native cyanogenic plant enzyme, linamarase. 
Both huBC-1 scFv and hCβG protein were expressed in Escherichia coli and purified 
by affinity and size exclusion chromatography. In vitro characterisation of the huBC-1 scFv 
showed that it retained antigen-binding specificity of the parental antibody, 
Immunoglobulin-G HuBC-1 towards the same antigen. Kinetic analysis of the wild type and a 
panel of mutant hCβGs showed that their catalytic activity was retained. Interestingly, one 
of the mutants, V168A hCβG, was shown to have increased cyanogenic activity towards 
linamarin. The Km was improved from 2.23 ± 0.03 mM to 0.79 ± 0.02 mM and the kcat from 
0.21 ± 0.01 min-1 to 5.49 ± 0.01 min-1. Following this discovery, construction and expression 
of the fusion protein, scFv-rehCβG (wild-type and V168A) was carried out using different 
expression systems to compare the best strategy in constructing the fusion protein.  
The huBC-1 scFv-hCβG fusion proteins were expressed cytosolically but as insoluble 
aggregates in inclusion bodies. Recovery of the fusion protein was made through refolding 
of the protein. Using the dilution method, the protein was solubilised and refolded, however 
it was functionally inactive. Another refolding method via dialysis experienced loss of the 
fusion protein. Final production of a cyanogenic scFv-hCβG requires further investigation by 
optimising the protein refolding protocol which could lead to further studies of AGENT. 
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pI    isoelectric point 
pNPGlc    p-Nitrophenyl--D-glucopyranoside   
pNP    p-Nitrophenol  
rpm    rotations per minute 
RU    response units 
scFv    single chain variable fragment 
SDS    sodium dodecyl sulphate 
SV40    simian virus 40 
t½    half life 
TAA    tumour-associated antigen 
TAE    tris acetate – EDTA 
TEA    triethylamine 
TEMED   tetramethylethylenediamine 
Tris    tris (hydroxymethyl) aminomethane 
U    unit 
UV    ultra violet 
v0    velocity of a reaction 
VH    variable heavy chain 
VL    variable light chain 
Vmax    maximum velocity 
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1.0 GENERAL INTRODUCTION 
1.1 Immunotherapy  
Standard chemotherapy is the basis of cancer treatment. The mechanism of action is based 
largely on the difference in the morphology of tumour and normal cells. Chemotherapy 
“target” the rapidly proliferating tumour cells which are more prone to cytotoxic effect of 
these drugs. However, at the same time, any actively proliferating normal cells such as bone 
marrow cells will also be affected by these drugs.  As a result, conventional anti-cancer 
chemotherapeutic drugs often suffer from lack of specificity leading to poor therapeutic 
index and high toxicity to normal tissues. Therefore, their administration is often limited to 
suboptimal doses to prevent cytotoxicity. The reason for these to occur was because the 
majority of anticancer drugs preferentially expose to normal tissues rather than neoplastic 
sites, due to irregular vasculature and high interstitial pressure in tumours as shown in 
Figure 1.1. Therefore, the issue of non-specificity is overcome by selectively targeting the 
therapeutics to the tumour sites by conjugation or fusion to antibodies. 
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Figure 1.1: Tissue distribution of doxorubicin (µg/g of tissue) after single intravenous injection of 
4.5mg/kg doxorubicin in tumour-bearing nude mice (Bosslet et al. 1998). This data shows that 
doxorubicin accumulates preferentially to normal than tumour tissues; thus reflecting the non-
specificity of the chemotherapy drug. 
 
Immunotherapy was first proposed at the end of the nineteenth century by Paul 
Ehrlich, who described antibodies as a magic bullet that would specifically trace and kill 
microbes and tumour cells. However, it was not until 1975 when Köhler and Milstein 
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reported the generation of murine monoclonal antibodies (MAbs); which have been the 
basis of clinical research both as therapeutic and diagnostic tools (Köhler and Milstein 1975). 
MAbs were produced by fusing Β-lymphoblasts from an immunised mouse with myeloma 
cells to generate antibody-secreting immortal cell lines. Individual cells could be isolated to 
produce a single species of antibody (monoclonal antibody). However, MAbs development 
as therapeutic agents was held back by their murine origin which caused major toxicity and 
immunological responses. The production of human anti-mouse antibody (HAMA) in 
patients led to the clearance of administered MAbs (Reynolds et al. 1989). In addition, non-
specific biodistribution to normal organs, low quantitative delivery to tumours (Foon 1989) 
and poor diffusion from vasculature into tumour (Jain 1987) were among the many 
problems reported concerning MAbs application. Issues concerning immunogenicity were 
overcome by recombinant technology and advances in antibody generation. Chimeric 
antibodies were generated in the late 1980s (Riechmann et al. 1988a, Liu et al. 1987). This 
involved genetic replacement of murine constant regions with human and therefore 
retained the murine variable region and binding specificity of original antibody (Figure 1.3). 
The human constant region also allowed better recognition by effector cells e.g. natural 
killer cells, macrophages etc. and minimised immunogenicity caused by murine origin. 
Despite these, chimeric antibodies did not completely overcome the issue of 
immunogenicity due to the presence of a large proportion of mouse variable region. 
Nevertheless, the first success with a chimeric antibody was with Rituximab (Rituxan; 
Genentech/Biogen Idec), approved by the United States Food and Drug Administration 
(FDA) for the treatment of B-cell non-Hodgkin’s lymphoma (Grillo-López et al. 2002). This 
success has inspired many other MAb-based therapies; in fact half of all the biotechnology 
therapies in clinical trials are MAbs and several of these have been approved by the FDA for 
diagnosis and treatment of cancer (see Table 1.1) (Walsh 2010). The mode of actions of 
these MAbs are through inducing effector activation, blocking highly expressed and 
activated growth-factor receptor signalling on tumour cells or inhibiting angiogenesis 
(Adams and Weiner 2005). Later, an alternative was proposed to humanise the antibody by 
engineering the complimentary-determining regions (CDRs) of murine antibody into the 
framework of a comparable human antibody. In this case, specificity and affinity of the 
antibody is still retained but major changes are made to minimise the immunogenicity 
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(Jones et al. 1986, Riechmann et al. 1988a). A great success was achieved with Trastuzumab 
(Herceptin; Genetech/Roche), a humanised MAb directed against human epidermal growth 
factor receptor 2 (HER2) and was approved by FDA to treat many cancers such as breast, 
lung, ovarian and pancreatic cancer. 
Following this, many tumour specific and other specificity antibodies were 
developed to target the tumour antigen that has been identified in both haematological 
malignancies and solid tumours. Accordingly antibody conjugation/fusion took place with 
cytotoxic drugs, cytokines, toxins or radionuclides and many of these products are in 
preclinical and clinical testing. Conjugation/fusion of antibodies to effector molecules aims 
to increase targeting specificity of this therapeutic approach while minimising the side 
effects on normal cells and maximising desired effects on target cells. Up to 2010, there are 
42 MAb antibodies that have been approved by the FDA for therapeutic purposes (see Table 
1.1), out of which 18 are for the treatment of various cancers and the rest are for a range of 
immunological targets (Walsh 2010). 
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Table 1.1: List of monoclonal antibodies (MAbs) approved by the FDA in United States and Europe for cancer diagnosis and treatment (Walsh 2010). 
 
 
FDA name Drug name  Ab type Target Indication Company Year of 
approval  
 
Satumomab 
pendetide  
OncoScint 
CR/OV 
Murine 111In 
conjugate 
Tumour-associated 
glycoprotein, TAG-
72. 
Detection, staging and 
follow-up of colorectal, 
ovarian, breast, pancreatic, 
lung, endometrial cancers. 
Cytogen 1992 (US) 
Igovomab  Indimacis -125 Murine F(ab)2 
fragment 
Tumour-associated 
antigen CA 125. 
Diagnosis of ovarian 
adenocarcinoma, 
gastrointestinal. 
CIS Bio 
(Gif-sur-Yvette, France) 
1996 (EU) 
Arcitumomab  CEA-scan Murine F(ab) 
fragment 111In 
conjugate 
Human 
carcinoembryonic 
antigen, CEA 
Detection of 
recurrent/metastatic 
colorectal, lung, breast 
cancer. 
immunomedics 1996 (EU and 
US);  
withdrawn 
EU 2005. 
Capromab 
pentetate  
ProstaScint Murine  Tumour surface 
antigen, PSMA. 
Detection, staging and 
follow-up of prostate 
adenocarcinoma. 
Cytogen (Princeton, NJ, 
USA). 
1996 (US) 
Nofetumomab  Verluma Murine F(ab), 
99mTc 
conjugate 
Carcinoma-
associated antigen. 
Detection of small-cell lung, 
colon, pancreatic and breast 
cancer. 
Boehringer 
Ingelheim/NeoRx 
(Seattle). 
1996 (US) 
Rituximab  
 
Rituxan Chimeric CD20 antigen on the 
surface of B-
lymphocytes. 
Treatment of Non-Hodgkin’s 
lymphoma. 
Genentech/Biogen IDEC. 1997 (US) 
Votumumab  Humaspect-Tc Humanised 
99mTc 
conjugate. 
Cytokeratin tumour-
associated antigen, 
CTAA. 
Detection of carcinoma of 
the colon, breast, prostatic, 
lung, ovarian, pancreatic 
cancer. 
Organon Teknika 
(Durham, NC, USA). 
1998 (EU), 
withdrawn 
2003. 
Rituximab  Mabthera Chimeric CD20 antigen of B-
lymphocytes. 
Treatment of Non-Hodgkin’s 
lymphoma. 
Hoffmann La-Roche. 1998 (EU) 
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Trastuzumab  Herceptin Recombinant 
humanised 
Human epidermal 
growth factor 
receptor 2 (HER2). 
Breast, lung, ovarian, 
pancreatic cancer. 
Genentech (US), Roche 
(EU). 
1998 (US),  
2000 (EU). 
Gemtuzumab 
ozogamicin  
Mylotarg Humanised, 
calicheamicin 
(cytostatic) 
conjugate 
CD33 antigen on 
leukemic blast cells. 
Treatment of acute myeloid 
leukaemia (AML). 
Wyeth. 2000 (US). 
Alemtuzumab  Mabcampath 
(EU) / Campath 
(US) 
Humanised CD52 antigen of B-
lymphocytes. 
Chronic lymphocytic 
leukaemia (CLL) and 
lymphoma 
Millennium (Cambridge, 
MA, USA) and Genzyme 
(EU); Berlex (Montvale, 
NJ, USA) and Millennium 
Pharmaceuticals (US). 
2001 (EU & 
US) 
Ibritumomab 
tiuxetan  
Zevalin Murine CD20 antigen Non-Hodgkin’s lymphoma, 
autoimmunity, 
transplantation, rheumatoid 
arthritis. 
Biogen/IDEC (US), 
Schering (EU). 
2002 (US), 
2004 (EU) 
Tositumomab  Bexxar Murine iodine 
131I conjugate 
CD20 antigen Non-Hodgkin’s lymphoma GSK 2003 (US) 
Bevacizumab  Avastin Recombinant 
humanised 
Vascular endothelial 
growth factor , VEGF 
Metastatic colorectal cancer, 
glioblastoma, metastatic 
renal carcinoma, breast 
cancer, lung cancer, 
mesothelioma 
Genentech (US),  
Roche (EU) 
2004 (US),  
2005 (EU) 
Cetuximab  Erbitux Chimeric Endothelial growth 
factor receptor, 
EGFR 
Breast, head and neck, 
pancreatic, colorectal, lung 
cancer, melanoma 
ImClone Systems (New 
York), Bristol Meyers 
Squibb (BMS, New York, 
US), Merck Serono (EU) 
2004  
(EU and US) 
Panitumumab  Vectibix Recombinant 
humanised 
EGFR Colorectal carcinoma Amgen 2006 (US),  
2007 (EU) 
Catumaxomab  Removab Bispecific 
humanised 
EpCAM Malignant ascites Fresenius Biotech 
(Graefefing, Germany) 
2009 (EU) 
Ofatumumab  Arzerra Humanised CD20 Chronic lymphocytic 
leukaemia 
GSK 2009 (US),  
2010 (EU) 
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1.1.1 Antibodies and formats 
In the presence of foreign substances such as bacteria and viruses, our body responds by 
producing antibodies (immunoglobulins) to remove or neutralise these organisms. 
Immunoglobulin (Ig) monomer is a ‘Y’-shaped molecule consists of two identical light chains 
and heavy chains , antigen-binding sites are located at the  N-termini (variable region) and 
stem Fc domain (constant region) for recruitment of effector functions (Figure 1.2).  
 
Figure 1.2: The immunoglobulin monomer molecule. The immunoglobulin (example is on IgG1) 
comprises two identical heavy chains (VH-CH1-CH2-CH3) and light chains (VL-CL) linked by an intra-
chain disulphide bonds (black). The two heavy chains are attached at the hinge region (green).  The 
IgG molecule is bivalent, interacting with two identical antigens. 
 
Each chain begins with variable domain (V) and followed by 1-3 constant domains 
(C). Pairs of heavy and light chains are linked together by an intra-chain disulphide bond in 
the hinge region. Each of the variable regions contains 3 areas of highly variable sequence 
known as complimentary determining region (CDR) and this is the important part for 
antigen binding. There are 5 different antibody isotypes in mammals (IgG, IgM, IgE, IgA and 
IgD) which have different roles and mechanisms in the immune system. Among these, IgG is 
the main serum antibody and is widely used in therapeutic applications. IgG is bivalent; thus 
able to bind to two epitopes at a time via two F(ab) regions of its molecule. Hence, IgG has 
high affinity for antigens and also high retention times (avidity). The Fc domain of IgGs 
functions in recruiting effector cells through complement activation and/or interaction with 
Antigen binding site 
Fragment antigen 
binding (Fab) 
Fragment crystallisable 
region (Fc) 
CL 
VL 
VH 
CH1 
CH2 
CH3 
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cellular FcγRI, II, III or FcRn receptors of macrophages/neutrophils for phagocytosis 
activation. In some cases where Fc-mediated effects are not required or undesirable, IgG 
can be digested through proteolysis (with enzymes such as papain and pepsin) to produce a 
smaller constituent domains. With the advances of technology, IgG could be genetically 
engineered into either monovalent [F(ab), scFv, single VH domains] or bivalent fragments 
[F(ab)2, diabodies, minibodies, etc] (Figure 1.3).  
 
Figure 1.3: Schematic diagram of different antibody formats. Development of antibodies from 
murine (green), humanised (blue) and various fusion proteins. Red=glycosylation on the CH2 domain; 
pink=VH/VL domains from one scFv;  yellow=any fusion partner;  bs=bispecific;  dAb=single domain 
antibody; ds=disulphide; scFv=single chain antibody fragment (Deonarain 2008). 
 
 
 
 
 m)   l) 
    
k) 
   j) 
i) h) 
g) 
f) 
   e) 
d)     c) b) a) 
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1.1.2 Single chain variable fragment (scFv) 
Fv fragments of immunoglobulin consisting of variable light chain domain and variable 
heavy chain domain of MAbs are among the smallest functional modules of antibodies with 
high affinity antigen binding. There have been few reports of successful isolation of Fv 
fragments by proteolytic digestion of intact antibody molecules due to practical limitations 
in reproducibility (Sen and Beychok 1986, Skerra and Plückthun 1988). Advances of 
recombinant technology have lead to the production of single chain Fv (scFv) and were first 
reported by two groups (Bird et al. 1988, Huston et al. 1988). Expression of scFv was done 
mostly in E. coli (Skerra 1993, Plückthun 1994) and myeloma cells (Riechmann, Foote and 
Winter 1988b). The association of VH and VL units in scFv is weaker than F(ab) fragment due 
to lack of CH1 and CL domains and are often unstable. Therefore, few methods were taken 
to stabilise Fv fragment including chemical cross linking, disulphide bond engineering and 
genetic linking by peptide linker. A study to compare these stabilisation strategies was 
performed in vitro (Glockshuber et al. 1990). The study reported that the linked fragments 
have similar affinity and stability over the natural Fv fragment; with the peptide linker 
showing a 10-fold increase in stability whilst up to a 60 fold increase was seen with 
disulphide linked fragments. Nevertheless, stabilisation of VH and VL fragments, together 
with a peptide linker, is the most popular approach due to convenience and ease, resulting 
in a fragment called single chain Fv. The length of linker could affect the folding of scFv 
polypeptide and it is reported that the optimal length is usually 15-25 amino acids consisting 
of glycine–serine (Gly4Ser)3 (Freund et al. 1993). An important factor to note is that the 
linker has no influence on the structure of the variable domain. Compared to the intact 
MAbs, conventional F(ab)2 and F(ab) fragments, scFv molecules offer several advantages in 
their pharmacokinetics and side effects as discussed in the following section.  
1.1.3 Antibody pharmacokinetics 
MAbs have always been ideal proteins for targeting antigens due to their specificity and 
affinity. They have shown a great promise in clinical studies either as naked antibody or 
used in conjugation with radionuclides, toxins or cytotoxic drugs. However, MAbs have 
limitations due to their large size (150 kDa) that leads to slow clearance from the blood and 
body fluid. Its β-phase elimination is typically with a half life on the orders of days in mice 
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and weeks in human (Milenic et al. 1991, Lobo, Hansen and Balthasar 2004). Modifications 
on IgG into F(ab)2 (~100 kda), F(ab) (~50 kDa) and scFv (~25 kDa) aimed to decrease the size 
and improve the pharmacokinetics of the antibody with a half life of minutes to hours 
(Milenic et al. 1991, Holt et al. 2003). The rapid clearance occurs primarily through the 
kidney for antibodies that are below ~60-70 kDa ; the cut off size for glomerular filtration 
(Deen, Lazzara and Myers 2001). Although rapid clearance may give greater tumour 
specificity due to fast reduction of scFv levels in normal tissues, the proportion of scFv 
accumulated at tumour sites is affected. This means that the antibody is rapidly cleared 
from the circulation before it is able to reach the tumour antigens. This results in lower dose 
to the target/tumour. However, rapid clearance may be desirable for certain applications to 
reduce toxicity towards healthy tissues or background radioimaging. Alternatively, systemic 
clearance rate could be reduced by conjugation of antibody fragments to polyethylene 
glycol (PEG)chains, covalent or non-covalent linkage to albumin or Fc domains (Chapman et 
al. 1999) and chemical polysialylation (Constantinou et al. 2009). 
The large size of IgG also makes them diffuse poorly from vasculature into and 
through the tumour. In contrast, smaller antibody fragments such as F(ab) and scFv are not 
only able to retain high affinity binding to the antigen but also have better tumour 
penetration. This was seen in many in vivo studies where scFv was shown to have an even 
distribution throughout the tumour mass compared to IgG which was concentrated in the 
region of or immediately adjacent to vessels (Yokota et al. 1992). Thus scFv is especially 
important for radioimmunotherapy applications due to its potential for increasing the 
homogeneity of radiation dose deposition in tumours. The distribution of F(ab) and F(ab)2 
fragments showed intermediate penetration in a size-related manner. In the case of tumour 
vasculature, if the target antigen is at the luminal surface (intima) of the vasculature (Figure 
1.4), the rate of extravasation could be eliminated due to easy accessibility. However, if the 
target antigen is at the adventitia region, rate of extravasation needs to be considered; 
small-sized antibodies will penetrate better compared to large-sized antibodies. Because of 
the leaky nature of tumour vasculature, antigen targeting is thought to be less dependent 
on the size of the antibody species but the size still impedes transport to the whole tumour. 
 
31 
 
 
The affinity of an antibody plays an important role in determining its distribution and 
retention in the tumour. Often a high affinity antibody is desirable for binding. However, 
studies have shown that antibodies with lower affinity would have more homogenous 
distribution in tumour tissues. This is due to the ability of the low affinity antibodies to 
dissociate from the antigen at a faster rate after binding and subsequently diffuse further 
into the tissues (Kievit et al. 1996, Adams et al. 2001, Thurber, Schmidt and Wittrup 2008). If 
the antibody affinity is too high, the antigen sites surrounding the vasculature will be rapidly 
saturated, forming a barrier for further antibody binding and antigen targeting (Adams et al. 
2001). However, this concept is still controversial. 
Extravasation is often the problem in targeting bulk tumour. Although it is known 
that tumour vasculature is leaky and the size of molecule that can extravasate through the 
tumour blood vessels is larger compared to normal blood vessels, the rate of extravasation 
is still very slow. This is due to  high interstitial fluid pressure in the extracellular matrix due 
to poor lymphatics system and fluid flow (Baxter and Jain 1989). This build-up of pressure 
stops fluid from leaving the vessels into the tumour and leads to poor tumour cell targeting.  
Depending on the therapeutic mode of action, antibody pharmacokinetic properties 
can be manipulated. Rapid clearance may be desirable for certain applications to reduce 
toxicity to healthy tissues or background imaging. For example, prodrug or 2-step 
approaches (see later) are highly dependent on selective antigen targeting and fast 
clearance rates of antibody to have high target to non–target drug ratio. The advances in 
recombinant antibody technology have allowed various scFv selection approaches. This 
   Intima 
  Media 
  Adventitia 
Figure 1.4: Normal vascular biology. 
The vascular is divided into three 
components; intima (endothelial 
cells), media (smooth muscle) and 
adventitia (connective tissues). 
(http://www.invitrogen.com 
/vascular-biology.html) 
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leads to the production of high affinity of scFv in nM or pM range, therefore monovalency is 
no longer a problem for scFv compared to their equivalent native bivalent IgG. 
1.2 Tumour vasculature 
Tumour neovascularisation involves angiogenesis, vaculogenesis and lymphanogenesis. 
Angiogenesis is the formation of new blood vessels from existing vessels and is the key 
factor in establishment of tumour vasculature (Folkman 1971) while vaculogenesis is the 
recruitment of associated supporting cells e.g. endothelial cells into the newly formed blood 
vessels and is a critical factor in tumour neovascularisation (Lyden et al. 2001). Likewise, 
lymphanogenesis is formation of lymphatic vessels from existing vessels and is important for 
regulation of tissue homeostasis, immune cell trafficking and transport of dietary lipids 
(Lund and Swartz 2010, Tammela and Alitalo 2010). Angiogenesis in both normal and 
disease tissues is governed by the net balance between pro- and anti-angiogenic factors 
(Carmeliet and Jain 2000). When pro-angiogenic growth factors (stimulators) are produced 
in excess of the inhibitors, the balance is tipped in favour of blood vessels growth. In normal 
healthy adults, this can be seen during wound healing and in the female reproductive 
system. However, in tumours and other diseases such as atherosclerosis and diabetic 
retinopathy, there is a persistent and significant up regulation of angiogenesis. Among the 
angiogenic growth factors is vascular endothelial growth factor (VEGF) which is highly 
specific for vascular endothelial cells. It is one of the most potent angiogenic factors and a 
target for FDA approved anti-angiogenic agent, Bevacizumab (Ferrara, Gerber and LeCouter 
2003). Other pro-angiogenic factors include basic fibroblast growth factor (bFGF), matrix 
metalloproteinases (MMPs), platelet derived growth factor (PDGF) and interleukin-8 (IL-8). 
These growth factors can be produced by the tumours themselves, surrounding tissues or 
infiltrating macrophages and fibroblasts. Likewise, angiogenesis is inhibited when the 
inhibitory factors are present in excess of stimulators. Examples of these are tumour 
necrosis factor (TNF), serotonin (5HT), nitric oxide, angiostatin or endostatin (Carmeliet 
2003). 
At an early stage of tumour development when the size of tumour is <2-3 mm3, it 
depends on the normal mature neighbouring vasculatures for the nutrients and oxygen 
supply. However, in order to grow beyond that size, it needs to form its own vascular system 
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(Folkman 1971). The neovasculature would grow towards and subsequently infiltrate the 
tumour mass (Kerbel 2000). Morphologically, normal blood vessels form a well-organised 
architecture consisting of arterioles, capillaries and venules (Figure 1.5 A).  In contrast, 
tumour vessels are different from the normal vasculature; hence they can be manipulated 
as a target for development of new disease treatments. Tumour blood vessels are described 
as immature as their walls are poorly developed, often with discontinuous endothelial-cell 
lining (Figure 1.5 B). They have relatively poor architecture of vascular smooth muscle cells 
and lack of connections between pericytes and endothelial cells (McDonald and Choyke 
2003, di Tomaso et al. 2005). The endothelial cells are reported to be disorganised and 
irregularly shaped, sometimes overlapping each other. In addition, they have structurally 
abnormal basement membrane including changes in matrix protein composition, assembly 
and structures (Baluk et al. 2003). 
(A)           (B)
Figure 1.5: Scanning electron microscopic (SEM) imaging of normal and angiogenic blood vessels 
from xenograft human tumour in nude mouse. (a) Normal microvasculature, showing simple, 
organised arrangement of arterioles, capillaries and venules. (b) Tumour microvasculature, showing 
disorganisation and lack of conventional hierarchy of blood vessels (arterioles, capillaries and 
venules are not identifiable as such (Konerding, Miodonski and Lametschwandtner 1995). 
 
These features contribute to high intrinsic vascular permeability to macromolecules 
and subsequently lead to high interstitial fluid pressure, which is augmented by inadequate 
lymphatic drainage. Thus, the tumour tissue is relatively hypoxic with poorly oxygenated 
blood. In summary, the tumour vascular networks are chaotic, show a lack of hierarchy and 
exhibit complex branching patterns (Fukumura and Jain 2007a).   
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For that reason, tumour vasculature is an attractive target for immunotherapy 
because many tumour cells depend upon the blood vessels for survival (an estimated 100 
tumour cells per vascular endothelial cell), as well as the means for metastatic spread. 
Tumour vasculature immunotherapy uses antibodies to target tumour vasculature antigens 
and discriminate them from normal blood vessels. However, antibody alone is not sufficient 
to destroy the vasculature; often it is conjugated to bioactive agents to enhance the killing 
effects. Tumour vasculature immunotherapies have been increasingly important due to an 
increase in local concentration of the delivered compound in tumour tissues, while 
minimising side effects to healthy tissues. It is an attractive approach due to their 
accessibility for blood-borne agents, their abundance and their stable expression that allow 
a wide range of therapeutic options. In addition, angiogenesis is an important feature in 
tumours; a single vascular targeting compound should in principle be applicable to a 
number of different tumour types. 
There are many benefits of tumour vascular targeting therapy over other cancer 
therapies. A single vessel provides the nutrition and is a means for removal of metabolic 
waste products from hundreds or thousands of tumour cells. Attack at only one point of the 
vasculature could cause damage that may interrupt blood flow both upstream and 
downstream. Tumour vascular targeting approaches are divided into two types (Figure 1.6) 
(Schliemann and Neri 2007, Siemann and Horsman 2009).  
Figure 1.6: Tumour vascular targeting therapies with two different approaches; anti-angiogenic 
agents and vascular disrupting agents (Siemann 2006.). 
Tumour vascular targeting therapy 
Anti-angiogenic agents 
 
agent  
Vascular disrupting agents 
Prevent new vessel growth Damage established vessels 
Chronic administration Acute administration 
Early-stage (preventive action)  Advanced stage (immediate effect) 
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The first is called anti-angiogenic therapy that aims to prevent the neovascularisation 
processes in tumours. This is through inhibition of the formation of new blood vessels 
sprouting from existing vessels in tumour sites by targeting of the angiogenesis-related 
signalling pathways. The second type is the anti-vascular approach which causes rapid and 
selective shutdown of the established tumour vasculature, leading to secondary tumour-cell 
death. Although there are differences between the two strategies, individual agents might 
possess both anti-angiogenic and anti-vascular actions. Understanding the mechanisms of 
action of these agents and their selectivity for tumour blood vessels is crucial for the 
development of new drugs and treatment strategies.  
1.2.1 Anti-angiogenic therapy 
The objective of anti-angiogenic therapies is to interfere with new vessel formation, thereby 
preventing tumour growth and limiting metastatic potential. These involve many essential 
aspects of angiogenesis, notably signalling pathways, endothelial and stroma cells, as well as 
endothelial cell function (Siemann et al. 2005). One of the well studied areas is targeting 
angiogenic signalling such as that provided by VEGF, which is over expressed in the majority 
of solid tumours. Indeed, neutralising antibodies against VEGF (bevacizumab) and its 
receptor (DC101) as well as VEGF receptor tyrosine kinase inhibitors (ZD6474 and PTK787) 
have been shown to inhibit the growth of tumour vasculatures and microenvironment in 
various tumour models (Fukumura and Jain 2007b, Burstein 2011, Flanigan, Deshpande and 
Gettinger 2010).  
There are two hypotheses regarding anti-angiogenesis therapy. The first was 
hypothesised by Judah Folkman, 1971 where he proposed the reliance of tumour cells on 
tumour blood vessels for oxygen and nutrient supply. Thus by targeting and destroying 
these blood vessels, the tumour undergoes starvation and eventually regresses. This has 
been the benchmark behind the anti-angiogenesis therapy and has shown many successes 
(Table 1.1). However, an alternative theory was proposed by Rakesh Jain (2005); that the 
anti-angiogenic agents can transiently “normalise” the abnormal structure and function of 
tumour vasculature to make it more efficient for oxygen and drug delivery. This is based on 
the concept of restoring the balance between pro-angiogenic agents and angiogenic 
inhibitors because in the tumour, the balance is in favour of the stimulators. By 
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administering anti-angiogenic inhibitors in the right amount, tumour vasculatures could be 
normalised. This would alleviate hypoxia and increase efficiency of drugs and oxygen to the 
tumour cells. On the other hand, tipping this balance in favour of inhibitors may lead to 
vascular regression and ultimately tumour regression. However, it is difficult to target only 
tumour vessels without harming normal vessels (Jain 2005). This concept is illustrated in 
Figure 1.7. 
 
 
  
 
 
Figure 1.7: Proposed role of vessel normalisation in the response of tumours to anti-angiogenic 
therapy. (A) Tumour vasculature is structurally and functionally abnormal. It is proposed that anti-
angiogenic therapies initially improve both the structure and the function of tumour vessels. 
However, sustained or aggressive anti-angiogenic regimens may eventually prune away these 
vessels, resulting in a vasculature that is both resistant to further treatment and inadequate for 
delivery of drugs or oxygen. (B) These phenotypic changes in the vasculature mat reflect changes in 
the balance of pro- angiogenic and angiogenic inhibitor factors in the tissue (Jain 2005). 
 
In vivo studies have supported this hypothesis. One example was demonstrated 
using bevacizumab, an anti-VEGF antibody, in rhabdomyosarcoma xenografts (Myers et al. 
2010). After bevacizumab treatment, a significant decrease in tumour microvessel density 
and an increase in tumour vessel maturity were observed. Tumour vessel permeability was 
significantly decreased and intratumoural oxygen tension was increased. Subsequent 
treatment with ionising radiation resulted in the greatest antitumour activity.  Currently, 
there are about 10 anti-angiogenic drugs approved for clinical use (Table 1.2). They are 
A 
B 
37 
 
commonly used as synergistic treatment along with standard chemotherapy and 
radiotherapy.   
FDA name Drug name Indication Company  Year 
approved 
Monoclonal antibody 
Trastuzumab  Herceptin Breast, lung, 
ovarian, 
pancreatic 
cancer. 
Genentech (US),  
Roche (EU). 
1998 (US),  
2000 (EU). 
Bevacizumab Avastin Metastatic 
colorectal cancer, 
glioblastoma, 
metastatic renal 
carcinoma, 
breast cancer, 
lung cancer, 
mesothelioma 
Genentech, 
Roche  
2004 (US) 
2005 (EU) 
 
Cetuximab  Erbitux Breast, head and 
neck, pancreatic, 
colorectal, lung 
cancer, 
melanoma 
ImClone Systems (New 
York), Bristol Meyers 
Squibb (BMS, New York, 
US), Merck Serono (EU) 
2004  
(EU and 
US) 
Panitumumab  Vectibix Colorectal 
carcinoma 
Amgen 2006 (US),  
2007 (EU) 
Small molecule tyrosine kinase inhibitors 
Erlotinib Tarceva Lung cancer, 
pancreatic cancer 
Genentech, OSI 
Pharmaceuticals, Roche 
2004 
Sorafenib Nexavar Advanced renal 
cell carcinoma, 
advanced 
hepatocellular 
carcinoma 
Onyx Pharmaceuticals 2005 
Sunitinib Sutent Gastrointestinal 
stromal tumour, 
advanced renal 
cell carcinoma 
Pfizer 2006 
Inhibitor of mammalian target of rapamycin (mTOR) 
Temsirolimus Torisel Advanced renal 
cell carcinoma 
Wyeth Pharmaceuticals 2007 
Other angiogenic agents 
Bortezomib Velcade Multiple 
myeloma 
Millennium 
Pharmaceuticals 
2003 
Thalidomide Thalomid Multiple 
myeloma 
Celgene Corporation 2003 
(Australia), 
2006 (US) 
Table 1.2: Anti-angiogenic drugs approved for clinical use (Folkman 2007, Walsh 2010). 
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1.2.2 Anti-vascular therapy 
Juliana Denekamp was the first to outline the concept of anti-vascular therapy, by showing 
that physical occlusion of the blood supply to tumours in rodents leads to tumour regression 
(Denekamp 1990). Subsequent studies further proved that a toxin targeted by an antibody 
specific for tumour blood vessels caused tumour regression in mice (Burrows and Thorpe 
1993). This therapy selectively disrupts the immature and rapidly (>20 times faster than 
normal) proliferating endothelial cells of established tumour vasculature. The vascular-
disrupting agents (VDA) aim to arrest the blood flow in tumours, with resulting ischemia 
leading to a cascade of secondary tumour cell death in the central part of tumours (Heath 
and Bicknell 2009, McKeage and Baguley 2010, Siemann 2011). There are two major types 
of anti-vascular therapy and they both could cause acute vascular collapse in tumours, 
leading to massive necrosis. First are the ligand-directed vascular disrupting agents (VDAs) 
that use antibodies, peptides and growth factors to deliver toxins, procoagulants and pro-
apoptotic effectors to tumour endothelium. They bind to markers that are selectively 
expressed on tumour endothelium to deliver an effector specifically to the tumour 
vasculature (Thorpe 2004, Schliemann and Neri 2007, Heath and Bicknell 2009). Pre-clinical 
investigations employing such ligand-directed VDA have shown not only the localisation of 
the therapeutic moiety to tumour vessels but also selective destruction of tumour 
vasculatures (Thorpe 2004). An example is the fusion protein consisting of IL-2 and IL-12 
fused to L19 scFv antibody directed against the ED-B domain of fibronectin, an extracellular 
matrix marker of angiogenic levels. Both IL-2 and IL-12 are cytokines with potent 
immunostimulatory activity. The fusion protein had marked activity towards aggressive 
murine tumours and metastases in lungs. The residual small tumour masses seen in treated 
mice were infiltrated with lymphocytes, macrophages and natural killer cells (Gafner, 
Trachsel and Neri 2006, Wagner et al. 2008, Schliemann et al. 2009).  
The second type is the small molecule VDAs that do not specifically localise to 
tumour endothelium but exploit pathophysiological differences between tumour and 
normal tissue endothelia to induce acute vascular shutdown in tumours. These differences 
include increased proliferation, permeability and reliance on a tubulin cytoskeleton which 
function in maintaining cell shape (Chaplin, Horsman and Siemann 2006, Siemann 2011). 
39 
 
The tubulin-depolymerising tumour-VDAs comprise a large and diverse group of compounds 
in clinical trial (Table 1.3).  Importantly, binding of these agents to tubulin causes 
microtubule depolymerisation, cytoskeletal rearrangements and activation of actin stress 
fibers in endothelial cells, leading to change in morphology (Heath and Bicknell 2009, 
McKeage and Baguley 2010). One of the VDA agents, CA4P has demonstrated selectivity and 
induced regression of unstable tumour neovessels (Siemann, Chaplin and Horsman 2004, 
Horsman and Siemann 2006). The mechanism of vascular death is primarily via necrosis and 
this therapy is administered synergistically with conventional treatments. Table 1.3 outlines 
the current clinical status of tumour-vascular disrupting agents.  
Tumour VDA Company Stage of clinical development 
Flavonoid 
ASA404 (vadimezan) Novartis Phase III (NSCLC),  
Phase II (HER2-ve MBC) 
Tubulin-binding 
CA4P (fosbretabulin) OXiGENE Phase II/III (anaplastic thyroid cancer), 
Phase II (NSCLC) 
AVE8062 (ombrabulin) Sanofi-aventis Phase III (sarcoma), Phase I (NSCLC) 
NPI-2358 (plinabulin) Nereus Phase II (NSCLC) 
ABT-751 (E7010) Abott Phase II (paediatric ALL, NSCLC, breast, 
colorectal, HRMPC, neuroblastoma, 
RCC) 
TZT-1027 (soblidotin) Daiichi Phase II (sarcoma) 
CYT997 Cytopia Phase II (multiple myeloma) 
Dolastatin 10 - Phase II (RCC, sarcoma, pancreatic, 
HRMPC, liver/bile duct/ gall bladder, 
lymphoma, CLL. 
ZD6126 Angiogene Phase II 
MPC-6827 Myriad Phase II (melanoma, glioblastoma) 
OXi4503 (CA41P) OXiGENE Phase I 
EPC2407 (crinobulin) EpiCept Phase I 
MN-029 Medicinova Phase I 
BNC105 Bionomics Phase I 
 
Table 1.3: Current clinical status of tumour-vascular disrupting agents (Tumour VDAs) in 
development (ALL-acute lymphoblastic leukaemia; CLL-chronic lymphocytic leukaemia; HRMPC-
hormone refractory metastatic prostate cancer; MBC-metastatic breast cancer; NSCLC-non-small cell 
lung cancer; RCC-renal cell carcinoma) (Siemann 2011). 
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1.3 Tumour associated vascular markers 
Vascular antigens can be either expressed on the surface of endothelial cells or in the 
subendothelial extracellular matrix (ECM) of tumour blood vessels. Although it would be 
assumed that the antigens expressed on the luminal side of endothelial cells may be the 
best target for immunotherapy, this might not be true for all. The reasons are due to the 
fact that they are present in low abundance and also the presence of other vascular 
targeting compounds at this site. In comparison, antigens that are expressed in perivascular 
matrix offer more convenience due to their high abundance and stable expression. Although 
they might seem less accessible, extravasation enables the ligand to bind to the antigens 
and this is further facilitated by the leaky nature of the tumour vasculatures.  
1.3.1 Fibronectin 
Fibronectins (FNs) are high molecular weight adhesive glycoproteins present in the 
extracellular matrix (insoluble form) and in body fluids (soluble form) (Hynes 1980). The 
insoluble form made by fibroblasts, epithelial and other cell types, that is deposited as fibrils 
in extracellular matrices and it is termed as cellular FN. On the other hand, the soluble 
dimeric form is synthesized by hepatocytes and secreted into the bloodstream called plasma 
FN (Hynes 1980, Atherton and Hynes 1981, Tamkun and Hynes 1983). FNs form dimers that 
are composed of 2 similar but not identical polypeptides of about 250-280 kDa joined by a 
pair of disulphide bonds near their carboxyl terminal (Ruoslahti 1988). Each monomer is an 
extended and flexible molecule that is folded in a series of domains known as type I, II and 
III repeats, which often display functionality distinctive properties (Figure 1.8).  
FNs play critical roles in maintenance of normal cell morphology, cell adhesion, 
migration, differentiation, proliferation, wound healing. It is clear that FNs influence a 
variety of cellular processes through interactions with other molecules including integrin 
and non-integrin cell surface receptors, which subsequently modulate signal transduction 
within cells (Ruoslahti 1988, Hynes 1990, Kornblihtt et al. 1996). 
FN is encoded by a single gene but alternative splicing of pre-mRNA as well as post-
translational modifications allow formation of multiple isoforms, with up to 20 variants 
possible in human (Schwarzbauer 1991). Splicing occurs in 3 regions of the FN gene (Figure 
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1.8). Two exons corresponding to type III repeat, known as extra-domain A (ED-A) and extra-
domain B (ED-B), are spliced to be totally included or excluded. A third region, type III 
connecting segment (IIICS), located near the C-terminal end of the molecule, may be spliced 
in several positions, giving rise to 5 potential variants in human (Schwarzbauer et al. 1983). 
     
 
Figure 1.8: Model of the domain structure of FN monomer. The FN monomer is made up of a series 
of repeating units of 3 different types (I, II and III). The two FN monomers are connected by two           
C-terminal disulphide bonds (-s-) to form a dimer. The extra domains (indicated in yellow) can be 
either inserted or omitted in the molecule by mechanism of alternative RNA splicing giving rise to 
ED-B, ED-A and IIICS. Arrows indicate antibodies binding to different epitopes (Kaspar, Zardi and Neri 
2006). 
 
 
The alternative splicing is regulated in a cell or tissue in a specific manner. In 
transformed cells and malignancies , the splicing pattern of FN pre-mRNA becomes altered, 
leading to an increased expression of oncofetal FN isoforms containing the EDA, EDB and 
IIICS sequences (Castellani et al. 1986, Zardi et al. 1987, Carnemolla et al. 1989). Defects in 
the FN gene have lead to early embryonic lethality shown in vivo study of a knockout mice 
lack of FN (George et al. 1993). Embryonic death is associated with widespread defects in 
mesoderm-derived structures, including absence of somites or notochord and 
developmental defects in the heart and vascular system. This shows the significant role that 
the FNs play in the developmental process of cells. 
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1.3.1.1  Extra domain-B (ED-B) 
ED-B is a complete type-III homology repeat with a sequence of 91 amino acids encoded by 
a single exon, which can be either completely included or omitted from mRNA. The domain 
was discovered during experiments of proteolytic cleavage of FN molecules obtained from 
different sources (Borsi et al. 1987, Zardi et al. 1987, Gutman and Kornblihtt 1987). In FN 
isoforms containing the ED-B sequence (B-FN), ED-B is inserted between type III domain 7 
and 8 (Figure 1.8). The presence of ED-B domain in the FN induces exposure of the cryptic 
site within the domain 7 type III repeat which would otherwise be masked by domain 9 
(Carnemolla et al. 1992). 
The ED-B domain is usually absent in both plasma and tissue FN of adults, except for 
some blood vessels of the endometrium in the proliferative phase and ovaries (Castellani et 
al. 1994). However, it can be inserted into the FN molecules during active tissue 
remodelling, for example during tumour angiogenesis, wound healing and embryogenesis in 
fetal tissues, giving rise to a prominent perivascular expression pattern (Ffrench-Constant et 
al. 1989). The accumulation around neovasculature has been extensively demonstrated in 
studies on many different tumour types e.g. invasive ductal carcinoma, brain tumour as well 
as head and neck malignant tumours (Kaczmarek et al. 1994, Castellani et al. 1994, Birchler 
et al. 2003). However, its high level of conservation in different species (identical in human, 
dog, rabbit, rat and mouse, 96% homology with chicken and 80% with Xenopus L) together 
with its highly restricted pattern of expression may be indicative of a specific role. Although 
B-FNs are highly expressed throughout early embryogenesis, an in vivo study on knock-out 
mice lack of ED-B exon showed that the ED-B-deficient mice developed normally and were 
fertile. No significant phenotype was observed but fibroblasts obtained from ED-B deficient 
mice grew slowly in vitro and deposited less FN in the pericellular matrix than fibroblasts 
from wild type mice. The results showed that the expression of ED-B containing isoforms is 
possibly omitted during embryonic development but might play a role in the growth of 
connective tissues via FN matrix (Fukuda et al. 2002). Considering the strict interspecies 
maintenance of sequence and its restricted pattern of expression, it is thought that ED-B 
domain is an excellent tumour marker. It must be noted that the ED-B sequence is highly 
conserved among species, but not the type III homology repeats itself. Therefore, antigen 
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recognition depends on the sites which are recognised by the antibody (Figure 1.8). In most 
cases the in vivo studies have been carried out with human tumours engrafted into a mice 
model to allow the recognition by antibody. Exception to this is with antibodies that 
recognised ED-B sequence directly such as L-19, CGS-1 and CGS-2 (Mariani et al. 1997, Borsi 
et al. 2002, Kaspar et al. 2006). 
1.3.1.2  Extra domain A (ED-A) 
FNs contain a second alternatively spliced domain, ED-A, which has been shown to display 
restricted pattern of expression in plasma and normal human tissues, while being over 
expressed in the neo-vasculature and/or stroma structures of some aggressive solid 
tumours (Borsi et al. 1998, Rybak et al. 2007, Villa et al. 2008). Similarly, ED-A can also be 
inserted in the fibronectin transcript by alternative splicing and is located between type III 
FN domain 11 and 12 (Figure 1.8). ED-A is predicted to share many functional similarities 
with ED-B. However, most of the studies on ED-A were done using in vitro cell culture 
systems. Thus more in vivo studies are necessary to specifically address these issues. The 
importance of ED-A splicing is strongly supported by the observation that mice either 
lacking or constitutively expressing the ED-A exon displayed a substantially reduced lifespan 
(Muro et al. 2003, Rybak et al. 2007). Elevated levels of ED-A are found in plasma and 
affected tissues of patients with certain disorders, such as psoriasis, rheumatoid arthritis, 
diabetes and cancer, although the functional role of ED-A in these diseases is still unclear. 
1.3.1.3  Type III connecting segment (IIICS) 
IIICS is located between the last two type III homology repeats; a single exon is subdivided 
to yield five alternative patterns of splicing (Hynes 1985). Study have shown that inclusion of 
the IIICS sequence contributed to the differences in size between the larger and smaller 
subunit of plasma FN (Schwarzbauer, Paul and Hynes 1985). It is also suggested that for 
some cell types, regulation of the adhesion-promoting activity of FN may occur by 
alternative RNA splicing in IIICS area (Humphries et al. 1986). However, there were not 
many studies done on this antigen. 
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1.3.2 Alternative neovascular markers 
 
Table 1.4: List of well-characterised vascular markers for antibody-based tumour targeting (Schliemann and Neri 2007). 
Target Characteristics Ligands (MAbs) Status of development 
Endothelial 
Integrins (αVβ3) -cell surface glycoproteins involved in cell adhesion 
-over expressed on sprouting endothelial cells 
-also detectable, but less accessible in normal endothelium 
LM609 and 
derivatives (Vitaxin, 
Abegrin) 
Vitaxin (Radioimaging) 
Phase II (Abergin) 
Annexin A1 -phospholipid binding protein 
-externalised on the surface of tumour endothelial cells 
-nuclear protein, -restricted to the nucleus in quiescent endothelium 
-shuttled to the cell surface of endothelial cells during angiogenesis 
Anti-AnnA1 antibody Preclinical (immunoscintigraphic imaging 
and radioimmunotherapy) 
Prostate-specific 
membrane 
antigen 
-membrane glycoprotein 
- first characterised in prostate cancer, later found to be expressed in the 
neovascular endothelium of various solid tumours 
Undetectable in normal vasculature 
J591 (MLN591) Phase I for various solid tumours 
(immunoscintigraphic imaging) 
Phase II for prostate cancer 
(radioimmunotherapy) 
VEGF and 
receptors 
-Key mediators of physiological and pathological angiogenesis 
-up regulation of VEGF and its receptor in tumour environment 
Various antibodies 
against VEGF, VEGFRs 
and VEGF-VEGFR 
complex (e.g. 
Bevacizumab, 
GV39M, 2C3, LL4) 
Preclinical (in vivo localisation experiments) 
and different imaging modalities). 
Bevacizumab is approved as anti-angiogenic 
agent for various cancers. 
Endoglin -transmembrane glycoprotein (TGF-β co-receptor) 
-over expressed in tumour endothelial cells, but also detectable in normal 
endothelium and tissues 
TEC-11, K4-2C10, 
other-endoglin 
antibodies 
Preclinical (immunoscintigraphic and 
ultrasound imaging; therapy with 
immuntoxins and radioimmunoconjugates) 
Phospatidylserine -normally restricted to the inner leaflet of the cell membrane lipid bilayer 
-Exposed and accessible on the outer surface of tumour endothelial cells 
3G4, Bavituximab Phase I (as naked antibody) 
Extracellular matrix 
Isoforms of 
tenascin C 
-Extracellular matrix glycoprotein, present in different connective tissues, 
including tumours 
- spliced, large isoforms containing extra domains are tumour associated 
antigens with a more restricted expression pattern in normal tissues 
compared with ‘small isoforms’ 
-Domain C shows most restricted pattern 
F16, G11 
 
 
81C6 
 
BC-2, BC-4, ST2146 
Entering phase I (immunocytokines) 
 
 
Phase II (radioimaging and 
radioimmunotherapy) 
Phase I/II (radioimmunotherapy; preclinical 
biodistribution studies with ST2146) 
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1.4 Antibodies to type III domain fibronectin 
1.4.1 BC-1 antibody 
Following the finding of ED-B splice variant of fibronectin, an excellent tumour marker in 
highly expressed transformed human cells, a study was carried out to produce and 
characterise an antibody towards this tumour antigen (Carnemolla et al. 1989). They 
described the isolation of the monoclonal antibody BC-1 through fusion of splenocytes 
from mice immunised using FN from the culture medium of SV-40 transformed human 
fibroblasts. A murine monoclonal IgG (muBC-1) was selected by screening the antibodies 
against fibronectin from plasma, SV-40 transformed human fibroblasts (WI38 VA13) and 
from their untransformed counterparts (WI38). The monoclonal antibody was proven to 
recognise human B-FN (WI38 VA13) but not the plasma FN and WI38, thus it confers 
specificity to tumour tissues. Further analysis on the binding site of muBC-1 antibody 
showed that the antibody did not directly recognise the human ED-B domain, but rather an 
epitope that is localised on the adjacent to type III FN domain 7 (Figure 1.9). In the 
presence of type III FN domain 9 this epitope became cryptic; suggesting that domain 9 
masked the antibody epitope. However, with the insertion of ED-B sequence, the cryptic 
epitope is unmasked and thus accessible to the antibody. This leads to a conclusion that 
muBC-1 binds to a cryptic epitope on domain 7 that is unmasked by the insertion of extra 
domain B. Thus, the presence of the ED-B sequence within FN molecules induces 
conformational modification in the central part of the molecule which in turn, leads to the 
unmasking of a previously cryptic sequence within type III FN domain 7 (Carnemolla et al. 
1992).  
The muBC-1 IgG is highly species-specific, as it does not cross-react with non-
human oncofetal fibronectin such as mouse or chicken B-FN. The tumour targeting 
potential of BC-1 was tested against oncofetal fibronectin in nude mice bearing B-FN 
expressing human tumour implants, showing favourable tumour targeting potential in 
which formation of neovasculature is highly active e.g. astrocytoma and malignant 
glioblastoma. Hence, muBC-1 IgG is a good candidate for detection of tumour cell and 
neovasculature formation induced by cancer (Mariani et al. 1997). Although muBC-1 
showed promising results and great potential, the antibody suffered from immunogenicity 
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problems due to its murine origin. Subsequently, efforts were done to make a mouse scFv 
(George A, unpublished data) but these were found to be highly insoluble and degraded 
upon storage within approximately 24 hrs. A continuing great interest into this antibody 
and its potential have led to a study to humanise the muBC-1 (Antisoma Plc, unpublished 
data) and further reformatted the antibody into single chain variable fragment (huBC-1 
scFv) for use in an AGENT approach (Harman 2006). Both huBC-1 IgG and scFv were found 
to be stable. The huBC-1 scFv was successfully cloned; it consisted of heavy and light chain 
variable domains and was assembled in the phagemid pHEN2. The protein was solubly 
expressed and purified. Preliminary characterisations have shown selective targeting of the 
huBC-1 scFv to ED-B FN fragments compared to the normal FN fragment. 
 
 
 
 
 
1.4.2 CGS-1 and CGS-2 
The scFv (CGS-1) and scFv (CGS-2) antibody fragments were the first example of successful 
tumour targeting with anti-ED-B antibodies reported using phage-derived antibodies (Neri 
et al. 1997). The library features antibodies with human heavy chain variable domain which 
was randomised in the loop region of CDR3, linked to human light chain variable domain. 
The precursors of CGS-1 and CGS-2 were subjected to subsequent affinity maturation, 
which involved randomization of positions in the CDR3 of the light chain variable domain. 
Both CGS-1 and CGS-2 antibodies bind to distinct epitopes on ED-B domains of human 
fibronectin, with binding affinities of 53 nM and 1.1 nM respectively. It has been 
demonstrated in immunohistochemical studies that the antibodies were able to recognise 
B-FN in tumour tissues (Carnemolla et al. 1996). In vivo studies showed that both 
antibodies could target tumour F9 teratocarcinoma in their dimeric scFv format (Neri et al. 
Figure 1.9: Schematic of BC-1 cryptic 
epitope. The epitope on domain 7 of 
fibronectin is hidden by domain 9 (both in 
green). The inclusion of extra domain B 
(blue) causes a conformational change that 
reveals the cryptic site (yellow) allowing 
access of BC-1 (pink) (Carnemolla et al. 1992, 
1992, Harman 2006)  
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1997). However, current targeting of the ED-B domain focuses on using scFv (L19) antibody 
fragment and its derivatives. 
1.4.3 L19 
L19 is a human scFv antibody which was isolated from phage display libraries using affinity-
maturation procedures, based on the randomisation of certain residues in the CDR1 and 
CDR2 loops of the heavy and light variable domains (Pini et al. 1998). It has a high affinity 
and specificity for type III ED-B domain (Figure 1.8). The scFv format of L19 displayed an 
excellent tumour targeting performance in tumour-bearing mice when used in monomeric 
or non-covalent homodimeric formats. In contrast, the parental scFv(E1) from which L19 
was derived, failed to efficiently localise at the tumours due to insufficient affinity towards 
the antigen (Viti et al. 1999). The enhanced binding affinity of L19 is mainly due to a lower 
dissociation constant (0.054 nM compared to 41 nM of E1) (Viti et al. 1999). Studies on 
different L19 formats include scFv monomer and non-covalent homodimer, larger 
homobivalent formats such as mini-antibody (SIP) and full IgG have been carried out using 
both immunophotodetection techniques and quantitative bio distribution analysis with 
radiolabelled protein preparations (Borsi et al. 2002, El-Emir et al. 2007, Wagner et al. 
2008, Sauer et al. 2009, Pedretti et al. 2010, Johannsen et al. 2010, Tijink et al. 2009, 
Czabanka et al. 2011). Different formats of L19 antibody allow direct comparison of 
alternative therapeutic modalities based on different antibody derivatives. Clinical studies 
with radiolabelled non-covalent homodimeric scFv (L19) of 20 patients with aggressive 
type of lung and colorectal cancers showed selective localisation in tumour lesions 
(Santimaria et al. 2003). More than 30 derivatives of L19-based biopharmaceuticals have 
been produced and tested in vivo and it is the most characterised anti-neovasculature 
antibody to date. More studies are ongoing for L19, showing the great potential of this 
antibody towards ED-B as the tumour and angiogenesis marker (Borsi et al. 2002, 
Johannsen et al. 2010, Czabanka et al. 2011). 
1.4.4 C6 
C6 is the new high-affinity murine monoclonal antibody that selectively recognises B-FN 
(Balza et al. 2009, Ventura et al. 2010). Similar to BC-1, C6 does not directly recognise the 
human ED-B domain, but rather a cryptic epitope that is localised on the adjacent type III 
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repeat 8 (Figure 1.8). This epitope is unmasked in the present ED-B within the FN 
sequence. The variable regions of C6 were cloned and a divalent, covalently linked mini-
antibody was generated. C6 has an affinity of 10 nM and biodistribution studies using the 
radiolabelled C6 mini-antibody on tumour-bearing mice demonstrated an efficient tumour 
targeting (Balza et al. 2009, Ventura et al. 2010). It should be noted that the type III FN 
domain 8 is much more stable compared to ED-B therefore longer retention time was 
observed in the tumour for C6 compared to L19. Hence, C6 represents a new tool for the 
study of potential targeting B-FN in tumour cells.   
1.5 Antibody Directed Enzyme Prodrug Therapy (ADEPT) 
1.5.1 Concept 
Standard chemotherapy is limited by its toxicity effects on normal tissues and dose limiting 
regime. By restricting the action of cytotoxic molecules to cancer sites it is possible to 
reduce systemic toxicity and side effects, hence leading to improvement of the drug 
efficacy.  Antibody-directed enzyme prodrug therapy (ADEPT) was proposed to restrict the 
cytotoxic action to cancer sites (Bagshawe 1987). This is done by selective targeting of the 
tumour associated antigen (TAA) with antibody conjugated/fused to an enzyme. The 
antibody-enzyme conjugate is allowed to bind to the TAA before clearance of the 
antibody/enzyme conjugate/fusion protein from the circulation and normal tissues (non-
targeted sites). Following this, a low toxicity prodrug (e.g. substrate for enzyme) is 
administered and remains inactive until the molecule reaches the tumour sites with bound 
antibody-enzyme immunoconjugate/fusion protein. The enzyme then catalyses the 
activation of the prodrug to a potent, active cytotoxic drug generated within the tumour 
sites and this results in cell killing of antigen-expressing tumour cells as well as the 
surrounding tumour cells. This is termed the by-stander effect (Freeman et al. 1993). By-
stander effect is an amplification of cytotoxicity resulting from the ability of one targeted 
enzyme to turnover many prodrugs/substrates into cytotoxic drugs. Thus, not only the cells 
to which the conjugates are bound be destroyed, but also neighbouring cells through 
diffusion of cytotoxic active drugs. This also includes those cells that are located further 
from tumour vasculature which are normally inaccessible to larger molecules and do not 
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express the target antigen (Figure 1.10). This is one of the primary advantages of the 
prodrug activation therapies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
Figure 1.10: Schematic diagram of Antibody Directed Enzyme Prodrug Therapy (ADEPT). This 
involves three main steps; 1: Administration of the antibody-enzyme conjugates; 2: Clearance of 
the conjugates from the blood and normal tissues and 3: Introduction of prodrug. 
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The advantages of this approach are many. The concentration of the resulting 
active cytotoxic drugs in tumour sites is much higher than could be safely achieved by 
conventional chemotherapy regimes. The small cytotoxic molecules are able to penetrate 
all cells in a tumour as well as any conventional drugs. This overcomes the problem of 
heterogeneity in tumour marker expression. With this approach normal tissues are 
protected from both short term effects such as myelosuppression and long-term effects 
including second malignancies. Above all, the antibody confers selectivity and specificity to 
the target antigen at tumour sites and therefore reduces non-targeted toxicity to normal 
cells. It is clear that although the system confers many advantages, it demands a 
multidisciplinary approach. Due to its complexity and high cost of production, the 
development of conjugate/fusion protein is often shadowed with many issues. Therefore, 
it is necessary to consider these individually. Main issues that need careful consideration 
are: 
i)  Antibody 
Antigen must be a specific target that is accessible to antibody. In most cases, the targets 
are cell surface antigens that may or may not be secreted into extracellular spaces. 
Internalising antibodies are unfavourable due to possibility of degradation of the complex 
and less efficiency whereas the non-internalising antibodies that attach to the cell surface, 
or in the extracellular space of cancer tissues, would have access to more prodrug 
(Bagshawe 2009). Antibodies that are of rodent origin would be immunogenic to human. 
But this is a temporary problem as many murine monoclonal antibodies were humanised 
and the increasing development of techniques to produce human antibodies have 
overcome this issue. In addition, anti-tumour antibodies must have a good binding affinity, 
perhaps in low nanomolar to picomolar range. Targeting vascular antigens offers great 
advantages for antibodies as tumour vessels are important for tumour survival and 
metastasis (as mentioned earlier). In addition, antigens on vasculature provide easier 
access for antibody coming from the blood stream, are genetically more stable than 
tumour cells and produce abundant markers that give them a better option for therapeutic 
purposes. Also, the targeting is less complex compared to tumour cell antigens with the 
absence of kinetic barriers such as interstitial hypertension, long penetration and 
heterogeneous antigen expression. 
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ii) Enzyme 
The choice of enzyme is critical in that the enzyme should be able to convert prodrug to 
active drug at high efficiency and no other enzyme homologue should be able to perform a 
similar action. Enzymes that have been used in ADEPT system can be divided into 3 
categories as shown below; 
Enzyme Example 
i) i) Non-mammalian    enzyme 
with no mammalian 
homologue 
 Carboxypeptidase G2 (Bagshawe et al. 1991)  
 β-lactamase(Vrudhula, Svensson and Senter 1995, Meyer 
et al. 1993) 
  cytosine deaminase (Wallace et al. 1994, Deckert et al. 
2003) 
  penicillin G amidase. 
ii) ii) Non-mammalian enzyme 
with a mammalian 
homologue 
 Bacterial β-glucoronidase 
  nitroreductase 
iii) iii) Enzyme of mammalian 
origin, including human 
enzyme 
 Human β-glucoronidase (Houba et al. 1996, Bosslet, 
Czech and Hoffmann 1994) 
  carboxypeptidase A (Smith et al. 1997) 
  alkaline phosphatise (Michael et al. 1996, Bhatia et al. 
2000, Deckert et al. 2003) 
 
The two important factors when selecting the enzyme are selectivity and immunogenicity. 
A human enzyme homologue overcomes the issue of immunogenicity but there is a 
possibility that the prodrug could be activated by endogenous human enzyme leading to 
non targeted cytotoxicity. On the other hand, a non-human enzyme such as bacterial or 
mammalian enzyme would elicit an immune response in human. A potential way to 
overcome this issue is by introducing a mutation site(s) to the human enzyme such that the 
prodrug is activated only by the mutated form. An example of this is mutant human purine 
nucleoside phosphorylase (hDM), which, unlike the wild type enzyme, accepts adenosine-
based prodrugs as substrates (Afshar, Asai and Morrison 2009a). The anti-HER2 
neu/mutant hDM enzyme fusion protein showed good cellular localisation of enzyme 
activity that leads to cytotoxic drug produced in vicinity of tumour cells.  
Another way is by de-immunising the non-human enzyme by altering the 
immunogenic sites through mutation to escape recognition by the human antibody. This 
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was shown by a study on bacterial enzyme carboxypeptidase G2 (CPG2) fused to MFE-23 
scFv antibody to produce MFECP fusion protein (Mayer et al. 2004). De-immunising of 
CPG2 was done through mutation on identified epitope and by addition of hexahistidine 
tag (His6-tag) to the C-terminus of MFECP. The fusion protein retains activity but lacks B-
cell epitope; hence resulting in an absence of HAMA response and significant reduction in 
antibody response to CPG2 in mice and human (Mayer et al. 2004, Mayer et al. 2006). 
An alternative approach is by reverse polarity of human enzyme which was shown 
with the study of human pancreatic ribonuclease (hpRNase) (Lowe et al., unpublished 
data). The hpRNase was mutated by converting the positively charged lysine 66 to a 
negatively charged glutamic acid. The mutation leads to reverse polarity of the enzyme 
binding site and reduces the recognition and affinity for RNA. Instead, the mutant has 
enhanced affinity towards novel bis-chloro-phenol prodrug of almost 16-fold. 
iii)  Prodrug and drug 
The choice of prodrug/substrate is also critical. It should be of low toxicity with an initial 
target of 100-fold difference in toxicity between prodrug and drug. This allows a 100 fold 
greater dose of cytotoxic agent in cancer sites. The concern of high concentration of drug 
at tumour sites may lead to some possibilities that the cytotoxic molecules leak into the 
blood, bone marrow and other susceptible tissues. Hence, the drug should produce 
cytotoxic action that is concentration dependent and has a short  in vivo half-life that 
allows it to be degraded before undesirable toxicity effect in normal tissues (Bagshawe 
2009). In ADEPT, drug resistance is a problem due to the use of drugs that are already in 
use in the standard cancer therapy. Therefore the effectiveness of the drug in the system is 
questionable. But this is not the case with Antibody Guided Enzyme Nitrile Therapy 
(AGENT; discussed later) as the cells should not develop resistance to cyanide. In addition, 
both the by-stander effect of cyanide and its short half life around 20-60 minutes (Baskin 
and Brewer 1997a, Dart 2004) confer an advantage in clinical settings. 
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iv) Clearance of unbound antibody-enzyme conjugate 
Following administration of the antibody-enzyme conjugate to target the antigen, it is 
necessary to remove any unbound enzyme conjugates from blood or other tissues before 
addition of the prodrug. The presence of activating enzyme in the blood when the prodrug 
is given clearly results in active drug and systemic toxicity. The clearance of enzyme from 
the blood usually takes too long post administration of the conjugate/fusion protein. 
Because the antibody binding to antigen is reversible, it is expected that when the enzyme 
blood concentration falls below that in the tumour, there will be a net return of enzyme 
from tumour back into blood (Bagshawe 2009). This further slows down the binding of 
antibody to antigen. Therefore it is critical to get a window time in which there is sufficient 
enzyme at cancer sites and zero enzyme in blood before administration of prodrug 
(Bagshawe 2009). Alternatively, an anti-enzyme antibody is administered to accelerate 
clearance of enzyme from the blood. This was shown in ADEPT study with the A5B7-F(ab)2 
anti-CEA antibody-CPG2 enzyme conjugate using a galactosylated SB43 clearing antibody 
which has shown good tumour: blood ratio of 10,000:1 (Napier et al. 2000). There is a 
possibility that the inactivating antibody could get into tumour sites and reduce the 
enzyme activity there. It was therefore galactosylated to ensure rapid removal from the 
blood via hepatic clearance with no detectable effect on the tumour (Sharma et al. 1990, 
Sharma et al. 1994, Napier et al. 2000). However, it has been suggested that ADEPT system 
employing a clearing antibody is too complicated both in clinical and commercial settings. 
Another way to increase clearance of conjugate/fusion protein from blood and normal 
tissues is through glycosylation. A fusion protein of MFE-CPG2 that was expressed in Pichia 
pastoris gave a stable and glycosylated product. The added glycosylation provides rapid 
normal tissue and blood clearance with favourable tumour localisation in vivo; hence 
leading to better pharmacokinetic properties (Medzihradszky et al. 2004, Shi and Siemann 
2005, Kogelberg et al. 2007). 
v)  Chemical conjugation or gene fusion 
The method of linking antibody and enzyme together is also an important factor to 
consider. Chemical conjugation involves direct covalent linkage of drugs, toxins or enzymes 
to antibodies using heterobifunctional agents while gene fusion involves manipulation of 
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antibody-enzyme gene construct, subsequently followed by expression of the fusion gene 
in a suitable expression system. The concern with chemical conjugation is whether the 
antibody would mask the enzyme’s active site and/or enzyme would mask the antibody-
binding site. Uniform products were difficult to attain with batch production methods in 
chemical conjugation when there is a need to produce large quantities of the conjugated 
product for clinical applications (Bagshawe 2009). Hence, gene fusion is often the 
preferable method as it overcomes the variability in chemically conjugated products. In 
addition, gene fusion allows modification of the genes (e.g. rational mutations) to meet the 
requirements and provides relative ease of production (discussed further in chapter 6). The 
difference in the chemical conjugation and gene fusion was  shown with anti-CEA F(ab)2 
antibody with CPG2 enzyme chemical conjugates which showed inadequate tumour to 
normal tissue ratios (Francis et al. 2002) whereas recombinant genetic fusion protein, 
composed of anti-CEA scFv fused to CPG2 gave improved tumour to normal tissue ratios in 
a colon carcinoma model (Bhatia et al. 2000) due to size and benefits of uniform products. 
1.5.2 ADEPT success so far 
1.5.2.1  Animal models 
One of the earliest in vivo studies employing ADEPT was with F(ab)2 fragments of anti-
carcinoembryonic antigen (CEA) murine monoclonal antibodies (A5B7) chemically 
conjugated to carboxypeptidase G2 (CPG2). This conjugate was directed at human 
chorionic gonadotropin (hCG) with retained antigen binding and full enzyme activity 
(Searle et al. 1986, Melton et al. 1993). The prodrug used was a benzoic acid mustard 
CMDA. Results showed significant elimination of human choriocarcinoma xenograft in mice 
and the tumour did not recur during the life of 9 surviving mice (Springer et al. 1991). Using 
the same prodrug and enzyme conjugated to the F(ab)2 fragment of monoclonal anti-CEA 
antibody (A5B7), a study on CEA positive LS174 colon cancer xenograft was carried out 
with the same protocol. The data showed fatal toxicity due to poor clearance of the 
enzyme from blood. Since then many of ADEPT studies used CPG2 enzyme with different 
combination of antibody and prodrug (Sharma et al. 1991, Blakey et al. 1995, Sharma et al. 
1994, Bhatia et al. 2000, Francis et al. 2002, Mayer et al. 2004, Mayer et al. 2006).  
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The most well characterised ADEPT system is a fusion protein consisting of anti-CEA 
scFv (MFE-23) fused to CPG2. This fusion construct was initially expressed in E. coli 
(Michael et al. 1996); however the yield was too low for clinical trials and in vivo 
pharmacokinetics data was not optimal. Nevertheless, some distinct improvement was 
observed compared to chemical conjugates. Also, the in vivo data showed promising 
pharmacokinetic results with high tumour:blood and tumour:tissue ratio, good tumour 
retention and penetration (Bhatia et al. 2000). Subsequently, the fusion protein was 
expressed in Pichia pastoris to give a larger yield of a stable and glycosylated product 
(Sharma et al. 2005). The glycosylated fusion protein showed a selective tumour 
localisation and better pharmacokinetic properties with tumour:plasma ratio of 1,400:1 
and 339:1 for human colon carcinoma xenograft, LS174T and SW1222 models respectively 
without significant toxicity (Medzihradszky et al. 2004, Sharma et al. 2005).  
Other studies using anti-melanoma scFv antibody-β-lactamase fusion protein with 
cephalosporin-based prodrug showed long term growth inhibition of mice bearing 
melanoma xenografts (Meyer et al. 1993, Siemers et al. 1997, McDonagh et al. 2003). Also, 
monoclonal antibody (L6)-cytosine deaminase was able to convert 5-fluorocytosine to 5-
fluorouracil and resulted in high tumour: blood ratio in H2981 lung adenocarcinoma with 
the use of second anti-idiotypic second antibody to clear conjugate form blood (Wallace et 
al. 1994).  
There are limited reports on human enzymes as the concept of using mutated 
human enzyme is still new. A mutant human purine nucleoside phosphylase which unlike 
the wild type enzyme, accepts adenosine-based prodrugs as substrates (Afshar et al. 
2009a). This mutant enzyme was fused to anti-HER2/neu peptide mimetic (AHNP). In vitro 
study on the enzyme mutant fusion construct showed cellular localisation of enzyme 
activity. No in vivo data has been reported so far but this mutant enzyme provides 
promising data that could overcome the issue of specificity and immunogenicity (Afshar et 
al. 2009b).  
Another example is by reverse polarity of human pancreatic ribonuclease 
(hpRNase) (Lowe et al., unpublished data). The hpRNase was mutated by converting the 
positively charged lysine 66 to a negatively charged glutamic acid. The mutation leads to 
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reverse polarity of the enzyme binding site and reduces the affinity for RNA. Instead, the 
mutant has 5 fold increase in affinity (Km), 3 fold increase in kcat and enhanced catalytic 
efficiency (kcat/Km) of 16 fold towards novel bis-chloro-phenol prodrug compared to the 
wild type enzyme. 
1.5.2.2 Clinical trials 
The first clinical trial with ADEPT was carried out on patients with advanced colorectal 
carcinoma. This was done using anti-CEA murine monoclonal antibody (A5B7) conjugated 
to CPG2 and prodrug benzoic acid mustard CMDA (Bagshawe et al. 1991). In addition, 
clearing antibody (SB43) was used to remove unbound conjugates in blood and normal 
tissues.  The conjugate showed some moderate toxicity but was able to localise at tumour 
sites with enzyme activity. However, most patients had myelotoxicity and all patients 
developed antibodies to the murine IgG and the bacterial enzyme (Sharma et al. 1992).  
The second trial was carried out with the same conjugates, a clearing antibody and 
prodrug (Napier et al. 2000). In this trial, the dose of conjugate was halved of that used in 
the first trial. The second trial showed some promising results with high tumour:plasma 
ratio (10,000:1) and tumour regression. The drawback of this trial was the activated drug 
had a long half-life, which diffused back into circulation that leads to myelosuppresion. 
The third trial of ADEPT used anti-CEA antibody conjugated to CPG2 (A5CP) and 
new prodrug (bis-iodo phenol mustard, ZD2767P) (Francis et al. 2002). The prodrug is 
highly potent and has a short half-life compared to CMDA in previous trials. This trial 
however does not include the clearing antibody.  Data showed that this approach had 
many problems with severe toxicity, inadequate tumour localisation and poor tumour: 
normal tissue ratio. It was concluded that the prodrug has potential use in ADEPT but a 
clearance system was necessary. 
The fourth clinical trial involved de-immunised bacterial enzyme carboxypeptidase 
G2 (CPG2) fused to MFE-23 scFv antibody to produce MFECP fusion protein (Mayer et al. 
2004). De-immunisation of CPG2 was done through mutation on identified epitope and by 
addition of hexahistidine tag (His6-tag) to the C-terminus of MFECP. The fusion protein 
retains activity but lacks B-cell epitope; hence results in absence of HAMA response and 
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significant reduction in antibody response to CPG2 with only 23% of patients (3 out of 13) 
treated with de-immunised MFECP having detectable antibody response to CPG2  (Mayer 
et al. 2004). 
The next trial of ADEPT used anti-CEA scFv antibody conjugated to CPG2 (MFECP1) 
and bis-iodo phenol (BIP) mustard prodrug (Mayer et al. 2006).  MFECP1 is manufactured 
in mannosylated form (Sharma et al. 2005) to facilitate fusion protein blood clearance. 
Phase I clinical trial showed that MCECP1 showed favourable tumour accumulation, which 
is comparable to previous studies with A5CP (Francis et al. 2002) but lower than that seen 
in the study with clearing antibody (Napier et al. 2000). In addition MFECP1 cleared rapidly 
via the liver, was less immunogenic than previous conjugates and showed 10% reduction of 
tumour diameter. The study also showed that the fusion protein was safe, well-tolerated 
and has a great potential for therapeutic purpose. These promising examples of ADEPT are 
summarised in Table 1.5. 
1.6 Antibody Guided Enzyme Nitrile Therapy (AGENT) 
AGENT is a variation of ADEPT that uses the enzymic hydrolysis of plant substrates, 
cyanoglycosides to release cyanide. The catalysis is carried out by the action of cyanogenic 
β-glucosidase enzyme conjugate that selectively binds to tumour sites (Rowlinson-Busza et 
al. 1992). Sources of common plant cyanogenic glycosides include amygdalin (bitter 
almond and apricot seeds), prunasin (cherry laurel), dhurrin (Sorghum) and linamarin 
(cassava and white clover) (Gregory 1999, Dart 2004).  
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Past ADEPT Present ADEPT 
F(ab)2 fragments of anti-carcinoembryonic antigen (CEA) murine 
monoclonal antibodies (A5B7) chemically conjugated to 
carboxypeptidase G2 (CPG2). The prodrug used was a benzoic acid 
mustard CMDA (Springer et al. 1991, Bagshawe et al. 1991, Sharma 
et al. 1992). 
Anti-CEA antibody conjugated to CPG2 (A5CP) and new prodrug (bis-
iodo phenol mustard, ZD2767P) but with severe toxicity, inadequate 
tumour localisation and poor tumour: normal tissue ratio (Francis et 
al. 2002). 
 
Anti-melanoma scFv antibody-β-lactamase fusion protein with 
cephalosporin-based prodrug showed long term growth inhibition 
of mice bearing melanoma xenografts (Meyer et al. 1993, Siemers 
et al. 1997, McDonagh et al. 2003). 
Anti-CEA scFv (MFE-23) fused to CPG2Fusion protein expressed in 
Pichia pastoris to give a larger yield of a stable and glycosylated 
product (Sharma et al. 2005). 
 
Monoclonal antibody (L6)-cytosine deaminase was able to convert 
5-fluorocytosine to 5-fluorouracil and resulted in high tumour: 
blood ratio in H2981 lung adenocarcinoma with the use of second 
anti-idiotypic second antibody to clear conjugate from blood 
(Wallace et al. 1994).  
De-immunised bacterial enzyme carboxypeptidase G2 (CPG2) fused 
to MFE-23 scFv antibody to produce MFECP fusion protein (Mayer et 
al. 2004). Showed absence of HAMA response and significant 
reduction in antibody response to CPG2  (Mayer et al. 2004). 
 
Anti-CEA scFv (MFE-23) fused to CPG2 expressed in E. coli (Michael 
et al. 1996). 
 
A mutant human purine nucleoside phosphylase, which unlike the 
wild type enzyme accepts adenosine-based prodrugs as substrates 
(Afshar et al. 2009a). This mutant enzyme was fused to anti-
HER2/neu peptide mimetic (AHNP). 
Anti-CEA murine monoclonal antibody (A5B7) conjugated to CPG2 
and prodrug benzoic acid mustard CMDA same conjugates, a 
clearing antibody and prodrug showed promising results with high 
tumour:plasma ratio (10 000:1) and tumour regression. The 
drawback of this trial was the activated drug had a long half-life, 
which diffused back into circulation leading to myelosuppresion 
(Napier et al. 2000). 
Reverse polarity of human pancreatic ribonuclease (hpRNase) (Lowe 
et al.) catalytic efficiency of 16 fold towards novel bis-chloro-phenol 
prodrug compared to the wild type enzyme. 
 
Table 1.5: List of the past and present ADEPT. 
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1.6.1 β-Glucosidases 
β-glucosidases (β-D-glucopyranoside glucohydrolases; EC 3.2.1.21) are enzymes that 
hydrolyse glycosidic bonds at the terminal, non-reducing glucosyl residues from saccharides 
and glycosides with release of β-D-glucose. They are found universally, in all domains of 
living organisms and demonstrate catalytic activity against a broad range of glycosides 
including aryl- and alkyl-β-D-glycosides.  The physiological function of β-glucosidases varies 
greatly depending upon their origin (plants, fungi, animals, bacteria or human) and 
substrate specificity. In plant, they play a role in cell wall lignifications, cell wall β-glucan 
turnover, phytochrome activation and release of aromatic compounds in plants. They also 
play a role in glycolipid and exogenous glycoside metabolism in animals or biomass 
conversion in microorganisms. The IUBMB Enzyme nomenclature of glycoside hydrolases 
was based on substrate specificity of enzyme. This led to assignment of many E.C. numbers 
of enzyme and gave little information on the enzyme nature such as the mechanism, 
structure and the relationship to other glycoside hydrolases. An improved enzyme 
classification system was then developed based on amino acid sequence and structural 
similarity (Henrissat 1991, Henrissat and Davies 1997). In this system, those enzymes with 
overall amino acid sequence similarity and well conserved sequence motif are grouped into 
same family. So far at least 125 glycoside hydrolase families are listed in the database 
“Carbohydrate-active Enzyme (CAZy)” at the website http://www.cazy.org. It is reported 
that there is a direct relationship between sequence and folding similarities and such 
classification would give some information on the structural features of these enzymes.  
β-glucosidases were described to be the member of glycosyl hydrolase (GH) families 
1, 3, 9 and 30 (Henrissat 1991, Henrissat and Davies 1997, Cantarel et al. 2009). GH1, GH3 
and GH30 β-glucosidases fall in GH clan A, which consists of protein with (β/α)8– barrel 
while GH9 enzyme has (α/α)6 barrel structures. Of these, GH1 consist of the largest number 
of characterised β-glucosidases. The mechanism by which GH1 enzymes recognise and 
hydrolyse substrates with different specificities remains an area of ongoing study. In most 
cases, the hydrolysis of the glycosidic bond is catalysed by two amino acid residues of the 
enzyme; a general acid (proton donor) and a nucleophile/base (Davies, Wilson and Henrissat 
1997). Hydrolysis occurs via overall retention or inversion of the anomeric configuration 
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depending on the spatial position of the catalytic residues. In GH1, the catalytic proton 
donor and nucleophile/base are glutamic acids and function by way of the retention 
mechanism (Legler and Bieberich 1988).  
1.6.2 Plant cyanogenic β-glucosidase (Linamarase) 
Linamarase has been widely studied and found mainly in white clover (Trifolium repens) and 
cassava (Manihot esculenta Crantz), a staple food in many tropical countries. The enzyme is 
responsible for the first step of the sequential breakdown of cyanoglycosides lotoustralin 
and linamarin (Figure 1.11). 
 
Figure 1.11: Linamarase catalysed hydrolysis of linamarin. The substrate linamarin is hydrolysed to 
cyanohydrin by the removal of glucose. The unstable cyanohydrin spontaneously breaks down, 
yielding acetone and hydrogen cyanide (Cortés et al. 1998). 
 
Linamarase is assumed to play a critical role in the plant’s defence mechanism to 
deter consumption by grazing animals (Baskin and Brewer 1997b, Esen 2003). In plant, both 
the enzyme and substrate are compartmentally separated. However, in the presence of 
mechanical force onto the plant tissues, the two components are released and subsequently 
react to produce cyanide. This natural reaction is an attractive candidate for enzyme-
directed cancer therapy and has been adapted into the AGENT approach which forms the 
basis of this study. By targeting the immunofusion enzyme to the tumour vasculature and 
subsequently administering its natural substrate (linamarin), cyanide could be generated 
specifically for tumour vessel destruction. The hydrolysis of linamarin at these sites is 
restricted by the bound active enzyme to reduce any non-specific cytotoxicity. 
Administration of linamarin to patients would be via intravenous to reach the tumour 
vascular-bound immunofusion protein and also to avoid non-targeted activation of the drug 
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by intestinal β-glucosidases or gut microbial flora. This was supported by two studies that 
have shown that toxicity of linamarin was significantly reduced by intravenous or 
intraperitoneal compared to oral administration that resulted in death in 18% of the 
hamsters (Frakes et al. 1986, Górniak et al. 1993). However, it is reported that the human β-
glucosidase does not hydrolyse linamarin to any significant level (Berrin et al. 2002), 
therefore the non-targeted toxicity due to endogenous human enzyme could be eliminated.  
1.6.3  Human β-glucosidases 
Humans contain several β-glucosidases that play roles in metabolism of glycolipids and 
dietary glucosides. The best characterised β-glucosidases are lysosomal β-glucosidases (also 
called acid β-glucosidases or glucocerebrosidases), lactase phlorizin hydrolase (LPH) and 
cytosolic (or broad specificity) β-glucosidases. They all belong to the GH1 family (Henrissat 
and Davies 1997). 
Lysosomal β-glucosidases hydrolyse glucocerebrosides that are present in the 
lysosomal membranes. Defects in the function of this enzyme and its transport to the 
lysosome lead to  Gaucher disease, one of the hereditary lysosomal storage disorders 
(Neufeld 1991). On the other hand, LPH enzyme is found in the mucosal membrane in the 
brush border of the small intestine, where it hydrolyses lactose that is present in milk. A 
deficiency of LPH is the cause of lactose intolerance (Auricchio et al. 1963, Dahlqvist et al. 
1963) that is common except among the Northern European, where the expression of this 
enzyme persists into adulthood due to large consumption of dairy products (Hollox et al. 
2001). 
The cytosolic β-glucosidase (hCβG) is present in the cytosol of liver, kidney, intestine 
and spleen of humans. Unlike the two previous enzymes, no phenotypes were observed for 
deficiencies solely in hCβG. Purification and characterisation of hCβG from the liver of type I 
Gaucher’s disease was first reported by (Daniels et al. 1981). They described the enzyme as 
monomeric with a molecular mass of 53 kDa, pI ~4.7, has a pH optimum of 5.5-6.0 and is not 
glycosylated. Following this, expression of recombinant hCβG (rehCβG) has been described 
in mammalian cells (de Graaf et al. 2001), in yeast (Berrin et al. 2002) and E. coli (Harman 
2006). Most of the reported hCβG characterisations were based on the rehCβG due to 
limitations with the isolated hCβG from patient’s samples. The biochemical, kinetic and 
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inhibition properties of the cloned enzyme were found to be in parallel with those reported 
for the enzyme purified from human liver. The hCβG was described to have a broad 
specificity with respect to glycone moiety of various aryl-glycosides (Daniels et al. 1981, 
Berrin et al. 2002). This was shown via kinetic analysis of the rehCβG with the kcat/Km value 
in a descending order of β-D-fucopyranoside > α-L-arabinopyranoside > β-D-
glucopyranoside > β-D-galactopyranoside > β-D-xylopyranoside > β-L-arabinopyranoside and 
highest Km value of 0.37 ± 0.01 mM with β-D-fucopyranoside (Table 1.6).  
 
Table 1.6: The glycone specificity of rehCβG for different substrates. For each substrate, data was 
obtained at various concentrations under a steady-state condition and fitted into the Michaelis-
Menten equation to obtain kinetic constants estimation  (Berrin et al. 2002). 
 
 
The hCβG enzyme was also shown to have activity towards plant-derived glycosides 
which are commonly ingested by humans including glycosides of phytoestrogens, 
flavonoids, simple phenolics and cyanogens. The enzyme hydrolysed many of the 
compounds tested particularly flavones, isoflavones and flavonols. The highest Km and 
kcat/Km values of 10 ± 0.06 µM and 117 mM
-1s-1 respectively were obtained with flavones 
glucoside luteolin-4-glucoside (Table 1.7). The study also mentioned that the rehCβG 
demonstrated high specificity with substrates conjugated at the 4’ and 7’-position over 3’-
linked flavonoid glucosides; showing the preference to the position of glycosylation (Berrin 
et al. 2002). 
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Table 1.7: The hydrolysis of xenobiotic glycosides by rehCβG. When significant rates of hydrolysis 
were observed, steady-state rates were obtained for a range of initial substrate concentrations and 
data was fitted to the Michaelis-Menten equation to obtain kinetic constant estimation. a specific 
activities are mean data (n≥2) and were determined with substrate at a concentration of 500µM, 
except for apigenin-7-Glc, which was determined at 200µM. b, c rate calculations were based on 
appearance of quercetin-3-Glc and luteolin aglycone, respectively. ND, not determined. (Berrin et al. 
2002). 
 
The structure of hCβG was described both in 3-dimentional modelling and structural 
biology (Berrin et al. 2003, Tribolo et al. 2007) using hCβG expressed in Pichia pastoris. The 
results from both studies were in agreement with each other. They described that the hCβG 
has the common characteristic of family 1 β-glucosidase which is the (β/α)8 –barrel and 
consists of two catalytic glutamate residues; located on strand 4 (the acid/base, Glu165) and 
on strand 7 (the nucleophile, Glu373).  These residues are involved in binding of quercetin 
4’-O-glucoside which was identified by molecular docking and site directed mutagenesis 
(Tribolo et al. 2007). The enzyme-substrate complex is discussed in detail in chapter 5.  
1.6.4 Cyanide 
Cyanide (CN-) is a rapidly acting lethal metabolic poison (Dart 2004). Intoxication 
occurs through inhibition of the terminal mitochondrial enzyme, cytochrome oxidase in the 
respiratory chain. Exposure to cyanide results in the loss of capacity to regulate the ion 
transport system that controls cytosolic pH. This could lead to potentially lethal effects. In 
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mammals, cyanide detoxification is catalysed by enzyme rhodanase, which is found in the 
liver. Rhodanase converts the majority of cyanide in the presence of thiosulfate to 
thiocyanate. The resulting non-toxic metabolites are excreted through the kidneys. In the 
case where the supply of thiosulfate is limited, alternative pathways include conversion of 
hydroxocobalamin (vitamin B12a) in the presence of HCN to non toxic cyanocobalamin 
(vitamin B12) (Dart 2004).  
The advantage of cyanide as a cytotoxin is its small size; which allows it to penetrate 
cells passively and does not require receptor-mediated internalisation to bring it into action. 
Also, the cells are proposed to be unable to develop cyanide resistance (Borowitz et al. 
1994, Kousparou, Epenetos and Deonarain 2002). These make cyanide an ideal active 
component for AGENT. In addition, its diffusive ability is restricted to close vicinity from 
tumour cells, thus limiting the damage caused to surrounding healthy tissues. The 
amplification of cyanide cytotoxicity effect is predicted through the ability of the individual 
targeted enzyme to turn over many molecules of cyanide. The lethal dose of cyanide 
compounds (CN-) generally ranges from 50-200mg CN- (0.7-2.9 mg/kg body weight in 
human); with the intravenous administration lethal dose being 1.1 mg/kg (Dart 2004).  But 
because of the ability of the body to detoxify small amounts of cyanide via the rhodanase-
catalysed reaction, the lethal dose of cyanide is time dependent; that is, a given amount of 
cyanide absorbed slowly may cause no biological effects even though the same amount 
administered over a very short period of time may be lethal (Baskin and Brewer 1997, (Dart 
2004). Previous studies have shown that the IC50 values (concentration of drug at which 50% 
of the cells are killed) after exposure to linamarin in various cell lines were around 2.3-3.8 
µM of linamarin (Cortés et al. 2002, Idibie, Davids and Iyuke 2007, García-Escudero, Gargini 
and Izquierdo 2008). This value is in parallel with most of the clinical chemotherapy drugs 
which shows IC50 values within the micro molar (µM) range. In fact, there are more potent 
FDA-approved chemotherapy drugs for cancer treatment such as Paclitaxel (Taxol®) and 
Docetaxel (Taxotere®) with the IC50 value within the nanomolar (nM) range (Kelland and 
Abel 1992, Yang et al. 2007). This suggests that cyanide is as toxic as other 
chemotherapeutic drugs and not too lethal to be administered to patients; hence shows a 
potential use in cancer therapy. 
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1.6.5 Previous studies with linamarin/linamarase system 
Many studies on linamarase showed variations in the enzyme activity due to the differences 
in isolation method and assay conditions. Although cassava root has long been a common 
source of linamarase (Cooke 1978), cassava stem and petiole were shown to be better 
sources of the enzyme in achieving homogenous preparation (Eksittikul and Chulavatnatol 
1988). The linamarase gene was cloned and characterised to overcome the issue for 
variations (Hughes et al. 1992). The linamarase cDNA encodes 532 residues; with a 
molecular weight of 65 kDa. Subsequently, the cloned linamarase  was used in gene therapy 
approach (GDEPT) in the treatment of brain cancer (Cortés et al. 1998). A retroviral vector 
was employed to carry the linamarase gene to glioma cells followed by administration of its 
substrate linamarin that resulted in release of cyanide and caused cell death in vitro (IC50 = 
0.5 -7µM linamarin in various cell lines) and tumour regression in the in vivo mice study. 
Total regression of tumour was observed in mice; believed to be due to the by-stander 
effect and no toxicity was observed. In the following in vitro study with rat glioblastoma C6 
cell lines, by-stander effect was observed in a mixed population of C6-linamarase cells and 
naive C6 cells. As few as 10% of C6-linamarase positive cells were sufficient to eliminate the 
entire cell culture in 96 hours (Cortés et al. 2002). This study showed the potential of the 
linamarase/linamarin gene therapy system to eliminate tumours. A study to improve the 
use of linamarase/linamarin system with the combination of non-toxic level of glucose 
oxidase (GO) enhanced the therapeutic potential with an IC50 of 0.8 µM at 48 hours 
compared to 3 µM without glucose oxidase in glioma cells (García-Escudero et al. 2008). 
Although gene therapy studies have provided much promising evidence in laboratory 
settings, there has been very few successful report in clinical trials (U.S. Department of 
Energy Genome Programs, http://genomics.energy.gov) due to the complexity of the 
approach involving integration into the host genome or immune response to gene carrier 
(e.g. adenovirus, retrovirus). Therefore, the feasibility of gene therapy with 
linamarase/linamarin/GO system in clinical settings is still uncertain. 
Targeting of cancer cells with antibodies conjugated to β-glucosidases using AGENT 
approach has been reported both in vitro and in vivo. Both studies have shown production 
of cyanide and cell killing (Rowlinson-Busza and Epenetos 1992, Syrigos, Rowlinson-Busza 
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and Epenetos 1998, Kousparou et al. 2002, de Graaf et al. 2003). However, no progress has 
been made into clinical trials. The use of linamarase was first described in AGEPT by 
(Kousparou et al. 2002). The linamarase was targeted extracellularly unlike with GDEPT 
approach. Therefore, the prodrug does not need to be internalised prior to activation and a 
single targeted enzyme can turnover many molecules of linamarin into cyanide which then 
leads to by-stander effect. The linamarase gene was genetically fused to the anti-CEA 
antibody MFE-23 gene which was described and referenced earlier (Chester et al. 1994), 
expressed in Saccharomyces cerevisiae and tested for specific cytotoxicity following 
activation of linamarin (Kousparou et al. 2002). Extensive functional in vitro characterisation 
of the fusion protein showed that it retained antigen binding, however the enzyme suffered 
from aggregation and reported to have reduced catalytic activity compared to the native 
material, which was a common problem reported by another lab (Keresztessy et al. 2001). 
Aggregation was predicted due to improper folding during protein expression in yeast that 
has resulted in multimerisation of the subunit. It is thought that the difference in post-
translational modifications between yeast and plant cassava may contribute to aggregation 
of the molecule (Hughes et al. 1992). Nevertheless, significant targeted cell killing was 
observed by cyanide intoxication with an IC50 value of 6 mM (Kousparou et al. 2002). The 
high IC50 value was affected by the enzyme issues mentioned above that led to insufficient 
amount of cyanide produced in the system. Preliminary in vivo characterisation showed that 
the fusion enzyme had high blood clearance rate presumably due to the carbohydrate 
mediated hepatic clearance and aggregation-induced splenocyte uptake. As a result, there 
was high amount of fusion protein in liver and spleen with poor tumour accumulation. 
Although it has been reported that there were some enzyme activities at the tumour sites, 
significant amount of cyanogenic activity in the liver and spleen would not be an ideal in 
clinical set up. These limitations indicate that the clinical prospects of the fusion protein 
were not too promising. Furthermore, another drawback was the origin of the proteins; 
with murine antibody and plant enzyme immune responses in human could be triggered. 
Nevertheless, the system showed potential for improvement of nitrile approach. 
Acknowledging the issue with the origin of plant linamarase, an alternative approach 
was investigated and the idea of using human cytosolic β-glucosidase (hCβG) was first 
shown by Harman, 2006.  The hCβG is from the same glycoside hydrolases family 1(GH1) 
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and has high homology with plant enzyme. The human enzyme was cloned and expressed in 
bacterial expression system. However, the hCβG enzyme does not hydrolyse linamarin to 
any significant level (Daniels et al. 1981) and it is a challenge to make this human enzyme 
into cyanogenic. Comparison of the difference in the substrate specificity of the plant and 
human β-glucosidase could provide some insight into this issue. With the advances of 
molecular and structural biology, the substrate binding sites of hCβG could be manipulated 
and engineered to accommodate the plant substrate linamarin and allow cyanogenesis. This 
requires rational thinking and study of residues which are responsible for linamarin 
recognition. Therefore, it is important to choose an expression system that is not only cost-
effective but easy to employ. The  bacteria expression system seems to fit into these criteria 
as it is proven to be rapid and economical for the production of recombinant proteins. 
Coupled with vast biochemical and genetic knowledge, it allows quick manipulation and 
ease of growth requirement optimisation. Taking these together, the advantages of hCβG lie 
in its origin, as a cytosolic enzyme and does not require glycosylation to be functionally 
active (Daniels et al. 1981). This could potentially overcome the issue regarding the high 
clearance rates shown in previous study. 
1.7 Aims of this PhD 
In this study, we proposed an Antibody Guided Enzyme Nitrile Therapy (AGENT) approach to 
selectively target extra-domain B fibronectin (B-FN), which is abundantly expressed in 
tumour vasculature. Humanised BC-1 single chain variable fragment antibody (huBC1 scFv) 
and a suitable re-engineered human cytosolic β–glucosidase (rehCβG) enzyme were 
investigated as the potential candidates for immunofusion in AGENT. The antibody moiety 
would allow targeting of the antigen on tumour vasculature cells while the rehCβG would 
hydrolyse the plant substrate linamarin to generate cytotoxic cyanide molecules specifically 
in tumour sites. However, endogenous human β-glucosidase does not hydrolyse cyanogenic 
glycoside linamarin to any significant level. Site-directed mutagenesis was therefore 
intended to alter its substrate specificity in order to promote reactivity towards linamarin. 
The hCβG was chosen due to its homology with the naturally cyanogenic plant enzyme, 
linamarase and human origin. Ultimately the study aimed to construct recombinant fusion 
protein of huBC-1-rehCβG and characterise its potential use in immunotherapy. 
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The project aims were to address the following questions: 
1. Can huBC-1 scFv specifically target tumours cells expressing ED-B fibronectin? 
2. Is it possible to generate a cyanogenic human enzyme? 
3. Can the re-engineered hCβG enzyme carry out the plant β-glucosidase function in 
recognising the substrate linamarin and generating cyanide? 
4. Is it possible to fuse the huBC-1 scFv and re-engineered hCβG enzyme to impart 
cyanogenesis and kill tumour cells?  
 
The study was achieved with the following objectives: 
1. Expression and purification of huBC-1 scFv antibody. 
2. In vitro characterisation of huBC-1 scFv and comparison with the native huBC-1 IgG. 
3. Expression, purification and characterisation of wild type hCβG to form a basis of 
comparison with the mutant rehCβGs. 
4. Design and construction of the mutant hCβGs with potential for cyanogenesis. 
5. Expression, purification and characterisation of hCβG mutants with focus on enzyme 
stability, kinetics and substrate specificity. 
6. Design and construction of huBC-1 scFv-hCβG mutant fusion gene construct. 
7. Expression of immunofusion construct in a suitable expression system, purification 
and characterisation for function on cells. 
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Chapter 2 
Materials and Methods  
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2.1  Materials 
2.1.1  Buffers and Stock Solutions 
Water 
Ultrapure  water treated with UV radiation was obtained from a Purite Select system and 
sterilized by autoclaving if necessary. Fermentas Nuclease Free water was used for 
molecular biology application. 
Phosphate-Buffered Saline (PBS) 
137mM NaCl, 2.7mM KCl, 2mM KH2PO4, 10mM Na2HPO4.  
Phosphate-Buffered Saline containing NaCl and MgCl2 (PBS/NaCl) 
As PBS, but with the addition of an additional 0.5M NaCl and 1mM MgCl2. 
Sodium"Phosphate"Buffer" 
Stock A: 27.8g NaH2PO4 in 1 litre of water. 
Stock B: 53.65g of Na2HPO4 in 1 litre of water. 
For 1 litre of a 100mM Sodium Phosphate Buffer (pH 7.8) containing 300mM NaCl, 95ml of 
stock A was added to 405ml of stock B and 17.5g of NaCl. The volume was increased to 1 
litre with 500ml of dH2O. 
Tris-acetate EDTA buffer (TAE) 
40mM Tris base, 1mM 0.5M EDTA pH 8, 57.1ml glacial acetic acid, in 1 litre water.   
pNPGlc buffer 
50mM sodium phosphate, 5mM EDTA, pH 6.0, filter sterilised. 
pNPGlc stop buffer 
100mM sodium borate, pH9.3. 
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Other general reagents 
Chemicals and general reagents were purchased from Sigma, BDH Merck/VWR, Promega 
UK, BIO-RAD and other companies. Reagents and buffers that are not listed here were 
prepared in accordance with standard laboratory protocols (Sambrook and Russell, 2001). 
2.1.2  Polyacrylamide Gel electrophoresis (PAGE) 
SDS-PAGE loading buffer (5 stock) 
50% (v/v) glycerol, 60mM Tris-HCl pH 6.8, 10% SDS, 200mM -mercaptoethanol, 25mg 
bromophenol blue. 
SDS-PAGE Running Buffer 
25mM Tris base, 250mM glycine, 0.1% SDS.  
12 % Resolving gel 
3.3ml H2O, 4ml 30% Bis/Acrylamide, 2.5ml 1.5 M Tris/HCl (pH8.8), 100µl 100% SDS, 100µl 
10% Ammonium persulfate (APS), 4µl TEMED. 
5 % Stacking gel 
3.4ml H2O, 833µl 30% Bis/Acrylamide, 630µl 0.5M Tris/HCl (pH 6.8), 50µl 10% SDS, 50µl 10% 
APS, 5µl TEMED. 
SDS-PAGE Coomassie stain 
40% methanol, 10% acetic acid, 0.25% Coomassie brilliant blue (R-250). 
SDS-PAGE destain 
40% methanol, 10% acetic acid, 50% H2O. 
Western Blot Transfer Buffer 
48mM Tris base, 39mM glycine, 0.04% (w/v) SDS, 20 %( v/v) methanol.  
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Marvel® milk powder 
Dried skimmed milk powder supplied by Premier Products for blocking nitrocellulose 
membranes in Western blots. 
2.1.3  Bacterial cell culture 
2.1.3.1 Bacterial media and solutions 
2TY broth 
16g bacto tryptone, 10g bacto yeast, 5g NaCl, made up to 1 litre with distilled water and 
autoclaved. 
2TY agar 
As 2TY (above) plus 15g bacto agar. 
Antibiotic concentrations 
Ampicillin/carbenicillin - 100mg/ml stock in a 50:50 solution of ethanol/distilled water and 
filter sterilised. Diluted to 100g/ml for use. 
2.1.3.2 Bacterial strains 
Species Strain Genotype 
E. coli BL21(DE3) F- ompT, hsdSB, (rB
- mB
-), gal dcm  (DE3) 
E. coli XL1-Blue ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 
thi-1 recA1 gyrA96 relA1 lac *F proAB lacIqZ∆M15Tn10 
(Tetr) 
E. coli HB2151 {nalr thi-1 ara Δ(lac-proAB) *F’ proAB lacIqZΔ M15+} 
E. coli Origami B (DE3) F- ompT hsdSB(rB
- mB
-) gal dcm lacY1 aphC (DE3) gor522:: 
Tn10 trxB (KanR, TetR) 
E. coli JM109 {e14 (McrA) recA1 endA1 gyrA96 thi-1 hsdR17 (rK– 
mK+) supE44 relA1 Δ(lac-proAB) [F′ traD36 proAB 
lacIqZΔM15+} 
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2.1.3.3 Bacterial plasmids 
Plasmid Manufacturer 
pHEN2 MRC Centre for Protein Engineering 
pET23b (+) Novagen 
pQE-12 Qiagen 
Plasmids confer ampicillin resistance (or carbenicillin), both at 100g/ml. 
2.1.4  Human cell culture 
2.1.4.1 Human cell culture media and solutions 
Media/solutions Manufacturer 
Dulbecco's Modified Eagle’s Medium with 
Glutamax-1 (with sodium pyruvate, 
4500mg/L glucose and pyridoxine) 
Gibco, Invitrogen #31966-021 
Trypsin EDTA Gibco, Invitrogen #25300-062, 0.05% 
Trypan Blue (diluted to 0.5% in PBS) Gibco, Invitrogen #15250-061 
Penicillin-Streptomycin Gibco, Invitrogen #15070-063 
0.02% EDTA solution Invitrogen, E8008 
 
2.1.4.2 Human cell lines 
Cell line Origin 
WI38 Human fibroblast cell line that expresses the ED-B negative 
form of fibronectin 
WA13(VA13) SV-40 transformed human fibroblast cell line that expresses 
the ED-B positive form of fibronectin 
U87 Human glioblastoma 
KB Human carcinoma of the nasopharynx 
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2.1.5 Antibodies and Detection 
Antibody Supplier Description Typical 
Dilution 
Anti-mouse 
HRPO Conjugate 
Sigma IgG from goat, conjugated to 
horseradish peroxidase, detects 
mouse Fc domain. 
1:5000 
Anti-His6-HRPO 
Conjugate 
Sigma Mouse IgG conjugated to 
horseradish peroxidase, detects 
penta-histidine peptide tag. 
1:5000 
9E10 Cancer 
Research UK 
Mouse IgG from hybridoma detects 
myc-tag epitope – unpurified 
serum. 
1:50 
Anti-Human-
HRPO 
Sigma IgG from goat, conjugated to 
horseradish peroxidase 
1:5000 
Anti-human-
FITC 
Sigma IgG from goat, conjugated to FITC 1:1000 
(FACS) 
Anti-mouse-FITC 
 
Sigma IgG from goat, conjugated to FITC 1:1000 
(FACS) 
 
BM-Blue POD  
3, 3’-5, 5’-Tetramethylbenzidine (TMB) ready to use solution as a chromogenic substrate for 
the peroxidase-mediated colour development in enzyme immunoassays (Roche). 
ECL™ Detection Kits 
Enhanced Chemiluminescence Detection kits for detection of HRPO-conjugated antibodies 
(GE Healthcare). 
EZ-Link Sulfo-NHS-LC-LC-Biotin 
Biotinylation reagent (Pierce). 
HABA/Avidin Reagent 
For estimating levels of biotin incorporation into proteins (Sigma). 
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Avidin 
For use in Avidin capture enzyme linked immunosorbent assay (ELISA) (Sigma). 
2.1.6 Primers 
Name 5’-3’ sequence 
T7 Prom TAATACGACTCACTATAGGG 
T7 Term GCTAGTTATTGCTCAGCGG 
V168A FWD GATCACCATAAATGAAGCTAATGCTCTTTCTGTGATGTCATATGACT 
V168A REV AGTCATATGACATCACAGAAAGAGCATTAGCTTCATTTATGGTGATC 
F334A FWD CTCCAGGATGCGGAAATTGAAGCTTTTCCAGATCCATCTTGGAA 
F334A REV TTCCAAGATGGATCTGGAAAAGCTTCAATTTCCGCATCCTGGAG 
hCβG 6 AGTGTCTGACCAGGAAGCTGCTAAAAGAGC 
hCβGNot1FOR GACAAGCTTGCGGCCGCTGCTTTCCCTGCAGGAT 
hCβGNot1REV TAGGCCATGCGGCCGCCTCGAGATGTGCTTCAAG 
BC1Nhe1FOR ACAGTACATGCTAGCGAGGTGCAGCTGGTGCAGTCTGGC 
BC1Not1REV CGGCGATGTGCGGCCGCACCATTGATCTCCAG 
BC1endFOR GGTAGTAGTATACCATTCACGTTTGGCCAGGGGACCAAGC 
hCβG10REV GGAAAGTGATGGCTCTTTTAGCAGCTTCCTGGTCAGACAC 
LMB3FOR CAGGAAACAGCTATGAC 
FDSEQ1REV GAATTTTCTGTATGAGG 
 
Primers were received as lyophilised and were resuspended in sterile water to a final 
concentration of 100 pmoles/l. All primers were HPLC-purified and stored in aliquots at -20 
°C  until required (Thermo Scientific). 
Restriction endonucleases, DNA Polymerase enzyme, T4 DNA ligase and FastAP™ 
Thermosensitive Alkaline Phosphatase were purchased from Fermentas. 
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2.2 Methods 
2.2.1 DNA ManipulationTechniques 
2.2.1.1 Preparation of plasmid DNA 
Plasmid DNA was purified using the Qiagen QIAprep kit according to the manufacturer's 
protocol, based on an alkaline lysis method. Briefly, the bacterial pellet was lysed in an 
alkaline buffer and the solution neutralised to precipitate cell debris. The DNA was bound to 
a silica-based resin column and washed with an ethanol-containing buffer to remove 
genomic DNA, RNA and other contaminants. Plasmid DNA was eluted using the buffer 
provided or sterile water (approximate yield was 5g per 5ml culture). N.B. Larger-scale 
DNA preparation was achieved using the Qiagen Midi- or Maxi-prep kits according to the 
manufacturer’s protocol. 
2.2.1.2 Measuring DNA concentration and purity 
The absorbance of the sample DNA was measured using NanoDrop ND-1000 
Spectrophotometer. This device allowed accurate determination of concentration and 
purity. Basically 1 µl of neat sample is pippetted onto the receiving fibre; avoiding dilutions 
which can introduce error. The sample absorption at 260nm and 280nm was measured. A 
reading of 1.0 at 260nm corresponds to 50µg/ml of DNA. A 260nm/280nm absorbance ratio 
of between 1.6 and 1.8 was used to indicate a good standard of purity.  
2.2.1.3 Restriction digests of plasmid DNA 
All digests were carried out in the buffer according to the manufacturer recommendations. 
Digests were incubated at 37°C (unless stated otherwise) for a minimum of 1hour. If the  
digested products were to be subsequently used in ligation reaction, 1 unit of FastAP™ 
Thermosensitive Alkaline Phosphatase was added and incubated for a 10 mins at 37°C. This 
was to prevent the DNA from re-circularising. The reaction was stopped by heating to 65°C. 
2.2.1.4 Ligation of DNA 
Ligations were carried out in the buffer supplied by the manufacturer with total volume 20 
µl. Typical molar ratio of linearised plasmid DNA: insert DNA were 1:1 or 3:1 (typically 50-
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100ng plasmid DNA). Reactions were incubated at room temperature for 1-2hours or 
overnight at 4°C prior to transformation into competent E. coli cells. 
2.2.1.5 Agarose gel electrophoresis of DNA 
A 1% agarose solution (w/v) was prepared in TAE buffer, heated to melt the agarose and 
cooled slightly before the addition of ethidium bromide to a concentration of 1g/ml. The 
gel was cast in a Horizon™ 58 horizontal gel system and allowed to set. The tank was filled 
with 1TAE buffer and DNA samples loaded into gel wells by addition of DNA loading buffer. 
Gels were electrophoresed at approximately 100V and subsequent visualisation of the DNA 
was achieved by exposure to UV light (UVP BioDoc-It™ UV Transilluminator). N.B. 
Appropriate lab coat, gloves, and protective eyewear were applied when handling ethidium 
bromide and/or ethidium bromide containing material. Exposing unprotected skin and eyes 
to intense UV sources were avoided and a face shield was used when necessary. 
2.2.1.6 Agarose gel DNA extraction 
DNA was purified from agarose gels by QIAquick gel extraction kits (Qiagen) according to the 
manufacturer’s instructions. Briefly, the agarose was dissolved in the supplied buffer at 
50C, and then the DNA was bound to a silica-based resin column before washed to remove 
residual agarose and other impurities. DNA was eluted using the buffer provided or sterile 
water. 
2.2.1.7 Amplification of DNA by the Polymerase Chain Reaction (PCR)  
A standard PCR reaction was as follows: 
Template DNA 10pg – 1µg 
dNTPs Mix, 2mM 5µl 
Forward primer 0.1-1µM 
Reverse primer 0.1-1µM 
10X Taq buffer 5µl 
Taq DNA Polymerase 1.25µ 
Water, nuclease-free To 50µl 
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* annealing temperature was tailored according to the primers used. 
∞ infinity. 
 
2.2.1.8 Screening colonies for positive ligation transformants by (PCR) 
The standard PCR (above) was used to analyse ligation transformants by replacing the DNA 
template component of the general reaction with bacterial cells transformed with a vector 
potentially containing the insert of interest. During the initial stage of the reaction, cells 
were heated to 96C causing them to lyse, releasing the DNA into the reaction mixture and 
amplification then continues as normal. Control reactions contained the insert of interest to 
be amplified (e.g. insert PCR product) or vector only.  
2.2.1.9 Site-Directed Mutagenesis (SDM)  
SDM was carried using a QuickChange® Site-Directed Mutagenesis Kit (Agilent, Stratagene 
Products). Standard PCR was used to introduce point mutations into the gene of interest by 
designing forward and reverse primers containing nucleotide substitutions as required and 
covering approximately 15 nucleotides either side of the mutation. A modified reaction was 
performed whereby the entire plasmid was amplified to yield a circular product containing 
the desired mutation(s). Following amplification, the reaction was subsequently treated 
with the 1µl methylation-sensitive restriction enzyme DpnI for 1hour at 37C, causing the 
methylated template DNA to be digested and the PCR product containing the mutation to 
Step Temperature 
(°C ) 
Time 
(min) 
Number             
of cycles 
Initial 
denaturation 
95 2 1 
Denaturation 95 1  
30 Annealing *Tm-5 1 
Extension 72 1 
Final Extension 72 10 1 
Incubation 4 ∞  
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be spared. The reaction was stopped by heating at 80C for 20 minutes. A typical reaction is 
as follows: 
Template DNA  5-50ng 
dNTPs Mix, 2mM 1µl 
Forward primer 125ng 
Reverse primer 125ng 
10X reaction buffer 5µl 
PfuTurbo DNA 
polymerase 
1µl 
Water, nuclease-free To 50µl 
 
 
 
 
 
 
 
   
∞ infinity. 
 
2.2.1.10 Automated DNA sequencing 
DNA sequencing was carried out through external DNA sequencing company, Eurofins MWG 
Operon (http://ecom.mwgdna.com). The protocol for sequencing is available at the website. 
The DNA and amino acid sequences were aligned using CLUSTALW multiple sequence 
alignment software (Thompson, Higgins and Gibson 1994) and analysed with ExPASY 
proteomics server (Gasteiger et al. 2003).  
 
Step Temperature 
(°C ) 
Time 
(min)           
Number                    
of cycles 
Initial 
denaturation 
95 2 1 
Denaturation 95 1  
16 Annealing 55 1  
Extension 68 1  
Final Extension 68 10  1 
Incubation 4 ∞  
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2.2.2  Bacterial techniques 
2.2.2.1 Preparation of chemically-competent E. coli 
A single colony from a freshly-streaked agar plate was used to inoculate an overnight 5ml 
culture without antibiotics. This starter culture was used to seed a fresh 50ml culture which 
was grown in a sterile 250ml conical flask at 37C with 250 rpm shaking in an orbital shaker 
to an O.D. at 600nm of approximately 0.4. Cells were chilled on ice for 30 minutes, 
centrifuged at 6500g for 15 minutes at 4C and resuspended in 50% of the culture volume of 
ice-cold sterile CaCl2. Cells were returned to ice for a further 30 minutes, then re-centrifuged 
for 5 minutes at 4C and resuspended in 3ml ice-cold sterile CaCl2/10% glycerol. Cells were 
transformed immediately or snap-frozen in aliquots for storage at -80C. 
2.2.2.2 Transformation of chemically-competent E. coli 
One tube of chemically competent cells per transformation required was allowed to thaw 
on ice.  Between 10-100ng plasmid DNA was added to each tube, the cells mixed by gentle 
agitation with the pipette. The cells were then incubated on ice for 30 minutes. Cells were 
heat-shocked for 45 seconds in a 42C water bath and returned to ice for a further 2 
minutes. The cells were revived by adding 800µl of pre-warmed SOC media (Sigma) followed 
by incubation for 1hour at 37°C with shaking at 250rpm in an orbital shaker. Typically, 10 µl 
of the transformed cell culture was plated on 2TY-agar containing 1% glucose with an 
appropriate antibiotic. A negative control reaction was included containing cells heat-
shocked in the presence of sterile water in the place of plasmid DNA. Plates were incubated 
inverted at 37C overnight to obtain single colonies. 
2.2.2.3 Preparation of electrocompetent E. coli 
A single colony from a freshly-streaked agar plate was used to inoculate an overnight 5ml 
culture without antibiotics. This starter culture was used to seed a 50ml fresh culture which 
was grown in a sterile 250ml conical flask at 37C with 250 rpm shaking in an orbital shaker 
to an O.D. at 600nm of approximately 0.4. Cells were chilled on ice for 30 minutes, 
centrifuged at 6500g for 15 minutes at 4C and gently resuspended in the culture volume of 
ice-cold sterile water. Following a further 15 minutes on ice, the cells were centrifuged as 
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before and resuspended in 50% of the culture volume of ice-cold sterile water. After a 
further 15 minutes on ice, the cells were centrifuged as before and resuspended in 5% of 
the culture volume of ice-cold sterile water containing 10% glycerol. After a final 15 minutes 
on ice, the cells were centrifuged at 2500g for 10 minutes at 4C and resuspended in 
approximately 0.5% of the culture volume of ice-cold sterile water containing 10% glycerol. 
Cells were transformed immediately or snap-frozen in aliquots for storage at -80C. 
2.2.2.4 Transformation of electrocompetent E. coli 
One tube of chemically competent cells per transformation required was allowed to thaw 
on ice.  Between 1-50ng plasmid DNA or up to 10l purified ligation reaction was added to 
each tube and placed on ice for approximately 10 minutes. Cells were transferred to a 
chilled electroporation cuvette (0.2cm electrode gap) and electroporated in a BioRad 
GenePulser Plus at the following settings: 
Voltage  2.5 kV 
Resistance 200 Ω 
Capacitance 25 µF 
 
Immediately following electroporation, 1ml of pre-warmed SOC media (Sigma) was added to 
the cuvette and the cells were transferred into a sterile tube. Cells were allowed to recover 
at 37C for 1 hour with 250 rpm shaking in an orbital shaker before plating on agar plates 
containing the appropriate antibiotic. A negative control reaction was included containing 
cells electroporated in the presence of sterile water in the place of plasmid DNA. Plates 
were incubated inverted at 37C overnight to obtain single colonies. 
2.2.3  Protein expression in Escherichia coli 
2.2.3.1 Small-scale expression 
The expression strain was transformed with the DNA construct (as above) and a single 
colony used to inoculate an overnight 5ml starter culture in 2TY medium containing 1% 
glucose and the appropriate antibiotic. This culture was centrifuged at 4000 rpm for 10 
minutes and the bacterial pellet resuspended in fresh 2TY medium to ensure minimal carry-
The pulse time constant was 
expected to be in the range 4.5-
5.0 milliseconds 
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over of antibiotic resistance gene products. The resuspended cells were then used to seed a 
50ml culture at 1:100 ratio, in a sterile 250ml conical flask with similar medium and grown 
at 37C with 250rpm shaking until an optical density (600nm) of 0.6-0.8 was reached. 
Following this, IPTG (Isopropyl--D-thio-galactopyranoside) was added to a final 
concentration of 1mM. This is to allow induction of protein expression. The cultures were 
grown at 30C overnight with 250rpm shaking (unless otherwise stated) to allow expression 
of the protein of interest. 
2.2.3.2 Large-scale expression 
Larger scale expression was achieved by seeding a 500ml culture of 2TY medium in a sterile 
2L conical flask and continuing the steps as for small-scale inductions until the point of 
induction. The cells were then induced with IPTG and grown at 30C overnight with 250rpm 
shaking (unless otherwise stated) to allow expression of the protein of interest. 
2.2.3.3 Preparation of soluble protein fraction from cell pellet 
Cells were centrifuged at 4000rpm in a Sorvall GS-3 rotor for 30 min and resuspended in 
PBS/NaCl containing a protease inhibitor cocktail (Roche). The preparation was lysed by two 
passages through a cell disrupter cell at 25,000 psi, according to the manufacturer's protocol 
(Constant Systems, model T5). The lysate was then ultracentrifuged at high speed (25 000g) 
for 30 minutes to separate the soluble and insoluble fractions. Soluble fraction was 
extensively dialysed against 5L PBS/NaCl at 4°C. Dialysis membrane with a 10,000 kDa 
molecular weight cut-off limit was used and at least three changes of dialysis buffer, before 
purification by affinity chromatography.  
2.2.3.4 Preparation of soluble protein fraction from cell culture supernatant 
Culture supernatant was harvested by centrifugation at 4000rpm in a Sorvall GS-3 rotor for 
30 minutes. Bacterial protease inhibitor cocktail tablets (Roche) were added to the 
supernatant (according to the manufacturer’s recommendation). Supernatant was then 
concentrated using a Vivaflow dialysis cassette attached to a peristaltic pump at 4°C. Upon 
reaching a volume of approximately 50ml, supernatant was extensively dialysed against 5L 
PBS/NaCl at 4°C. Dialysis membrane with a 10,000 kDa molecular weight cut-off limit was 
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used and at least three changes of dialysis buffer, before purification by affinity 
chromatography.  
2.2.4  Purification of bacterial expressed protein 
2.2.4.1 Talon™ Immobilised Metal Affinity Chromatography (Co-IMAC) 
Talon™ Metal Affinity Resin (BD Biosciences) was decanted into a column containing a filter 
(approximately 5ml of slurry) and washed with approximately 40ml of distilled water, 
followed by equilibration in PBS/NaCl. The culture supernatant (dialysed into PBS/NaCl) or 
soluble protein fraction was then added to the resin to allow the His6-tagged proteins to 
bind. The preparation was incubated overnight at 4°C or for 1hour at 37 °C. The column was 
washed with approximately 10 bed volumes of PBS/NaCl, followed by two further PBS/NaCl 
washes containing 10 and 20mM Imidazole (adjusted to pH 8) respectively. Proteins were 
eluted from the column with PBS/NaCl containing 200mM Imidazole. 
2.2.4.2 Nickel Immobilised Metal Affinity Chromatography (Ni-IMAC) 
Chelating Sepharose (Fastflow, GE Healthcare) was decanted into a column containing a 
filter (approximately 5ml of slurry) and washed with approximately 40ml of distilled water. 
Chelating Sepharose was charged with nickel ions by allowing 2 bed volumes of 0.2M NiCl2 
to pass thorough before washing with distilled water followed by 0.02M sodium acetate, 1 
M NaCl, pH4.0 to elute loosely bound ions that might otherwise leak out during the 
purification process. Column was then equilibrated with PBS/NaCl. The culture supernatant 
(dialysed into PBS/NaCl) or soluble protein fraction was added to the resin to allow the His6-
tagged proteins to bind. The column was washed with approximately 10 bed volumes of 
PBS/NaCl, followed by two further PBS/NaCl washes containing 10 and 20mM Imidazole 
(adjusted to pH 8) respectively. The retained His6-tagged proteins were eluted with 200mM 
Imidazole (adjusted to pH 8) and dialysed extensively against PBS to remove Imidazole prior 
to analysis by SDS-PAGE. All fractions and washes were retained at each stage for analysis of 
purification efficiency. 
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2.2.4.3 Antigen affinity chromatography 
2.2.4.3.1 Preparation of a fibronectin fragment antigen affinity column 
The fibronectin fragment containing domains 7, B, 8 and 9 was expressed cytosolically as 
described in section 2.2.3.2 and 2.2.3.3 and purified by IMAC as described in section 2.2.4.2. 
Approximately 1.5g of activated CH Sepharose 4B (GE Healthcare) was swelled and washed 
with approximately 200ml of 1mM HCl, then filtered to separate the resin. Approximately 
6mg of the antigen fragment was dialysed into coupling buffer (0.1M NaHCO3 containing 
0.5M NaCl, pH 8), then added to the washed sepharose. Following overnight incubation with 
tumbling at 4°C, the coupled sepharose was centrifuged and resuspended in 0.1M Tris-HCl 
(pH 8.0) to block any remaining active groups. The resin was then decanted into a 10ml 
chromatography column containing a filter and washed 6 times with alternating cycles of 
0.1M acetate buffer containing 0.5M NaCl (pH4.0) and 0.1M Tris-HCl buffer containing 0.5M 
NaCl (pH 8). The column was then stored at 4°C in PBS/NaCl containing 0.05% azide until 
required.  
2.2.4.3.2 Purification by antigen affinity chromatography 
The column was pre-equilibrated in PBS/NaCl, and then loaded with induction culture 
supernatant containing huBC-1 scFv (also dialysed into PBS/NaCl). The column was washed 
once with approximately 10 bed volumes (40ml) of PBS/NaCl, then protein was eluted with 
100mM triethylamine (TEA) into 1M HEPES (ratio of 1:1). Fractions were extensively 
dialysed against PBS to remove TEA/HEPES prior to analysis by SDS-PAGE. All fractions and 
washes were retained at each stage for analysis of purification efficiency. The column was 
regenerated by washing 6 times with alternating cycles of 0.1M acetate buffer containing 
0.5M NaCl (pH4.0) and 0.1M Tris-HCl buffer containing 0.5M NaCl (pH 8) and stored at 4ºC 
in PBS/NaCl containing 0.05% azide. 
2.2.4.4  Anti-myc 9E10 chromatography 
2.2.4.4.1 Preparation of 9E10 column 
The 9E10 antibody has a high affinity for the c-myc tag. By manipulating this feature, the 
column was prepared by coupling of the 9E10 antibody to protein A resin. Firstly, 1ml of 
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protein A packed beads were washed twice in PBS pH 7.4 and incubated by with 2mg of 
9E10 antibody at room temperature to allow antibody binding. Any unbound 9E10 was spun 
out by centrifuging at 1800rpm for 2 minutes and the resin was then washed with 10 
volumes of 0.2M borate buffer pH 9.0 (boric acid/OH) twice. In order to cross-link the 9E10 
to the protein A resin, Dimethyl Pimelimidate Dihydrochloride (DMP) was added to a final 
concentration of 20mM (52mg of solid DMP per 1ml of packed beads in 10ml borate buffer). 
The DMP cross-linker was incubated with the resin-coupled 9E10 for 30 minutes at room 
temperature and then centrifuged for 2 minutes at 1800 rpm, where the supernatant was 
discarded. The crosslinking reaction was terminated by washing the beads twice with 0.2M 
ethanolamine and the resin was tumbled in 0.2M ethanolamine for 2 hours at room 
temperature. Finally, the resin was spun down at 1800 rpm for 2 minutes, washed twice in 
PBS and stored in PBS/0.01% azide. 
2.2.4.4.2 Purification by 9E10 column 
The protein to be purified was incubated with the 9E10 column either at 4°C overnight or at 
room temperature for 1 hour. The sample was packed into a 5ml polypropylene disposable 
column (Pierce) and the flow-through was collected. Again the column was washed twice 
with PBS (10 bed volumes) and the protein was eluted from the column with increasing 
acidity of 0.2M glycine. Firstly, 3ml of 0.2M glycine pH 5.0 was applied and collected as 
3x1ml fractions. This was followed by 3x1ml fractions with 0.2M glycine pH 3.0, which is the 
buffer with which most of the protein was eluted and finally any remnants of the protein of 
interest were eluted with 0.2M glycine pH 2.5. Each fraction was neutralised with 1M Tris 
pH 8.0 (50mM final concentration). The column was immediately put back into PBS and 
stored in PBS/0.01%azide. The flow through, washes and eluted fractions were analysed by 
SDS-PAGE (see section 2.2.3.6) and accordingly the fractions containing the protein of 
interest were pooled and dialysed against PBS.  
2.2.4.5 Size exclusion chromatography 
Proteins were purified using a SuperdexTM 200 gel filtration column (GE Healthcare) 
composed of dextran and cross linked agarose attached to a Bio-Rad BioLogic DuoFlow 
system.  The column was equilibrated with sterile, de-gassed PBS/NaCl to ensure that the 
system was completely free of any air bubbles.  The sample volume applied to the column 
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was between 0.5-2ml, and the column was run at a flow rate of 1ml/minute with the 
collection of 1ml fractions.  The absorbance of the elutes from the column was monitored at 
214 nm and the readings plotted. Fractions were chosen for further analysis according to 
the absorbance readings and in association with a standard curve of previously-run protein 
standards of known size (see Appendix 5). 
2.2.4.6 Preparation of protein inclusion bodies 
Cell pellets from overnight induction cultures were centrifuged at 4000rpm in a Sorvall GS-3 
rotor for 30 minutes and resuspended in PBS/NaCl containing a protease inhibitor cocktail 
(Roche). The preparation was lysed by two passages through a cell disrupter cell at 25,000 
psi, according to the manufacturer's protocol. The lysate was then ultracentrifuged at high 
speed (25 000g) for 30 minutes to separate the soluble and insoluble fractions. The 
insoluble fractions were resuspended with 50mM Tris-HCl, 20mM EDTA, pH 8. Following 
this, the pellet was washed with 2% Triton X-100, 0.5M NaCl to remove contaminating 
bacterial proteins. Between each wash, inclusion bodies were re-centrifuged for 1 hour at 
25 000g for three washes. The final preparation of inclusion bodies if was not processed 
immediately, was frozen at -20 °C until required.  
2.2.4.7 Protein refolding techniques 
2.2.4.7.1 Dilution method 
Protein refolding using the dilution method performed using a modified version of that used 
by (Buchner, Brinkmann and Pastan 1992, Deonarain and Epenetos 1998). The inclusion 
body solution was diluted to approximately 0.5mg/ml in 6M GuHCl, but with the addition of 
100mM Tris-HCl (pH 8.0), 2mM EDTA and 0.3M DTT by continuous agitation 1hour at room 
temperature. The preparation was ultracentrifuged 30 000g for 30 min at room 
temperature. This solution was added drip-wise in 1:100 ratio into 500ml of refolding buffer 
containing 100mM Tris-HCl, pH 8.0, 2mM EDTA, 0.4M L-Arginine and 8mM oxidised 
glutathione at 10 °C. Refolding was carried out overnight at 10 °C with constant stirring. The 
solution was then centrifuged at 20,000g for 30 minutes to remove precipitated proteins, 
dialysed in PBS and concentrated to about 10-50 fold. The sample at each stage was 
collected for SDS-PAGE gel assay. 
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2.2.4.7.2 Dialysis method 
The inclusion body solution was diluted to approximately 0.5mg/ml in 6M GuHCl, but with 
the addition of 100mM Tris-HCl (pH 8.0), 2mM EDTA and 0.3M DTT by continuous agitation 
for 1 hour at room temperature. The preparation was ultracentrifuged at 30 000g for 30 min 
at room temperature. The sample (supernatant) was further reduced with addition of β-
mercaptoethanol. Following overnight dialysis in PBS at 10 °C, any protein precipitates were 
removed by centrifugation at 20,000g for 30 minutes then concentrated to about 10-50 
fold. The sample at each stage was collected for SDS-PAGE gel assay. 
2.2.5 Tissue culture techniques 
2.2.5.1 Growth and maintenance of cell lines 
All cell lines were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented 
with 10% foetal calf serum (FCS) and 50units/ml of penicillin and 100ug/ml streptomycin (all 
from Life Technologies). All cells were grown in a 37C humidified incubator at 5% CO2. 
FCS was depleted of fibronectin before use by passage through a column containing gelatin 
coupled to sepharose (gelatin sepharose 4B, GE Healthcare), followed by filter sterilisation. 
Bound fibronectin was eluted with PBS/NaCl containing arginine. The column was then 
regenerated by washing 6 times with alternating cycles of 0.1M acetate buffer containing 
0.5M NaCl (pH4.0) and 0.1M Tris-HCl buffer containing 0.5M NaCl (pH 8) and stored at 4 °C 
in PBS/NaCl containing 0.05% azide. Depleted fibronectin of FCS (dFCS) was used in all 
subsequent cell culture steps associated with huBC-1. 
2.2.5.2 Passaging of cells 
Cells were split at approximately 50-80% confluence. Culture medium was removed and 
cells were rinsed with sterile PBS. Cells were then detached with trypsin or 0.05% solution of 
EDTA (Sigma) by incubation at 37C for approximately 5 minutes. Cells were centrifuged at 
low speed (1500 rpm) for 2 minutes and the cell pellet was resuspended in fresh media. 
Cells were diluted to an appropriate level in a fresh 25ml culture medium. 
 
89 
 
2.2.5.3 Cryopreservation and resuscitation of cell lines 
For storage, cells were trypsinised as above, washed once by centrifuging at 1500rpm for 2 
minutes and then resuspended in a sterile PBS. The cells were then re-centrifuged and 
resuspended in FCS containing 10% DMSO. Cells were aliquoted and frozen at -80C in a 
Nalgene Cryo freezing container containing isopropanol overnight, and then transferred into 
liquid nitrogen for long-term storage. Resuscitation of cells was achieved by rapidly thawing 
vials at 37C before resuspension in culture medium in 75cm2 cell culture flasks with 
approximately 15ml culture medium.  
2.2.5.4 Counting viable cells 
A 10µl of cell suspension (in 2 ml of buffer) was added to 90 µl of trypan blue solution 
(Sigma). Cells were visualised in a haemocytometer under light microscopy. Trypan blue 
stains dead cells blue whereas viable cells appear white. The number of viable cells per ml of 
the original solution was calculated according to the following equation: 
Number of viable cells per ml  
 = average number viable cells x 104 X 10 (dilution factor) X 2 (cell suspension volume) 
 
2.2.6  Protein analysis and characterisation 
2.2.6.1 SDS - Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Polyacrylamide gels were cast in the supplied gel-casting apparatus according to the 
manufacturer’s instructions (Bio-Rad), typically consisting of a resolving gel of 12% resolving 
gel resolving (4ml acrylamide/bis, 2.5ml 1.5M Tris/HCl pH 8.8, 100l 10% SDS, 3.3 ml 
distilled water, 100l 10% APS, 4µl TEMED) and a 5% of stacking gel (833 µl  acrylamide/bis, 
630 µl 0.5M Tris/HCl pH 6.8, 50l 10% SDS, 3.4 ml distilled water, 50l 10% APS, 5l TEMED. 
Protein samples were boiled in SDS loading buffer, loaded onto SDS-PAGE gel wells and 
electrophoresed at 20mA per gel in SDS running buffer to achieve separation of proteins 
(approximately 1 hour). Gels were either stained with Coomassie blue and visualised 
following destaining for several hours in SDS-PAGE destaining buffer or western blotted as 
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described below. Coomassie-stained protein gels were scan or dried by soaking the gels in 
1% glycerol, placing them between sheets of wet gel drying film (Promega) and securing the 
film tautly over a frame until dry.  
2.2.6.2 Western blotting 
Acrylamide gels were soaked in transfer buffer for at least 10 minutes along with filter paper 
(Bio-Rad) and a nitrocellulose membrane (Hybond C, GE Healthcare). Then the filter papers, 
nitrocellulose membrane and the gel were assembled on the bed of the transblotter (Bio-
Rad Semi-Dry Transfer Cell) with care taken to eliminate any air bubbles. Gels were 
electrophoresed at a constant potential of 15 volts for 45 minutes to transfer the proteins to 
the nitrocellulose membrane. The membrane was then blocked in 3% Marvel/PBS for 1 hour 
at 37C or at 4C overnight. The membrane was incubated with the primary antibody at an 
appropriate dilution (section 2.1.5) for 1 hour at room temperature, followed by the 
secondary antibody. Between antibody incubations, the membrane was washed in three 
changes of PBS/0.1% Tween-20 followed by three changes of PBS. The membrane was 
developed using the GE Healthcare ECL detection kit according to the manufacturer’s 
instructions. 
2.2.6.3 Enzyme-Linked Immunosorbant Assay (ELISA) 
2.2.6.3.1 Fixed antigen ELISA 
Microsorb 96-well flat-bottomed plates (Nunc) were coated with 100l of antigen at 
10ug/ml in PBS and left overnight at 4C or 2 hours at 37 °C. Following the incubation, the 
plates were washed twice with PBS and blocked by the addition of 300l 3% milk protein 
solution (Marvel) in PBS for 2 hours at 37C and then washed 3x with PBS. 100 µl of BC-1 
antibody was added in a dilution series with the highest concentration of 200 µg/ml 
followed by 2-fold dilution of 10 concentrations. The plate was incubated at 1 hour at room 
temperature. The wells were treated with three washes of PBS/Tween and three washes of 
PBS, followed by incubation with the further detection antibodies (100 µl/well) as necessary 
at an appropriate dilution (section 2.1.5). Each antibody incubation step was carried out at 
37C for an hour, and wells were washed between each incubation as before. Development 
was achieved by adding 100l BM-Blue POD substrate (Roche) to each well, incubated ~30 
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mins at room temperature. The reaction was stopped by the addition of 100l 1M HCl. 
Absorbance were read at 450nm using a BioRad ELISA plate reader.  
2.2.6.3.2 Biotinylated ELISA 
Biotinylated ELISA was carried as fixed antigen ELISA (above) but with additional steps. The 
microsorb 96-well flat-bottomed plates (Nunc) were coated with 100l of strepavidin at 
10ug/ml in PBS and left overnight at 4C or 2 hours at 37 °C. Following the incubation, the 
plates were washed twice with PBS and blocked by the addition of 300 l 3% milk protein 
solution (Marvel) in PBS for 2 hours at 37C and then washed 3x with PBS. 100 µl of 
biotinylated antigen at 10 µg/ml in PBS and washed three times with PBS. 100 µl of BC-1 
antibody was added in a dilution series with the highest concentration of 200 µg/ml 
followed by 2-fold dilution of 10 concentrations. This was followed by incubation with the 
further detection antibodies (100 µl/well). At each steps the plate was incubated at 1 hour 
at room temperature and the wells were washed between each incubation with three 
washes of PBS/Tween and PBS. Development was achieved by adding 100 l BM-Blue POD 
substrate (Roche) to each well, incubated ~30 mins at room temperature. The reaction 
stopped by the addition of 100l 1M HCl. Absorbance was read at 450nm using a BioRad 
ELISA plate reader. 
2.2.6.4 Biotinylation of antigen 
EZ-Link™ Sulfo-NHS-LC-LC-Biotin (Pierce) was made up to 10mM in ultrapure distilled water. 
Each antigen fragments of a 1 mg/ml protein concentration was biotinylated at molar 
coupling ratios of 1:1 in a 1 ml total volume. The reaction was allowed to proceed for 1 hour 
at room temperature. Excess biotinylation reagent was then removed using PD10 column. 
Aggregated protein was removed by centrifugation and protein concentration measured by 
BCA assay. HABA assay was used to assess biotin: protein substitution ratio.  
The Sigma HABA/Avidin reagent system was used to estimate the level of biotin 
incorporation into the fibronectin fragments. HABA is a dye that binds to avidin and can be 
displaced by biotin in stoichiometric proportions with a particular extinction coefficient at 
500 nm. Biotinylated samples were added to the HABA/Avidin reagent in a ratio 1: 10. The 
O.D. at 500nm of the HABA/Avidin with sample is subtracted from the corrected control 
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value and the change in absorbance is determined. The change in absorbance is decided by 
the molar extinction coefficient of 34 and multiplied by a factor of 10 to account for dilution, 
to obtain the µmole biotin/ml of sample. The ratio of biotin to sample is determined by 
dividing the number of µmoles of biotin per ml of sample by the µmoles of protein per ml of 
sample. 
2.2.6.5 Surface plasmon resonance (BIACore) 
BIACore analysis was carried out with the fully automated flow cell system BIACore 3000. 
The biotinylated fibronectin fragments were immobilised in separate flow cells of a 
streptavidin-coated carboxy-methyl dextran chip. Flow cell 1 and 3 were used as the 
negative control, onto which 750RU of ED-B negative fibronectin fragment (containing 
domains 7, 8 and 9) was immobilised. The positive antigen fragment (containing domains 7, 
B, 8 and 9) was immobilised onto flow cell 2 and 4 to give 1000 response units (RU), so 
equimolar amounts of antigen were utilised, taking into account the difference in molecular 
size between the antigen fragments. 
Regeneration scouting was conducted to determine under what conditions would strip any 
remaining bound antibody, without irreversibly denaturing the antigen. This was achieved 
using 100mM TEA, followed by a 10 minutes injection of buffer only to allow regeneration of 
the antigen.  
Kinetic study was performed with a 'kinetic wizard' function which allows the application of 
increasing concentration of antibody and measuring the kon and koff rates plus regeneration 
between runs. To gain kinetic data the number of response units required on application of 
the antibody is ideally between 200-1000 RU.  Each experiment is conducted in duplicate 
with all samples applied in PBS with 0.005% Tween. The antibodies were applied at a range 
of concentrations spanning their estimated Kd.  The huBC-1 IgG was applied to flow cells 1 & 
2 at the concentration range of 83.3-1.30 nM. The huBC-1 scFv was applied to flow cells 3 & 
4 at the concentration range of 625-9.79 nM.  
Binding of the antibodies to the negative control antigen (flow cell 1 & 3) was subtracted 
from the binding obtained from the positive antigen (flow cell 2 & 4) in order to calculate 
final dissociation constant (Kd) values. Analysis was carried out with BIAEvaluation software. 
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2.2.6.6 Flow cytometry 
The media was removed from the flasks and the cells were rinsed with a sterile PBS. Cells 
were detached by addition of 0.05% solution of EDTA followed by an incubation at 37C for 
approximately 5 minutes. Cells were centrifuged at low speed (1800rpm, 10 minutes, 4°C) to 
pellet the cells which were then washed twice in ice cold PBS containing 2% dFCS, 1 mM 
EDTA. Following the second wash, cells were resuspended in ice cold PBS/ 2% dFCS / 1 mM 
and tumbled for 1 hour at 4 °C to block the cells. Cells were then aliquoted into the required 
number of samples and centrifuged to recover the blocked cells (14,000 rpm, <1 minute). 
Each cell sample was resuspended in 50-100 µl of the primary antibody at a concentration 
of 100 μg/ml diluted in PBS/2%FCS/1mM EDTA and tumbled for 1 hour at 4 °C as before. 
The cells were centrifuged as above and washed 3 times in ice cold PBS/ 2%FCS/ 1 mM 
EDTA, interspersed with spins of 2000rpm for 2 minutes. This process was then repeated for 
primary and secondary detection antibodies (if required). Following the final three 
PBS/2%FCS/1mM EDTA washes, each cell sample was washed once in ice cold PBS only, 
then resuspended in 500μl ice cold PBS. Samples were analysed using a single laser at an 
excitation wavelength of 460-500nm, using a FACS Caliber Instrument (FACS, Fluorescence-
Activated Cell Sorter), Centre for Microbiology and Molecular Infection, Imperial College, 
South Kensington Campus. 
Analysis of the data was done using Flow Jo analysis software. For each data set, the 
bar was fitted to the cells alone and cells plus detection antibody negative control samples, 
where 95% of the cells to the left of the bar are considered to be non-binders and the 
remaining 5% of the cells fall under the bar. The fluorescent intensity was determined and 
this value which represent the number of cells that display antibody binding. 
2.2.6.7 Analysis of enzyme stability 
2.2.6.7.1 Thermal stability 
The hCβG enzymes were incubated at various temperatures (0, 25, 37, 43, 50 and 100 °C) 
for 15 mins. Following the incubation, the residual hCβG activity was measured using 
continuous pNPGlc assay (see section 2.2.6.9.2). Reactions were set up in duplicates, 
containing 1µg of each enzyme variant and 10mM pNPGlc; followed by the standard 
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continuous pNPGlc assay. This is to show that the mutations have not destabilised the 
enzymes. The temperature range was selected to have a good representative of the assay.  
2.2.6.7.2 Protease stability 
All the hCβG enzymes were treated with trypsin or chymotrypsin (Sigma, prepared as 
1mg/ml stock) separately in a tube. The reaction was done as recommended by the 
manufacturer in a ratio of 1:50 (trypsin: hCβG enzyme). Although protease cleavage could 
take 5 minutes as mentioned by the manufacturer (Sigma), reaction was incubated for 2 
hours at 37 °C to ensure maximum exposure. Following this, the samples were loaded onto 
SDS-PAGE gel. 
2.2.6.8 Structural computer modelling  
All computer modelling was done using Pymol program http://www.pymol.org/. Pymol is a 
powerful tool for protein modelling and allows interactive molecular visualisation of the 
protein.  
2.2.6.9 Analysis of enzyme activity  
2.2.6.9.1 End-point assay 
Reactions were set up in triplicates containing between 0.2-20mM pNPGlc substrate and 
5μg enzyme in pNPGlc assay buffer, in a final volume of 500μl. The reactions were 
monitored at regular time points by removal of 30l from the reaction and immediately 
discharging it into 270l of pNPGlc stop buffer before measuring the absorbance at 400nm. 
The rate of reaction for each substrate concentration (v0) was calculated in absorbance units 
per minute (abs/min) by plotting the absorbance of each stopped reaction versus the time 
at which the sample was taken and subjecting the data to linear regression. 
2.2.6.9.2 Continuous assay 
Reactions were set up in triplicates using the 96-well microtitre plates. Each reaction 
contained pNPGlc substrate at a range of concentration between 0.2-20mM and 1μg 
enzyme in a final volume of 100μl. The substrate was pre-equilibrated at 37 °C, then 
immediately on addition of enzyme, the reaction was placed into an ELISA plate reader 
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(SpectraMax 340PC, Molecular Devices), also pre-equilibrated at 37°C. The plate reader was 
programmed to mix the reaction by shaking and take an absorbance measurement at 
400nm every 30 seconds for 5 minutes to yield a plot of absorbance versus time 
(SoftmaxPro® 3.1.1). The rate of reaction for each substrate concentration (v0) was 
calculated in absorbance units per minute (abs/min) by subjecting the data to linear 
regression. 
2.2.6.9.3 Data analysis 
β-glucosidase enzyme activity was assayed by measuring the release of p-Nitrophenol (pNP) 
from the substrate p-Nitrophenyl--D-glucopyranoside (pNPGlc). The reciprocal value of the 
rate (1/v0) was plotted against the reciprocal substrate concentration (1/[S] or 1/ [pNPGlc]) 
in a Lineweaver-Burk plot. Linear regression of this data yields an equation in the form y = 
mx + c that allows calculation of Vmax and Km as follows: 
 
y = mx + c            OR          
1
𝑣0
=  
1
𝑉max
+  
𝐾m
𝑉max
1
 [S]
 
Therefore,   
   𝑉max =  
1
c
  ; (c = y-intercept) 
and   
 𝐾m =  𝑉max  ×  m ;   (m =gradient) 
 
The extinction coefficient for p-nitrophenol (pNP) is 18,300 M-1cm-1and can be used to 
calculate the amount of pNP released during each assay as follows: 
1 M of pNP = 18, 300 Absorbance Unit (AU) at 1 cm. In a 96-well microtitre plate set up, 100 
µl total volume of reaction gave the height of liquid of 2.5 mm.  
Therefore in that reaction, 1 M of pNP = 4575 AU at 2.5 mm. 
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Hence, 1 AU of reaction in microplate gave 219 µM pNP. 
So,  
Amount pNP (nmol) = (absorbance – blank absorbance) x 219 µM 
 
The hCβG enzyme has a Molecular weight (MW) = 53 000.  
Therefore, 1 µg of enzyme = 0.0189 nmoles 
Thus, the turnover number for the enzyme can be calculated as follows; 
 
 𝑘cat =  
𝑉max
Et
    
 
2.2.6.9.4 Cyanide assay 
The production of cyanide was assessed using a modified version of that used by Lambert et 
al (1975). Reactions were set up in duplicates, containing 5g of each enzyme variant and 
10mM linamarin diluted into 0.1M sodium acetate buffer (pH 7.4) in a final volume of 500μl. 
Enzyme samples were extensively dialysed into the same buffer prior to the assay. The 
negative control reaction contained 0.1M sodium acetate buffer or unrelated protein [e.g. 
bovine serum albumin (BSA)] in replace of the enzyme sample. Likewise, for the positive 
control reaction, cassava linamarase or potassium cyanide were used instead. Reactions 
were left overnight at 37C in sealed tubes, and then tested for the presence of cyanide at 
certain time points post-reaction. In a fume hood, 225μl of succinimide buffer (containing 
10mg/ml succinimide and 1mg/ml N-Chlorsuccinimide) was placed into a 96-well microtitre 
well plate and 30µl of the reaction was added into it to immediately block the cyanide 
groups. The assay was developed by addition of 45μl freshly prepared barbituric 
acid/pyridine reagent (0.06g/ml barbituric acid, 0.3ml pyridine and 0.7ml distilled water). 
Reactions were left to stand for 10 minutes at room temperature, before measuring the 
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absorbance at 562nm versus the buffer-only control. N.B. Appropriate lab coat, gloves, 
protective eyewear and mask were applied when performing cyanide assay. Experiments 
were carried out in a fume hood all the time in. 
2.2.6.9.5 Data analysis 
Cyanogenesis of β-glucosidase enzyme was assayed by measuring the release of cyanide 
(CN) from the substrate linamarin.  
Based on the potassium cyanide standard curve generated (Figure 5.13), a 300µl total 
volume of reaction in a 96-well microtitre plate gave  the following;  
1 M of CN = 4923 Absorbance Unit (AU). Therefore in that reaction, 1 AU of CN = 203 µM. 
So, 
Amount of CN = (absorbance – blank absorbance) x 203 µM 
 
The hCβG enzyme has a Molecular weight (MW) = 53 000.  
Therefore, 1 µg of enzyme = 0.0189 nmoles 
The plant linamarase has MW=63 000. Therefore, 1 µg of plant linamarase = 0.0159 nmoles. 
Thus, the turnover number for the enzyme can be calculated as follows;  
 
𝑘cat =  
𝑉max
Et
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2.2.6.9.6 Cell kill assay 
Cells were grown as described previously. Cells were detached using a trypsin solution, 
centrifuged at low speed (1500rpm, 2 minutes) and resuspended in sterile PBS. Cells were 
counted (as above), seeded into 96-well tissue culture-treated plates at the required density 
(typically 5000 cells/well) and incubated overnight at 37°C, 5% CO2 overnight. Following 
growth and attachment, cells were washed gently in sterile PBS. Cells were then treated 
with enzyme and substrate (linamarin), incubated at 37°C, maximum 48 hours before being 
assayed for percentage of cell survival using CellTiter 96® AQueous One Solution Cell 
Proliferation Assay kit (Promega). The CellTiter 96® AQueous Assay is composed of solutions 
of a novel tetrazolium compound [3-(4, 5-dimethylthylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(-4-sulfophenyl)-2H-tetrazolium, inner salt; MTS and an electron 
coupling reagent (phenazine methosulfate; PMS). A small amount of MTS solution (20 
µl/well) was added directly to culture wells, incubated for 2 hours before reading the 
absorbance at 490nm. MTS is bio-reduced by dehydrogenase enzyme in metabolically active 
cells into formazan product. The quantity of formazan product is measured by the 
absorbance at 490nm and this is directly proportional to the number of living cells in 
culture. The respective positive and negative controls were included in the assay. 
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3.1 INTRODUCTION   
BC1 antibody was first selected as a murine monoclonal immunoglobulin (muBC-1 IgG) by 
(Carnemolla et al. 1989) and as has been discussed in great detail in section 1.4.1. 
Biodistribution studies in mouse models have shown that muBC-1 IgG is ideal for targeting 
FN7B89 in the tumour vasculature (Mariani et al. 1997). However, due its murine origin, 
some immunological reactions may be observed in patients through production of human 
anti-mouse antibodies (HAMA) (Colcher et al. 1990, Schroff et al. 1985, Yokota et al. 1992). 
Therefore, the future of its clinical application was questionable. Following this concern, 
steps were taken to humanise muBC-1 IgG in order to make it less immunogenic in patients. 
Humanisation was done through CDR-grafting by Antisoma Plc. but subsequent drawbacks 
were encountered with the IgG format of the humanised antibody (huBC-1 IgG). Although 
IgG has a high affinity and longer retention rates (avidity) at tumour sites, they are known to 
have poor tumour penetration and slow blood clearance rates. Both these factors are 
undesirable in AGENT application and therefore further steps were taken to improve this 
antibody for AGENT.  
 From the AGENT point of view, the size of scFv gives it an advantage to be 
manipulated in cloning for genetic fusion with enzyme. This allows expression of a single 
fusion protein with a smaller total protein size which would otherwise be too large if IgG 
was used. If a whole IgG is used, the total size of the fusion protein could be > 200 kDa and 
this would affect the pharmacokinetics of the fusion protein e.g. slow clearance rate, low 
tumour penetration. These prompted the study by Harman (2006) to reformat the huBC-1 
IgG into a scFv through PCR cloning.  The construct composed of a heavy and light chain 
variable domain cloned into the pHEN2 vector. The pHEN2 vector consists of lac promoter, 
followed by pelB leader sequence for extracellular protein secretion.. The heavy and light 
chains are linked by the commonly used 15 amino acid glycine-serine (G4S)3 linker sequence 
(Huston et al. 1988) and consists of C-terminal hexa-histidine and myc-tags for purification, 
followed by amber stop codon and phage gene III sequence (Figure 3.1).  
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Figure 3.1: Schematic diagram of pHEN2-huBC-1 scFv. The lacP=lac operon promoter, 
RBS=ribosomal binding site, pelB= secretion signal, VH=heavy chain, Linker= interdomain linker 
sequence, VL=light chain, STOP= amber stop codon, His=hexa-histidine tag, myc=myc-tag, gIII=phage 
coat protein gene III, colE1 ori=bacterial origin of replication, M13 ori=phage origin of replication and 
AmpR=ampicillin resistance gene. 
 
 
The recombinant fibronectin fragment consists of domains 7, 8, 9 and (± EDB); is the 
smallest complete portion of the fibronectin molecule that is required to allow antibody 
binding to the cryptic epitope (Carnemolla et al. 1989). The sub-gene was cloned into 
plasmid pQE-12 under the control of T5 promoter. The clones were a kind gift from 
Professor L. Zardi, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy and obtained in 
bacterial strain JM109. The plasmid contains C-terminal histidine tag and thus, it was 
particularly crucial that the huBC-1 scFv contains a myc-tag that allows differential detection 
of the protein simultaneously during characterisation.  The presence of both the antigen 
positive, FN7B89 (fibronectin containing ED-B) and antigen negative, FN789 (fibronectin 
without ED-B) allows direct comparison of antibody binding to tumour and normal 
fibronectin antigens.   
ELISA and BIACore are two assays that provide the estimation value of antibody 
equilibrium dissociation constant (Kd). This allows affinity comparison among the different 
formats of antibody. In this way, the effect of reformatting on the antibody could be 
compared directly, in this case scFv to IgG. Owing to the monovalency, scFv would be 
expected to have a lower affinity compared to the bivalent IgG. However, the Kd value 
although significantly lower should still be within the range of 10-6 to 10-10 M and would still 
confer specificity to antigen. Unlike ELISA, BIACore has greater advantages in such a way 
that the antibody binding is measured in real-time. In addition, the experiment was done in 
a flow system which would more closely reflect the physiological binding conditions in 
 pelB  VH linker VL STOP myc His gIII RBS lacP 
                      pHEN2 
 AmpR colE1 
ori 
M13 ori 
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humans. BIACore uses Surface Plasmon Resonance (SPR)-based optical method that occurs 
in thin conducting films at an interface between media of different refractive index. In the 
BIACore system, the media is the glass of the sensor chip and the sample solution, the 
conducting film is a thin layer of gold on the sensor chip surface. This surface forms the floor 
of a small flow cell, through which an aqueous solution (running buffer) passes under 
continuous flow (1-100 µL/min). In order to detect an interaction, a ligand is covalently 
immobilised onto the carboxymethylated dextran gold surface.  Its binding partner (analyte) 
is injected in aqueous solution through the flow cell, also under continuous flow. As the 
analyte binds to the ligand, the accumulation of protein on the surface results in mass 
increase within the matrix. This leads to an increase in the refractive index (RI) near the 
sensor surface. The change in RI is measured in real time and the result is plotted as 
response or resonance units (RUs) versus time (a sensorgram) (van der Merwe and Barclay 
1996, BIACore Oct 2003). From this, the rate of association (kon, M
-1s-1) and dissociation (koff, 
s-1) can be obtained. This would indicate how fast the antibody binds to the antigen (kon) and 
how fast the antibody takes to dissociate from the antigen (koff). This is particularly 
important as antibodies could have the same Kd value but different kon and koff rates. 
Depending on the nature of the study, the relevance of koff value varies. In this study, 
because the antibody binds to surface antigen, a slow koff is desirable to allow sufficient 
active cytotoxic molecules to be activated by the enzyme at the tumour sites.  
Aims 
This chapter aims to generate and characterise huBC-1 scFv antibody. The antibody would 
be used as a vehicle to direct the enzyme to the targeted tumour sites in AGENT. 
Objectives 
 To express huBC-1 scFv in E. coli  
 To optimise the purification method 
 To assess the binding affinity and specificity of huBC-1 scFv for recombinant antigen 
peptide and cell-secreted antigen in relation to the parental IgG antibody 
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3.2  RESULTS 
3.2.1 Expression and purification of recombinant antigen fragments 
In order to evaluate the huBC-1 scFv antibody binding affinity and specificity, fibronectin 
antigens were expressed cytosolicaly in plasmid pQE-12 under the control of T5 promoter.  
Both the fibronectin antigen clones consist of fragments 7, 8 and 9. However, in the positive 
antigen fragment, FN7B89, an extra domain B was inserted between fragments 7 and 8 
(Figure 1.8) whereas, in the negative antigen fragment, FN789, this domain was absent. 
Insertion of extra domain B in the fragment mimics what would appear in most ED-B 
positive cancer cells. FN789 was used as negative control in the characterisation of huBC-1 
scFv along side with FN7B89. 
Protein expression was carried out as detailed in section 2.2.3. Cells were harvested, 
lysed using cell disrupter, dialysed and Ni-IMAC purified as detailed in 2.2.3.3 and 2.2.4.2. 
Samples from the purification were analysed using electrophoresis by reducing SDS-PAGE 
and stained with Coomassie blue and anti-His antibody for the western blot (Figure 3.2).   
 
                                                                                      
        
 
     
            
 
 
 
 
Figure 3.2: Purification of fibronectin fragments for both FN7B89 (positive antigen containing ED-Β 
splice variant of fibronectin) and FN789 (negative antigen without the ED-Β). SDS-PAGE gels 
analysed by (A) Coomassie staining and (Β) anti-His6 western blot. M=marker; CL=cleared lysate; 
FT=column flow through; W=PBS/NaCl wash; E1-E2=elution fractions (200mM imidazole). The 
positive fibronectin can be seen at approximately 55 kDa and the negative antigen at 35 kDa as 
expected. 
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Both the FN7B89 and FN789 eluted samples showed a dominant band of 55 kDa and 35 kDa 
respectively of > 90% purity. On average, the yield of protein expression for both antigens 
was approximately 4-6 mg/L of bacterial culture. The samples were buffer exchanged into 
sodium phosphate pH7.4 to remove imidazole to avoid protein aggregation and stored at -
80°C. These proteins were used in the characterisation of huBC-1 scFv described in this 
chapter. 
3.2.2 Expression of recombinant huBC-1 scFv antibody 
Humanised BC-1 scFv was previously cloned in pHEN2 vector and obtained in the bacterial 
strain HB2151 (Harman 2006).  The DNA and corresponding amino acid sequence of huBC-1 
scFv can be found in Appendix 1.  Certain biophysical parameters of huBC-1 scFv are shown 
in Table 3.1. It is a 30 kDa protein with a theoretical pI of 6.23. Expression of huBC-1 scFv 
was carried out as described in section 2.2.3.  
Parameter value 
Theoretical pI 6.23 
Molecular weight (kDa) 30.4 
Number of amino acids 285 
Extinction coefficient (M-1cm-1) 51590 
Abs (0.1%) =1g/L 1.695 
 
Table 3.1: Basic biophysical properties of huBC-1 scFv. The data derived from ExPASy ProtParam 
Tools, Swiss Institute of Bioinformatics (http://expasy.org/tools/protparam.html). 
 
3.2.3 Purification of huBC-1 scFv 
3.2.3.1 FN 7B89 antigen affinity chromatography 
An initial attempt to purify huBC-1 scFv was made using antigen affinity chromatography. In 
this approach, FN 7B89 antigen to which the huBC-1 scFv antibody binds specifically was 
attached to activated CH Sepharose 4B beads (Amersham Biosciences), as described in 
section 2.2.4.3.1. The logic behind this approach was that the antigen column would confer 
specific and functional antibody capture compared to Immobilised Metal Affinity Column 
(IMAC). However, the approach suffered from antigen contamination during elution of the 
antibody due to loss of antigen from the column (data not shown). Thus, more antigen 
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needed to be coupled to the column in a more stable way. In addition, the eluted scFv was 
of a low yield. This method would have been ideal for the scFv and subsequent fusion 
protein, but due to its unreliability, was not pursued. 
3.2.3.2 Immobilised metal affinity chromatography (IMAC) using Cobalt 
Further attempts to purify the huBC-1 scFv were made using Talon® metal affinity resin 
(Clonetech) which has cobalt immobilised onto chelating Sepharose. The huBC-1 scFv 
concentrated supernatant was pre-incubated with Talon® resin for 1hr at room temperature 
or overnight at 4°C with gentle agitation to maximise the binding, as described in section 
2.2.4.1.  Eluted fractions were analysed electrophorectically using reduced SDS-PAGE gel 
and stained with Coomassie blue and western blot using anti-His antibody (Figure 3.3). The 
eluted huBC-1 scFv showed the expected band of approximately 30 kDa with poor purity 
(20-30%). 
 
  
 
 
 
 
Figure 3.3: Purification of huBC-1 scFv using IMAC. SDS-PAGE gels analysed by (A) 
coomassie staining and (Β) anti-His6 western blot. M=marker; C=concentrated supernatant; 
FT=column flow through; W=PBS/NaCl wash; E1-E9=elution fractions (200mM Imidazole). 
The huBC-1 scFv can be seen at approximately 30 kDa as expected (arrow). 
 
Figure 3.3: Purification of huBC-1 scFv using IMAC. SDS-PAGE gels analysed by (A) Coomassie 
staining and (Β) anti-His6 western blot. M=marker; C=concentrated supernatant; FT=column flow 
through; W=PBS/NaCl wash; E1-E9=elution fractions (200mM Imidazole). The huBC-1 scFv can be 
seen at approximately 30 kDa as expected (arrow). 
 
 
3.2.3.3 Anti-myc 9E10 chromatography 
Due to poor purity, further steps were taken to improve the purity of the antibody by 
manipulating the myc-tag. An anti-myc immuno-affinity column was prepared as mentioned 
in section 2.2.4.4. This allowed the capture of myc-tagged huBC-1 scFv. It should be noted 
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that prior to this second step of purification, the eluted samples from the primary Cobalt 
IMAC were first buffer exchanged to sodium phosphate, pH7.4 to remove Imidazole,  
therefore preventing interference with the antibody binding to the 9E10 column. Antibody 
was eluted with 0.2 M glycine with decreasing pH. Most of antibody was eluted at pH 2.5. 
(Figure 3.4). The eluted samples were analysed with under reduced SDS-PAGE as before. 
                                                              
                                                                       
Figure 3.4: Purification of huBC-1 scFv by anti-myc column. SDS-PAGE gels of purification fractions 
analysed by (A) Coomassie blue and (Β) anti-His6 western blot. M=marker; FT= column flow through; 
W= PBS/NaCl wash; E1-E7=elution fractions (pH 2.5-3.0; 0.2M glycine). The huBC-1 scFv can be seen 
at approximately 30 kDa as expected (arrow). 
 
From the SDS-PAGE gel, it was shown that the huBC-1 scFv was 99% pure with the 
correct molecular size. The eluted samples were neutralised with 1M Tris-HCL, pH8 to a final 
concentration of 50mM, dialysed into PBS and stored at -80°C. It is proven that the anti-myc 
9E10 column is the most suitable column to obtain the huBC-1 antibody with highest purity 
with no contamination. This was shown both in the Coomassie blue staining and western 
blot with anti-his antibody. Subsequently, anti-myc 9E10 column was employed as a single 
step for huBC-1 scFv purification in order to minimise the loss of protein in two- step 
purification.  The result from the single step purification with 9E10 column was comparable 
to the two-step purification with a better yield than in the former (data not shown).    
3.2.4 Binding studies of huBC-1 scFv  
3.2.4.1 Immobilised antigen ELISA 
This section describes the characterisation of huBC-1 scFv antibody. This involves 
determination of antibody binding affinity and specificity relative to their parent IgG. Owing 
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to the monovalency, the scFv antibody is expected to have a lower functional affinity but 
still retains the specificity compared to the parental format. However, scFv antibody and 
subsequent fusions should penetrate tumours more efficiently due to their relative size and 
thus have improved tumour targeting.  
Both the antibodies were added at the same molarity. Therefore, the scFv was 
applied at a starting concentration of 100 µg/ml (3.3 µM) compared to the whole IgG       
500 µg/ml (3.3 µM), which was due to the difference in format. The binding curves were 
plotted, hence allowing estimation of the dissociation constant Kd for each antibody species 
(Figure 3.5). The graphs show a sigmoidal curve which is characteristic of a one phase ligand 
association with saturation at the high concentration. The mid-points of these graphs give 
an estimation of equilibrium dissociation constants, Kd. This value indicates the 
concentration of antibody at which half the amount of the fixed concentration of antigen is 
being bound.  The smaller the Kd value, the stronger the binding between the antigen and 
antibody and vice versa.  Based on the graph obtained, the estimated Kd values for scFv and 
IgG were 53 ± 0.07 nM and 4.0 ±0.05 nM, respectively (Figure 3.5 A & B). As expected, the 
bivalent IgG displays a higher affinity for the FN 7B89 antigen compared to its monovalent 
scFv counterparts. It was observed that there were discrepancies in the maximal absorbance 
values between IgG and scFv due to the differences in detection signals. Since the anti-HRPO 
detects the Fc region of the antibody, IgG was detected directly with anti-human HRPO 
while scFv was with mouse anti-myc and anti-mouse HRPO. It is also thought that there 
were more binding with IgG than scFv due to the difference in valency. 
As immobilised antigen ELISA was carried out with recombinant FN antigen, which 
was directly adsorbed to the plastic surface; it was thought that this process of immobilizing 
the antigen could possibility hinder or disrupt the conformation of the cryptic epitope to 
which the antibody binds. This could result in  higher Kd values than the true value. Thus, 
biotinylation of antigen was done in order to allow the antigen to stay in the solution phase 
in the experiment setup and mimic that in nature. Also, biotinylation of FN antigen was 
done for the subsequent BIACore SPR analysis. 
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(B) huBC1 scFv binding by immobilised antigen ELISA
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(C) huBC-1 scFv binding by immobilised biotinylated antigen
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Figure 3.5: Analysis of huBC-1 binding by immobilised 
antigen ELISA. Binding to recombinant fibronectin 
fragments FN789 (red curve) and FN7B89 (blue curve) 
were analysed for (A) huBC-1 IgG; (B) huBC-1 scFv and 
(C) huBC-1 scFv on biotinylated antigen. Sigmoidal 
binding curves were fitted to give an estimation of Kd 
values. The IgG binds FN7B89 with the higher affinity 
compared to the scFv due to its increased valency. Error 
bars were calculated from the absorbance mean values 
of the triplicate samples (n=3) 
 
(A) huBC-1 IgG binding by immobilised antigen ELISA
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Kd =                  
4.0 ± 0.05 nM 
Kd =                
53 ± 0.07 nM 
Kd =                    
144.0 ± 0.15 nM 
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Biotinylation was carried out using Pierce EZ® Sulfo NHS LC-LC Biotin reagent. For 
recombinant 7B89 and 789 antigens, 1 ml of a 1 mg/ml protein concentration was 
biotinylated at molar coupling ratios (biotin:protein) of 1:1, 3:1 and 5:1. After biotinylation, 
free biotin reagent was removed by a PD10 gel filtration column. The HABA assay (section 
2.2.6.4) was used to assess the coupling efficiency to assess biotin: protein substitution ratio 
(Table 3.2).  
 
Biotin : protein HABA assay 
reaction ratio Biotin : protein substitution ratio 
 
FN7B89 FN789 
1 : 1 0.50 : 1 0.90 : 1 
3 : 1 3.24 : 1 3.16 : 1 
5 : 1 2.43 : 1 3.45 : 1 
 
Table 3.2: Biotinylation of FN7B89 and FN789 antigen. Biotin to protein coupling ratios is shown 
after various reaction conditions. 
 
These samples were then run on  SDS-PAGE gels and transferred onto nitrocellulose. The 
blots were probed in parallel with anti-His6 HRPO conjugate antibody and streptavidin HRPO 
conjugate to evaluate the integrity of biotinylated antigen (Figure 3.6). The bands were 
detected at expected size 55kDa and 35kDA for FN7B89 and FN789, respectively, indicating 
the presence of covalently biotinylated his-tagged fibronectin antigen. These signals seemed 
consistent with the HABA assay results. 
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Figure 3.6: Biotinylation of antigens. SDS-PAGE gels of biotinylated antigens by (A) anti-His6 western 
blot (B) extravidin HRPO. M, marker; 1:1, 1 molecule of biotin to 1 molecule of antigen ratio; 3:1, 3 
molecule of biotin to 1 molecule of antigen ratio, 5:1, 5 molecule of biotin to 1 molecule of antigen 
ratio.   
 
Based on the HABA assay and western blots, the ideal ratio of biotin to fibronectin antigen 
appears to be 3:1. In order to ensure that the biotinylated antigen is functional, ELISA was 
conducted as before with the biotinylated antigens. However, in this case, the Nunc™ 
Maxisorp ELISA plate was coated with Avidin at 20µg/ml, incubated overnight at 4 °C. 
Following a blocking step, the biotinylated samples of antigens were bound at a 
concentration of 10 ug/ml. The subsequent steps were the same as described before 
(section 2.2.6.3.2).  
The Kd value of scFv in the immobilised biotinylated antigen ELISA was almost 3-fold 
higher than non-biotinylated antigen ELISA (Figure 3.5 B & C) probably due to experimental 
variation or an affect of biotinylation on protein structure. It should also be noted that these 
Kd values were for an artificial ligand and likely to be only indicative of the true Kd values for 
the natural polymeric antigen. Taken together, these data illustrate the observation that it is 
the transformation from bivalent species to monovalent species that causes the decrease in 
affinity.   
 
             A         B          
 
 
 
                         
55 
 
34 
55 
 
34 
  FN 7B89               FN789   FN 7B89               FN789 
 M      1:1     3:1   5:1     1:1   3:1    5:1        
4      5         6 
M     1:1    3:1   5:1      1:1  3:1    5:1 
111 
 
3.2.4.2 Surface Plasmon Resonance  
Surface Plasmon Resonance (SPR) technology is a real-time detector to monitor 
biomolecular events, thus allowing quantitative kinetic measurements on the biomolecules 
being studied.  This technology monitors the formation and dissociation of biomolecular 
complexes on a sensor surface as the interaction occurs.  BIACore 3000 system is an 
instrument used in this study which employs SPR technology for measuring the interactions 
of macromolecules with each other and with small ligands.  
Taking the advantage of this technology, the binding kinetics and affinity of huBC-1 
antibody towards the biotinylated antigens were investigated on a streptavidin coated 
carboxyl-methyl (CMS) chip. The recombinant fibronectin antigen fragments allow 
simultaneously binding of the antibody to FN7B89 and FN789. Therefore, this would take 
into account any background binding to the negative antigen in its calculation of kinetic 
parameters. In the protocol used (see section 2.2.6.5) flow cell 1 and 3 were used as a 
negative control onto which FN789 was immobilised and flow cell 2 and 4 contained FN7B89 
immobilised to give 750 and 1000 response units (RU) respectively (equimolar amounts, 
taking into account the difference in molecular size between the antigen fragments). The 
huBC-1 IgG and scFv antibody were applied onto the chip surface at a range of 
concentrations spanning the anticipated Kd value and measurements were done in duplicate 
at a flow rate of 30 µl/min. Each binding cycle was followed by regeneration of the antigen 
chip by injection of 100 mM TEA, followed by an antigen recovery period in which buffer 
alone was flowed over the chip, the requirement for which was indicated by preliminary 
regeneration scouting studies.  
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Figure 3.7: BIACore analysis of huBC-1. (A) Concentration of IgG ranged from 83.3– 1.30 nM.  (B) Concentration of scFv ranged from 625-
9.79 nM. Graphs showed net positive antigen binding following subtraction of binding to the negative antigen using 1:1 Langmuir binding 
model.  The BIACore kinetics wizard was able to fit binding curves to the IgG and scFv binding data with chi-squared values of 9 and 5 
respectively which is well within the 10% of Rmax.  
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The graphs in figure 3.7 show both association and dissociation curves for binding of 
the huBC-1 IgG and scFv to fibronectin, respectively. For each antibody concentration, two 
curves were plotted representing the duplicate of two kinetic experiments. Each curve is the 
total net binding to the FN7B89 following subtraction of background binding to the FN789 at 
different concentrations of antibody.  The data fit best to a 1:1 Langmuir binding model with 
chi-squared values estimated to be 9 and 5 for IgG and scFv, respectively. This value gives an 
indication of the closeness of the fit. Therefore, any values within 10% of the Rmax are 
considered as good fit (Karlsson and Larsson 2004). 
 The Kd obtained for the huBC-1 IgG and scFv were calculated as 4.52 ± 0.11 nM and 
47.2 ± 0.57 nM respectively, showing 10 fold difference (Table 3.3). The IgG demonstrated a 
faster association rate (kon) and a slower dissociation rate (koff) which contributes to a better 
Kd. However, a slightly slower association rate was observed in scFv with a faster 
dissociation rate, resulting in a higher Kd constant. The phenomenon observed here was due 
to differences in the antibody format, the bivalent species of IgG and monovalent species of 
scFv. Nevertheless, the koff rate of scFv was just 2.4 fold difference from the IgG. The 
BIACore data is summarised in Table 3.3 in comparison with the previous ELISA data. 
From the BIACore assay, the affinity of the IgG was demonstrated to be higher than 
scFv, as expected. Due to this nature, it is assumed that huBC-1 IgG would require more 
stringent regeneration conditions to completely remove any residual antibody from the chip 
during each cycle as shown by Harman 2006. However this study successfully regenerated 
the chip exactly under the same conditions as with scFv by applying 100mM TEA without 
any additional steps.  
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k on
Antibody (1/Ms) (1/s) (nM) (biotinylated standard
antigen (nM)
(nM)
IgG 1.44 X 105 6.53 X 10-4 4.5 ± 0.11 ND 4.0 ± 0.05
± 0.08 ± 0.18
scFv 3.27 X 104 1.54 X 10-3 47.2 ± 0.57 144.4 ± 0.16 53.0 ± 0.07
± 0.20 ± 0.02
Fold difference 4.4 fold 2.4 fold 10.3 fold 0 13.3
of scFv in slower faster weaker weaker
comparison to IgG association dissociation binding binding
BIACore analysis                         ELISA
k off K d K d K d
 
Table 3.3: Summary of antibody binding parameters calculated by BIACore and ELISA. In the 
BIACore analysis, the IgG was shown to have faster association and slower dissociation rates in 
comparison to the scFv. The slower on and faster off rate of the scFv yielded higher Kd for this 
species. The Kd values estimated by standard and biotinylated antigen ELISA are included for 
comparison. (ND=not determined). 
 
 
It is well accepted that BIACore analysis provides a more accurate Kd value because 
the technique eliminates the dependence on antigen saturation during the antibody binding 
which is often the case with ELISA. However, the Kd values determined by BIACore were in 
agreement with those determined by ELISA method for both huBC-1 antibody formats as 
shown in Table 3.3. These data proved that the two techniques were comparable and the 
nature of antibody reduced affinity was due to kon/koff rate effects. Nevertheless, the affinity 
of the scFv still high (~50nM).  
3.2.4.3 Binding of huBC-1 scFv on live cells 
So far, the binding studies described above employed a small fragment of antigen 
fibronectin which harbours only few potential binding sites. Therefore, further steps were 
taken to determine the antibody binding study in live cells expressing the antigen of interest 
using flow cytometry. Live cells mimic the true nature of the cells in patient’s body and allow 
the specificity of antibody binding.  
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The flow cytometry was performed on three cell lines, 
1) WI38 (VA13), SV-40 transformed human fibroblast that expresses FN7B89 
2) U87, human glioblastoma (ED-B FN positive) 
3) KB cells, human carcinoma of the nasopharynx (ED-B FN negative) 
Both WI38 (VA13) and U87 cells express ED-B fibronectin while KB cells are ED-B negative 
and used as a negative control. The binding of huBC-1 IgG and scFv was tested using the 
method described in section 2.2.6.6.  Basically, the cells were grown to confluence, each 
preparation was treated with huBC-1 IgG and scFv at 3.33 µM (equimolar amount) followed 
by a fluorescently-labelled secondary detection antibody. Between the steps, series of 
washes were applied using PBS containing 2% dFCS. For all the cell lines, two negative 
controls were included; the cells alone control sample without any treatment of antibodies 
and cells treated with secondary antibody alone. IgG antibodies were detected using anti-
human IgG-FITC and the scFv was detected anti-myc followed by anti-mouse-FITC due to the 
differences in recognition sites by the detection antibody. In nature, the antigen is a 
secreted protein. However, it is assumed that some of the antigen protein would still remain 
as the cell surface associated during the secretion via the plasma membrane. Because flow 
cytometry is able to detect the cell surface protein, this approach was carried out to 
investigate the feasibility of this technique, also to detect the ability of antibody to bind to 
the ‘cell surface’ antigen protein. In addition, it provides a clue whether there was enough 
antigen protein produced on the cell surface to allow the antibody binding. 
Figure 3.8 summarised the overlay graphs of the flow cytometry data for the three 
cell lines. Firstly, the results showed that there is sufficient cell surface associated 
fibronectin antigen for binding of huBC-1 antibody. Both the huBC-1 IgG and scFv showed 
definite binding to ED-B positive WI38 (VA13) and U87 cell lines that were indicated by 
visible fluorescent shift/increase when compared to the control reactions containing cells 
alone and cells treated only with detection antibodies. No significant binding to ED-B 
negative KB cells.  The frequency of fluorescent cells within the whole sample indicates the 
antibody binding within the cell population. From the graph, both WI38 (VA13) and U87 
cells show significant frequency of binding compared to the negative control cell. 
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(A) WI38(VA13) cells     (B) U87 cells    (C) KB cells 
                          
                             
huBC-1 
IgG 
huBC-1 
scFv 
Figure 3.8: Overlay graph of flow cytometry data analysis of huBC-1 antibody binding to live cells expressing fibronectin containing ED-B.      
(A) WI38 (VA13) cell line. (B) U87 cell line. (C) KB cell line.  cell alone ,   cells detected with anti-human IgG FITC,    cells detected 
with huBC-1 IgG and anti-human IgG FITC,  cells detected with anti-myc and anti-mouse IgG FITC and  cells detected with huBC-1 
scFv, anti-myc and anti-mouse IgG FITC. The percentage represents the frequency of FL1-H + cells in the whole sample.  
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3.3  DISCUSSION 
With the aim of producing an immunofusion protein designed for AGENT, huBC-1 antibody 
scFv was constructed in pHEN2 vector consisting of a heavy and light chain (Harman 2006). 
This clone was expressed in HB2151 E. coli under lac promoter and secreted extracellularly 
via the pelB (Erwinia carotovora pectate lyase) leader sequence. This allows formation of 
disulphide bond at the periplasmic membrane and facilitates correct folding of the protein. 
The gene consist of a C-terminal hexa-histidine and myc-tag to facilitate purification 
(Harman 2006). 
This chapter describes the expression and purification of huBC-1 scFv using the 
previously optimised protocol in order to investigate its reproducibility and therefore 
allowing further characterisation of the antibody. Humanised BC-1 scFv was expressed 
soluble with poor yield of approximately 400-600 ug/L of bacterial culture. Previous studies 
have tried to investigate different methods to improve the expression system using 
different vectors and optimise the expression conditions. However, it has been found that 
the above mentioned is the most optimised method so far. Bacterial expression system 
offers great advantages compared to other systems because it is cost and time effective 
with ease to handle. However, there are some other possibilities that could be investigated 
to improve protein expression.  
Previously, (Harman 2006) investigated the use of pET27 vector and BL21 (λDE3) 
strain. The vector consists of T7 promoter, which is a strong expression tool and is expected 
to increase the protein yield. The huBC-1 scFv was expressed but not secreted 
extracellularly despite the addition of pelB sequence in the construct. It was suggested that 
the T7 promoter might have caused intracellular or periplasmic aggregation of the protein. 
It is possible to use an alternative bacterial strain to improve the yield of huBC-1 scFv in the 
pET vector. Bacterial strains that contain mutated versions of thioredoxin reductase and/or 
glutathione reductase such as BL21trxB (DE3) and OrigamiTM might offer some promise. 
These mutant cells allow disulphide bonds formation in the bacterial cytoplasm through 
accumulation of oxidized, enzymatically alkaline phosphatase in the cytoplasm (Prinz et al. 
1997, Bessette et al. 1999). This potentially allows a fully-folded and functional antibody to 
be produced intracellularly. Other alternatives could  include expression in other expression 
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systems such as yeast and mammalian cells. However, for the benefit of the future fusion 
protein work, it is best to keep the expression system of both antibody and enzyme in the 
same organism to avoid complexity. 
Protein yield is normally proportional to the cell mass of the host cells. Cell mass in 
turn equals cell density times the culture volume. By using a larger volume and increasing 
the cell density, huBC-1 scFv protein yield in pHEN2 vector could be increased. In laboratory 
settings, the culture volume is usually limited to culture flasks and cell density highly 
depends on the culture conditions and the growth medium. Changing culture conditions 
from shake flask to large-scale fermenter will potentially increase cell density 10 times or 
higher. A fed batch fermenter can reach a cell density of OD600= 30-50 for most E. coli 
strains. Under an optimised fermentation condition, OD600= 200-250 could be obtained. 
Other advantages of this method are the pH, temperature and aeration conditions, which 
are all controlled by the system.. Therefore, it provides consistent product and protein yield 
may be increased from microgram to milligrams per litre. The disadvantages to this method 
are the extensive protocol optimisation required for large scale production, its high costs 
and the difficulties for protein purification in a small laboratory set-up. Previously described, 
the huBC-1 scFv was purified by FN 7B89 antigen affinity chromatography (Harman 2006). 
The advantage of using this method is that protein contaminants or incorrectly folded scFv 
will pass through the column. Therefore, this column is useful for isolating functional 
proteins and reduces the probability of any non binding antibody. Thus, purification using 
this antigen column is expected to be better compared to other approaches. However, due 
to poor column capacity the yield of antibody was low and there was contamination from 
the FN7B89 antigen in the elution sample suggesting that the coupling of antigen to the 
Sepharose beads was not stable. This phenomenon was observed despite several repeats. 
Factors that may affect the coupling include pH, buffers, salt and temperature. Although 
antigen affinity column confers absolute advantage over other purification methods due to 
its binding specificity, this method consumes large amounts of antigen,  typically 6mg 
attached to the Sepharose beads. Also, the column is considered quite time consuming in 
relation to the need of expressing and purifying the antigen for the column.   
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Although antigen affinity is a good method, IMAC is more common due to the 
availability of C-terminal His6-tag. Therefore, purification was carried out using pre-charged 
cobalt and significant amount of huBC-1 scFv was obtained through this method. However, 
problems were encountered with removal of contaminating host proteins during the 
washes. This is because, IMAC is a low affinity chromatography with the Kd for the 
interaction between His6-tag and Cobalt estimated to about 10
-6 M at neural pH 6 compared 
to 10-8 to 10-9 M for antigen affinity column (Nieba et al, 1997). Thus, the antigen column is 
1000 times better affinity compared to IMAC. Also, many host proteins have intrinsic 
histidine and/or cysteine amino acid residues that allow non-specific host proteins to bind 
to the IMAC, competing with huBC-1 scFv for the same side binding sites on cobalt.  Because 
these protein contaminants occupying the column, they reduce the efficiency of huBC-1 
scFv binding and lead to contamination in the elution samples. These problems lead to 
another alternative purification strategy using myc-tag. 
Following unsuccessful attempts to get purified huBC-1 scFv, an alternative 
purification was devised using anti-myc 9E10 chromatography. This column manipulates the 
C-terminal myc-tag in huBC-1 scFv. The column proved to be the best one-step purification 
method in obtaining good yield and pure huBC-1 scFv. Although it has the high affinity of 
antigen-based column    (10-8 M), like the IMAC, it does not select for folded antibodies 
exclusively. After developing an alternative purification method to that described before 
(Harman 2006), it was necessary to re-evaluate the binding of the scFv to ensure that the 
affinity was comparable. In the antigen affinity column used previously, only functional scFv 
was purified. However in this study, anti-myc column resulted in a mixture of soluble scFv to 
be obtained. It was assumed that the affinity of scFv from the anti-myc column could be 
worse as there was a mixture of functional and non-functional scFv in the eluted samples. In 
spite of this, characterisation of the scFv from anti-myc column showed that the antibody 
was comparable to the one previously from an antigen affinity column. 
Initial characterisation of huBC-1 scFv was carried out using standard ELISA and 
BIACore analysis. Since the recombinant fibronectin fragments were available in both the 
positive and negative EDB, this allowed direct comparison of the specificity of antibody 
binding. Previous studies have shown that muBC-1 IgG is specific to a cryptic epitope in 
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FN7B89 and not FN789, through immunohistochemical analysis (Carnemolla et al. 1989). 
Nonetheless, no dissociation constant has been reported so far. Harman (2006) failed to 
show any antibody binding using antigen coated directly onto immunosorbant micro-titre 
plates. It was thought that the process of coating the assay plates directly with the antigen 
may in some way make the cryptic epitope on the antigen inaccessible to the antibody. 
However, this thesis eliminated this issue and obtained an estimated Kd value for both 
huBC-1 IgG and scFv antibody in agreement with BIACore analysis. The Kd value is an 
important parameter as mentioned before to investigate the effect of reformatting on the 
affinity and specificity of the newly reformatted antibody in comparison to the parental, in 
this case, scFv to IgG. 
Following on, ELISA which was carried out on biotinylated fibronectin antigen 
showed a slight increase in Kd value compared to previous standard ELISA and BIACore 
analysis. This discrepancy is probably due to the nature of experiment. Investigating the 
biotinylated antigen with ELISA assay was to obtain a suitable ratio for biotinylation since 
overbiotinylated antigen may hinder the antibody binding to the cryptic epitope. This 
biotinylated antigen was then used in BIACore analysis as a continuation of antibody 
characterisation. 
The use of BIACore analysis is important in antibody drug development studies as it 
allows determination of kon (association rate) and koff (dissociation rate). Ideally, in AGENT, 
faster association and slower dissociation rate are desirable because the antibody will be 
retained at the tumour sites longer and thus increases the chance for the prodrug to reach 
the antibody-enzyme fusion site and thus hydrolysing the cytotoxic cyanide. Although this 
theory favours the IgG, the koff value for scFv was not too altered from the parental antibody 
(Table 3.3). The reformatting of scFv significantly affects its binding affinity by 10 fold; 
however the dissociation rate, koff was only two fold faster than the parental IgG. From a 
therapeutic point of view, this could be compensated by increasing the dose of scFv to get a 
comparable level of tumour localisation. In AGENT application, scFv offers better 
advantages in terms of size and better penetration. It also to produce an immunofusion that 
is not too large once it is fused to enzyme.  
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It is important to note that during BIACore analysis, an excess of antigen can lead to 
experimental artefacts such as mass transfer effects. However, this outcome was eliminated 
by conducting the experiment at different flow rates and by ensuring the consistency of 
results obtained. In previous studies, multiple regeneration steps were required, 
presumably to allow antibody and antigen to correctly dissociate (Harman 2006). However, 
in this study the regeneration was successfully done with a one step treatment of 100mM 
TEA without any additional steps. This may be due to a better experimental set up, good 
quality of scFv or antigen and improved techniques. 
Following the promising results in both the ELISA and BIACore analysis, it was 
interesting to investigate the binding of this antibody to live antigen expressing cells using 
flow cytometry. In ELISA and BIACore analysis, the assays were done with recombinant 
antigen fragments, whereas, the flow cytometry involved a full length native antigen 
expressed by live cells. This would give a better idea of what would be expected in tumours.  
Initially, the experiment was conducted using ED-B transformed WI38 (VA13) cells against 
their untransformed counterpart, WI38 fibroblast cells. This would give a direct comparison 
and a perfectly matched negative control for the binding assay. However, in practise it was 
difficult to grow and maintain the normal fibroblast as they took a longer time to reach 
confluency. Often, the cells slowly die before reaching confluency and they also have a 
limited passage half life. This is expected because normal cells do not grow as fast as  
transformed cells. Due to the great limitation of this cell line, alternative cell lines were 
sought out and KB cells were identified as an excellent negative control. In the negative 
control cell line, there were many other non-specific proteins on the cells, yet there was no 
binding or signalling in flow cytometry within these cells compared to the ED-B expressing 
cells. This shows the specificity of the huBC-1 antibody binding. In addition to WI38 (VA13), 
U87 cells were also used to show the binding as some studies have shown that U87 cells 
express ED-B positive fibronectin (Balza et al. 2009). The flow cytometry data confirmed 
specificity of huBC-1 IgG and scFv antibody binding to ED-B expressing cells WI38 (VA13) and 
U87, shown by a significant fluorescent shift. No shift was observed in the negative control 
experiment and the KB cells (Figure 3.8). It is worth mentioning that in the standard flow 
cytometry, the antibody binds to the cell surface receptor antigen. However, in this study 
the antibody binding differs slightly from the standard flow cytometry because the huBC-1 
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scFv and IgG binding were based on the secreted antigen that were still remain on the cell 
surface. Thus, it would be expected that the fluorescent signals were much weaker than the 
cell surface receptor antigen. Therefore, it was interesting to know whether there was 
antibody binding on the secreted antigen present in the cell media. The work was done by a 
colleague, Dr. Irene Sanjuan, to further investigate whether there was any discrepancy in 
antibody binding to ‘surface antigen’ and secreted antigen. The data showed that both the 
results were similar and have no significant difference (unpublished results). Also, it could 
be possible that the cells were slightly permeable to intracellular antigen and the antibody 
was able to get into the cells during cell manipulation to give some signal.  
Advantages of flow cytometry is that it simultaneously measures and analyses 
multiple physical characteristic of a single cell in a heterogeneous population of cells. Within 
minutes, flow cytometry can acquire data on all subpopulations of a sample. No other 
method allows such rapid, quantitative, and detailed analysis of subpopulations. In addition, 
millions of cells can be analyzed in a relatively short time. The acquisition data can be 
displayed and re-analyzed in different ways using many different programs. Despite these, 
there are some disadvantages to this method. It only allows analysis of cell suspension and 
thus cells from solid tissues have to be disaggregated for use in this method (Robinson 
2004). 
Although the data shown in Figure 3.8 is qualitative, it is possible to obtain 
quantitative data to generate affinity constants by using varying concentrations of antibody 
using flow cytometry. A step further for characterisation was carried out using this approach 
and the Kd values obtained was in accordance with the values from BIACore and ELISA 
previously shown in Table 3.3 (Dr. Sanjuan, unpublished data). 
The promising data showed that huBC-1 scFv is a good candidate for AGENT in 
targeting ED-B fibronectin, a tumour marker for angiogenesis.  It has shown good specificity 
and affinity towards the FN7B89 antigen compare to FN789 antigen. Nevertheless, it should 
be noted that the results however, were only done through in vitro analysis. The question 
whether it could be translated into in vivo and clinical practice has yet to be proven. 
Immunohistochemical analysis on tumour tissue sections and in vivo targeting studies on 
mice would give further insights on the biodistribution in tumour cells and 
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microenvironment.  This would give a broader picture because it involves the tumour 
microenvironment as well as the true nature of the antigen distribution in tumour blood 
vessels. There were earlier immunohistochemical studies done using murine monoclonal 
BC-1. They found that 38% of different primary human tumours showed binding of muBC-1 
to ED-B fibronectin (Carnemolla et al. 1989). The tumour targeting potential was also tested 
against oncofetal fibronectin in nude mice bearing ED-B fibronectin expressing human 
tumour implants and showed favourable tumour targeting (Mariani et al. 1997).  
Another laboratory using a different antibody, L-19 which also binds to ED-B 
fibronectin showed wide distribution of binding to the antigen in different human cancer 
and murine experimental tumour sections (Balza et al. 2009). L-19 has an enhanced binding 
affinity of 1000 fold stronger (0.054 nM) than the huBC-1 scFv (Pini et al. 1998).  This was 
mainly contributed by lower dissociation rate (6.0 X10-6 s-1 compared to 1.54 X10-3 s-1 of 
huBC-1 scFv). Strong binding affinity observed in L19 was a result of combinatorial 
mutagenesis in the heavy and light chains that lead to improved targeting of tumour 
angiogenesis, as shown in biodistribution studies in F9 murine teratocarcinoma bearing 
nude mice (Viti et al. 1999). This could be the future steps taken for huBC-1 scFv to improve 
its affinity. Nevertheless, it must be noted that although both L19 and huBC-1 scFv target 
ED-B fibronectin, they each bind to different epitopes. L-19 binds to ED-B domain while the 
huBC-1 scFv binds to the cryptic epitope in domain 7 type III repeat (Figure 1.8).  
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wild type human cytosolic  
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4.1 INTRODUCTION 
4.1.1 Human cytosolic β-glucosidase (hCβG) 
The plant cassava β-glucosidase, linamarase, was first recombinantly expressed in yeast 
(Keresztessy et al. 2001, Kousparou, Epenetos and Deonarain 2002). They have shown that 
the recombinantly expressed protein is similar to the native protein from the plants in terms 
of purity and in vitro activities. When tested with the plant natural substrate, linamarin, the 
recombinant protein was able to hydrolyse the substrate and produce cyanide. Their data 
showed comparable enzyme kinetic data to the purified plant protein. However, with 
regards to the origin of the enzyme, it is thought that the plant enzyme would give 
disadvantages in future clinical application and might not be suitable for use in AGENT 
approach. Besides, the enzyme suffered from aggregation and was reported to have 
reduced catalytic activity compared to the native material in vivo, which was a common 
problem reported by another lab (Kousparou et al. 2002). 
Subsequent work from other laboratories involved purification and characterisation 
of a cytosolic broad specificity β-glucosidase (hCβG) from human liver (Daniels et al. 1981).  
However, the method which involved isolation of hCβG from human tissues was not an easy 
procedure. Many issues were encountered during the process such as limited access to 
suitable human tissues, large variation in activity between tissues from  different individuals 
and multistep fractionation to obtain pure protein (Daniels et al. 1981). 
Realising the problems encountered before, several laboratories cloned and 
expressed the enzyme. This allowed easier and faster access to study the human enzyme. 
Expression of recombinant hCβG was described in mammalian cells (de Graaf et al. 2001), in 
yeast (Berrin et al. 2002) and E. coli (Harman 2006). The biochemical, kinetic and inhibition 
properties of the cloned enzyme were found to be identical with those reported for the 
enzyme purified from human liver. Following these, many of the hCβG characterisation was 
based on the recombinantly expressed hCβG enzyme. 
Cloning of the hCβG cDNA from total human liver RNA into pcDNA3.1 vector was first 
described by (de Graaf et al. 2001). Expression of the contruct was carried out in a 
mammalian expression system,  COS-7 cells. Through amino acid sequence analysis, they 
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found that hCβG is most closely related to lactase phlorizin hydrolase and kloto protein, 
both are in the same family 1 glycoside hydrolases. They reported that the recombinantly 
expressed hCβG has the enzyme properties which are in accordance to the native enzyme.  
Following this, Berrin et al. 2002, described a successful heterologous expression of 
hCβG in Pichia pastoris. They cloned the full length gene from human liver cDNA library into 
pHIL-S1 vector and expressed in Pichia pastoris to give a yield of ~ 10 mg/L. Purification was 
carried out with single step chromatography and characterisation of the enzyme was 
reported to be similar to the native enzyme. This study showed that the hCβG has significant 
activity towards many common dietary xenobiotics therefore, confirmed that this enzyme 
has broad range specificity towards dietary glucosides and may play a critical role in 
xenobiotic metabolism.  
Simultaneously, Harman 2006 studied the construction and expression of the hCβG 
enzyme in yeast. Cloning was done in pPICZα vector and on the first trial, expression was 
carried out in yeast strain X-33. Unfortunately, this first attempt was not a success as the 
enzyme had poor protein expression. Even though strong β-glucosidase activity was 
detected during the clones’ selection, low enzyme activity was observed in the secreted 
soluble protein. It is assumed that this was due to endogenous proteolysis or protein 
instability in the large scale expression. Efforts were done to minimise the proteolysis but 
did not show any promising results. Consequently, the strategy was changed into using 
yeast strain GS115, a similar system that was described by (Berrin et al. 2002). However, the 
enzyme protein suffered excessive aggregation and inconsistent reproducibility. On top of 
that, there were issues with the yield and ease of protein production. Nevertheless, some 
initial characterisation was performed and enzyme specific activity showed ~ 6 fold lower 
than reported by an earlier study (Berrin et al. 2002). 
Following the unsuccessful expression in yeast system, further investigation was 
explored using bacterial system (Harman 2006). This was in parallel with the aim of 
establishing an expression system that could be used for production of mutant hCβG 
enzymes for later immunofusion. A system which is convenient, cheap, able to produce a 
good protein yield and consistent reproducibility is required. Optimisation of hCβG protein 
production was described through analyses of protein solubility, expression temperature, 
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purification method and also possibility of using an alternative vector to secrete the protein 
extracellularly.  
Bacteria expression system offers many advantages compared to others. It is proven 
to be rapid and economical for the production of recombinant protein. Coupled with vast 
biochemical and genetic knowledge, it allows quick manipulation and ease of growth 
requirements optimisation. As this study involved the production of a number of mutant 
hCβGs, it is important to choose a system that is not only cost-effective but easy to employ. 
Nevertheless, bacterial expression systems are limited compared to the higher order cells 
such as yeast or mammalian cells. This is mainly due to the limitation in the protein folding 
and post-translation modification such as glycosylation. However, Daniels et al. 1981 
described a study on liver-purified hCβG enzyme and suggested that the enzyme is active in 
its monomeric, non-glycosylated form. Therefore, the enzyme could be expressed in E. coli 
intracellularly for it to be functionally active. Furthermore, for the benefit of subsequent 
immunofusion with the huBC-1 scFv antibody which was also expressed in the same species, 
hCβG expression in bacteria would offer the most favourable approach.  
In this study, the hCβG clone was obtained from a glycerol stock (Harman 2006). The 
construct composed of 1500 bp gene, flanked by NotI and XhoI restriction sites cloned into 
pET23b vector. Protein expression was driven by T7 polymerase in E. coli BL21 (λDE3) cells 
under the control T7 promoter. For identification and purification purposes, the vector 
contained N-terminal T7 tag and C-terminal His6-tag. The vector did not have a secretion 
signal, therefore protein was expressed intracellularly. As mentioned before, the enzyme is 
a cytosolic protein and does not need to be secreted extracellularly for correct folding. 
Figure 4.1 illustrates the schematic diagram of the construct (see Appendix 3 for details). 
 
 
 
 
Figure 4.1: Schematic diagram of pET23b-hCβG. T7P=T7 promoter, RBS-ribosomal binding site, T7 
tag= N-terminal T7 tag, hCβG=human cytosolic β-glucosidase gene, His6=hexa-histidine tag, T7 term 
=T7 terminator and Amp’=ampicillin resistance β-lactamase gene. 
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4.1.2 Michaelis-Menten kinetics 
The basic concept of enzyme kinetics is expressed by the Michaelis-Menten equation. This 
concept assumes that enzyme-catalysed reactions involve the formation of an enzyme -
substrate complex (ES) which may then dissociate in either of the two ways: 
 
 
Where E, S and P represent the concentration of enzyme, substrate and products 
respectively and ES that of the enzyme-substrate complex (Wilkinson 1971). 
The enzyme and substrate first combine to give an enzyme-substrate complex, ES.  
This step is assumed to be rapid and reversible with no chemical changes taking place; the 
enzyme and substrate are held together by the non-covalent forces. The chemical processes 
then occur in a second step with a first-order rate constant, kcat, the turnover number of 
enzyme.  
Most reactions in biological systems usually include two substrates and two 
products. This is also the case with β-glucosidases where the two substrates are glucoside 
and water (solution) as shown in Figure 4.2. The enzyme is a hydrolase that catalyse the 
hydrolysis of the glycosidic linkage. The reactions consider that the glucose is the substrate 
whilst ignoring the water because it was present in excess (~55 M). As a result, the equation 
simplifies to pseudo first order reaction and can be followed by Michaelis-Menten kinetics.  
In the first reaction involving p-Nitrophenyl--D-glucopyranoside (pNPGlc) (Figure 4.2 A), 
absorbance measurement of p-Nitrophenol (pNP) provides the value for kcat, which is the 
turnover number of the β-glucosidase. The amount of the product, pNP could be calculated 
using the extinction coefficient 18 300 M-1cm-1. Conversely, the reaction with linamarin 
(Figure 4.2 B) gives the value for Km, the amount of linamarin that is needed to produce a 
significant catalysis to occur, which is half of the maximum reaction rate. Also, it shows how 
tightly the linamarin binds to the enzyme. 
 
 
                     k 1                      k 2 
E + S                          ES                       E + P     (1) 
                     k -1                        
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Figure 4.2: β-glucosidase catalysed reaction. A) p-Nitrophenylphenyl glucopyranoside B) linamarin. 
Hydrolysis of these substrates by the enzyme releases glucose and product (Harman 2006). 
 
Referring to Michaelis-Menten equation, the rates of formation and breakdown of ES are 
given by; 
 Rate of formation of ES = k1 [E] [S] 
 Rate of breakdown of ES = (k-1 +k2) [ES] 
 
Under the steady state assumption, rates of formation and breakdown of ES complex are 
equal. Therefore, Michaelis-Menten constant, Km can be define as  
 Km =  (k-1 +k2)                        
              k1 
In the case where k-1 is much greater than k2, ES complex dissociates to E and S much more 
rapidly than the product is formed. Under this condition (k-1 >> k2); 
 Km=  k-1 
    k1 
 
      H20 
A  
B 
(2) 
(3) 
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Therefore, Km value is equal to dissociation constant of ES complex if k2 is much 
smaller than k-1. When this condition is met, Km measures the strength of the ES complex. A 
high Km indicates weak binding whereas a low Km indicates strong binding. Thus, Km 
indicates the affinity of the ES complex. 
The maximal rate, Vmax is attained when the catalytic sites on the enzymes are 
saturated with substrate. The Michaelis-Menten equation could be written in the form, 
        v0 =    Vmax    [S] 
                           [S] + Km 
 
where v0 is the reaction rate at substrate concentration [S], Vmax is the maximum rate at the 
highest substrate concentration (usually *S+ =∞) and Km is concentration of substrate when 
reaction rate is half of Vmax.  
It is useful to transform the Michaelis-Menten equation into linear form for accurate 
analysis that allows detection of any deviations from the data. One of the methods is the 
double reciprocal plot or Lineweaver-Burk plot. This is done through inverting the equation 
(2). Therefore, 
 
 
 
A plot of 1/v0 versus 1/[S] allows the estimation of the Vmax and Km to be determined. 
From the Vmax value, the turnover number of the enzyme, kcat could be derived. Km provides 
the dissociation constant and gives an indication of the enzyme affinity for the substrate 
when k2<k-1. 
 
 
 
       (4) 
  1             1       Km 
         =                   +                       (5) 
 v0           Vmax  Vmax[S] 
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Aims 
This chapter aims to generate and characterise the wild type human cytosolic beta- 
glucosidase (hCβG).  The kinetic parameters of hCβG would provide a baseline value for 
comparison with the mutant hCβGs described in Chapter 5. This would be used as a means 
to establish a system for the production of hCβG mutants that could be fused to huBC-1 scFv 
using immunofusion.  
 
Objectives 
 To express hCβG in E. coli. 
 To optimise the purification method in order to obtain an active enzyme for kinetic 
analysis. 
 To perform enzyme kinetic analysis and assess the Km and Vmax of hCβG. 
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4.2 RESULTS 
4.2.1 Expression of the human cytosolic β-glucosidase (hCβG) gene in bacteria 
Human CβG was previously cloned in pET23b vector and obtained in the bacterial strain XL-1 
blue (Harman 2006).  Expression is driven by T7 RNA polymerase in BL21 (λDE3) under the 
control of T7 promoter system in the pET23b vector. The DNA and corresponding amino 
acid sequence of hCβG can be found in Appendix 4.  The pET23-hCβG plasmid DNA was 
isolated (Qiagen QIAprep kit) and digested with restriction enzymes NotI and XhoI to check 
the size of both the plasmid and hCβG DNA (Figure 4.3).  
  
                    
Certain biophysical parameters of hCβG are shown in Table 4.1. It is a ~ 55 kDa protein with 
a theoretical pI of 5.67.        
 Parameter value 
Theoretical pI 5.67 
Molecular weight (kDa) 54.7 
Number of amino acids 478 
Extinction coefficient (M-1cm-1) 118635 
Abs (0.1%) =1mg/ml 2.168 
 
Table 4.1: Basic biophysical properties of hCβG. The data derived from ExPASy ProtParam Tools, 
Swiss Institute of Bioinformatics (http://expasy.org/tools/protparam.html). 
 
    M        1         2         3        4 bp 
 
5000 
4000 
 
 
1500 
Figure 4.3: Analysis of pET23-hCβG clones by 
restriction digest. Purified DNA was digested 
NotI and XhoI.  
 
M- DNA marker;  
1 - Double digestion with NotI and XhoI;  
2 - Single digestion with NotI;  
3 - Single digestion with XhoI;  
4 - Undigested plasmid DNA.  
 
The plasmid and hCβG DNA can be seen at 
approximately 4000 bp and 1500 bp 
respectively as expected. 
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As shown previously, hCβG enzyme expression was observed in cell pellets (Harman 2006). 
The cells were lysed by two passages through a cell disrupter at 25 kpsi (see section 2.2.3.3) 
and centrifuged at 20, 000g for 1 hr to separate the soluble and insoluble fractions.  
4.2.2 Purification of human cytosolic β-glucosidase 
4.2.2.1 Nickel Immobilised Metal Affinity Chromatography (Ni-IMAC) 
Purification of hCβG was carried out with Ni-IMAC by manipulating the His6-tag. Soluble 
protein was incubated and tumbled with the resin overnight to maximise the binding as 
described in section 2.2.4.2. Elution was carried out with 200 mM Imidazole, pooled and 
analysed for purity via SDS-PAGE both by Coomassie staining and western blot (anti-His6) 
analysis. The bands run just below the 55 kDa molecular size marker as expected (Figure 
4.4).  
The Coomassie staining suggests that a number of bacterial protein contaminants 
still remain in the eluted fractions. However, western blots analysis showed the correct 
molecular size of protein at 55kDa. The analysed fractions were therefore pooled and 
concentrated before further separation by second step purification via size exclusion 
chromatography. Estimated purity from Ni-IMAC was ~ 60-75%. 
 
          
Figure 4.4: Purification of human cytosolic -glucosidase by Ni-IMAC. SDS-PAGE gels analysed by 
(A) Coomassie staining and (B) western blot (anti-His6). M=marker; FT=column flow through; W1= 
PBS/NaCl wash; W2=10mM Imidazole wash; W3=20mM Imidazole; E1-E7=fractions of hCβG eluted 
with 200mM Imidazole; P=pooled fraction. The enzyme was observed at approximately 55KDa as 
expected. However, there were many bands of impurities observed in the SDS-PAGE gel. 
 
55 
 kDa 
    M   FT W1W2W3E1 E2 E3 E4  E5  E6  E7  P 
B A 
 
A 
55 
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4.2.2.2 Size exclusion chromatography 
Due to poor purity from Ni-IMAC, size exclusion chromatography was carried out to improve 
hCβG protein purity. This column is well suited to samples that are sensitive to changes in 
pH, concentration of metal ions or co-factors and harsh environmental conditions. In order 
to use this column, the samples must be dominantly expressed and there must be a 
significant size difference between protein of interest and other contaminant proteins. 
Analysis of hCβG by size exclusion column showed that the enzyme was eluted at 84 
minutes (Figure 4.5), corresponding to an expected molecular size of 55 kDa when 
compared to the standard curve (refer to Appendix 5 for the standard curve). 
 
Figure 4.5: Size exclusion chromatography of hCβG expressed in E. coli. The enzyme eluted as a 
sharp peak at approximately 84 minutes, corresponding to a molecular size of 55 kDa as expected. 
The numbers represent the standard protein 1; β-amylase (200 kDa), 2; albumin (66 kDa), 3; 
carbonic anhydrase (29 kDa) and 4; cytochrome c (12.4 kDa). 
 
Protein fractions containing the monomer protein were analysed by SDS-PAGE to 
assess the level of purity (Figure 4.6). The enzyme was judged to be over 95% pure and the 
average yield of pure protein was approximately 3-4 mg/L of bacterial culture, sufficient to 
allow subsequent kinetic analysis. 
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         A 
                                   
Figure 4.6: SDS-PAGE of hCβG following size exclusion chromatography. The protein was judged to 
be over 95% pure.  
 
4.2.3 Kinetic Analysis of human cytosolic β-glucosidase 
Determination of Km value from hCβG reaction with the substrate p-Nitrophenyl--D-
glucopyranoside (pNPGlc) was achieved by measuring p-Nitrophenol (pNP) production. The 
purpose of this assay was to obtain a baseline kinetic value of the wild type hCβG for later 
comparison with the mutant hCβG described in Chapter 5. Absorbance was taken at 400 nm 
wavelength at different substrate concentrations. Each reaction was carried out in 
triplicates, with the substrate made up to a range of concentrations between 20 and 
0.1mM. A fixed concentration of enzyme was applied at a fixed final volume of reaction (see 
section 2.2.6.9 for details). The data were plotted on a graph of absorbance versus time to 
determine initial rates of reaction (v0) (Figure 4.7 A), which were then analysed by a 
Lineweaver-Burk plot to reveal Vmax and Km values for the enzyme (Figure 4.7 C).  
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4.3.2.1  End-point assay 
The data shown below is a representative of at least three separate experiments using 
different samples preparations. 
A
Kinetic analysis of wild type hCBG enzyme reaction 
with p-NPGlc substrate  
Time (min)
0 1 2 3 4 5 6
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)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
20 mM
10 mM
5 mM
2 mM
1 mM
0.5 mM
0.2 mM
 
B   
[pNPGlc] mM 1/[pNPGlc] mM-1 V0  (abs/min) 1/v0  (abs/min)
-1 
20 0.05 0.103 9.7087 
10 0.1 0.0908 11.0132 
5 0.2 0.0719 13.9082 
2 0.5 0.061 16.3934 
1 1 0.0557 17.9533 
0.5 2 0.0425 23.5294 
0.2 5 0.03 33.3333 
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Figure 4.7: Kinetic Analysis of hCβG reaction with pNPGlc (end-point assay). 
(A) Graph of reaction of hCβG and pNPGlc. Initial rates of reaction (v0) were calculated by linear 
regression. 
(B) Table of reaction rates (v0) obtained from (A) and their reciprocals (absorbance units/minute). 
(C) Michaelis-Menten curve of v0 versus substrate concentration 
(D) Lineweaver-Burk plot of data in Table (B). Linear regression of the data was performed in order 
to yield values of Vmax and Km, fitted to the Michaelis-Menten equation. Error bars were 
calculated from the v0 mean values of the triplicate samples (n=3). 
 
Figure 4.7 (C) shows that the hCβG and pNPGlc reaction obeys the Michaelis-Menten 
equation. No substrate inhibition was observed at high substrate concentration. Although 
Lineweaver-Burk is known to give a better form of analysing data graphically, often the main 
C 
D 
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disadvantage of this plot is the data points at high substrate concentration are compressed 
into a small region near the y-axis, thus the plot emphasized on the points at lower 
substrate concentration. Therefore, the gradient of the plot is highly influenced by the lower 
substrate concentration. In some instances, the lowest substrate concentration is 
eliminated to give a better R2 value for the graph and accuracy. 
From Lineweaver-Burk plot, the y-axis intercept (c) is the reciprocal of Vmax, therefore;  
 
Vmax  = 0.08 ± 0.02 (abs/min)     
= 1.75 nmol of pNP/min  
Km is the gradient (m) multiplied by Vmax = 0.36 ± 0.03 mM. 
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4.2.3.2  Continuous assay 
Previously in the end point assay, the readings were taken by removing the reaction 
samples and exposing them to a high pH stop buffer before measuring the colorimetric 
signal. In the end point assay, timing and volume inaccuracy may be introduced, associated 
with the termination of the reaction and withdrawal of samples at fixed times. Hence, an 
alternative assay was carried out to follow the continuous change of reaction in situ and this 
was conducted with continuous assay (see section 2.2.6.9.2). The data shown below is a 
representative of at least three separate experiments using different sample preparations. 
       
Kinetic analysis of wild type hCBG enzyme reaction 
with p-NPGlc substrate 
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[pNPGlc] 
mM 
1/[pNPGlc] 
mM-1 
v0  
(abs/min) 
1/v0  
(abs/min) -1 
20 0.05 0.0193 51.81 
10 0.1 0.0206 48.54 
5 0.2 0.0197 50.76 
2 0.5 0.0178 56.18 
1 1 0.0159 62.89 
0.5 2 0.0152 65.79 
0.2 5 0.0139 71.94 
A 
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Figure 4.8: Kinetic Analysis of hCβG reaction with pNPGlc (continuous assay). 
(A) Graph of reaction of hCβG and pNPGlc. Initial rates of reaction (v0) were calculated by   linear 
regression of the data. 
(Β)  Table of reaction rates (v0) obtained from (A) and their reciprocals (absorbance 
units/minute). 
(C) Michaelis-Menten curve of v0 versus substrate concentration 
(D)   Lineweaver-Burk plot of data in table (B). Linear regression of the data was performed in 
order to yield values of Vmax and Km (below). Error bars were calculated from the v0 mean 
values of the triplicate samples (n=3). 
 
 
From Lineweaver-Burk plot, the y-axis intercept (c) is the reciprocal of Vmax, therefore;  
Vmax  = 0.02 ± 0.01 (abs / min) 
 = 0.438 nmol of pNP/min. 
Km is the gradient (m) multiplied by Vmax = 0.28 ± 0.02 mM. 
D 
C 
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Figure 4.8 (C) shows that the hCβG and pNPGlc reaction obeys the Michaelis-Menten 
equation. However, a slight substrate inhibition was observed at 20mM substrate 
concentration. At the lowest substrate concentration of 0.2 mM, substrate exhaustion is 
observed before the duration of reaction is completed and this leads to a slow increase in 
the reaction rate. Therefore, the readings at both points were not included in the 
Lineweaver-Burk plot to obtain a good data fit (R2 value). 
The Km value is in a good agreement with that obtained by the ‘end-point’ method 
utilised previously (section 4.3.2.1; Km = 0.36 mM) and with published data 0.38 mM (Tribolo 
et. al, 2007) and 0.20 mM (Harman, 2006). 
To ensure the validity of both end-point and continuous kinetic assays, the reactions 
were done in parallel with positive control β-glucosidase from almond. The Km values 
obtained were 7.90 and 7.00 mM for the end-point and continuous assays, respectively 
(data not shown). This is in accordance with published data, Km = 8 mM (Kiss et. al 1981) and 
Km = 7.15 mM (Tate et al. 2006).  
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4.3 DISCUSSION 
This chapter describes successful expression and purification of hCβG from the clone 
provided (Harman 2006). The yield of soluble, purified protein was 3-4 mg/L of bacterial cell 
culture. The hCβG gene was constructed in pET23b vector and expressed under T7 
promoter. This promoter was selected due to its strength; however this could have some 
disadvantages. The strong promoter in combination with high inducer concentration could 
lead to accumulation of recombinant protein as insoluble aggregates formed in the  
inclusion bodies (Singh and Panda 2005). This happens when the rate of protein expression 
is faster than protein folding. In order to minimise aggregation leading to inclusion bodies, 
the protein expression rate could be controlled either by reducing the inducer concentration 
or lowering the expression temperature. If neither approaches work, the inclusion bodies 
could be isolated, solubilised and refolded. Usually this would be the last approach due to 
the complexity of the refolding process and variations in the protocol depending on 
individual proteins. Hence, significant optimisation is needed to get the best condition for 
protein refolding in addition to the possibility of losing protein in the multistep protocol.  
In this study, hCβG enzyme expression was done with BL21 (λDE3) which contains 
the T7 RNA polymerase that was needed to activate the T7 promoter for protein expression. 
Soluble protein was expressed intracellularly with a good yield. It has been shown that the 
expression of hCβG was reproducible using the previously optimised method. High 
contamination from the bacteria protein was observed on SDS-PAGE gel stained with 
Coomassie blue after Ni-IMAC purification. This shows that the series of washes were 
insufficient to remove the contaminants efficiently. It is however quite predicted as Ni-IMAC 
is a low affinity chromatography with the Kd for the interaction between His6-tag and Nickel 
at ~10-6 M at neural pH 6 (Nieba et al, 1997). Since many of the host proteins have intrinsic 
histidine and/or cysteine amino acid residues that could bind non-specifically to the IMAC, 
competition with hCβG to the same binding sites would be expected leading to 
contamination observed in the eluted samples.  In addition, although the hCβG protein is 
well expressed, purification of this protein through Ni-IMAC is highly dependent on the 
exposure or steric hindrance of His6-tag in the sample. This is related to the viscosity of 
sample during its application in the column. Samples that were too viscous may hinder the 
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binding of the His6-tag to the metal and that could lead to a decrease in binding capacity 
and poor protein yield in the eluted samples. Ideally, an alternative to Nickel would be 
Cobalt metal ion which has a lower Kd than Nickel. Cobalt is bigger in size and binds more 
weakly to His6-tag compared to Nickel. Cobalt-IMAC binds the His6-tag protein at a lower Kd, 
but requires a different purification window. Nevertheless, an effort to switch to cobalt did 
not reduce the amount of impurities. In fact, the result showed less hCβG protein binding 
observed in the eluted sample (data not shown). Therefore, Ni-IMAC was the best option for 
hCβG purification. 
Due to poor purity in the eluted protein from the Nickel column, a second step 
purification was taken which involved purification using size-exclusion column. It is should 
be noted that the protein of interest must be dominantly expressed and well separated 
compared to the rest of contaminating proteins before using this column. Although there 
were many sizes close to the size of interest, attempts were made to purify the protein 
using this column. The SDS-PAGE gel result showed the protein of interest with a correct 
molecular size and with 95% purity was obtained (Figure 4.6). 
The enzyme kinetic assay was done in two different methods. The first was the end- 
point assay, to give an estimation of the enzyme activity. In theory, this method of analysing 
is inaccurate due to the time lag involved when a small volume of the reaction was removed 
and stopped with high pH stop buffer before the colorimetric absorbance was measured. It 
could be argued that there may be some traces of enzyme activity after addition of the stop 
buffer, leading to inaccuracies in the reading. Despite these drawbacks, the endpoint assay 
is more sensitive compared to the continuous assay because it gives a higher extinction 
coefficient value with the addition of high pH stop buffer. This gives a strong absorbance of 
yellow coloured product that is readily detected by spectrophotometer. An alternative 
approach given by continuous assay allows measurement of enzyme reaction to be carried 
out in situ within the microplate format. This approach offers measurement in real time as 
the reaction was done continuously without interruption. The downside is the yellow 
coloured product is not as strong as in the end-point assay due to the absence of high pH 
stop buffer. As a result, a lower extinction coefficient value was obtained which was 
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reflected in low absorbance readings. This affects the sensitivity of the assay. Also, 
continuous assay needs a specific spectrophotometer which is not always possible. 
In spite of these considerations, the Km and Vmax values obtained from the two 
different experimental setups were in close agreement with each other (Table 4.2). Hence, 
continuous assay was employed in subsequent analysis involving kinetic analysis of the 
mutant hCβGs as described in Chapter 5. Not only was this approach more convenient, but 
also less amount of enzyme was needed per reaction as the assay was performed in a 
microtitre plate format. 
hCβG End-point assay Continuous assay 
Km (mM) 0.36 ± 0.03 0.32 ± 0.02 
Vmax (abs/min) 0.08 ± 0.02 0.02 ± 0.01 
Vmax (nmol pNP/min) 1.75 ± 0.02 0.44 ± 0.01 
Table 4.2: Summary of the Km and Vmax values obtained from end point and continuous assays. 
 
It must be emphasised that the aim of this enzyme kinetic study was to provide a 
baseline value for later comparison with the mutant hCβGs. The kinetic values obtained 
here are not for kinetic understanding of the enzyme. The Km values obtained from this 
study were not far off from published data, Km=0.38 mM (Tribolo et al. 2007) and 0.20 mM 
(Harman 2006). Thus, Km values obtained in this study were in agreement with the 
published data.  The discrepancy in the Vmax value may be due to the substrate inhibition 
observed in the continuous assay. However, the difference was not significant. Therefore, in 
the subsequent analysis, this point was not taken into consideration when plotting the 
Lineweaver-Burk plot. 
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Chapter 5 
Construction, expression and 
characterisation active-site mutants  
of human cytosolic β-glucosidase   
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5.1 INTRODUCTION 
The early studies on the crystal structures of β-glucosidase were described for plant β-
glucosidase; white clover (Barrett et al. 1995) and maize (Zea mays) (Czjzek et al. 2000). 
There were no structural studies on animal β-glucosidases. However, the first 3-dimentional 
model of human cytosolic β- glucosidase (hCβG) was done through homology modelling 
with Zea mays β-glucosidase (Berrin et al. 2003). They reported that the human enzyme had 
the common characteristic of family 1 β-glucosidases, the (β/α)8 –barrel and contained two 
catalytic glutamate residues which were located on strand 4 (the acid/base, Glu165) and on 
strand 7 (the nucleophile, Glu373) (Jenkins et al. 1995).  The structural differences between 
the enzymes in this family were mainly in the loops regions surrounding the aglycone 
binding sites and these were likely to influence the substrate specificity and recognition. On 
the other hand, glucose-binding sites were well-conserved. Several mutations were made in 
the aglycone sites and the expressed mutant proteins showed a decrease in activity towards 
a broad range of substrates. These amino acid residues were predicted to be essential for 
flavonoid glucoside binding and catalysis (Berrin et al. 2003, Tribolo et al. 2007). 
In the same lab, Tribolo et al. 2007 described the first crystal study on hCβG. Their 
finding was in a close agreement with the previous modelling study, particularly Val168,  
Phe225 and Try308 amino acids, which were predicted to play an important role for 
substrate recognition. Furthermore, they mentioned additional sites such as Trp345, 
Phe179, Phe334 and Phe433 were potentially crucial for substrate specificity. One 
interesting finding from this study was that in comparison to other eukaryotic β-
glucosidases, hCβG did not contain any disulphide bonds between any of the cysteine 
residues. This further supports our previous wild type hCβG expression that the enzyme was 
a cytosolic enzyme and did not need to be secreted extracellularly to be folded correctly. 
They also described another unique catalytic residue which was only found in hCβG but not 
in other β-glucosidases. This residue was Glutamine (Gln307) located between the two 
previously described catalytic residues. In other members of family 1 β-glucosidase, this 
amino acid was Asparagine residue. This site was reported to be essential for catalysis in 
hCβG.  The overall shape and hydrophobic elements of aglycone binding residues of hCβG 
structures were in agreement with the substrate specificity of hCβG which prefers rigid, 
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planar, hydrophobic moieties compared to long flexible alkyl chains (Figure 5.1)  (Tribolo et 
al. 2007, Berrin et al. 2002). As a comparison, the linamarin structure is shown in Figure 5.2, 
as a potential substrate for hCβG in this study. 
 
 
 
       
Figure 5.2: Structure of substrates for human cytosolic β-glucosidase. A) quercetin-4’-
glucoside and B) linamarin.  
Advances in protein engineering have provided access to altering enzyme specificity. 
These allow scientists to generate novel proteins with the particular chemical and biological 
properties which otherwise would not be possible. This technology is particularly useful in 
industry and medical applications and also in the study of structure-function relationships. 
Alteration of protein specificity could be done through either random/directed evolution or 
rational mutation of the parent gene. 
 In random mutation, as the name suggests, one applies random changes to the 
amino acid sequence through error-prone PCR. The strategy mimics the natural process of 
evolution. This method although easy to perform, has challenges in developing efficient and 
Figure 5.1: Surface representation of hCβG. 
Detailed view of the surface representation of 
hCβG showing the position of the modelled 
quecetin-4-glucosidase within the active site 
pocket. Residues responsible for the specific 
form of the aglycone binding pocket are 
highlighted as yellow sticks.  
The figure was prepared using PyMol 
[http://pymol.sourceforge.net/]. Co-ordinates 
were from 2JFE PDB file, (Tribolo et al. 2007). 
A B 
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high throughput screening methodology for the selection and identification of variants with 
the desired phenotype. On the other end, it is frequently reported that random mutations 
may confer great benefit as the mutations that might alter the substrate specificity are not 
always found in the active site of the enzyme (Arnold et al. 2001) although majority are to 
be found in areas associated with substrate binding, catalysis or maintenance  of active sites 
environment (Dalby 2003).  
Another type of mutation is rational approach/site-directed mutagenesis involves 
selectively altering an enzyme by replacing amino acids at specific sites in the protein with 
other amino acids. In this approach, the site of mutation is controlled and specific. The 
disadvantage is that it requires detailed structural knowledge of the protein and a rational 
understanding of the determinants that are regarded as important in the substrate 
selectivity and catalytic mechanism of the enzyme. In comparison to random mutagenesis, 
this approach involves small number of alteration. Therefore, screening is not an issue and 
characterisation of the new protein could be carried out in comparison to the parent 
protein. In addition, rational mutagenesis is also useful for testing hypotheses about the 
structural and functional roles of specific amino acid residues in a protein. 
Aims 
This chapter aims to generate a hCβG which has increased specificity for linamarin, whilst 
retain activity and stability. Such an enzyme would be suitable for AGENT. 
Objectives 
 To design appropriate site-directed mutants  
 To introduce targeted mutations into hCβG gene by PCR 
 To express the mutant hCβGs in E. coli 
 To purify the mutant hCβGs for obtaining functional active enzyme for                                        
further characterisation of enzyme 
 To assess reactivity of hCβG towards pNPGlc and linamarin 
 To assess the stability of the enzyme 
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5.2 RESULTS 
Based on the published data by (Berrin et al. 2003, Tribolo et al. 2007), the residues that 
were regarded as important in substrate specificity and binding are highlighted (Figure 5.3). 
Alteration of the substrate specificity could require substitution of these residues. This was 
done by comparing the amino acid sequence of hCβG with cyanogenic β-glucosidase 
(linamarase) from cassava (Manihot esculenta Crantz) and white clover (Trifolium repens). 
Highly conserved glucose binding residues are highlighted in blue and catalytic glutamate 
residues are highlighted in green. Residues identified by (Tribolo et al. 2007) and (Berrin et 
al. 2003) as potentially important for aglycone binding are highlighted in red. Residues 
conserved between all three sequences are marked with an asterisk. Positions retaining high 
homology are marked with two dots and those retaining low homology are marker with one 
dot. Residue numbers are indicated to the right of each sequence. Residues which were 
selected for mutations are indicated by arrows (Figure 5.3). Table 5.1 shows the mutant 
hCβG enzymes that were designed. 
   hCβG mutant   
Single mutation Double mutations Triple mutations 
V168A V168A/M172F V168A/M172F/F334A 
M172F V168A/F334A   
F334A M172F/F334A   
Table 5.1: Mutant hCβG enzymes. Site-directed mutagenesis was carried out on the hCβG gene 
through PCR to produce single, double and triple hCβG mutants. 
 
Substitution was decided based on rational decision of the amino acid sequence 
alignment of cassava and white clover. It was crucial to retain the hydrophobic nature of 
amino acid in order to maintain the characteristic of the native residues. In addition, the aim 
of the mutations was to reduce the size of amino acid so that it could open up the active site 
pocket and thus providing a deeper docking site for the substrate. As shown in structural 
biology study, the substrate entrance site for hCβG was shown to be flat and not extremely 
deep which could be the factor for the inability of hCβG to accommodate the bulky 
substrates (Tribolo et al. 2007).  All the double and triple mutants were engineered by 
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combining the two single mutations and three single mutations respectively with sequential 
PCRs.  
There were many other possible sites for mutations (Figure 5.3, highlighted in red). 
However, amino acid alignment showed that most of these sites were either occupied by 
non-hydrophobic residues in the plant sequences or were highly conserved between all the 
three sequences. Therefore, it was assumed that these sites were very unlikely to be 
involved in recognition of the substrate linamarin.  
Clover          FKPLPISFDDFS---------------DLNRSCFAPGFVFGTASSAFQYEGAAFEDGKGP 45 
Cassava         MLVLFISLLALTRPAMGTDDDDDNIPDDFSRKYFPDDFIFGTATSAYQIEGEATAKGRAP 60 
Human           -------------------------------MAFPAGFGWAAATAAYQVEGGWDADGKGP 29 
                                                 *. .* :.:*::*:* **    .*:.* 
 
Clover          SIWDTFTHKYPEKIKDRTNGDVAIDEYHRYKEDIGIMKDMNLDAYRFSISWPRVLPKGKL 105 
Cassava         SVWDIFSKETPDRILDGSNGDVAVDFYNRYIQDIKNVKKMGFNAFRMSISWSRVIPSGRR 120 
Human           CVWDTFTHQGGERVFKNQTGDVACGSYTLWEEDLKCIKQLGLTHYRFSLSWSRLLPDG-T 88 
                .:** *:::  ::: .  .**** . *  : :*:  :*.:.:  :*:*:**.*::*.*   
 
Clover          SGGVNREGINYYNNLINEVLANGMQPYVTLFHWDVPQALEDEYRGFLGRNIVDDFRDYAE 165 
Cassava         REGVNEEGIQFYNDVINEIISNGLEPFVTIFHWDTPQALQDKYGGFLSRDIVYDYLQYAD 180 
Human           TGFINQKGIDYYNKIIDDLLKNGVTPIVTLYHFDLPQTLEDQ-GGWLSEAIIESFDKYAQ 147 
                   :*.:**::**.:*:::: **: * **::*:* **:*:*:  *:*.. *: .: .**: 
 
Clover          LCFKEFGDRVKHWITLNEPWGVSMNAYAYGTFAPGRCSDWLKLNCTGGDSGREPYLAAHY 225 
Cassava         LLFERFGDRVKPWMTFNEPSAYVGFAHDDGVFAPGRCSSWVNRQCLAGDSATEPYIVAHN 240 
Human           FCFSTFGDRVKQWITINEANVLSVMSYDLGMFPPG-----IPHFGTGG------YQAAHN 196 
                : *. ****** *:*:**.      ::  * *.**     :     .*      * .**  
 
Clover          QLLAHAAAARLYKTKYQASQNGIIGITLVSHWFEPAS-KEKADVDAAKRGLDFMLGWFMH 284 
Cassava         LLLSHAAAVHQYRKYYQGTQKGKIGITLFTFWYEPLS-DSKVDVQAAKTALDFMFGLWMD 299 
Human           LIKAHARSWHSYDSLFRKKQKGMVSLSLFAVWLEPADPNSVSDQEAAKRAITFHLDLFAK 256 
                 : :** : : * . :: .*:* :.::*.: * ** . ..  * :*** .: * :. : . 
 
Clover          PLTKG-RYPESMRYLVR----------KRLPKFSTEESKELTGSFDFLGLNYYSSYYAAK 333 
Cassava         PMTYG-RYPRTMVDLAG----------DKLIGFTDEESQLLRGSYDFVGLQYYTAYYAEP 348 
Human           PIFIDGDYPEVVKSQIASMSQKQGYPSSRLPEFTEEEKKMIKGTADFFAVQYYTTRLIKY 316 
                *:  .  **. :               .:*  *: **.: : *: **..::**::      
 
Clover          APRIPNARPAIQTDSLINAT-FEHNGKPLGPMAASSWLCIYPQGIRKLLLYVKNHYNNPV 392 
Cassava         IPPVDPKFRRYKTDSGVNATPYDLNGNLIGPQAYSSWFYIFPKGIRHFLNYTKDTYNDPV 408 
Human           QENKKGELG-ILQDAEIEFFPDPSWKN-------VDWIYVVPWGVCKLLKYIKDTYNNPV 368 
                             *: ::        :        .*: : * *: ::* * *: **:** 
 
Clover          IYITENGRNEFNDPTLSLQESLLDTPRIDYYYRHLYYVLTAIG-DGVNVKGYFAWSLFDN 451 
Cassava         IYVTENGVDNYNNESQPIEEALQDDFRISYYKKHMWNALGSLKNYGVKLKGYFAWSYLDN 468 
Human           IYITENGFPQSD------PAPLDDTQRWEYFRQTFQELFKAIQLDKVNLQVYCAWSLLDN 422 
                **:****  : :        .* *  * .*: : :   : ::    *::: * *** :** 
 
Clover          MEWDSGYTVRFGLVFVDFKN-NLKRHPKLSAHWFKSFLKK-------------------- 490 
Cassava         FEWNIGYTSRFGLYYVDYKN-NLTRYPKKSAHWFTKFLNISVNANNIYELTSKDSRKVGK 527 
Human           FEWNQGYSSRFGLFHVDFEDPARPRVPYTSAKEYAKIIRNNGLEAHL------------- 469 
                :**: **: **** .**:::    * *  **: : .::.                      
 
Clover          ---- 
Cassava         FYVM 531 
Human           ---- 
 
Figure 5.3: Sequence alignment of β-glucosidase. Alignment of human cytosolic β-glycosidase 
against with cyanogenic β-glucosidase (linamarase) from cassava (Manihot esculenta Crantz) and 
white clover (Trifolium repens). 
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5.2.1 Construction of mutant hCβGs gene  
Primers were designed using Strategene web-based QuickChange® Primer design program 
available online at http://www.strategene.com/qcprimerdesign. All the primer sequences 
were listed in section 2.1.6. Both the M172F and V168A/M172F mutants were previously 
made but not characterised in detail (Harman 2006). This study re-verified these mutants 
and made additional ones. 
Each of the DNA mutant clones was transformed into chemically super competent 
XL-1 blue cells and selected on carbenicillin agar plate. Selection of bacteria colonies 
containing recombinant plasmid DNA was done by employing the blue/white screening 
technique in the presence of X-gal or X-glu and IPTG. 60% (~200) of the colonies contained 
the mutation and appear as blue colonies. For each of the clones, plasmid DNA was isolated 
from 5 ml of the overnight culture from bacterial colonies and DNA quantification was 
carried out (see section 2.2.1). Concentration showed that plasmid DNA was of a good 
quality ranging from 100-200 ng/µl and reasonable pure. Ratio of ~1.8 is generally accepted 
as pure for DNA. The entire mutant construct DNAs were confirmed by sequencing using T7 
promoter, T7 terminator and hCβG6 internal sequencing primers to check for the mutation 
sites and any other possible errors during the PCR process. A full sequence of the mutants is 
summarised in Figure 5.4. The fully sequence-verified clones for each mutant were retained 
for subsequent investigation of expression. 
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Figure 5.4: Annotated sequence of mutant pET23-hCβG. The sequence shown contains V168A, 
M172F and F334A mutations, shown in pink for the nucleotide and amino acid sequences. Plasmid 
DNA and protein sequence between the initiation codon and NotI cloning site is shown in red, 
followed by the human cytosolic -glucosidase gene sequence in blue. The His6-tag for purification 
and detection purposes is shown in green and the amber stop codon is marked with an asterisk. 
Restriction sites used for cloning are underlined in the nucleotide sequence.  
 
        10        20        30        40        50        60  
atggctagcatgactggtggacagcaaatgggtcgggatccgaattcgagctccgtcgac 
taccgatcgtactgaccacctgtcgtttacccagccctaggcttaagctcgaggcagctg 
 M  A  S  M  T  G  G  Q  Q  M  G  R  D  P  N  S  S  S  V  D  
 
        70        80        90        100       110       120  
aagcttgcggccgctgctttccctgcaggatttggatgggcggcagccactgcagcttat 
ttcgaacgccggcgacgaaagggacgtcctaaacctacccgccgtcggtgacgtcgaata 
 K  L  A  A  A  A  F  P  A  G  F  G  W  A  A  A  T  A  A  Y  
 
       130       140       150        160       170       180  
caagtagaaggaggctgggatgcagatggaaaaggcccttgtgtctgggacacatttact 
gttcatcttcctccgaccctacgtctaccttttccgggaacacagaccctgtgtaaatga 
 Q  V  E  G  G  W  D  A  D  G  K  G  P  C  V  W  D  T  F  T  
 
       190       200       210        220       230       240  
catcagggaggagagagagttttcaagaaccagactggcgatgtagcttgtggcagctac 
gtagtccctcctctctctcaaaagttcttggtctgaccgctacatcgaacaccgtcgatg 
 H  Q  G  G  E  R  V  F  K  N  Q  T  G  D  V  A  C  G  S  Y  
 
       250       260       270        280       290       300 
actctgtgggaggaagatttgaaatgtatcaaacagcttggattgactcattaccgcttc 
tgagacaccctccttctaaactttacatagtttgtcgaacctaactgagtaatggcgaag 
 T  L  W  E  E  D  L  K  C  I  K  Q  L  G  L  T  H  Y  R  F  
 
       310       320       330        340       350       360 
tctctttcctggtcacgtctgttacctgatgggacgacaggtttcatcaaccagaaagga 
agagaaaggaccagtgcagacaatggactaccctgctgtccaaagtagttggtctttcct 
 S  L  S  W  S  R  L  L  P  D  G  T  T  G  F  I  N  Q  K  G  
 
 
       370       380       390        400       410       420 
attgattattacaacaagatcatcgatgatttgttaaaaaatggggttactcccattgtg 
taactaataatgttgttctagtagctactaaacaattttttaccccaatgagggtaacac 
 I  D  Y  Y  N  K  I  I  D  D  L  L  K  N  G  V  T  P  I  V  
 
       430       440       450        460       470       480 
accctctaccactttgatttgcctcagactttagaagaccaaggaggttggttgtcagag 
tgggagatggtgaaactaaacggagtctgaaatcttctggttcctccaaccaacagtctc 
 T  L  Y  H  F  D  L  P  Q  T  L  E  D  Q  G  G  W  L  S  E  
 
       490       500       510        520       530       540 
gcaatcattgaatcctttgacaaatatgctcagttttgcttcagtacctttggggatcgt 
cgttagtaacttaggaaactgtttatacgagtcaaaacgaagtcatggaaacccctagca 
 A  I  I  E  S  F  D  K  Y  A  Q  F  C  F  S  T  F  G  D  R  
 
       550       560       570        580       590       600 
gtcaagcagtggatcaccataaatgaagctaatgctctttctgtgttttcatatgactta 
cagttcgtcacctagtggtatttacttcgattacgagaaagacacaaaagtatactgaat 
 V  K  Q  W  I  T  I  N  E  A  N  A  L  S  V  F  S  Y  D  L  
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       610       620       630        640       650       660 
ggtatgtttcctccgggtatccctcactttgggactggaggttatcaggcagctcataat 
ccatacaaaggaggcccatagggagtgaaaccctgacctccaatagtccgtcgagtatta 
 G  M  F  P  P  G  I  P  H  F  G  T  G  G  Y  Q  A  A  H  N  
 
       670       680       690        700       710       720 
ttgattaaggctcatgccagatcctggcacagctatgattccttatttcgaaaaaagcag 
aactaattccgagtacggtctaggaccgtgtcgatactaaggaataaagcttttttcgtc 
 L  I  K  A  H  A  R  S  W  H  S  Y  D  S  L  F  R  K  K  Q  
 
       730       740       750        760       770       780 
aaaggtatggtgtctctatcactttttgcggtctggttggaaccagcagatcccaactca 
tttccataccacagagatagtgaaaaacgccagaccaaccttggtcgtctagggttgagt 
 K  G  M  V  S  L  S  L  F  A  V  W  L  E  P  A  D  P  N  S  
 
       790       800       810        820       830       840 
gtgtctgaccaggaagctgctaaaagagccatcactttccatctggatttatttgctaaa 
cacagactggtccttcgacgattttctcggtagtgaaaggtagacctaaataaacgattt 
 V  S  D  Q  E  A  A  K  R  A  I  T  F  H  L  D  L  F  A  K  
 
       850       860       870        880       890       900 
cccatattcatcgatggtgattatcctgaagttgtcaagtctcagattgcctccatgagt 
gggtataagtagctaccactaataggacttcaacagttcagagtctaacggaggtactca 
 P  I  F  I  D  G  D  Y  P  E  V  V  K  S  Q  I  A  S  M  S  
 
       910       920       930        940       950       960 
caaaagcaaggctatccatcatcgaggcttccagaattcactgaagaagagaagaaaatg 
gttttcgttccgataggtagtagctccgaaggtcttaagtgacttcttctcttcttttac 
 Q  K  Q  G  Y  P  S  S  R  L  P  E  F  T  E  E  E  K  K  M  
 
       970       980       990       1000      1010      1020 
atcaaaggcactgctgatttttttgctgtgcaatattatacaactcgcttaatcaagtac 
tagtttccgtgacgactaaaaaaacgacacgttataatatgttgagcgaattagttcatg 
 I  K  G  T  A  D  F  F  A  V  Q  Y  Y  T  T  R  L  I  K  Y  
 
       1030      1040      1050      1060      1070      1080 
caggagaacaagaaaggagaactaggtattctccaggatgcggaaattgaagcttttcca 
gtcctcttgttctttcctcttgatccataagaggtcctacgcctttaacttcgaaaaggt 
 Q  E  N  K  K  G  E  L  G  I  L  Q  D  A  E  I  E  A  F  P  
 
       1090      1100      1110      1120      1130      1140 
gatccatcttggaaaaatgtggattggatctacgtggtaccttggggagtatgtaaacta 
ctaggtagaacctttttacacctaacctagatgcaccatggaacccctcatacatttgat 
 D  P  S  W  K  N  V  D  W  I  Y  V  V  P  W  G  V  C  K  L  
 
       1150      1160      1170      1180      1190      1200 
ctgaaatatattaaggatacatataataaccctgtaatttacatcactgagaatgggttt 
gactttatataattcctatgtatattattgggacattaaatgtagtgactcttacccaaa 
 L  K  Y  I  K  D  T  Y  N  N  P  V  I  Y  I  T  E  N  G  F  
 
       1210      1220      1230      1240      1250      1260 
ccccagagtgacccagcgcctcttgatgacactcaacgctgggagtatttcagacaaaca 
ggggtctcactgggtcgcggagaactactgtgagttgcgaccctcataaagtctgtttgt 
 P  Q  S  D  P  A  P  L  D  D  T  Q  R  W  E  Y  F  R  Q  T  
 
       1270      1280      1290      1300      1310      1320 
tttcaggaactgttcaaagctatccaacttgataaagtcaatcttcaagtatattgtgca 
aaagtccttgacaagtttcgataggttgaactatttcagttagaagttcatataacacgt 
 F  Q  E  L  F  K  A  I  Q  L  D  K  V  N  L  Q  V  Y  C  A  
 
 
155 
 
       1330      1340      1350      1360      1370      1380 
tggtctcttctggataactttgagtggaaccagggatacagcagccggtttggtctcttc 
accagagaagacctattgaaactcaccttggtccctatgtcgtcggccaaaccagagaag 
 W  S  L  L  D  N  F  E  W  N  Q  G  Y  S  S  R  F  G  L  F  
 
       1390      1400      1410      1420      1430      1440 
cacgttgattttgaagacccagctagaccccgagtcccttacacatcggccaaggaatat 
gtgcaactaaaacttctgggtcgatctggggctcagggaatgtgtagccggttccttata 
 H  V  D  F  E  D  P  A  R  P  R  V  P  Y  T  S  A  K  E  Y  
 
       1450      1460      1470      1480      1490      1500 
gccaagatcatccgaaacaatggccttgaagcacatctcgagcaccaccaccaccaccac 
cggttctagtaggctttgttaccggaacttcgtgtagagctcgtggtggtggtggtggtg 
A  K  I  I  R  N  N  G  L  E  A  H  L  E  H  H  H  H  H  H  
 
tga 
act 
 * 
 
5.2.2  Expression of mutant human cytosolic β-glucosidase enzymes in E. coli 
As expected and seen with the wild type, expression of the mutant hCβGs were observed in 
cell pellets. The production of soluble mutant enzyme was assessed by lysing a sample of 
cell pellet by two passages through a cell disrupter at 25 kpsi (see section 2.2.3.3.) and 
centrifuged using ultra-centrifuge for 1 hr to separate the soluble and insoluble fractions. 
The average yield of protein expression for hCβG mutants were approximately 2-4 mg/L of 
bacterial culture. All the mutants were observed to express solubly and yields found to be 
comparable to the wild type protein. Hence, they could be used in the subsequent kinetic 
analysis and other characterisation. Between all the mutants, protein expression for single 
mutant was good and triple mutant was poorest, as expected. As with the wild type protein, 
the mutant hCβGs soluble proteins were subjected to a two-step purification; Nickel-IMAC 
and size exclusion column. Some bacterial protein contaminants remained in the elution 
fractions in Nickel-IMAC as shown in (Figure 5.5). Therefore, an additional size exclusion 
chromatography was necessary to obtain material with a high purity and suitable for further 
enzyme analysis. All the samples were subjected to SDS-PAGE gel both by Coomassie blue 
staining and by western blot (anti-His6) analysis. 
 
 
Xho I 
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Figure 5.5: Purification of mutant hCβG enzymes by Ni-IMAC. SDS-PAGE gels analysed by Coomassie 
blue stain (left) and anti-His6 western blot (right). M=marker; FT=column flow through; W1= 
PBS/NaCl wash;  W2=PBS/10mM Imidazole wash; W3=PBS/20mM Imidazole; 1-9=fractions of hCβG 
mutants eluted with 200mM Imidazole. Each of the mutant enzymes was observed at approximately 
55kDa as expected. However, there were many bands of impurities observed in the SDS-PAGE gel. 
 
(A)  V168A hCβG single mutant 
 
          
(B)  M172F hCβG single mutant 
 
         
 
(C)  F334A hCβG single mutant 
 
         
 
 
            M   FT   W1W2W3  1    2   3    4    5     6    7     8   9 
55  
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M     FT  W1 W2 W3 1   2    3   4   5    6   7   8   9 
    M    FT  W1 W2  W2 W3  1    2     3     4     5     6           M    FT W1 W2 W2 W3  1  2    3     4     5     6        
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 (D) V168A/M172F hCβG double mutant 
 
           
 
(E) V168A/F334 hCβG double mutant 
  
            
 
(F) M172F/F334A hCβG double mutant 
 
          
 
 
 
 
  M     FT   W1   W2  W3   1     2     3    4     5     6      7  
         M    FT  W1W2 W3 1   2   3    4    5   6     7     8    M   FT   W1  W2  W3   1     2    3    4    5     6    7    8 
55 
kDa 
M   FT   W1 W2 W3   1    2    3    4     5     6    7    
55 
kDa 
 
55 
kDa 
 M      FT   W1 W2 W3    1    2    3    4     5     6    7    
    M   FT   W1 W2  W3    1    2    3    4     5    6    7    
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 (G) V168A/M172F/F334A hCβG triple mutant 
 
           
 
It was observed that the washes with 10 mM and 20 mM Imidazole did not 
efficiently remove many contaminants in the SDS-PAGE gels. During the purification 
optimisation steps, the washes were increased to 40 mM Imidazole. However, this has 
caused some lost of the protein of interest (data not shown); therefore the washes were 
limited up to 20 mM Imidazole. Following the presence of many bacterial contaminants in 
the Ni-IMAC purified samples in all the mutants, the samples were subjected to second step 
of purification.  This was done through size exclusion chromatography. All enzymes were 
observed to elute at approximately 80-95 mins, corresponding to a molecular size of 55 kDA. 
A comparison of elution volume with the standard calibration curves (Appendix 6) and the 
wild type protein (Figure 5.6) allows an estimation of apparent molecular weight of 
fractionated proteins. Referring to the chromatograms, it is noticeable that there was a 
strong peak at around 50-60 minutes. This represents the void volume observed in all the 
hCβG samples including the wild type. This is likely due to the bacterial protein 
contamination, high salt content in the buffer used in the first step Ni-IMAC and possibly 
aggregated enzymes. Confirmation of these was done with SDS-PAGE gel which indicated 
that the protein was indeed of a higher molecular weight other than the protein of interest 
(data not shown).  
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Figure 5.6: Size exclusion chromatography of mutant human cytosolic β-glucosidase enzymes. Each 
of the mutant enzymes was eluted approximately 80-90 min, at the time expected for the 
monomeric ~55 kDa protein.  Wild type hCβG chromatography profile was included for comparison 
purposes. The numbers represent the standard protein ; 1=β-amylase (200kDa); 2=albumin (66kDa); 
3=carbonic anhydrase (29 kDa) and 4=cytochrome C (12.4 kDa). 
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Subsequent analysis was carried out to confirm the eluted protein fractions obtained 
from the size exclusion column.  Figure 5.7 summarised all the mutant hCβGs along with 
wild type hCβG protein run in a single SDS-PAGE gel.  All the hβCG protein samples were 
loaded at 1 ug of protein. The bands run identical to the wild-type protein, approximately  
55 kDa as expected and of a good purity. Notice that there were few bands at the size of 
between 17-28 kDa. These smaller size protein has also has been reported by other studies  
(Harman 2006, Tribolo et al. 2007). In this study, much effort was endeavoured to eliminate 
the small fragment but nothing was successful. It seems that something non-covalently 
aggregates with the protein or it could also be that the protein is undergoing endogenous 
proteolysis. Nevertheless, comparing this gel with the previous gels obtained by Ni-IMAC, 
the protein purity has improved greatly. By judging with naked eye, proteins were 70-90 % 
pure. Therefore, these samples were used in subsequent analysis. 
 
 
                       
Figure 5.7: Expression of β-glucosidase mutants. SDS-PAGE gels analysed by (A) Coomassie staining 
and (B) western blot (anti-His6). M=protein marker, Lanes 1=wild-type β-glucosidase, lane 2=V168A 
single mutant, lane 3=M172F single mutant, lane 4=F334A single mutant, lane 5=V168A/M172F 
double mutant, lane 6=V168A/F334A double mutant, lane 7=M172F/F334A double mutant, lane 
8=V168A/M172F/F334A triple mutant. Protein expressions were from 1L culture from freshly-
transformed BL21 (DE3) cells. One µg of each protein was loaded onto SDS-PAGE gel. 
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5.2.3 Thermal stability of hCβG  
The effect of temperature on the enzymes stability was carried out by incubating 1 µg of 
hCβG enzymes at various temperatures (0, 25, 37, 43, 50 and 100 °C); followed by the 
standard pNPGlc assay as mentioned before (see section 2.2.6.7.1). This is to show that the 
mutations have not destabilised the enzymes. The temperature range was selected to have 
a good representative of the assay.  
Figure 5.8 shows the curve of hCβG enzymes absorbance against temperatures. All 
the hCβG enzyme variants were relatively stable at 0, 25 and 37 °C shown by 100% enzyme 
activity remaining after incubation at these temperatures. As the temperature increases 
above 37 °C, the enzymes activity started to reduced. At 43 °C, most the enzymes retained 
approximately 50% of their activity with the triple mutant showed only 30% of its original 
activity. Activity of enzymes further reduced to less than 20% at 50 and 100 °C. This finding 
contradicts with that reported previously by (Berrin et al. 2002) where they described the 
hCβG enzyme has a highest hydrolysis rate at 50 °C with pNPGlc.  Judging from the graph, 
the triple mutant was observed to be less stable than the rest of the variant because there 
was a sudden drop in the activity from 100 % to 20 % between 37 to 43 °C (purple curve). 
On overall, the graph showed that all the enzymes are less stable at a temperature above 37 
°C.    
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Figure 5.8: Temperature effects on enzyme activity performed through pNPGlc assay with 1 µg of 
enzyme and 10 mM of pNPGlc substrate. The range of temperature was 0-100 °C. The percentage of 
maximal activity was calculated in reference to the enzyme activity at 0 °C. 
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5.2.4  Susceptibility of the enzyme to proteolysis 
Sensitivity of enzyme to serine proteases were carried out through treatment of the enzyme 
with trypsin and α-chymotrypsin. Trypsin is a serine protease that cleaves the peptides on 
the C-terminal side of positively-charged amino acid residue such as lysine and arginine. 
Likewise, α-chymotrypsin recognises bulky hydrophobic amino acid residues such as 
tyrosine, phenylalanine, tryptophan and leucine. Exposure of these cleavage sites within the 
hCβG enzyme to proteases will give information regarding the protein folding and stability. 
All the hCβG enzymes were subjected to the trypsin and chymotrypsin treatment separately 
as described in section 2.2.6.7.2. The digested samples were subsequently analysed on a 12 
% SDS-PAGE gel. Results shown in Figure 5.9 were compared with untreated samples (Figure 
5.7). No digestion was observed, suggesting that all the hCβG variants were resistant to both 
proteases that were tested. The result shows that the residues were inaccessible to the 
proteases due to the way the protein are folded.  The smaller bands that were seen on the 
gel between 17-28 kDa were also previously seen in the untreated samples and they were 
not a product of trypsin and α-chymotrypsin digestion. 
 
                
Figure 5.9: SDS-PAGE gels of the proteolytic analysis of the hCβG variants with A) Trypsin B) α-
chymotrypsin. The gels were analysed by Coomassie staining. M=protein marker; lanes 1=wild-type 
β-glucosidase; lane 2=V168A single mutant; lane 3=M172F single mutant; lane 4=F334A single 
mutant; lane 5=V168A/M172F double mutant; lane 6=V168A/F334A double mutant; lane 7= 
M172F/F334A double mutant; lane 8=V168A/M172F/F334A triple mutant. One µg of each protein 
was loaded onto SDS-PAGE gel. 
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5.2.5 Computer modelling of the hCβG variants 
The outcome of mutations on hCβG surface was modelled using the Pymol program 
(http://www.pymol.org/). The model was based on the information obtained from previous 
studies (Berrin et al. 2003, Tribolo et al. 2007) . The active site aglycone pocket of hCβG 3D 
structure forms an oval shaped pocket with cluster of hydrophobic amino acid chains lining 
the wall of the active site. The residues (Phe225, Val227, Tyr308, Tyr309, Phe334, Trp345 
and Phe433) representing one wall of the binding pocket marked as red and (Phe121, 
Val168, Val171, Met172, Leu176, Met178, Phe179, Phe186, Ile326 and Leu327) forming the 
opposite wall marked as green (Figure 5.10). The authors also mentioned that in hCβG 
model, loop B, C and D are shorter than the rests of the member in glycoside hydrolyses 
family, resulting in small entrance to the binding pocket. Therefore the mutations 
introduced in this study aimed to broaden the binding pocket to accommodate bulky 
linamarin substrate. The mutations that were introduced are marked and arrowed.  
Results show that V168A mutant might provide a deeper site as opposed to flatter 
rim to the pocket entrance for substrate docking (Figure 5.10 (b), yellow). The M172F 
mutation, performed previously by Harman, 2006 seemed to make the binding pocket 
smaller than before as phenylalanine is bigger in size compared to methionine (Figure 5.10 
(c), dark blue). It is thought that this might further hinder the binding of substrate into the 
active site. Although F334A mutant seemed to be quite a distance from the catalytic site, 
this mutant might have an influence on the overall structural arrangement in this region 
because this site was dominated by alanine in both cassava and white clover (Figure 5.10 
(d), light blue).                                                                
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Figure 5.10: Surface representation of hCβG variant. V168A mutation (yellow), M172F mutation (dark blue) and F334A as light blue. Double and triple 
mutations will have the combination of the colours and marked with arrows.  
         
 
        
a) Wild type  b) V168A 
mutant 
c) M172F 
mutant 
d) F334A 
mutant 
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e) V168A/M172F f) V168A/F334A  
g) M172F/F334A  h) V168A/M172F/F334A  
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5.2.6 Kinetic analysis of mutant hCβGs with p-Nitrophenyl--D-glucopyranoside (pNPGlc) 
In order to evaluate whether the expressed proteins were functionally active, kinetic 
continuous assays were carried out as described in section 2.2.6.9.2. This assay was 
performed as before with wild type hβCG towards substrate pNPGlc. The continuous assay 
was selected over end-point assay due to its convenience, speed and lower amount of 
enzyme needed. In addition, the results from both end point and continuous assays were 
comparable (as mentioned in 4.2.3.2). Figure 5.11(A) shows the effect of increasing pNPGlc 
substrate concentration on the rate of pNP production, determined by the increased in 
absorbance at 400 nm. The initial rates of reaction (v0) were calculated by linear regression 
of the data.  Each of the graphs is a representative of at least two separate experiments 
using different sample preparations. Based on the (v0) value of this graph, Lineweaver-Burk 
graph was plotted to give a straight line, from which the Vmax and Km values could be 
determined [Figure 5.11 (B)].  For analysis, all the kinetic data is summarised in Table 5.2. All 
kinetic parameters in this chapter were computed by regression fitting of the 1/v0 versus 
1/[S] graph points to the Michaelis-Menten equation. Analysis was performed using the 
Sigma Plot 11.0 software package.  
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Figure 5.11 (A): Kinetic analysis of hCβG and pNPGlc. Initial rates of reaction (v0) were calculated by linear regression of the data. 
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Figure 5.11 (B):  Lineweaver-Burk plots of the data from Figure 5.11 (A). Linear regression of the data was performed by Sigma software in order to yield 
values of Vmax and Km. Error bars were calculated from the v0 mean values of the triplicate samples (n=3).
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Human CβG  Vmax 
(abs/min) 
Vmax 
(nmol of pNP/min) 
kcat 
(sec-1) 
Km 
(mM) 
kcat/Km 
(mM-1.sec-1) 
Wild type 
 
0.02 ± 0.01 
 
0.438 ± 0.01 0.386 ± 0.01 0.29  ± 0.04 1.33 ± 0.01 
V168A 0.04 ± 0.01 0.876 ± 0.01 0.772 ± 0.01 
 
0.48 ± 0.03 1.61 ± 0.02 
M172F 
 
0.05 ± 0.01 1.095 ± 0.01 0.996 ± 0.01 0.57 ± 0.01 1.69 ± 0.01 
 
F334A 
 
0.05 ± 0.02 1.095 ± 0.02 0.996 ± 0.02 0.66 ± 0.01 1.46 ± 0.01 
 
V168A/M172F 
 
0.02 ± 0.03 0.438 ± 0.03 0.386 ± 0.03 0.38 ± 0.02 1.02 ± 0.01 
 
V168A/F334A 
 
0.03 ± 0.02 0.657 ± 0.02 0.579 ± 0.02 0.59 ± 0.02 0.98 ± 0.02 
 
M172F/F334A 0.05 ± 0.01 1.095 ± 0.01 
 
0.966 ± 0.01 0.49 ± 0.01 1.97 ± 0.01 
 
V168A/M172F/ 
F334A 
0.02 ± 0.01 0.438 ± 0.01 0.386 ± 0.01 0.38 ± 0.01 1.02 ± 0.01 
 
 
Table 5.2: Summary of the kinetic data of hCβG wild type and mutants. For reference, Vmax=rate at which all enzyme active sites are saturated with 
substrate; Km=concentration of substrate needed to achieved half of Vmax where half of the enzyme sites are filled; kcat=turnover number of enzyme in 
seconds; kcat/Km=catalytic efficiency of the enzyme. The amount of pNP released (nmol) was calculated from the absorbance value using the extinction 
coefficient of pNP (18 300 M-1cm-1) (section 2.2.6.9.3).  
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These data show that all the hCβG variants demonstrated similar affinities (Km). This 
suggests that the mutations that were engineered in hCβG were not significantly affecting 
their activities toward pNPGlc substrate. This is the key point in the enzyme mutation 
because the goal for re-engineering the mutant hCβGs was not to disrupt the enzyme 
original activity but to improve the substrate specificity of hCβG enzyme towards linamarin. 
It is very crucial that the enzyme activity is maintained as normal to functionally active, 
which has been supported by the data above.  
5.2.7 Enzyme activity with linamarin 
5.2.7.1 End point cyanide assay - screen for the best mutant 
Cyanide assays were carried out to investigate whether the mutations that were introduced 
into hCβG gene have altered the specificity of the hCβG towards plant substrate linamarin. 
Details on the experimental set up were described in section 2.2.6.9.4. The negative control 
reaction contained buffer or unrelated protein bovine serum albumin (BSA) in the place of 
the enzyme sample. Likewise, for the positive control reaction, cassava linamarase or 
potassium cyanide were used to replace the enzyme. Figure 5.12 shows the graph for 
cyanide activity.  
Based on the graph, V168A mutant showed two fold increased in cyanide activity 
compared to the wild type hCβG. This indicates the production of cyanide in the assay. 
However, the absorbance for V168A mutant was observed to be 6 and 8 fold less compared 
to the positive control cassava linamarase and the expected amount of potassium cyanide 
respectively. Previous study by Harman, 2006 did not show any activity in all the mutants 
(M172F and V168A/M172F). Hence, an increased in the activity for V168A mutant compared 
to the native enzyme showed some promising prospect of this mutation in cyanogenesis. 
The rest of the mutants showed decrease in activity, suggesting that the mutations did not 
improve the linamarin specificity in hCβG. Also, in this study it would be expected that 
F334A substitution might show some increase in activity towards linamarin for the reason 
that at this position, the phenylalanine was replaced by alanine in both cassava and white 
clover. The absorbance for F334A after overnight incubation was only 0.90nm, a fold less 
than wild type reading. From the graph, it can be concluded that any mutations which 
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involved M172F and F334A showed decreased in cyanide activity. Likewise, mutation that 
contained V168A showed some detectable cyanide activity compared to the native enzyme. 
The absorbance values obtained above were compared to the potassium cyanide 
standard curve (Figure 5.13). The graph is a representative of at least two separate 
experiments using different sample preparations. An estimation of cyanide produced by 
each of the enzymes was summarised in Table 5.3. The V168A mutant produced 1.08 ± 0.01 
mM compared to wild type hCβG (0.47 ± 0.03 mM), cassava linamarase (6.56 ± 0.03 mM) 
and potassium cyanide (8.88 ± 0.12 mM).  Notice that 1 µg of cassava linamarase produced 
the same amount of cyanide compared to 5 µg cassava linamarase. Initially it is thought that 
5 µg linamarase would give far too high activity and therefore it was run along with 1 µg of 
linamarase. This data illustrates that 1 µg of linamarase was sufficient to give maximum 
cyanogenesis with 10 mM linamarin.   
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Figure 5.12: Cyanide activity of human cytosolic β-glucosidase variants. The assay was performed with 10 mM Linamarin and 5 µg of enzyme variants. The 
bar chart shows the readings taken at 4, 8 and 24 hours. The data labels are indicated for 24 hours of reaction. The insert focussed on the bar chart for the 
hCβG enzyme variants. Error bars were calculated from the absorbance mean values of the triplicate samples (n=3). 
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Human CβG 
 enzyme variant WT V168A M172F F334A 
V168A/ 
M172F 
V168A/ 
F334A 
M172F/ 
F334A 
V168A/ 
M172F/ 
F334A 
Cassava 
Linamarase 
1ug 
Cassava 
Linamarase 
5ug 
KCN 
10mM 
Negative 
control 
(buffer) 
Negative 
control 
(BSA) 
Absorbance (562 nm) 
after 24 hrs 
2.3168   
± 0.03 
5.3505   
± 0.01 
0.9660   
± 0.01 
0.8983   
± 0.03 
1.2760   
± 0.01 
1.2545   
± 0.01 
0.5710   
± 0.01 
1.8355 
± 0.01 
32.6250     
± 0.06 
32.3225     
± 0.03 
43.7400 
± 0.12 
0.3463    
± 0.00 
0.0128   
± 0.00 
CN- concentration 
(mM) 
0.47        
± 0.03 
1.08       
± 0.01 
0.19       
± 0.01 
0.18       
± 0.03 
0.25        
± 0.01 
0.25        
± 0.01 
0.11        
± 0.01 
0.37     
± 0.01 
6.62            
± 0.06 
6.56            
± 0.03 
8.88        
± 0.12 
0.07        
± 0.00 
0.00       
± 0.00 
 
Table 5.3: Cyanide activity of hCβG variants. The table shows the absorbance from the cyanide assay and cyanide concentration produced was calculated 
from the potassium cyanide standard curve (above). The data is a representative of at least two experiments using different samples preparations. 
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Figure 5.13: KCN standard standard curve. 
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5.2.7.2 Kinetic Analysis of mutant hCβGs with cassava linamarin 
Following the interesting result for V168A mutant, a full kinetic analysis was carried out to 
follow the reaction in a timely manner and also to obtain the Michaelis constants (Km) and 
maximum velocity (Vmax). The kinetic assay was carried using the end point assay, similar as 
before but with shorter interval for the sample reading (see section 2.2.6.9.4). The end point 
assay was selected due to safety reason because the addition of the succimide buffer would 
stop cyanogenesis and avoid evaporation of the cyanide while readings were taken. The 
assay was carried out with wild type hCβG, V168A mutant and cassava linamarase. Figure 
5.14 (A) shows the graph of these enzymes with different concentration of cassava 
linamarin ranging from 10 – 0.5 mM. Similar to what was seen in pNPG assay (section 5.2.6), 
there was a direct correlation between linamarin and the rate of cyanide production, which 
was shown by the increased in absorbance readings at 562 nm and intense colour 
formation. The initial rates of reaction (v0) were calculated by linear regression of the data. 
Each of the graphs is a representative of at least two separate experiments using different 
sample preparations. Based on the v0 value of this graph, a Lineweaver-Burk graph was 
plotted to give a straight line, from which the Michaelis constants (Km) and maximum 
velocities (Vmax) were determined [Figure 5.14 (B)]. All the kinetic data is summarised in 
Table 5.4. The value of the Michaelis constants for cassava linamarase (Km=1.11 ± 0.04 mM) 
was essentially in agreement with those obtained in other studies; Km between 0.88 ± 0.01 
to 1.2 ± 0.1 mM (Keresztessy, Kiss and Hughes 1994, Keresztessy et al. 1996, Kousparou, 
Epenetos and Deonarain 2002). On the other hand, the Vmax values differed due to many 
factors such as the purity of the protein, assay temperature and variation in assay 
procedures. Many other authors isolated and purified cassava enzyme themselves with 
various purity and homogeneity. However, linamarase used in this study was commercially 
prepared and of a high purity (AG Scientific, Inc) (gel not shown). In this study, the assay 
with cassava linamarase was carried out at 37 :C because it was used as a positive control 
against the wild type hCβG and V168A mutant, under the same experimental condition. It 
would be expected that the cassava linamarase activity obtained in this study was lower 
than those obtained in previous studies because the enzyme was reported to have an 
optimal activity at 55 °C (Mkpong et al. 1990, McMahon, White and Syare 1995).     
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Figure 5.14 (A): Kinetic analysis of wild type hCβG, V168A 
mutant and cassava linamarase with cassava linamarin.  
Initial rates of reaction (v0) were calculated by linear 
regression of the data. 
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Figure 5.14 (B): Lineweaver-Burk plots of the data from Figure 
5.14 (A). Linear regression of the data was performed by Sigma 
software in order to yield the values of Vmax and Km. Error bars were 
calculated from the v0  mean values of the triplicate samples (n=3). 
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β-Glucosidase  
 
Vmax 
(abs/hr) 
 
Vmax 
(nmol of cyanide/hr) 
 
kcat 
(min-1) 
 
Km 
(mM) 
 
kcat/Km 
(mM-1.min-1) 
Wild type 0.02 ±0.01 1.22 ±0.01 0.21 ±0.01 2.23 ±0.03 0.09 ±0.02 
V168A 0.51 ±0.02 31.1 ±0.01 5.49 ±0.01 0.79 ±0.02 6.95 ±0.01 
Cassava 
linamarase 
4.27 ±0.02 260 ±0.02 54.5 ±0.02 1.11 ±0.04 49.1 ±0.04 
 
Table 5.4: Summary of the kinetic data of wild type hCβG, V168A mutant and cassava linamarase 
with cassava linamarin. For reference, Vmax=rate at which all enzyme active sites are saturated with 
substrate; Km=concentration of substrate needed to achieved half of Vmax where half of the enzyme 
sites are filled; kcat=turnover number of enzyme in minute; kcat/Km=catalytic efficiency of the enzyme. 
 
 
The Km value for V168A mutant has improved almost 3 fold than wild type hCβG and 
was comparable to the cassava linamarase. This shows that the mutation has increased the 
binding affinity for linamarin. The Vmax for V168A mutant was 25 fold higher than the wild 
type but 8 times lower than the cassava linamarase. Generally, mutation on enzyme is 
expected to affect the Km value but not change the Vmax. In an event where the enzyme has 
poor affinity, Vmax could still be achieved by saturating the enzyme with excess substrate. 
However, the increased of Vmax seen here suggests that the mutation have altered the active 
sites by providing a deeper site for substrate docking and subsequently exposing the 
substrate to the catalytic sites. This hypothesis was supported with the computer modelling 
(Figure 5.6 b) that showed the altered site . However structural biology studies have to be 
done in future to verify this hypothesis. In addition, the catalytic efficiency of the mutant 
enzyme has improved 77 times compared to the wild type although it was 7 times less than 
the cassava linamarase. These data suggest that the substitution of V168A leads to 
significantly increase in hydrolysis of linamarin. Although the value is far from the cassava 
linamarase, the increased in activity suggests possible ways to generate a human 
cyanogenic enzyme. 
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5.2.8 In vitro cytotoxicity of β-glucosidase 
The kinetic enzyme assays have shown that the V168A mutant has shown significant 
increase in the hydrolysis of cassava linamarin to produce cyanide. However, this assay was 
taken based on colorimetric measurement and therefore might not accurately represent the 
amount of cyanide produced. Also, it is crucial that the cyanide that is being produced could 
actually demonstrate some cell kill activity in tumour cells. Therefore, a cell kill assay was 
carried out in order to determine the cell survival rates after incubation of the enzyme with 
linamarin. The assay was described in detail in section 2.2.6.9.6. The kit utilises the MTS 
tetrazolium compound (Owen’s reagent) which is bio-reduced by live cells into a coloured 
formazan product. This conversion is accomplished by NADPH or NADH produced by 
dehydrogenase enzymes in metabolically active cells. The assay was conducted to test the 
ability of the hCβG enzyme to hydrolyse linamarin and produce cell kill effect. This assay was 
a non-targeted cyanide assay; which means no antibody binding was involved in the setup 
and cells were treated with free enzyme in the cell medium. Therefore, the result obtained 
here might be higher than that would be expected for the targeted cyanide assay. Figure 
5.15 shows the result of the cell killing with 3 different cell lines [WI38 (VA13), U87 and 
SKOV3 cells]. These cell lines represent some of the most common cancers affecting man 
and also known to have significantly high levels of ED-B FN expression (Czabanka et al. 
2011). The assay was repeated three times and the following graph is a representative of 
the data.  
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Figure 5.15: In vitro cell cytotoxicity assay. Survival percentages of WI38(VA13), U87 and SKOV3 cells treated with wild type hCβG and V168A mutant  
enzyme with linamarase  along with negative and positive controls. Error bars were calculated from the absorbance mean values of the triplicate samples  
(n=3).
                             Negative controls                                                  Experimental                            Positive controls 
                                                                                                                  samples 
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All the negative controls either with only cell, enzyme, substrate, unrelated protein 
(BSA) or BSA with linamarin, showed no killing effect on the cells and hence approximately  
100% cell survival was observed. Despite this, some significant cell killing was seen when the 
SKOV3 cells were treated with BSA alone or BSA with linamarin (Figure 5.15). The cell killing 
effect was not due to cyanide production and not expected because the BSA was used as 
negative control experiment. Hence, it is thought that BSA might have cytotoxicity effect on 
SKOV3 cells or perhaps the addition BSA to the medium prevents cells adhesion onto the 
plates. 
Likewise, with the positive controls where the cells were treated with either 
potassium cyanide, Triton X-100 (cell lysis) or plant linamarase with linamarin showed 
approximately 90-100% cell killing. For the experimental samples, each contained either the 
wild type hCβG or V168A mutant with linamarin showed some cell killing. The calculated 
percentage of cell survival for wild type hCβG in all the cell lines was within the range of   
51-62 % while for V168A mutant was 6-38 %. Among the three cell lines, U87 cells were 
observed to be more sensitive to the cyanide killing while SKOV3 showed more resistant to 
the toxic molecules. Previous studies with linamarase/linamarin system using gene therapy 
approach have shown the IC50 values (concentration of cytotoxic agents required at which 
50% of the cells are killed) in various cell lines were around 2.3-3.8 µM of linamarin (Cortés 
et al. 2002, Idibie, Davids and Iyuke 2007, García-Escudero, Gargini and Izquierdo 2008). This 
values are in parallel with most of clinical chemotherapy drugs which show IC50 values 
within micro molar (µM) range. Another study using AGENT approach  showed rather higher 
IC50 value of 6 mM (Kousparou et al. 2002). It was suggested that not enough cyanide was 
produced in the system and many other issues regarding to the enzyme as mentioned 
earlier.   
The assay was further extended to study the effect of varying concentration of either 
enzymes or substrate. This was done with U87 because it was the most sensitive cell among 
the three cell lines. Cyanide induced cytotoxicity in U87 cells appeared to be in a 
concentration-dependent manner with either the enzyme or substrate varying 
concentration. Figure 5.16 (A) and (B) show percentage of cell survival after 48 hours post-
treatment with the relevant samples. As predicted, when the enzyme concentration 
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increases, the cell kill activity increases. This however reaches a point where there were no 
significant increase in the cell kill activity regardless of the amount of enzyme applied. 
Similar percentages of survival ~50 % (wild type hCβG) and 8 % (V168A mutant) when 
treated with either 5 µg or 10 µg of the enzyme and constant amount of substrate linamarin 
(10 mM). This suggests the depletion of substrate in the present of excess of enzyme in the 
reaction [Figure 5.16 (A)]. Likewise when treated with constant amount of each enzyme      
(5 µg), the percentages of cell survival were similar for 10 mM and 20 mM of linamarin;    
~50 % (wild type hCβG)  and  8%  (V168A mutant) [Figure 5.16 (B)]. It is assumed that at this 
point the enzymes have been fully saturated with the substrate and therefore there was no 
further increase in the rate of cyanogenesis. 
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Figure 5.16 (A): In vitro cell cytotoxicity with varying enzyme concentration. Survival percentages of U87 cells treated with different concentration of wild 
type hCβG and V168A mutant enzyme (1 µg, 5 µg and 10 µg) and constant 10 mM linamarin.             = negative controls,           = positive controls,         = wild 
type hCβG and          = V168A mutant. Error bars were calculated from the absorbance mean values of the triplicate samples (n=3). 
                     Negative controls                                                 Positive controls            Wild type hCβG      V168A mutant 
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Figure 5.16 (B) : In vitro cell cytotoxicity with varying substrate concentration. Survival percentages of U87 cells treated with different concentration of 
substrate linamarin (2mM, 5mM, 10mM and 20mM) and constant each enzyme wild type hCβG and V168A mutant (5 µg each).           = negative controls,             
         = positive controls,        = wild type hCβG and        = V168A mutant. Error bars were calculated from the absorbance mean values of the triplicate 
samples (n=3). 
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5.3 DISCUSSION 
This chapter describes the production of 7 mutant hCβG enzymes with the aim of  altering 
the enzyme specificity towards cyanogenic glycoside linamarin. The mutant hCβGs 
expression followed the previously optimised method used to produce wild type hCβG using 
pET23b vector and expressed in BL21(λDE3) E. coli. The main issue concerning the human 
enzyme is that the enzyme is not highly biological active towards cyanogenic substrate 
linamarin. It is thought that through molecular biology manipulation in combination with 
structural biology information; substrate binding properties of the human enzyme could be 
engineered to allow enzyme hydrolysis of substrate linamarin. 
Based on the structural biology knowledge and amino acid sequences of the β-
glucosidases family, site directed mutagenesis (SDM) was carried out on the hCβG gene. 
This method of mutation was preferred over the random mutagenesis as it allows specific, 
fast and convenient way of mutagenesis. In addition, it overcomes the screening problem 
associated with random mutagenesis. Also, structural knowledge was available from the 
previous studies (Berrin et al. 2003, Tribolo et al. 2007), therefore rational SDM was possible 
in this study. Mutation valine at position 168 (V168) in hCβG was selected because this site 
was concluded by many (Keresztessy et al. 1994, Berrin et al. 2003, Tribolo et al. 2007) to be 
essential for binding of aglycone moiety and was considered as one of the residues that 
forms an inner hydrophobic cluster that surrounds the glycosidic linkage within the enzyme.  
The shape of the aglycone binding pocket prefers rigid and planar substrate with some of 
the loops are shorter than other members of this enzyme family, resulting in flatter rim to 
the pocket entrance (Berrin et al. 2003, Tribolo et al. 2007). It is assumed that the side 
chains of hCβG may provide a steric hindrance and might be the reason why hCβG could not 
accommodate the tetrahedral structure of linamarin aglycone in its binding pocket.  
Substitution of this valine into smaller alanine at position 168 was decided after aligning the 
hCβG amino acid sequence with cassava and white clover enzyme. This position is 
dominated by alanine in cassava.  A study has described a mutation at this site with 
tyrosine, the corresponding amino acid in LPH domain III (Berrin et al. 2003). The mutation 
showed a significant decrease in activity towards many substrates tested showing the 
importance of the residue in substrate specificity. 
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The second residue was engineered previously by Harman 2006, where it involved 
methionine at position 172 (M172) in human enzyme. M172 was described as unique 
residue for hCβG and one of the residues that represent hydrophobic environment that is 
further away from the cleavage point (Berrin et al. 2003, Tribolo et al. 2007). It was also 
reported to be important for contacting the aglycone moiety. Comparison with the plant 
enzyme revealed that phenylalanine (cassava) and asparagine (white clover) are at the 
equivalent position. Because the asparagine is more neutral and hydrophilic whilst 
phenylalanine is hydrophobic, the latter was chosen to substitute methionine to retain its 
hydrophobic character at this position. Previous study have also selected this site for 
mutation but replaced this site with a smaller, hydrophobic leucine residue (Tribolo et al. 
2007). The mutant enzyme activity was observed to be comparable to the native hCβG with 
pNPGlc.  
The third residue selected for mutation was phenylalanine at position 334 in hCβG. 
Similar to M172, this residue is also positioned at a distance from the cleavage point. 
Alignment of hCβG with plant enzymes showed that alanine dominates this position. 
Alanine is smaller than phenylalanine and retains its hydrophobic nature, therefore is a good 
candidate for mutagenesis. In addition, this residue was mentioned to be one of the 
residues that is important for substrate binding (Berrin et al. 2003, Tribolo et al. 2007). 
There were other residues that constitute the aglycone binding pocket within hCβG. 
Alignment of hCβG, cassava and white clover showed that many of these residues are well 
conserved among these three species. For example, F179 and F433 residues are present in 
the binding pocket of many GH1 enzymes and at the same physical position with hCβG 
(Tribolo et al. 2007). Also, Trp345 is highly conserved among GH1 and function in 
hydrolysing the bulky aromatic conjugated glycosides. Nevertheless, there are few sites that 
could possibly be the candidate for future mutations. In this study, three single mutants 
were selected and each of them was combined to give double mutations and triple 
mutations. If time was permitted, other mutations would have been investigated. Possible 
sites are V171G and M172V. 
All the mutants were successfully expressed within the acceptable range 2-4 mg/ml 
with the addition of IPTG as opposed by previous study (Harman 2006). However, it was 
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observed that the protein expression efficiency decreases as the number of mutation 
introduced into the gene increases. For example, expression of triple mutant 
V168A/M172F/F334A was the poorest compared to the single mutant. This was perhaps 
due to stability of the mutant protein, codon usage, endogenous proteolysis and incapability 
of the mutant protein to fold correctly. Generally, all 7 mutant enzymes were stable 
compared to the wild type but the triple mutant looked a little less stable which could 
account for its decreased in expression. 
Temperature effect on the activity and stability of enzyme showed that the hCβG 
enzymes were relatively stable with 100 % activity between 0-37 °C. A sharp decreased in 
activity about 50 % at 43 °C was observed showing that the enzymes were not stable after 
incubation at temperature above 37 °C. As the tumour microenvironment would have 
slightly higher temperature approximately 37.5-38.0 °C, the enzyme would be expected to 
retain at least 80 % of the activity. Thermal inactivation occurs at 50 and 100 °C as expected 
because the protein was denatured at high temperature.  Likewise, assay with proteinases 
gave a good indication regarding the protein folding and conformation (Evnin et. al, 1990). 
As seen in the results with both trypsin and chymotrypsin, all the hCβG variants showed 
resistant to serine proteases. It is predicted that the proteins are correctly-folded resulting 
in a compact structure which was inaccessible by the proteases. The importance of this 
assay was to investigate the susceptibility of the enzyme to proteases as they are 
responsible for catalyzing the hydrolysis of the peptide bonds. If in any case the hCβG 
variants are sensitive to the proteases and show fragmentation, this suggests that enzymes 
are instable and might be misfolded. Both the temperature and proteases assays showed 
that the stability of the mutant enzymes was well tolerated. Hence, any decreased or 
increased in activities were due to mutations and not degradation of proteins. In future, 
chemical stability of the hCβG enzymes could also be tested with guanidium hydrochloride 
(GuHCl) or urea. This is to investigate the sensitivity of hCβG enzymes to GuHCl or urea 
denaturation. Loss of pNPGlc activity and changes in secondary structure upon increasing 
concentration of GuHCl or urea would be predicted. 
The ability of the wild type and mutant hCβGs to hydrolyse pNPGlc substrate was 
assessed to investigate the effect of mutations on enzyme specificity. The associated kinetic 
191 
 
parameters Vmax, Km, kcat and kcat/Km were determined from the average of triplicate 
reactions at varying substrate concentration. All the hCβG mutants showed some activity 
towards pNPGlc which were comparable to wild type hCβG. Although the activity was 
slightly increased, the ability of the mutant enzymes to hydrolyse pNPGlc was not altered 
significantly. This was seen in all the kinetic parameters. Previous study (Tribolo et al. 2007) 
reported similar Km for the wild type hCβG (0.38 ±0.02 mM) which is in a good agreement 
with the data obtained in this study. It is important that the mutations that were introduced 
in the hCβGs did not alter the enzyme activity as the aim was to improve the ability of the 
enzyme to hydrolyse the substrate linamarin. However, (Berrin et al. 2003, Tribolo et al. 
2007) have shown a higher kcat and kcat/Km value, due to the higher Vmax value that resulted 
in high turnover number. This discrepancy could be due to the differences in the protein 
expression system, method of enzyme purification and assay system. However, in overall 
the kinetic parameters of the mutants were in a good agreement with the wild type hCβG. 
As a eukaryote, yeast has many advantages over bacteria for the expression of 
recombinant protein. It has more advance systems for protein processing, folding and post-
translational modification than bacteria and therefore suits the production of human 
protein. Pichia pastoris is particularly attractive host for secreted expression as it does not 
secrete many endogenous proteins. Therefore, heterologous expressed protein represents 
the dominant species in the media, hence facilitates the purification process. Also, the 
secreted hCβG in Pichia pastoris may get glycosylated and this might affect the enzyme 
activity. These might be the reasons why the hCβG expressed by (Berrin et al. 2003, Tribolo 
et al. 2007) showed better activity compared to this current study. 
On the other hand, bacterial expression system has limitation compared to the 
higher order organism such as yeast or mammalian cells. This is due to less complex protein 
folding machinery and absence of post-translation modification such as glycosylation. 
However, the enzyme was reported to be active in its monomeric, non-glycosylated form 
(Daniels et al. 1981) and was shown in this study to be expressed intracellularly in E. coli and 
functionally active. Nevertheless, protein expression in bacterial expression system was 
contaminated with bacteria host protein and exposed to endogenous proteolysis. Hence, 
less purity might be the reasons for the reduced activity observed here in comparison with 
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enzyme expressed in yeast. Above all, bacterial system provides ease for manipulation, 
rapid, cost-effective for mutants production and benefit of later fusion work with the huBC-
1 scFv that uses E. coli expression system. 
Following the kinetic assay with pNPGlc substrate, cyanogenesis activity of the hCβG 
enzymes with linamarin was investigated using an end-point assay. This was the highlight of 
this study in order to investigate whether the rational mutagenesis have any significant 
effect on the ability of enzyme to produce cyanide. Increased in V168A mutant activity 
approximately 2–fold compared to wild type showed that substitution of this residue into 
smaller alanine had some improvement in the ability of the enzyme to recognize the 
cyanogenic glycoside. It is predicted that alanine has provided a deeper docking for the 
substrate at the pocket entrance seen in the surface representation of this mutant (Figure 
5.10 b).  All other mutants showed decrease in cyanogenesis activity. Reduced activity in 
M172F mutant might be due to the increase in size of the residue from 149 to 165 g/mol 
(methionine to phenylalanine). The rationale behind this mutation because the site was 
unique to hCβG and the equivalent residue at this position in cassava was phenylalanine. 
M172F mutation assumed to have further hindered the substrate binding in the  active site 
which was reflected by poor activity on linamarin. Mutation F334A was predicted to give a 
promising result since this site was dominated by alanine in both cassava and white clover. 
In addition, phenylalanine was mutated into a smaller alanine residue that could open up 
the docking site for linamarin. Surprisingly, enzyme activity with linamarin did not show any 
increase in cyanogenesis activity. This might be due to F334A is located further away from 
cleavage site and might function in contributing to the hydrophobic character of the wall. 
Double mutations which involved V168A mutant showed some activity but were still far too 
low compared to wild type hCβG. This might be due to the effect of other mutants that 
hinder the substrate binding.   
In Table 5.3, cyanide activity with 10 mM of KCN gave 8.88 mM measureable amount 
of cyanide, which was quite near to the expected value. The 10% discrepancy might due to 
inaccuracy of the colorimetric assay or the cyanide was evaporated away. Likewise, upon 
complete conversion, 1 µg and 5 µg of linamarase was expected to give 10 mM of cyanide. 
However, it was observed that the enzyme has lost approximately 30% of the cyanide 
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suggesting that the enzyme has not completed the reactions. This might require prolong 
incubation for completion of the reactions. 
To further elucidate the effect of V168A mutant on hydrolysis of linamarin, enzyme 
kinetics were carried out to obtain some kinetic data (Figure 5.14).  The data further support 
the increase in enzyme activity with linamarin done previously (Figure 5.12). The Km of the 
V168A mutant was 3 fold better than wild type hCβG and comparable to the cassava 
linamarase (Table 5.4). The V168A mutant catalytic efficiency (kcat/Km) dramatically 
increased up 77 fold higher in comparison to wild type hCβG and 7 fold lesser than cassava 
linamarase. These results suggest that the substitution of valine into alanine at position 168 
has improved enzyme binding and specificity for linamarin. The result was in accordance 
with the previously published data that mentioned Val168 is a key residue to determine 
aglycone specificity (Berrin et al. 2003, Tribolo et al. 2007). 
The increase of V168A mutant activity addressed the question whether the mutant 
could actually show some cell kill. The result of in vitro cytotoxicity showed what would be 
expected for the mutant with cell killing up to 60-90 % depending on the cell lines (Figure 
5.15). Surprisingly there were some cell kill activities observed for wild type hCβG despite 
many other studies mentioning the inability of the wild type enzyme to hydrolyse the 
linamarin. It is not known whether the absorbance was due to the background or could be 
spontaneous cleavage. Further investigation on varying concentration of either enzyme or 
substrate showed that the amount needed for optimal cell kill was 5 µg (enzyme) and 10 
mM (substrate) (Figure 5.16). It should be noted that the cell kill assay was run for maximum 
48 hours following treatment of enzyme and substrate linamarin. Any cyanide generation 
and accumulation was only limited during this duration to make sure that the cell death was 
not due to acidity of media.  
The IC90 value for V168A mutant was estimated to be approximately 10 mM of 
linamarin (Figure 5.16 B). In the previous gene therapy studies which exploited the plant 
linamarase gene, the IC90 values were estimated to be around 10 µM linamarin (Cortés et al. 
1998, Cortés et al. 2002, García-Escudero et al. 2008). Based on this, the V168A mutant is 
1000 times less effective compare to plant linamarase in cell killing. On the other hand, 
another AGENT study utilising plant linamarase gene (Kousparou et al. 2002) showed that 
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MFE anti-CEA-linamarase fusion protein achieved an IC90 value of 10 mM linamarin; which 
was similar obtained in non-targeted cell kill assay in this study. Thus, it would be expected 
that the IC90 of fusion V168A mutant in a targeted assay would be higher than 10 mM. The 
crude comparison suggests that the mutant enzyme might not be as effective as the plant 
linamarase in cell killing. At the very least, the result could provide the basis for future 
mutation even if it is not a good candidate for AGENT.  
There are many successful examples of site-directed mutagenesis in altering the 
enzyme active site for substrate recognition. NADH and NADPH are ubiquitous coenzymes in 
biological reactions. They have distinct metabolic functions, but they differ only by an 
additional phosphate group. Normally, glutathione reductase catalyses the reduction of 
oxidized glutathione (GSSG) to glutathione (GSH) using NADPH as reducing coenzyme. The 
enzyme is of wide-spread importance in maintaining the reduced state of the cell and in 
more specialised pathways, such as DNA biosynthesis.  However, because NADPH is much 
more expensive than NADH, a study to change the enzyme preference for NADH is of great 
importance for biotechnology applications. Therefore, the coenzyme specificity of E. coli 
glutathione reductase was switched from NADPH to NADH by modifying the environment of 
the 2’-phosphate binding sites through a set of point mutations based on known structure 
of human enzyme (Scrutton, Berry and Perham 1990). Among the mutants produced, 
replacement of Ala179 by glycine through single or multiple mutations were found to be 
beneficial. A dramatic increased of E. coli glutathione reductase affinity for NAD, with Km 
value of 40-fold lower than the wild type enzyme and up to 24 fold increased in catalytic 
efficiency (kcat/Km). Also, this mutation has little effect on kinetic parameters of NADPH. 
Another work was done to alter the substrate specificity of lactate dehydrogenase 
(LDH) from pyruvate to oxaloacetate; which naturally is the substrate for malate 
dehydrogenase (MDH) (Wilks et al. 1988). Three point mutations were carried out on LDH 
and one of these mutations, Gln102Arg provided an effective and highly specific for the new 
substrate. The effect of mutation was very large; the kcat/Km of LDH for oxaloacetate was 
improved by three orders of magnitude while that for pyruvate was worsened by four 
orders of magnitude. The LDH mutant enzyme has a catalytic efficiency for oxaloacetate of 
195 
 
4.2 X 106 M-1s-1 and turnover number of 250 s-1, which were equal to that of native LDH for 
its natural substrate, pyruvate.  
2-deoxyribose-5-phosphate aldolase (DERA) reversibly catalyses the condensation of 
two aldehydes and has been used in synthesis of anti-tumour agent epothilone A. However, 
DERA has a strong preference for phosphorylated substrates, which severely limits its 
applicability in organic synthesis. (DeSantis et al. 2003) have used a rational design approach 
to switch the substrate preference of DERA from phosphorylated to non-phosphorylated D-
2-deoxyribose substrates. Therefore, they designed 5 variants and of these, S238D mutant 
was capable of catalysing the new substrate with 2.5 fold increase in activity to yield D-
glyceraldehyde and acetyldehyde. Also, the mutant enzyme was approximately 7000-fold 
more selective than wild type enzyme toward this new non-phosphorylated substrate 
compared to the natural substrate.  
All of the above examples provide a tool to generate proteins with new or improved 
properties as a means to complement the shortcomings of known natural enzymes. The 
principles and strategies described form the basis of this study and could be applicable to 
other enzymes to further expand their scope of utility. 
Although the structural biology knowledge was available for the hCβG enzyme 
(Berrin et al. 2003, Tribolo et al. 2007), lack of detail understanding of position and 
interaction of substrate linamarin may be the cause of less successful result in this study. 
There was no structure of hCβG with a bound linamarin available. The X-ray crystallography 
or NMR study would provide information regarding the length, type of interactions and the 
atomic-scale differences due to the arrangement of the linamarin within the hCβG enzyme 
active sites. It would also provide the information on the charges involve in the enzyme-
substrate binding that could help in mutant sites selection. Charges play a role in the overall 
balance on the stability of the complexes in enzyme. The binding of enzyme and substrate 
might produce conformational changes through rearrangement of loop. This was shown 
previously with the native lactate dehydrogenase (LDH), a rearrangement of a polypeptide 
chain loop (residues 98-110) which was originally positioned away from the body of the 
protein, would close over the active sites due to the binding of coenzyme and substrate 
pyruvate (Wilks et al. 1988). Knowledge of this could help to bring the correct substrate 
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recognition groups into the active centre and the charge-pairing would enable prediction of 
the catalytic and charged residues to rearrange at their catalytically effective positions.  It 
would have been useful to get some expert opinion on enzyme modelling with linamarin. 
Nevertheless, the basic computer modelling (Figure 5.10) provides the preliminary data 
regarding the substrate specificity of hCβG mutants towards linamarin. Also, it  gives an idea 
on the position of substrate docking into the enzyme active sites. 
Another important tool is to perform circular dichroism (CD) spectra to estimate the 
protein secondary structure and folding properties of the mutant hCβGs. It would be 
interesting to know whether the mutations or binding interactions between the enzyme and 
substrate would affect the enzyme conformation or stability. Thus it would give some 
information on the protein interactions. Although CD does not give structure of specific 
residues as X-ray crystallography or NMR study, the method is rapid and easy to perform 
with small amount of sample. In this study, CD was performed for all the mutant hCβGs and 
compared to the wild type hCβG. The data all looked similar suggesting that the secondary 
structures of the mutant proteins have not been altered (data not shown). However, more 
input is needed to interpret the data. 
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6.1 INTRODUCTION 
This chapter describes the construction and expression of huBC-1 scFv antibody-V168A 
mutant hCβG enzyme fusion protein. The construct was cloned into different vectors and 
expressed in several E. coli strains. Also, it details the strategies employed to produce the 
fusion, purify and refold the insoluble protein.  
There are a number of scFv-enzyme fusion proteins has been explored and 
developed as tools in diagnostic and therapy. Two ways of joining the antibody and enzyme 
are either through chemical conjugation or gene fusion. Each of these methods has its own 
advantages and disadvantages but the resulting fusion protein is expected to retain the 
selectivity of the parent molecule to the tumour sites; hence minimising cytotoxicity of the 
active drug to normal cells. In the early years, chemical conjugations were employed widely 
but with the advances in molecular biology, interest has shifted towards gene fusion. 
 Chemical conjugation involves direct covalent linkage of drugs, toxins or enzymes to 
antibodies using heterobifunctional agents. Thus, antibody conjugates are relatively large 
molecule with less potential for diffusing through a tumour than small drug molecule itself.  
The method raised concerns whether the enzyme would mask the antibody-binding site or 
the antibody would mask the enzyme active site. In addition, uniform products were 
difficult to attain with batch production methods and there is a need to produce large 
quantities of the conjugated product for clinical applications. It is clear that an alternative 
method is needed and thus gene fusion provides a better choice for this purpose. The 
principle is to engineer a fusion construct which consists of gene encoding the antibody and 
enzyme, subsequently expressing the fusion protein in a suitable expression system.  
The advantages of fusion protein over the conjugation method include the ability 
and ease to modify these genes to match requirements. This means amino acid substitution 
could be introduced in order to customise the proteins for their intended applications. Such 
fusion proteins are molecularly defined and following purification would consist of single 
molecular entities. In addition, the relatively small size fusion protein in comparison to 
chemical conjugation, favours tumour penetration and rapid clearance from blood or other 
normal tissues. However, retention time at tumour sites may be shorter than that obtained 
with earlier chemical conjugates, thus this requires a different strategy in timing of prodrug 
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administration. Technically, in some cases, it can be difficult to express a fully functional 
fusion protein due to the difference in expression and folding requirements of the two 
proteins. In this study, the antibody requires disulphide bond for stability and correct 
folding. Thus, the antibody needs to be secreted extracellularly via the periplasm of E. coli 
due to the oxidising environment compared to the reducing environment in cytoplasm. In 
contrast, the hCβG enzyme is a cytosolic protein that is active as monomer. This results in 
dilemma of whether the fusion protein should be secreted extracellularly or cytosolically. 
Also, the choice of protein expression system whether it is eukaryotic or prokaryotic 
organism, needs to be compatible for both the fusion genes under the same growth 
requirement. In this study, it is proposed that the gene fusion of huBC-1 scFv-V168A mutant 
hCβG would give a dimeric molecule with a potential targeting characteristic and cell 
cytotoxicity for AGENT. The immunofusion was favoured over chemical conjugation because 
the recombinant fusion protein can be reproducibly expressed, tailored to give optimal 
results and overcome hurdles such as immunogenicity and tumour penetration.  
One of the well characterised systems for antibody-enzyme fusion protein and is the 
only system for which the pilot clinical studies have commenced is anti-carcinoembryogenic 
antigen (CEA) antibody fused to carboxypeptidase G2 enzyme (CPG2)(Bagshawe et al. 1991, 
Francis et al. 2002, Mayer et al. 2006). CEA is an oncofetal antigen, detectable on many 
tumours and luminal surface of the gut while the CPG2 is a bacterial enzyme with no 
mammalian homologue. The enzyme has been exploited to cleave glutamic acid from a 
variety of prodrugs to release potent nitrogen mustards (Springer et al. 1990, Chester et al. 
2000, Sharma et al. 2005, Mayer et al. 2006). The CEA-CPG2 immunofusion showed 
favourable tumour : plasma and tumour : normal tissue ratios, with high tumour localisation 
and retention of active enzyme. There are many studies done with this system with 
different variants of antibodies, prodrugs and clearing agent to enhance its application in 
clinical use (as mentioned earlier in section 1.5.2) (Napier et al. 2000, Francis et al. 2002, 
Mayer et al. 2004, Sharma et al. 2005, Mayer et al. 2006, Kogelberg et al. 2007). 
Another example of successful fusion protein is CC49 scFv antibody-β-lactamase 
enzyme. CC49 is a clinically validated antibody with specificity for TAG-72, a carbohydrate 
epitope that is over expressed and exposed on the cell surface in a large fraction of solid 
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malignancies. Likewise, β-lactamase is highly specific for β-lactam-based prodrugs with 
minimal interference from mammalian enzymes.  The fusion protein possessed a similar 
binding specificity relative to the parent antibody and also showed prolonged retention in 
tumour-bearing mice with tumour : plasma ratio of up to 1000. Preliminary evaluation of 
the fusion protein in combination with a prodrug resulted in significant efficacy in a 
colorectal xenograft tumour model and supports the utility of the protein as an agent for 
tumour-selective prodrug activation (Alderson et al. 2006). 
In AGENT, cancer cells targeting with antibody-plant β-glucosidase (linamarase) 
fusion protein was first described by (Kousparou, Epenetos and Deonarain 2002). The 
linamarase gene was genetically fused to the MFE-23 anti-CEA antibody gene, expressed in 
Saccharomyces cerevisiae and tested for binding and specific cytotoxicity following 
activation of linamarin. Fusion protein showed that it retained antigen binding; however the 
enzyme suffered from aggregation and was reported to have reduced catalytic activity 
compared to the native material. Aggregation was predicted due to improper folding during 
protein expression in yeast that has resulted in multimerisation of the subunit. Also, the 
difference in post-translational modifications between yeast and plant cassava might 
contribute to aggregation of the molecule (Hughes et al. 1992). Nevertheless, significant and 
targeted cytotoxicity could still be observed by cyanide intoxication. Preliminary in vivo 
characterisation showed that the fusion enzyme had high blood clearance rate presumably 
due to the carbohydrate mediated hepatic clearance and aggregation-induced splenocyte 
uptake. Due to these, there was high amount of fusion protein in liver and spleen but poor 
tumour accumulation. Although some enzyme activity was seen at the tumour sites, 
significant amount of cyanogenic activity in the liver and spleen would not be an ideal for 
clinical application. These limitations indicate that the clinical prospects of the fusion 
protein were not too promising. Furthermore, another drawback of the fusion protein was 
the origin of the proteins, with murine antibody and plant enzyme, immune response in 
human could be triggered. Nevertheless, the system showed potential for improvement of 
nitrile approach and used as the basis in this current study.  
Following the convincing data from previous studies and the potential for AGENT 
approach, an alternative enzyme was sought to overcome the problems encountered 
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before. The human cytosolic β-glucosidase (hCβG) represents an attractive candidate for the 
enzyme fusion due to its broad specificity and its human origin, hence minimising the 
immunogenic issues. Since the enzyme is a non-glycosylated protein (Daniels et al. 1981), 
clearance rate could be minimised to allow longer retention time at the tumour sites. Also, 
it allows protein expression in a simple bacterial system. On the other hand, despite 
hydrolysing a wide range of substrate, hCβG does not hydrolyse linamarin to any significant 
level. Consequently, by reshaping the enzyme active site, it is anticipated that the enzyme 
could show some significant activity towards linamarin and produce active cyanide (as 
discusses in mentioned in chapter 5). These mutant enzymes were designed to mimic the 
natural cyanogenic plant linaramase and eventually fused to antibody for AGENT. 
Aims 
This chapter aims to generate and characterise a fusion protein of huBC-1 scFv-V168 mutant 
hCβG enzyme. The fusion protein would be a used in AGENT. 
Objectives 
 To design and engineer different strategies for fusion gene construct  
 To express the fusion gene in E. coli 
 To purify the fusion protein for further characterisation of enzyme 
 To assess antibody binding affinity and enzyme reactivity towards pNPGlc and  
linamarin 
 To assess the stability of the fusion protein 
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6.2 RESULTS 
6.2.1 Strategies for the fusion constructs 
To target the enzyme to the tumour sites, V168A mutant hCβG gene was fused at its N-
terminal to huBC-1 scFv antibody gene to produce a fusion construct. The hypothesis is by 
fusing the huBC-1 scFv antibody and hCβG mutant enzyme, the antibody will allow specific 
targeting to the ED-B FN expressing cells while the active hCβG V168A mutant enzyme 
would hydrolyse substrate linamarin to produce cyanide at the tumour blood vessels. Fusion 
protein expression was carried out in E. coli strain using two different strategies to allow 
comparison of a better expression system for the fusion construct (Figure 6.1). The dilemma 
encountered when the huBC-1 scFv antibody required disulphide bond formation for its 
stability and thus must be secreted to the bacterial periplasm that provides oxidising 
environment. In contrast, the hCβG enzyme is a cytosolic enzyme and does not need to be 
secreted. Thus, the strategies utilised two different plasmids in order to have the option of 
extracellular and intracellular fusion protein expression, in each case favours the expression 
of huBC-1 scFv antibody or hCβG enzyme respectively. In parallel with the V168A mutant 
fusion construct, wild type hCβG fusion constructs was also performed as a control.  
 
 
Figure 6.1: Schematic diagram of the recombinant construct for huBC-1 scFv- hCβG fusion gene. 
Manipulations were carried out for each wild type hCβG and V168A mutant in (A) pHEN2 vector and 
(B) pET23b.  
Figure 6.1 illustrates the schematic diagram of the fusion constructs.  Construction of 
recombinant huBC-1 scFv-wild type hCβG and huBC-1 scFv-V168A mutant were carried out 
in pHEN2 (original plasmid for huBC-1 scFv construct) and pET23b (original plasmid for hCβG 
construct). The former plasmid is controlled by a lac promoter, followed by pelB leader 
pHEN2 vector 
pET23b vector 
B 
A 
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sequence for protein secretion into extracellular and consists of C-terminal His6- and myc -
tags for protein purification. The latter plasmid is driven by T7 promoter and consists of C-
terminal His6-tag. In both cases, the C-terminal antibody gene was linked to the N- terminal 
enzyme at the respective restriction sites. Digestions, ligations and transformations were 
performed as described in section 2.2.1.3, 2.2.1.4 and 2.2.2. 
6.2.2 Cloning of fusion construct into bacterial expression vector pHEN2 
The gene for wild type or V168A mutant hCβG enzyme was inserted into the pHEN2-huBC-1 
scFv vector which serves as a template. However, in order to facilitate the subcloning into 
the vector of interest, new restriction sites were needed to be incorporated at either 5’ or 3’ 
end of the gene. Because the gene itself contains several restriction sites, careful 
considerations were taken in designing the new restriction sites. Primers hCβGNot1FOR and 
hCβGNot1REV were employed to incorporate the corresponding sites at 5’ and 3’ end. For 
the sequence of oligonucleotides, see section 2.1.6. Amplification reaction was set up with 
pHEN2-huBC-1 scFv as the template (section 2.2.1.7). Products of expected size were 
analysed by    1% agarose gel electrophoresis, extracted and subsequently digested with the 
respective restriction enzyme. Figure 6.2 shows the hCβG genes and pHEN2-huBC-1 scFv 
template for cloning.        
         WT hCβG gene             V168A mutant gene               pHEN2 huBC-1 scFv template              
 Not I/Not I       Not I/Not I          linearised (Not I) and  
                  dephosphorylated 
                                            
   
Figure 6.2: Analysis of hCβG gene and pHEN2 vector-huBC-1 scFv template. Amplified DNAs 
were gel purified and digested with NotI.  
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The fragments were ligated into the multiple cloning sites of similarly digested template to 
create a fusion gene construct of a) pHEN2-huBC-1 scFv-WT hCβG and b) pHEN2-huBC-1 
scFv–V168A mutant. The contructs in pHEN2 vector were transformed into chemically 
competent HB2151 E. coli. Transformants were analysed by colony PCR screening using 
BC1endFOR and hCβG10REV primers and gave a band of approximately 800 bp (Figure 6.3).  
(A) pHEN2-huBC-1 scFv/WT hCβG 
                           
(B) pHEN2-huBC-1 scFv /V168A mutant  
             
Figure 6.3: Colony PCR screening of the fusion construct transformants. Reactions were carried out 
using BC1endFOR and hCβG10REV primers. A) pHEN2-huBC-1 scFv-WT hCβG transformants and        
B) pHEN2-huBC-1 scFv-V168A mutant transformants. Lane M=Molecular marker; Lane 1-20= 
reactions containing transformants of pHEN2-huBC-1 scFv–hCβG; N=negative control reactions 
containing water in replacement of transformant; P=positive, reactions containing pET23b-huBC-1 
scFv–hCβG. The correctly ligated clones were identified by the presence of a single band at 
approximately 800 bp, as observed in the positive reaction. 
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Fusion constructs from pHEN2 vector were selected and confirmed by DNA sequencing 
primers (LMB3FOR, FDSEQ1REV, BC1endFOR and hCβG10REV). The primer sequences are 
listed in section 2.1.6. The fully sequence-verified clones (Appendix 15) were retained for 
each of the fusion constructs. This allowed subsequent investigation of protein expression.  
6.2.3 Small scale expression with pHEN2 vector 
Small scale expression was carried out for both pHEN2-huBC-1 scFv-WT hCβG and pHEN2-
huBC-1 scFv-V168 mutant in HB2151 strain using the method used previously to express 
huBC-1 scFv antibody (see section 2.2.3.1). Temperature for protein expression was lowered 
to 18 °C to allow sufficient time for the enzyme fusion protein to fold correctly like the 
native enzyme in pET23b vector. A control was done with pHEN2 vector DNA only. In each 
of the expression set ups, samples both from supernatant and pellet were run on a 12 % 
SDS-PAGE gel (Figure 6.4). 
The pHEN2 vector contains a pelB leader sequence, therefore would direct the 
secretion of fusion protein expression extracellularly. Thus, the fusion protein would be 
expected in the bacterial culture supernatant. This strategy was to target the fusion protein 
into the periplasm, where the presence of protein-disulphide isomerase and an oxidizing 
environment would ensure proper folding and disulphide bond formation of the antibody 
domain. However, based on result in Figure 6.4, no detectable expression of fusion protein 
was observed (~81 kDa) in both Coomassie blue and western blot (anti-His6) for the 
supernatant. Investigation on the cell pellet also showed that no protein was present. 
Additional investigation on the bacterial periplasm showed the same result (data not 
shown). Although the clones were sequence-verified, it was surprising that no expression 
was observed. Further attempts to elucidate the reasons were not followed as the parallel 
cytosolic fusion protein expression was more promising. 
 
 
 
 
206 
 
(A) Supernatant  
 
                  
(B) Pellet 
 
                    
Figure 6.4: SDS-PAGE gel of huBC-1 scFv-WT hCβG and huBC-1 scFv-V168A mutant protein 
expression from pHEN2 in E. coli strain HB2151. A) Samples were taken from supernatant                 
B) samples were taken from cell pellets. M=marker; 1-5=clones from huBC-1 scFv-WT hCβG samples;    
6 – 10=clones from huBC-1 scFv -V168A mutant; 11= pHEN2 vector only control.  
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6.2.4  Cloning of fusion construct into an alternative bacterial expression pET23b vector 
In parallel to the secreted vector, an alternative vector was also selected. Vector pET23b 
was the original vector for the hCβG enzyme expression. Therefore fusion construct was 
carried out by inserting huBC-1 scFv gene into each pET23b-WT hCβG and pET23b-V168A 
mutant. This vector suited the enzyme well. Therefore, fusion protein would be expressed in 
cytosol. Similar to before, new restriction sites were needed to be incorporated at either 5’ 
or 3’ end of the gene. Primers BC1Nhe1FOR and BC1Not1Rev were used to incorporate the 
corresponding sites at 5’ and 3’ end of huBC-1 scFv gene. For the sequence of 
oligonucleotides, see section 2.1.6. Amplification reaction was set up as described in section 
2.2.1.7. Products of expected size were analysed by 1 % agarose gel electrophoresis, 
extracted, subsequently digested with respective restriction enzyme and ligated. Figure 6.5 
shows the huBC-1 scFv genes, pET23b-WT hCβG and pET23b-V168 mutant.  
             HuBC-1 scFv BC1 gene             pET23b-WT hCβG template       pET23b-V168A hCβG template                      
                        NheI/NotI                                    (NheI         NotI)                        ( NheI        NotI)  
 
                                                                                       
 
Figure 6.5: Analysis of huBC-1 scFv gene and pET23b-hCβG template. Amplified DNAs were gel 
purified and digested with NheI and NotI.  
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The constructs in pET23b vector were transformed into chemically competent XL-1 blue 
strain. Transformants were analysed by colony PCR screening using BC1endFOR and 
hCβG10REV primers and gave a band of approximately 800 bp (Figure 6.6).  
               (A) pET23b-huBC-1 scFv -WT hCβG   (B) pET23b-huBC-1 scFv -V168Amutant 
 
                           
Figure 6.6: Colony PCR screening of the fusion construct transformants. Reactions were carried out 
using BC1endFOR and hCβG10REV primers. A) pET23b-huBC-1 scFv-WT hCβG transformants and       
B) pET23b huBC-1 scFv-V168A mutant. M = Molecular marker; Lane 1-10 = reactions containing 
transformants of pHEN2-huBC-1 scFv –hCβG. The correctly ligated clones were identified by the 
presence of a single band at approximately 800 bp. 
 
The complete DNA sequence of fusion constructs from pET23b vector was confirmed 
by DNA sequencing using T7, T7 Term, BC1endFOR and hCβG10REV primers (See Appendix 
16 for the full sequence). The fully sequence-verified clones for each fusion constructs were 
retained for subsequent investigation of expression.  
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6.2.5 Small scale expression in pET23b 
Small scale expression was carried out for both pET23b -huBC-1 scFv-WT hCβG and pET23b-
huBC-1 scFv-V168 mutant in BL21 (λDE3) cells. However, as mentioned earlier, pET23b does 
not have secretion signals, thus the protein expression would be in cytosol. This will be a 
problem for correct antibody folding due to the reducing environment in cytosol. Therefore, 
another expression system was employed to overcome these issues; using Origami (λDE3) 
cells.  
Origami(λDE3) cells were favoured compared to BL21 (λDE3) cells because the cells 
have mutations in both the thioredoxin reductase (trxB) and glutathione reductase (gor) 
genes, which greatly enhance disulfide bond formation in cytoplasm (Bessette et al. 1999). 
Studies have shown convincing evidence regarding significant amount of functional, 
disulphide-containing scFv antibody expression in the Origami (λDE3) cells cytoplasm 
(Proba, Ge and Plückthun 1995, Heo et al. 2006). Some of these studies reported a 10-fold 
more active protein obtained in Origami (λDE3) cells than in another host (Heo et al. 2006). 
Both the E. coli strains contained IPTG inducible T7 RNA polymerase which was crucial for T7 
promoter in pET23b. It would be interesting to compare both expression systems for the 
huBC-1 scFv-hCβG fusion protein. Figure 6.7 shows SDS-PAGE gel for the fusion constructs in 
both E. coli strains. A whole cell was loaded on gel as a preliminary screening of protein 
expression.  
(A) Expression in BL21 (λDE3) cells  
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(B) Expression in Origami (λDE3) cells 
  
                 
Figure 6.7: SDS-PAGE gel of huBC-1 scFv-WT hCβG and huBC-1 scFv-V168A mutant protein 
expression from pET23b in E. coli strain (A) BL21 (λDE3) and (B) Origami (λDE3). All the samples 
were taken from cell pellets. M=marker; 1-5=clones from huBC-1 scFv-WT hCβG samples; 6–10= 
clones from huBC-1 scFv -V168A mutant; 11-12=pET23b vector only control.  
 
SDS-PAGE gel analysis from bacterial cell pellets revealed that fusion protein expression at 
81 kDa for both BL21 (λDE3) and Origami (λDE3) cells and was confirmed with anti-His6-tag. 
This was in parallel with the estimated protein molecular weight. Considering the significant 
expression observed from pET23b expression plasmid compared to pHEN2, it was decided 
that the pET23b system should be utilised for subsequent analysis on protein expression.  
6.2.6 Large scale expression in pET23b 
The fusion protein expression was scaled-up to produce sufficient material for subsequent 
analysis. For each pET23b-huBC-1 scFv-WT hCβG and pET23b-huBC-1 scFv-V168 mutant, 
expression was done with both BL21 (λDE3) and Origami (λDE3) cells. It is worth mentioning 
that although good protein yield was observed in the small scale expression, the solubility of 
the protein was still in question.  SDS-PAGE gels in Figure 6.7 were the result of the proteins 
from whole cells; therefore there were a mixture of insoluble and soluble proteins in the 
bands observed. The question was how much of these proteins were soluble to allow 
further analysis. Large scale protein expression was done as described before in section 
2.2.3.2. Cells were lysed, centrifuged to separate the soluble and insoluble fractions and Ni-
IMAC purified (see section 2.2.3.3 and 2.2.4.2).  
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(A) Expression in BL21(λDE3) 
  
                     
              
Figure 6.8: Large scale expression of fusion constructs from pET23b in BL21 (λDE3). SDS-PAGE gels shows (i) huBC-1 scFv- WT hCβG (ii) huBC-1 scFv –V168A 
mutant (iii) vector only analysed by Coomassie staining and anti-His6 western blot. M=marker; 1=supernatant from overnight expression; 2=pellet after cell 
lysis; 3=supernatant after cell lysis; 4=Flow through from Nickel column; 5=wash with PBS/NACl; 6=wash with 10mM Imidazole; 7=wash with 20mM 
Imidazole; 8-13=elution with 200 Imidazole. 
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(B) Expression in Origami (λDE3) 
 
                             
                            
Figure 6.9: Large scale expression of fusion constructs from pET23b in Origami (λDE3). SDS-PAGE gels shows (i) huBC-1 scFv- WT hCβG (ii) huBC-1 scFv –
V168A mutant (iii) vector only analysed by Coomassie staining and anti-His6 western blot. M=marker; 1=supernatant from overnight expression; 2=pellet 
after cell lysis; 3=supernatant after cell lysis; 4=Flow through from Nickel column; 5=wash with PBS/NACl; 6=wash with 10mM Imidazole; 7=wash with 
20mM Imidazole; 8-13=elution with 200 Imidazole. 
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SDS-PAGE analysis with Coomassie blue staining for both BL21 (λDE3) and Origami (λDE3) 
cell pellets showed bands at the expected size at around 81 kDa. However, confirmation 
with anti-His6 western blotting shows that the fusion proteins remained in bacterial cell 
pellet after cell lysis. No detectable expression of the fusion protein in the supernatant after 
cell lysis and subsequent purification samples. The bands observed in the Coomassie 
staining were contaminants from endogenous bacterial protein of a similar size as seen also 
in the control vector only expression. These suggest that the fusion protein from both 
bacterial strains formed insoluble inclusion bodies in the cytosol.  
Ideally, optimisation of protein expression should be performed. This is to improve 
the protein solubility through analysis of optimal expression temperature, IPTG induction 
concentration, buffer etc.  However due to time constraint, the study focussed on efforts to 
refold the insoluble proteins. 
6.2.7 Refolding of huBC-1 scFv – hCβG fusion protein 
Correct antibody folding required disulphide bond formation and this was compensated by 
using Origami (λDE3) cells. It was expected that fusion protein was able to be expressed as a 
soluble material. Instead, the protein was observed as insoluble aggregates in the inclusion 
bodies. This might be due to improper folding of the protein. Therefore initial attempts to 
salvage the insoluble aggregates were made through protein refolding. This utilised a simple 
and rapid dilution approach that was used successfully in previous study for scFv-RNase 
fusion protein (Deonarain and Epenetos 1998) (see section 2.2.4.7.1). This method was 
selected as the enzyme protein in particular was not expected to require disulphide bond 
formation. Hence, a less complex redox condition to fold correctly was chosen for the 
system. Samples at each step were retained to follow the process and run on 12 % SDS-
PAGE gel (Figure 6.10). 
The refolding protocol appeared to generate a lower yield of soluble protein because 
refolding was done with half of the starting material. Loss of soluble protein might also 
possible during extensive concentration step. Nevertheless, soluble fusion protein was 
produced with the method and confirmed with anti-His6 western blot.  
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Binding assay was performed by ELISA (see section 2.2.6.3.1) to investigate whether 
the antibody was correctly refolded and functional. In addition, enzyme activity assay was 
also carried out using pNPGlc substrate (see section 2.2.6.9.2.) to determine whether the 
enzyme was functionally active. Both ELISA and enzyme assays did not show any 
measurable activity although soluble fusion proteins were produced (data not shown). 
These results suggest that the fusion proteins although soluble, did not recover its 
functionality.  
 
  
 
               
 
Figure 6.10: Dilution method of refolding. Analysis of fusion protein huBC-1 scFv/ hCβG inclusion 
bodies. SDS-PAGE gel shows M=Marker, 1=pellet after cell lysis suspended in wash buffer; 
2=supernatant from washed sample; 3=supernatant after denaturation; 4=pellet after denaturation; 
5=samples after dilution in refolding buffer; 6=concentrated sample after dialysis. 
An alternative refolding protocol was tested in an attempt to produce soluble and 
active fusion protein. The protocol employed rapid dialysis as described in section 2.2.4.7.2 
and was carried out with the other half of the starting material. Samples were retained at 
each step and run on 12 % SDS-PAGE gel. Figure 6.11 shows that the fusion proteins were 
observed in the pellet after dialysis. This implies that the fusion proteins have not folded 
correctly using simple dialysis method and as a result excessive white precipitate was 
noticed during the dialysis. There was no soluble protein in the supernatant after dialysis as 
confirmed with the anti-His6 western blot. This suggests that the refolding protocol was not 
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successful. Unfortunately, due to time constraint, the investigation has put be put on hold 
up to this point as there are too many other possibilities that could be considered. 
 
 
 
 
             
 
Figure 6.11: Dialysis method of refolding. Analysis of fusion protein huBC-1 scFv/ hCβG inclusion 
bodies. SDS-PAGE gel shows M=Marker, 1=pellet after cell lysis suspended in wash buffer; 
2=supernatant after denaturation with β-mercapthoethanol; 3=pellet after dialysis in PBS; 
4=supernatant after dialysis; 5=concentrated sample after refolding. 
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6.3 DISCUSSSION 
This chapter describes the attempts to express a huBC-1 scFv–hCβG fusion protein. The E. 
coli cells were chosen for fusion protein expression as it provides ease, speed and low 
maintenance cost. Also, both the huBC-1 scFv antibody and hCβG enzyme protein were 
previously expressed individually in bacterial cells. In spite of this, the discrepancies in the 
nature of protein expression for each protein have provided the challenge in fusion protein 
engineering. The antibody required a disulphide bond to fold correctly and therefore 
protein would be secreted via the periplasm of E. coli to escape the reducing environment in 
cytoplasm. In contrast, the hCβG enzyme was active as a single polypeptide chain and 
showed no tendency to aggregate (Daniels et al. 1981, Harman 2006). A summary of the 
strategies that was employed for the engineering of the fusion construct is simplified in 
Figure 6.12. 
Successful PCR cloning of the huBC-1 scFv–hCβG fusion gene into two plasmid 
vectors were described. Small scale expression of the pHEN2 vector-fusion protein in 
HB2151 did not show any detectable amount of the protein in supernatant, periplasm or 
cell pellet. In previous studies, expression of secreted β-glucosidases utilising bacterial cells 
have been reported for only a handful of species; maize (Cicek and Esen 1999), conferin 
(Dharmawardhana, Ellis and Carlson 1999) and human lysosomal β-glucosidase (Grace and 
Grabowski 1990). All of other studies described the expression of the enzyme in bacterial 
cytosol. There were no reports of extracellular expression of the hCβG enzyme in E. coli, 
suggesting that the enzyme could possibly prefer the reduced cytosol environment and 
might be too toxic to be secreted to the periplasm. This might explain why the fusion 
protein expression in the pHEN2 secreted vector was not successful in this study. In previous 
study, there were attempts to add secretion signal (pelB leader sequence) into an 
alternative pET20b vector, however no detectable expression of hCβG enzyme either in 
induced or uninduced cultures (Harman 2006). Nevertheless, successful secreted hCβG 
expression were reported in other expression systems such as Pichia pastoris (Berrin et al. 
2002, Tribolo et al. 2007) and mammalian cells COS7 (de Graaf et al. 2001). 
In parallel to the secreted vector, an alternative pET23b vector was also selected and 
the protein expression was done with two types of E. coli strains, BL21 (λDE3) and Origami 
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(λDE3) cells. The data showed some promising results in small scale expression. In spite of 
this, large scale expression demonstrated that the fusion proteins were insoluble and 
remained in pellet after cell lysis. This might due to high level of recombinant protein 
expressed in E. coli, leading to accumulation of the insoluble aggregates as inclusion bodies. 
Inclusion bodies occur as a result of intracellular accumulation of partially folded expressed 
protein which aggregates through non-covalent hydrophobic, ionic interactions or a 
combination of both. 
Subsequent steps involved solubilisation of these inclusion bodies with high 
concentration of denaturants such guanidium hydrochloride. These methods have been 
successful for many proteins including scFvs and fusion proteins (Buchner, Pastan and 
Brinkmann 1992, Deonarain and Epenetos 1998). Exposure to the chaotropic reagents 
results in loss of secondary structure leading to random coil formation of the protein 
structure and exposure of the hydrophobic surfaces (Dill and Shortle 1991). In some cases, 
reducing agent may be used (β-mercaptoethanol) as described in the dialysis refolding 
(Section 2.2.4.7.2). This helps to maintain cysteine residues in a reduced state and thus 
prevents non-native intra- or inter-disulphide bond formation in highly concentrated protein 
solutions at alkaline pH. Also, chelating agent like EDTA prevents metal-catalysed air 
oxidation of cysteines. Solubilised proteins are then refolded in a refolding buffer by slow 
removal of the denaturant in the present of oxidizing agent (oxidized glutathione) (Vallejo 
and Rinas 2004, Fischer, Sumner and Goodenough 1993, Mayer and Buchner 2004).  
Some successful refolding examples are with fusion protein composed of a panel of 
single-chain Fv-bovine seminal ribonuclease (BSRNase) (Deonarain and Epenetos 1998). The 
insoluble fusion protein produced in E. coli inclusion bodies required extensive in vitro 
processing to recover antigen binding and ribonuclease activity. Refolding of the fusion 
protein using dilution method gave a good antigen-binding activity as well as reasonable 
ribonuclease activity. The method which was based on the earlier study by (Buchner, 
Brinkmann and Pastan 1992) is the basis of the protocol used in this study. Another example 
is a study on recombinant immunotoxins in which the VH or VL domains of MAb B3 were 
fused to a truncated form of Pseudomonas exotoxin (PE38KDEL) in E. coli (Brinkmann, Lee 
and Pastan 1993). The B3 (VH)-PE38KDEL and B3 (VL)-PE38KDEL were expressed as insoluble 
218 
 
form. Thus to obtain active recombinant toxin molecules, the proteins were refolded via 
dilution method. The refolding experiments showed that the protocol was successful in 
maintaining the antibody binding and cytotoxity as the parental molecules.  
Figure 6.12: An overview of fusion construct engineering strategies. 
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Previous study has performed protein refolding of the insoluble native hCβG enzyme 
using simple dilution, dialysis and bound matrix methods (Harman 2006). The study showed 
good recovery of soluble proteins but lack of enzyme activity. It was suggested that the 
hCβG enzyme formed a stable partially-folded aggregates during the refolding process that 
could inhibit completion of the full folding procedure. Due to lack of success in these 
approaches, the study focussed on optimising the hCβG expression conditions to its 
solubility which turned into a success. Taking this into account, it might be too complex to 
refold the hCβG enzyme in vitro and thus future strategies should be focussed on optimising 
the expression conditions of the fusion protein in order to improve the solubility of fusion 
protein.  
Refolding of inclusion body proteins into bioactive forms is cumbersome, requires 
many operational steps and most of the time results in very low recovery of refolded 
protein. The loss of secondary structure during solubilisation and interaction among the 
denatured protein molecules during refolding could result in aggregation. This is the main 
factor for the poor recovery of bioactive proteins from the inclusion bodies. Overall yield of 
bioactive protein from inclusion bodies is around 15-25% of the total protein and accounts 
for the major cost in production of recombinant protein from E. coli (Clark 2001, Panda 
2003). Thus, major challenges of bioprocess engineering have been to convert these inactive 
and insoluble proteins more efficiently into soluble and correctly folded product.  
It is possible that the fusion proteins have issues with stability and that the 
conformation of the proteins are such that they cannot be tolerated in the cytosol or 
secreted in the periplasm, thus formed inclusion bodies. The different requirements which 
affect refolding and renaturation of an active molecule differ from one protein to another, 
in this case, between huBC-1 scFv antibody and hCβG enzyme. With respect to antibody 
production, disulphide bond formation was crucial whereas that was not the case for the 
hCβG enzyme. Thus, there was a conflict regarding suitable vector and expression system. In 
the case where disulphide bonds are crucial for the protein stability such as antibody, 
formation of aggregates as inclusion bodies is quite predicted due to the reducing 
environment of bacterial cytosol. While vector pHEN2 favoured the production of huBC-1 
scFv antibody, pET23b benefited hCβG expression. However, in order to support the needs 
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for both protein productions, an alternative bacterial strain, the Origami (λDE3) cells were 
employed. These cells have mutations in both the thioredoxin reductase (trxB) and 
glutathione reductase (gor) genes, which greatly enhance disulfide bond formation in the 
cytoplasm. Despite the attempts, expression of soluble and active fusion protein was not 
successful. Based on these results, perhaps the gene construct itself should be revised.  
Looking back at the fusion protein construct, it involves linking of two proteins, 
huBC-1 scFv antibody and hCβG enzyme by a peptide linker. The selection of the linker 
sequence is particularly important for the construction of functional protein. Several studies 
have been made on linker selection (Arai et al. 2001, Crasto and Feng 2000, Robinson and 
Sauer 1998). These studies suggested that the flexibility and hydrophilicity of the linker were 
important as not to disturb the function of the domains. In this study, the loss of binding 
and enzyme activity might due to the application of the simple and short linker (Ala-Ala-Ala, 
from the Not I fusion point), causing some sort of interaction and interference between the 
two proteins. A longer linker that would provide a better spatial separation of the 
heterofunctional domains of a fusion protein might work effective. A computer program 
named LINKER has been described and could generate linker sequences for fusion protein. 
However, it should be noted that linkers that are too long could lead to instability of the 
fusion protein. A study has described a computer program that could generate linker 
sequences for fusion protein (Crasto and Feng 2000). The only required input is the desired 
linker sequence length and the program is specifically designed to assist in fusion protein 
construction. A linker sequence is important and has been shown to have significant effect 
on the folding stability of a fusion protein (Robinson and Sauer 1998). Linker sequence with 
high propensity for forming α-helical or β-strand structures should be avoided because this 
would limit the flexibility of the fusion protein and consequently affect its functional activity 
(Crasto and Feng 2000). However, there are no reliable selection criteria available for use in 
linker design, but glycine-serine linkers have been used very successfully by many 
researchers (Michael et al. 1996, Sharma et al. 2005, Afshar, Asai and Morrison 2009, Taylor 
et al. 2010).  
Dilution of solubilised protein directly into refolding buffer is a traditional and most 
commonly used method for small-scale proteins. Although it is a simple and most 
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convenient way of refolding, this method is not suitable for a large amount of recombinant 
protein as it will need large refolding vessel, a huge amount of buffer and additional 
concentration steps after protein renaturation. This will eventually leads to high cost of 
protein production (Vallejo and Rinas 2004, Tsumoto et al. 2003).  
On the other hand, in the dialysis method, the denatured and unfolded protein 
samples in concentrated denaturant solution (6M GuHCl) were dialysed against PBS. Hence, 
the protein was exposed to descending concentration of the denaturant. As the 
concentration of denaturant decreases with time to the concentration of dialysis buffer, the 
rate of protein folding into intermediate and native structure increases. However, the rate 
of misfolding or aggregation could also increase as seen in the result. In particular, 
aggregation can be greatly enhanced if the rate of folding is slow, because the decreasing 
concentration of denaturant may not be enough to keep the unfolded or intermediate 
structure stays soluble (Tsumoto et al. 2003, Singh and Panda 2005). 
There are few considerations to take into account when deciding where to fuse the 
proteins. Some proteins are expressed well as C-terminal fusions, whereas others express 
better as N-terminal fusions; this is likely the result of structural constraints that allow for 
proper folding in one orientation or another. In this study, fusion protein took place at the 
C-terminal of scFv antibody linked to N-terminal of hCβG enzyme. This orientation was 
selected because it is the most likely orientation in many antibody-protein fusions (Michael 
et al. 1996, Deonarain and Epenetos 1998, Kousparou et al. 2002, Sharma et al. 2005, Afshar 
et al. 2009). Also, proteins that contain N-terminal signal sequence (such as the scFv) are 
post-translationally processed, thus fusion to these proteins should be placed at the C-
terminus.  
It was obvious that the insoluble fusion proteins obtained in this study were due to 
improper folding. It was initially assumed that the position of N- or C- terminus might be 
buried within the enzyme that leads to structural constraint in the folding. If that is the case, 
then the fusion construct needs to be re-engineered into an alternative orientation. 
However, with reference to the crystal structure work on hCβG (Tribolo et al. 2007), both 
the N- and C- terminus were found to be exposed. This shows that there is a good chance 
for the fusion protein to work and subsequent effort could focus on finding the best method 
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for protein refolding as the protocol varies from one protein to another. However, for long 
term benefit, refolding is not an ideal option especially when the V168A single mutant itself 
had average protein yield and low activity. Future work should highlight on optimising the 
condition for fusion protein expression in E. coli to get soluble and active material. 
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Chapter 7 
General discussion and future work 
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7.1 GENERAL DISCUSSION 
Standard chemotherapy has a limited use in clinical application due to lack of specificity and 
cytotoxicity. This causes numerous side effects due to destruction of healthy tissues; 
therefore limited doses could be administered to patients. By restricting the action of 
cytotoxic molecules at cancer sites, it is possible to reduce systemic toxicity and improve the 
efficacy. Numerous efforts have been focussed on developing immunotherapy as an 
alternative to overcome the issues regarding non-specificity. Currently, there are 42 MAb 
antibodies that have been approved by FDA for therapeutic purposes, out of which 18 are 
for the treatment of various cancers and the rest are for a range of immunological targets 
(Walsh 2010). Even now, there are hundreds of MAbs that are still in laboratory 
development reflecting the promising future in this area.  
Angiogenesis is an important feature in tumour biology and an attractive target for 
immunotherapy because of the reliance of many tumour cells upon the blood vessels for 
oxygen and nutrients supply, as well as the means for metastatic spread. Due to the 
complexicity of targeting antigens on tumour cells and the many physical and kinetic 
barriers associated with this, a particularly attractive alternative is the targeting of tumour 
associated antigens expressed in blood vessels. This is due to their accessibility for blood 
borne agents, their abundance and their stable expression. The technique is known as 
vascular targeting therapy, a method which causes vasculature normalisation but also can 
lead to rapid and selective shutdown of the established tumour vasculature with the 
cytotoxic molecules, leading to secondary tumour-cell death.  
The aim of this study was to investigate the potential of anti-neovasculature 
humanised BC-1 single chain variable fragment antibody (huBC-1 scFv) and a suitable re-
engineered human cytosolic β-glucosidase (hCβG) for use in the AGENT approach. AGENT 
was developed initially as a variation of the ADEPT approach that manipulates the plant β-
glucosidase enzyme reaction of its natural substrate, cyanoglycosides to release cyanide 
(Rowlinson-Busza and Epenetos 1992). The targeted enzyme is an attractive approach in 
immunotherapy since the cyanide generated from the hydrolysis of linamarin is a small toxic 
molecule which could penetrate cells without any receptor-mediated internalisation to 
exert its action. This could potentially overcome the drug resistance issues in patients. In 
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addition, cyanide also produces the bystander effect that kills both the antigen positive and 
negative cells within the tumour microenvironment. The killing effect is further enhanced by 
the ability of the enzyme to convert many molecules of prodrug (linamarin) to cytotoxic 
cyanide. Intoxication of cyanide occurs through inhibition of the terminal mitochondrial 
enzyme, cytochrome oxidase in the respiratory chain.  
Cancer treatments using AGENT and early forms of ADEPT have remained 
experimental due to immunogenicity issues. The AGENT approach has been previously 
studied through the recombinant fusion protein composed of a scFv (MFE-23) reactive 
against carcinoembryonic antigen (CEA) and a plant derived β-glucosidase (linamarase) 
(Kousparou, Epenetos and Deonarain 2002). However, many problems were encountered 
such as the origin of the enzyme, aggregation and reduced catalytic activity which affected 
the enzyme pharmacokinetics and pharmacodynamics. The study was then followed up by 
using human cytosolic β-glucosidase (hCβG) targeting a different tumour marker; ED-B 
fibronectin (Harman 2006). Although the hCβG has broad specificity of substrate, this 
enzyme does not hydrolyse linamarin to any significant level (Berrin et al. 2002). Therefore, 
it was proposed that mutation of hCβG might be feasible to alter its substrate specificity. 
However, mutations that were carried out previously failed to improve the reactivity of the 
enzyme towards linamarin (Harman 2006).  
The ultimate goal of this study is to engineer an immunofusion composed of huBC-1 
scFv antibody and hCβG enzyme based on the concept of AGENT. The antibody would 
function in the targeting moiety and was shown to bind selectively toward ED-Β fibronectin,  
an excellent tumour marker in highly expressed transformed human cells undergoing 
angiogenesis (Carnemolla et al. 1989). The huBC-1 scFv was constructed and expressed in E. 
coli (Harman 2006). Further characterisations were necessary to re-evaluate the binding 
affinity as a comparison to the one obtained in the previous study. This was done through 
binding assay ELISA and BIACore analysis with antigen positive FN7B89 and antigen negative 
FN789 peptides. The availability of a control antigen, lacking ED-B greatly facilitates direct 
comparison for the characterisation of the antibody. The binding affinity of the huBC-1 scFv 
was compared to the parental IgG to evaluate the effects of reformatting procedure. 
Although scFv had a lower affinity compared to their parental IgG due to loss of avidity, scFv 
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still retained the selectively towards ED-B fibronectin peptide. This was proven through 
consistent and comparable Kd values obtained in both assays. In addition, BIACore analysis 
showed the reformatting of scFv significantly affects its binding affinity (kon) by around 10 
fold; however the dissociation rate (koff) was only 2 fold faster than the parental IgG. From a 
therapeutic point of view, kon could be compensated by increasing the dose of scFv with no 
resulting toxicity to get a comparable level of tumour localisation but with better 
penetration. This allows the scFv to remain at the tumour site for almost as long as IgG.  In 
the AGENT application, scFvs potentially offers a better advantage in terms of the size, 
better penetration and ultimately with the aim to produce immunofusion that is not too 
large once it is fused to enzyme. Binding of this antibody was further investigated on live 
antigen expressing cells using flow cytometry. The flow cytometry data confirmed specificity 
of huBC-1 IgG and scFv antibody binding to ED-B expressing cells WI38 (VA13) and U87, 
shown by a significant fluorescent shift. No shifts were observed in negative control 
experiment and negative antigen KB cells. This shows that huBC-1 is a good candidate for 
targeting in prodrug therapies such as AGENT. Preferably, in vivo characterisation of the 
scFv is necessary to access its relevance in clinical application. Previously, it was difficult to 
establish a model of angiogenesis because humanised BC-1 antibody does not bind to 
mouse fibronectin. However, with recent developments, this is possible using transgenic 
mice with human vasculature markers or graft human skin with blood vessels in mouse 
models which could be adapted in vivo studies near future (Petitclerc, Schalscha and Brooks 
2000, Samaniego et al. 2002, Nakada et al. 2006). 
The second part of AGENT involves a β-glucosidase enzyme, which is responsible for 
the hydrolysis of cyanogenic glycoside (linamarin) into cytotoxic cyanide to produce cell 
cytotoxicity. The hCβG has high homology and is in the same glycoside hydrolysis family 
1(GH1) with plant β-glucosidase (linamarase). Thus, the substrate binding sites of hCβG was 
manipulated and engineered to accommodate the plant substrate linamarin to allow 
cyanogenesis. This requires a rational approach and study of residues which are responsible 
for substrate recognition in hCβG. The advantage of hCβG lies in its human origin and 
because it is a cytosolic enzyme, it does not require glycosylation to be functionally active 
(Daniels et al. 1981). This overcomes the issue regarding the high clearance rates shown 
previously. 
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The hCβG enzyme was constructed and expressed in E. coli (Harman 2006) and 
showed an optimised and reproducible method. Average protein yield was 3-4 mg/L 
bacteria culture with >95% purity using a 2-step purification. Kinetic analyses were done in 
two assays; the end point and continuous assays with pNPGlc substrate respectively. 
Average Km and Vmax values from both assays were 0.34 mM and 1 nmol pNP/min which 
were in accordance with previous publish data (Harman 2006, Tribolo et al. 2007). The end 
point assay, although inaccurate due to the nature of the experiment, is more sensitive 
because of higher extinction coefficient value of the pNP product with the addition of high 
pH stop buffer. On the other hand, continuous assay was carried out in situ and gave more 
accurate readings although it was less sensitive due to low extinction coefficient value of the 
product. Kinetic values obtained for the wild type hCβG were used as a baseline parameter 
for later comparison with the mutant hCβGs. 
The main goal for this study involved construction of the human cytosolic β-
glucosidase (hCβG) mutants that are potentially able to hydrolyse the substrate linamarin. 
The structural difference among the enzyme in this family lies mainly in the loops region 
surrounding the aglycone binding sites and these are likely to influence the substrate 
specificity and recognition. On the other hand, glucose binding sites are well-conserved. 
Previous studies have shown that several mutations at the aglycone sites caused a decrease 
in activity towards a broad range of substrates. Hence, these amino acid residues were 
predicted to be essential for flavonoid glucoside binding and catalysis (Berrin et al. 2003, 
Tribolo et al. 2007). From these two studies, amino acids that were predicted to play an 
important role for substrate recognition are Val168, Phe225 and Try308. Furthermore, 
additional sites such as Trp345, Phe179, Phe334 and Phe 433 are potentially crucial for 
substrate specificity.  Glutamine (Gln307) is reported to be the unique catalytic residue 
which was only found in hCβG but not in other β-glucosidases. This residue is located 
between the two common catalytic glutamate residues Glu165 and Glu373 (Jenkins et al. 
1995). In other members of family 1 B-glucosidase, this amino acid is Asparagine (Asn) 
residue. This site is reported to be essential for catalysis in hCβG.  The overall shape and 
hydrophobic elements of aglycone binding residues of hCβG structures was in agreement 
with the substrate specificity of hCβG that prefers rigid, planar, hydrophobic moieties 
compared to long flexible alkyl chains (Tribolo et al. 2007, Berrin et al. 2002).  
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Based on these structural studies and amino acid alignment between hCβG, cassava 
and white clover, 7 mutants were constructed in this study. Average protein expression of 
mutant hCβGs was between 2-4 mg/ml. As more mutations were introduced into the gene, 
the protein expression efficiency decreased perhaps due to codon usage, endogenous 
proteolysis and incapability of the mutant protein to fold correctly. Temperature and 
protease stability tests showed that the hCβG enzymes were stable and circular dichroism 
(CD) spectra data all looked similar suggesting that the secondary structures of the mutant 
proteins have not been altered (data not shown). Also, kinetic analysis showed that all the 
hCβG mutants have no significant changes on activity towards pNPGlc and were comparable 
to wild type hCβG. This was crucial to ascertain that the mutations in the hCβG did not alter 
the enzyme activity but improved the ability of the enzyme to hydrolyse the substrate 
linamarin. One of these mutants, V168A mutant showed some significant increase in activity 
towards linamarin and generated cyanide both in spectrophotometric and cell cytotoxicty 
assays. These showed that the substitution of valine at position 168 into smaller alanine has 
provided a deeper docking for substrate at the pocket entrance of the enzyme and 
therefore improved the ability of the enzyme in recognising the linamarin. Although the Vmax 
of the mutant was low compared to cassava linamarase, the Km value was comparable and 
catalytic efficiency dramatically increased compared to wild type. The result was in 
accordance with the previously published data that V168 mutant is a key residue to 
determine aglycone specificity (Berrin et al. 2003, Tribolo et al. 2007). This promising data is 
further supported with in vitro cell cytotoxicity assay; where 60-90% cell killing was 
observed in different cell lines treated with the V168A mutant and substrate linamarin. The 
V168A mutant showed 3-8 fold increase in cell killing activity compared to wild type hCβG. 
This suggests the potential of mutant V168A as a good candidate for fusion with huBC-1 
scFv in AGENT system. Optimal cell killing effect was obtained within 48 hours, with 5 µg of 
enzyme and 10 mM of substrate. Further mutations will be required to increase the rate of 
cyanogenesis, but V168A may be enough for some in vivo tumour killing. The use of this 
mutant hCβG enzyme not only confers structural similarity with the wild type hCβG, but is 
also predicted to reduce immunogenicity in comparison with other non-human enzyme 
used in previous studies. 
229 
 
The fusion gene consists of huBC-1 scFv and V168A mutant was successfully 
constructs in pET23b vector and expressed in both BL21 (λDE3) and Origami (λDE3) bacteria 
cells.  In this study, the nature of protein expression for both antibody and enzyme has 
provided a challenge in fusion protein engineering. The antibody requires disulphide bonds 
to fold correctly and therefore protein is secreted via the periplasm of E. coli to escape the 
reducing environment in cytoplasm. In contrast, the hCβG enzyme is a cytosolic protein, 
active as a single polypeptide chain and does not need disulphide bonds to fold correctly. A 
way to overcome this conflicting issue was through expression of the fusion gene in the 
Origami (λDE3) cells. Origami(λDE3) was favoured over BL21 (λDE3) because the cells have 
mutations in both the thioredoxin reductase (trxB) and glutathione reductase (gor) genes, 
which greatly enhance disulfide bond formation in the cytoplasm (Bessette et al. 1999). This 
facilitated the fusion protein expression in the cytosol and allowed the antibody to fold 
correctly. For comparison purpose, expression of fusion protein was done in parallel with 
BL21 (λDE3).  
 Small scale expression showed that both systems yield good protein expression. 
However, large scale expression showed that the protein was insoluble and formed 
inclusion bodies.  This might due to high level expression of recombinant protein in E. coli, 
resulting in accumulation of the insoluble aggregates as inclusion bodies. Efforts were taken 
to refold the protein to gain its solubility. The first approach for refolding was by simple and 
rapid dilution method. This involved solubilisation of these inclusion bodies with high 
concentration of denaturants such as guanidium hydrochloride. This method was able to 
recover some soluble protein with low yield. However, the functional test showed that both 
antibody and enzyme had lost their activity. 
The second refolding method was done with rapid dialysis where a reducing agent 
(β-mercaptoethanol) was employed. However, the protocol was unsuccessful, fusion 
protein was retained in the pellet after dialysis and excessive white aggregate were 
observed. There was no soluble protein in the supernatant after dialysis. This might due to 
increased rate of misfolding or aggregation as the concentration of denaturant decreases. In 
particular, aggregation can be greatly enhanced if the rate of folding is slow, since the 
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decreasing concentration of denaturant may then not be enough to keep the unfolded or 
intermediate structure soluble (Tsumoto et al. 2003, Singh and Panda 2005). 
 Refolding of inclusion body protein into bioactive forms is not a preferable method 
as it is not a real therapeutic option due to inconvenience, too many steps involved and very 
low yield end product. There are some clinically-approved products that have been 
recovered by refolding (Walsh 2010). Due to time constraints, the investigation has been 
put on hold up to this point as there are too many other possibilities that could be 
endeavoured. Future studies should focus on re-optimising the refolding protocol used 
especially with the dilution method because lower yield of soluble protein was obtained 
compared to the dialysis method. Refolding done with a high concentration of starting 
material and optimised protocol would possibly produce a better yield of soluble and 
functional fusion protein. Alternatively, there are many refolding methods that could be 
employed but the two protocols chosen in this study were the most commonly used, simple 
and rapid. Another possible refolding method is through matrix-assisted refolding. The 
chelating Sepharose matrix is charged with Nickel and manipulates the His6-tagged of the 
fusion protein by binding to it. This method is similar to IMAC for protein purification 
mentioned previously but with a different series of buffers and  a linear gradient of urea 
used to carry out protein refolding.  
It could also be possible to try to express the fusion protein using different 
expression systems. The hCβG enzyme although being a non-glycosylated and cytosolic 
enzyme (Daniels et al. 1981) has been expressed and secreted extracellularly in Pichia 
pastoris (Berrin et al. 2002) and COS-7 mammalian cells (de Graaf et al. 2001). The rehCβG 
enzyme was shown to retain the biochemical, kinetic and inhibition properties with that 
wild type hCβG enzyme purified from human liver. It could be possible that expression in 
these systems may help in the protein folding as both yeast and mammalian cells contain 
complex folding machinery which is absent in the bacterial system.  As for the scFv, there 
are reported successfully expression in yeast system. A good example is shown with MFE-CP 
fusion protein (Sharma et al. 2005). The MFE antibody was first expressed in E. coli (Michael 
et al. 1996) but later changed to the yeast system to have a better protein yield and higher 
clearance rate through glycosylation, which were not feasible in the bacterial system.  
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The loss of binding and enzyme activity upon refolding might be due to the use of a 
simple and short linker (Ala-Ala-Ala, from the Not I fusion point), causing some sort of 
interaction and interference between the two proteins. A longer linker that would provide a 
better spatial separation of the heterofunctional domains of a fusion protein might work 
more effectively. A computer program named LINKER was described and could generate 
linker sequences for fusion protein (Crasto and Feng 2000). The only required input is the 
desired linker sequence length and the program is specifically designed to assist in fusion 
protein construction. A linker sequence is important and has been shown to have significant 
effect on the folding stability of a fusion protein (Robinson and Sauer 1998). Linker 
sequence with high propensity for forming α-helical or β-strand structures should be 
avoided because this would limit the flexibility of the fusion protein and consequently affect 
its functional activity (Crasto and Feng 2000). However, there are no reliable selection 
criteria available for use in linker design, but glycine-serine linkers have been used very 
successfully by many researchers (Michael et al. 1996, Sharma et al. 2005, Afshar, Asai and 
Morrison 2009, Taylor et al. 2010). The next step would be testing the soluble and 
functional fusion protein with in vitro cell targeting cytotoxicity assay and in vivo targeting in 
animal models to get the pharmacokinetics and pharmacodynamic data. 
The site-directed mutagenesis approach to alter hCβG enzyme specificity showed 
significant improvement in Km and kcat, however the values were not as good as the plant 
linamarase. Many successful studies using similar approach have shown dramatic change in 
the enzyme kinetic and specificity. A study to change the coenzyme specificity of E. coli 
glutathione reductase from NADPH to NADH by modifying the environment of the 2’-
phosphate binding sites showed a dramatic increase of E. coli glutathione reductase affinity 
for NAD, with Km value of 40-fold lower than the wild type enzyme and up to 24 fold 
increased in catalytic efficiency (kcat/Km) (Scrutton et al. 1990). Work with lactate 
dehydrogenase (LDH) to change the substrate specificity from pyruvate to oxaloacetate; 
which is the natural substrate for malate dehydrogenase (MDH) (Wilks et al. 1988). 
Mutation of Gln102Arg improved the kcat/Km of LDH for oxaloacetate by three orders of 
magnitude while that for pyruvate was worsened by four orders of magnitude. The LDH 
mutant enzyme has a catalytic efficiency for oxaloacetate equal to that of native LDH for its 
natural substrate, pyruvate. A rational design approach was also applied in switching the 
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substrate preference of 2-deoxyribose-5-phosphate aldolase (DERA) from phosphorylated to 
non-phosphorylated D-2-deoxyribose substrates. One of the mutants, S238D mutant was 
capable of catalysing the new substrate with 2.5 fold increase in activity to yield D-
glyceraldehyde and acetyldehyde. Also, the mutant enzyme was approximately 7000-fold 
more selective than wild type enzyme toward this new non-phosphorylated substrate 
compared to the natural substrate (DeSantis et al. 2003). With reference to these examples, 
future mutations with hCβG could be investigated with other possible sites such  V171G and 
M172V that were listed to be important in substrate specificity (Tribolo et al. 2007). From 
the published work, such dramatic changes in Km and activity are possible by protein 
engineering. 
Because SDM involves small variants and depends largely on structural knowledge, 
computational modelling and structural biology data are valuable for estimation of short-
range interactions involving steric contacts and hydrogen bonds between substrates and 
enzyme. Hence, this technique can provide some insights regarding the molecular basis of 
substrate selectivity and how this specificity might be changed by mutagenesis. 
Nevertheless, the challenge lies in predicting long-range electrostatic interactions and the 
effects the individual mutations might have upon protein flexibility and enzyme catalysis 
(Antikainen and Martin 2005). A powerful computational tool DENZYMER has been 
developed to assist in reprogramming the specificities and properties of proteins (Marvin 
and Hellinga 2001, Yang et al. 2003, Antikainen and Martin 2005). This program predicts the 
hydrogen-bonding, hydrophobic effect, potential hydrogen donors and acceptors, steric and 
electrostatics interactions. This technique has been applied to the design of novel variants 
of E. coli periplasmic binding proteins to bind the non-natural ligands with high affinity 
(Looger et al. 2003) and could be adapted to predict the mutant hCβGs in future. Another 
disadvantage of SDM is that it is often limited by the difficulty of predicting what specific 
amino acid replacements will lead to the preferred altered selectivity even when structural 
data is available. This is because simple mutations can lead to significant changes in protein 
catalytic activity and substrate specificity that induce large, unexpected consequences.  
Alternatively, random mutagenesis could be carried out to find mutations that 
cannot be predicted from the modelling. The technique involves random mutation of amino 
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acid sequence that leads to generation of protein library. Subsequently, the mutants are 
screened to identify novel enzyme variants that display the desired phenotype. Critical to 
the success of this technique is the availability of an efficient, reliable and rapid means of 
screening and/or selection of the library for activity (Chica, Doucet and Pelletier 2005, 
Antikainen and Martin 2005, Shaikh and Withers 2008). In the case of mutant hCβGs, if the 
library size is modest, pNPGlc enzyme activity and cyanide assay can be performed in a 
straightforward manner to determine the catalytic activity of the mutants. One could even 
contemplate screening by the gain of function using a chromogenic cyanogenic substrate, 
rather like the X-glu substrate which turns blue upon cleavage of the glucose sugar. Another 
advantage of random mutagenesis is that it involves different domains of the protein unlike 
the SDM which usually focuses on the enzyme active site. 
Another method of altering enzyme substrate selectivity is through in vitro 
evolution.  This involves randomisation of the entire gene of interest by error prone PCR 
followed by iterative rounds of screening and selection. One example for this technique is 
DNA shuffling (Stemmer 1994a, Stemmer 1994b) where a group of genes, each consisting of 
a double stranded DNA and having relatively similar sequences (from different organism or 
generated by error-prone PCR) is randomly cleaved into small fragments by enzyme 
digestion DNaseI. The fragments are then purified and reassembled in a PCR which uses 
these fragments as their primers. The fragments align and cross-prime each other for 
replication to give a hybrid DNA strand with components from different parent genes 
thereby resulting more diverse library. However, the disadvantage of this technique is that 
cross-over sites can be biased to coincide with existing restriction sites. 
Although a bacterial expression system offers many advantages, it has some 
limitations compared to the higher order systems such as yeast or mammalian cells. This is 
mainly due to the folding machinery and absence of post-translation modification such as 
glycosylation.  It is assumed that this might be the factor that affects the protein solubility. 
Expression of the soluble huBC-1 scFv-hCβG fusion protein could not be determined 
accurately due to the unsuccessful refolding method. However, the amount of insoluble 
protein in the inclusion bodies was estimated to be ~ 3-4 mg/L bacteria culture. Other 
studies have shown that expression of fusion protein (MFE-23-CPG2) in the bacteria system 
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gave an average yield of soluble purified protein of 0.25-2.20 mg/1L culture (Bhatia et al. 
2000). Subsequently, the group re-expressed the protein in Pichia pastoris to get a better 
yield and glycosylate the protein. This protein showed a marked increase in expression with 
soluble purified protein of ~ 65-110mg/L culture.  In addition, glycosylated fusion protein 
showed good clearance rate of the fusion protein from the circulation toxicity compared to 
before. Therefore, changing the expression system might be the area to focus on in the 
future studies with huBC-1 scFv-hCβG fusion protein expression. 
It is worth mentioning that AGENT is still in its early stage and still requires a lot of 
work. It is very much an experimental approach trying to deliver the benefits of cyanide as a 
cytotoxin. In comparison, it took 16 years to develop the ADEPT approach and only limited 
numbers have been tested against human tumour xenografts in nude mice with only MFE-
23-CPG2 taken into clinic (as mentioned and referenced earlier). Nevertheless this thesis is 
in the right direction towards it and provides some basis for future work.  
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Appendix 1: Sequence of huBC-1 scFv antibody 
 
 
 
  
10        20        30        40        50        60  
atgaaatacctattgcctacggcagccgctggattgttattactcgcggcccagccggcc 
tactttatggataacggatgccgtcggcgacctaacaataatgagcgccgggtcggccgg 
 M  K  Y  L  L  P  T  A  A  A  G  L  L  L  L  A  A  Q  P  A  
 
        70        80        90        100       110       120  
atggccgaggtgcagctggtgcagtctggggctgacgtgaagaagcctggggcctcagtg 
taccggctccacgtcgaccacgtcagaccccgactgcacttcttcggaccccggagtcac 
 M  A  E  V  Q  L  V  Q  S  G  A  D  V  K  K  P  G  A  S  V  
 
        130       140       150       160       170       180 
aaggtctcctgcaaggcttctggatacaccttcaccaactacgtaatgcactgggtgcga 
ttccagaggacgttccgaagacctatgtggaagtggttgatgcattacgtgacccacgct  
K  V  S  C  K  A  S  G  Y  T  F  T  N  Y  V  M  H  W  V  R  
 
        190       200       210       220       230       240 
caggcccctggacaagggcttgagtggctgggatatattaatccttacaatgatggtact 
gtccggggacctgttcccgaactcaccgaccctatataattaggaatgttactaccatga 
 Q  A  P  G  Q  G  L  E  W  L  G  Y  I  N  P  Y  N  D  G  T  
 
        250       260       270       280       290       300 
cagtacaatgagaggttcaaaggcagggtcaccatgaccggggacacgtccatcagtaca 
gtcatgttactctccaagtttccgtcccagtggtactggcccctgtgcaggtagtcatgt 
 Q  Y  N  E  R  F  K  G  R  V  T  M  T  G  D  T  S  I  S  T  
 
        310       320       330       340       350       360 
gcctatatggagctgagcaggctgacttctgacgacaccgcggtgtattactgtgcgaga 
cggatatacctcgactcgtccgactgaagactgctgtggcgccacataatgacacgctct 
 A  Y  M  E  L  S  R  L  T  S  D  D  T  A  V  Y  Y  C  A  R  
 
        370       380       390       400       410       420 
gaggtctatggtaactacatctggggcaactggggccagggaaccctggtctccgtctcg 
ctccagataccattgatgtagaccccgttgaccccggtcccttgggaccagaggcagagc 
 E  V  Y  G  N  Y  I  W  G  N  W  G  Q  G  T  L  V  S  V  S  
 
        430       440       450       460       470       480 
agtggtggaggcggttcaggcggaggtggctctggcggtagtgcacttgaaattgtgttg 
tcaccacctccgccaagtccgcctccaccgagaccgccatcacgtgaactttaacacaac 
 S  G  G  G  G  S  G  G  G  G  S  G  G  S  A  L  E  I  V  L  
 
        490       500       510       520       530       540 
acgcagtctccaggcaccctgtctttgtctccaggggaaagagccaccctctcctgcagt 
tgcgtcagaggtccgtgggacagaaacagaggtcccctttctcggtgggagaggacgtca 
 T  Q  S  P  G  T  L  S  L  S  P  G  E  R  A  T  L  S  C  S  
 
        550       560       570       580       590       600 
gccagttcaagtataagttccaattacttgcattggtaccagcagaaacctggccaggct 
cggtcaagttcatattcaaggttaatgaacgtaaccatggtcgtctttggaccggtccga 
 A  S  S  S  I  S  S  N  Y  L  H  W  Y  Q  Q  K  P  G  Q  A  
 
 
        610       620       630       640       650       660 
cccaggctcctcatctataggacgtccaatctggcttctggcatcccagacaggttcagt 
gggtccgaggagtagatatcctgcaggttagaccgaagaccgtagggtctgtccaagtca 
 P  R  L  L  I  Y  R  T  S  N  L  A  S  G  I  P  D  R  F  S  
Annotated sequence of huBC-1 single-chain antibody. The pelB leader sequence is shown in purple, 
followed by the huBC-1 variable heavy and light chains in blue and green respectively. The two antibody 
domains are separated by a linker region (shown in red). His6- and myc-tags for purification and 
detection purposes are shown in orange and pink respectively and the amber stop codon is marked with 
an asterisk. Restriction sites used for cloning are underlined in the nucleotide sequence. 
NcoI 
XhoI ApaLI 
237 
 
 
        670       680       690       700       710       720 
ggcagtgggtctgggacagacttcactctcaccatcagcagactggagcctgaagatttt 
ccgtcacccagaccctgtctgaagtgagagtggtagtcgtctgacctcggacttctaaaa 
 G  S  G  S  G  T  D  F  T  L  T  I  S  R  L  E  P  E  D  F 
  
        730       740       750       760       770       780 
gcagtgtattactgtcagcagggtagtagtataccattcacgtttggccaggggaccaag 
cgtcacataatgacagtcgtcccatcatcatatggtaagtgcaaaccggtcccctggttc 
 A  V  Y  Y  C  Q  Q  G  S  S  I  P  F  T  F  G  Q  G  T  K  
 
        790       800       810       820       830       840 
ctggagatcaatggtgcggccgcacatcatcatcaccatcacggggccgcagaacaaaaa 
gacctctagttaccacgccggcgtgtagtagtagtggtagtgccccggcgtcttgttttt 
 L  E  I  N  G  A  A  A  H  H  H  H  H  H  G  A  A  E  Q  K  
 
        850       860       870 
ctcatctcagaagaggatctgaatggggccgcatag 
gagtagagtcttctcctagacttaccccggcgtatc 
 L  I  S  E  E  D  L  N  G  A  A  * 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not I 
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Appendix 2: Raw absorbance data from ELISA 
a) Binding assay of huBC-1 IgG with FN 7B89 (Antigen positive) 
Antibody 
concentration 
(ng/ml) nM Abs 1 Abs 2 Abs 3 Mean Abs SD 
No Antigen 0.00 0.049 0.063 0.051 0.054 0.01 
No Antibody 0.00 0.05 0.065 0.096 0.070 0.02 
100 000 66.67 2.906 3.385 3.161 3.151 0.24 
50 000 33.33 3.069 3.025 3.009 3.034 0.03 
25 000 16.67 3.047 3.017 2.869 2.978 0.10 
12 500 8.33 3.026 3.061 2.769 2.952 0.16 
6250 4.17 2.851 2.912 2.613 2.792 0.16 
3125 2.09 2.821 2.746 2.473 2.680 0.18 
1562.5 1.04 2.534 2.68 2.425 2.546 0.13 
781.25 0.52 1.912 1.725 1.82 1.819 0.09 
390.63 0.26 1.762 1.692 1.581 1.678 0.09 
195.31 0.13 1.021 1.029 0.971 1.007 0.03 
97.66 0.07 0.748 0.612 0.789 0.716 0.09 
48.83 0.03 0.37 0.414 0.454 0.413 0.04 
24.41 0.02 0.213 0.217 0.204 0.211 0.01 
12.21 0.008 0.124 0.135 0.144 0.134 0.01 
6.10 0.004 0.095 0.099 0.1 0.098 0.00 
3.05 0.002 0.079 0.073 0.074 0.075 0.00 
1.53 0.001 0.07 0.063 0.066 0.066 0.00 
0.76 0.0005 0.061 0.062 0.07 0.064 0.00 
 
b) Binding assay of huBC-1 IgG with FN 789 (Antigen negative) 
Antibody 
concentration 
(ng/ml) nM Abs 1 Abs 2 Abs 3 Mean Abs SD 
No Antigen 0.00 0.054 0.062 0.055 0.057 0.00 
No Antibody 0.00 0.06 0.062 0.056 0.059 0.00 
100 000 66.67 0.08 0.089 0.079 0.083 0.01 
50 000 33.33 0.072 0.082 0.068 0.074 0.01 
25 000 16.67 0.063 0.075 0.067 0.068 0.01 
12 500 8.33 0.056 0.071 0.061 0.063 0.01 
6250 4.17 0.056 0.072 0.062 0.063 0.01 
3125 2.09 0.054 0.066 0.06 0.060 0.01 
1562.5 1.04 0.057 0.066 0.057 0.060 0.01 
781.25 0.52 0.054 0.069 0.059 0.061 0.01 
390.63 0.26 0.062 0.056 0.058 0.059 0.00 
195.31 0.13 0.057 0.066 0.057 0.060 0.01 
97.66 0.07 0.054 0.055 0.056 0.055 0.00 
48.83 0.03 0.055 0.057 0.057 0.056 0.00 
24.41 0.02 0.055 0.054 0.062 0.057 0.00 
12.21 0.008 0.065 0.06 0.058 0.061 0.00 
6.10 0.004 0.065 0.067 0.068 0.067 0.00 
3.05 0.002 0.057 0.057 0.061 0.058 0.00 
1.53 0.001 0.056 0.055 0.066 0.059 0.01 
0.76 0.0005 0.057 0.07 0.059 0.062 0.01 
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c) Binding assay of huBC-1 scFv with FN 7B89 (Antigen positive) 
 
Antibody 
concentration 
(ng/ml) nM Abs 1 Abs 2 Abs 3 Mean Abs SD 
No Antigen 0.00 0.059 0.065 0.055 0.060 0.01 
No Antibody 0.00 0.061 0.084 0.118 0.088 0.03 
100 000 66.67 0.454 0.475 0.454 0.461 0.01 
50 000 33.33 0.403 0.439 0.487 0.443 0.04 
25 000 16.67 0.425 0.352 0.488 0.422 0.07 
12 500 8.33 0.375 0.395 0.353 0.374 0.02 
6250 4.17 0.363 0.347 0.363 0.358 0.01 
3125 2.09 0.274 0.299 0.301 0.291 0.02 
1562.5 1.04 0.271 0.321 0.312 0.301 0.03 
781.25 0.52 0.237 0.271 0.265 0.258 0.02 
390.63 0.26 0.198 0.213 0.198 0.203 0.01 
195.31 0.13 0.152 0.151 0.156 0.153 0.00 
97.66 0.07 0.113 0.116 0.126 0.118 0.01 
48.83 0.03 0.153 0.111 0.116 0.127 0.02 
24.41 0.02 0.116 0.09 0.096 0.101 0.01 
12.21 0.008 0.077 0.091 0.114 0.094 0.02 
6.10 0.004 0.08 0.083 0.111 0.091 0.02 
3.05 0.002 0.079 0.076 0.07 0.075 0.00 
1.53 0.001 0.073 0.076 0.075 0.075 0.00 
0.76 0.0005 0.079 0.065 0.081 0.075 0.01 
 
d) Binding assay of huBC-1 scFv with FN 789 (Antigen negative) 
Antibody 
concentration 
(ng/ml) nM Abs 1 Abs 2 Abs 3 Mean Abs SD 
No Antigen 0.00 0.064 0.073 0.058 0.065 0.01 
No Antibody 0.00 0.057 0.072 0.062 0.064 0.01 
100 000 66.67 0.06 0.076 0.074 0.070 0.01 
50 000 33.33 0.071 0.073 0.063 0.069 0.01 
25 000 16.67 0.059 0.076 0.06 0.065 0.01 
12 500 8.33 0.06 0.09 0.061 0.070 0.02 
6250 4.17 0.055 0.077 0.061 0.064 0.01 
3125 2.09 0.059 0.086 0.062 0.069 0.01 
1562.5 1.04 0.058 0.079 0.061 0.066 0.01 
781.25 0.52 0.059 0.076 0.061 0.065 0.01 
390.63 0.26 0.06 0.06 0.062 0.061 0.00 
195.31 0.13 0.06 0.059 0.062 0.060 0.00 
97.66 0.07 0.061 0.06 0.065 0.062 0.00 
48.83 0.03 0.062 0.059 0.058 0.060 0.00 
24.41 0.02 0.067 0.059 0.068 0.065 0.00 
12.21 0.008 0.062 0.058 0.057 0.059 0.00 
6.10 0.004 0.067 0.064 0.059 0.063 0.00 
3.05 0.002 0.069 0.061 0.062 0.064 0.00 
1.53 0.001 0.065 0.063 0.066 0.065 0.00 
0.76 0.0005 0.089 0.064 0.063 0.072 0.01 
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Appendix 3: Vector map for pET23b(+) - Novagen 
 
pET23b cloning / expression region 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pET23b 
3665 bp 
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Appendix 4: Sequence of wild type hCβG enzyme 
 
Annotated sequence of pET23-hCBG. Plasmid DNA sequence between the initiation codon and Not I cloning 
site is shown in red, followed by the human cytosolic -glucosidase gene sequence in blue. The His6-tag for 
purification and detection purposes is shown in orange green and the amber stop codon is marked with an 
asterisk. Restriction sites used for cloning are underlined and the deleted Nco I restriction site is shown in 
italics in the nucleotide sequence.  
 
 
        10        20        30        40        50        60  
atggctagcatgactggtggacagcaaatgggtcgggatccgaattcgagctccgtcgac 
taccgatcgtactgaccacctgtcgtttacccagccctaggcttaagctcgaggcagctg 
 M  A  S  M  T  G  G  Q  Q  M  G  R  D  P  N  S  S  S  V  D  
 
        70        80        90        100       110       120  
aagcttgcggccgctgctttccctgcaggatttggatgggcggcagccactgcagcttat 
ttcgaacgccggcgacgaaagggacgtcctaaacctacccgccgtcggtgacgtcgaata 
 K  L  A  A  A  A  F  P  A  G  F  G  W  A  A  A  T  A  A  Y  
 
       130       140       150        160       170       180  
caagtagaaggaggctgggatgcagatggaaaaggcccttgtgtctgggacacatttact 
gttcatcttcctccgaccctacgtctaccttttccgggaacacagaccctgtgtaaatga 
 Q  V  E  G  G  W  D  A  D  G  K  G  P  C  V  W  D  T  F  T  
 
       190       200       210        220       230       240  
catcagggaggagagagagttttcaagaaccagactggcgatgtagcttgtggcagctac 
gtagtccctcctctctctcaaaagttcttggtctgaccgctacatcgaacaccgtcgatg 
 H  Q  G  G  E  R  V  F  K  N  Q  T  G  D  V  A  C  G  S  Y  
 
       250       260       270        280       290       300 
actctgtgggaggaagatttgaaatgtatcaaacagcttggattgactcattaccgcttc 
tgagacaccctccttctaaactttacatagtttgtcgaacctaactgagtaatggcgaag 
 T  L  W  E  E  D  L  K  C  I  K  Q  L  G  L  T  H  Y  R  F  
 
       310       320       330        340       350       360 
tctctttcctggtcacgtctgttacctgatgggacgacaggtttcatcaaccagaaagga 
agagaaaggaccagtgcagacaatggactaccctgctgtccaaagtagttggtctttcct 
 S  L  S  W  S  R  L  L  P  D  G  T  T  G  F  I  N  Q  K  G  
 
       370       380       390        400       410       420 
attgattattacaacaagatcatcgatgatttgttaaaaaatggggttactcccattgtg 
taactaataatgttgttctagtagctactaaacaattttttaccccaatgagggtaacac 
 I  D  Y  Y  N  K  I  I  D  D  L  L  K  N  G  V  T  P  I  V  
 
       430       440       450        460       470       480 
accctctaccactttgatttgcctcagactttagaagaccaaggaggttggttgtcagag 
tgggagatggtgaaactaaacggagtctgaaatcttctggttcctccaaccaacagtctc 
 T  L  Y  H  F  D  L  P  Q  T  L  E  D  Q  G  G  W  L  S  E  
 
       490       500       510        520       530       540 
gcaatcattgaatcctttgacaaatatgctcagttttgcttcagtacctttggggatcgt 
cgttagtaacttaggaaactgtttatacgagtcaaaacgaagtcatggaaacccctagca 
 A  I  I  E  S  F  D  K  Y  A  Q  F  C  F  S  T  F  G  D  R  
 
       550       560       570        580       590       600 
gtcaagcagtggatcaccataaatgaagctaatgttctttctgtgatgtcatatgactta 
cagttcgtcacctagtggtatttacttcgattacaagaaagacactacagtatactgaat 
 V  K  Q  W  I  T  I  N  E  A  N  V  L  S  V  M  S  Y  D  L  
 
Not I 
242 
 
       610       620       630        640       650       660 
ggtatgtttcctccgggtatccctcactttgggactggaggttatcaggcagctcataat 
ccatacaaaggaggcccatagggagtgaaaccctgacctccaatagtccgtcgagtatta 
 G  M  F  P  P  G  I  P  H  F  G  T  G  G  Y  Q  A  A  H  N  
 
       670       680       690        700       710       720 
ttgattaaggctcatgccagatcctggcacagctatgattccttatttcgaaaaaagcag 
aactaattccgagtacggtctaggaccgtgtcgatactaaggaataaagcttttttcgtc 
 L  I  K  A  H  A  R  S  W  H  S  Y  D  S  L  F  R  K  K  Q  
 
       730       740       750        760       770       780 
aaaggtatggtgtctctatcactttttgcggtctggttggaaccagcagatcccaactca 
tttccataccacagagatagtgaaaaacgccagaccaaccttggtcgtctagggttgagt 
 K  G  M  V  S  L  S  L  F  A  V  W  L  E  P  A  D  P  N  S  
 
       790       800       810        820       830       840 
gtgtctgaccaggaagctgctaaaagagccatcactttccatctggatttatttgctaaa 
cacagactggtccttcgacgattttctcggtagtgaaaggtagacctaaataaacgattt 
 V  S  D  Q  E  A  A  K  R  A  I  T  F  H  L  D  L  F  A  K  
 
       850       860       870        880       890       900 
cccatattcatcgatggtgattatcctgaagttgtcaagtctcagattgcctccatgagt 
gggtataagtagctaccactaataggacttcaacagttcagagtctaacggaggtactca 
 P  I  F  I  D  G  D  Y  P  E  V  V  K  S  Q  I  A  S  M  S  
 
       910       920       930        940       950       960 
caaaagcaaggctatccatcatcgaggcttccagaattcactgaagaagagaagaaaatg 
gttttcgttccgataggtagtagctccgaaggtcttaagtgacttcttctcttcttttac 
 Q  K  Q  G  Y  P  S  S  R  L  P  E  F  T  E  E  E  K  K  M  
 
       970       980       990       1000      1010      1020 
atcaaaggcactgctgatttttttgctgtgcaatattatacaactcgcttaatcaagtac 
tagtttccgtgacgactaaaaaaacgacacgttataatatgttgagcgaattagttcatg 
 I  K  G  T  A  D  F  F  A  V  Q  Y  Y  T  T  R  L  I  K  Y  
 
       1030      1040      1050      1060      1070      1080 
caggagaacaagaaaggagaactaggtattctccaggatgcggaaattgaattttttcca 
gtcctcttgttctttcctcttgatccataagaggtcctacgcctttaacttaaaaaaggt 
 Q  E  N  K  K  G  E  L  G  I  L  Q  D  A  E  I  E  F  F  P  
 
       1090      1100      1110      1120      1130      1140 
gatccatcttggaaaaatgtggattggatctacgtggtaccttggggagtatgtaaacta 
ctaggtagaacctttttacacctaacctagatgcaccatggaacccctcatacatttgat 
 D  P  S  W  K  N  V  D  W  I  Y  V  V  P  W  G  V  C  K  L  
 
       1150      1160      1170      1180      1190      1200 
ctgaaatatattaaggatacatataataaccctgtaatttacatcactgagaatgggttt 
gactttatataattcctatgtatattattgggacattaaatgtagtgactcttacccaaa 
 L  K  Y  I  K  D  T  Y  N  N  P  V  I  Y  I  T  E  N  G  F  
 
       1210      1220      1230      1240      1250      1260 
ccccagagtgacccagcgcctcttgatgacactcaacgctgggagtatttcagacaaaca 
ggggtctcactgggtcgcggagaactactgtgagttgcgaccctcataaagtctgtttgt 
 P  Q  S  D  P  A  P  L  D  D  T  Q  R  W  E  Y  F  R  Q  T  
 
       1270      1280      1290      1300      1310      1320 
tttcaggaactgttcaaagctatccaacttgataaagtcaatcttcaagtatattgtgca 
aaagtccttgacaagtttcgataggttgaactatttcagttagaagttcatataacacgt 
 F  Q  E  L  F  K  A  I  Q  L  D  K  V  N  L  Q  V  Y  C  A  
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       1330      1340      1350      1360      1370      1380 
tggtctcttctggataactttgagtggaaccagggatacagcagccggtttggtctcttc 
accagagaagacctattgaaactcaccttggtccctatgtcgtcggccaaaccagagaag 
 W  S  L  L  D  N  F  E  W  N  Q  G  Y  S  S  R  F  G  L  F  
 
       1390      1400      1410      1420      1430      1440 
cacgttgattttgaagacccagctagaccccgagtcccttacacatcggccaaggaatat 
gtgcaactaaaacttctgggtcgatctggggctcagggaatgtgtagccggttccttata 
 H  V  D  F  E  D  P  A  R  P  R  V  P  Y  T  S  A  K  E  Y  
 
       1450      1460      1470      1480      1490      1500 
gccaagatcatccgaaacaatggccttgaagcacatctcgagcaccaccaccaccaccac 
cggttctagtaggctttgttaccggaacttcgtgtagagctcgtggtggtggtggtggtg 
 A  K  I  I  R  N  N  G  L  E  A  H  L  E  H  H  H  H  H  H  
 
tga 
act 
 * 
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Appendix 5: Superdex-200 Gel Filtration Column Calibration Curve (A). 
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Appendix 6: Superdex-200 Gel Filtration Column Calibration Curve (B). 
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Appendix 7: Data for hCβG thermal stability. 
 
  Temp (
o
C) 0 25 37 43 50 100 
Wild type  Abs 0.5423 0.5497 0.4561 0.2671 0.1551 0.1210 
  (400 nm) 0.5635 0.5626 0.6508 0.3056 0.1577 0.1155 
    0.5618 0.5291 0.5443 0.2954 0.1648 0.1089 
  mean 0.5560 0.5471 0.5504 0.2894 0.1592 0.1151 
  SD 0.0118 0.0169 0.0975 0.0199 0.0050 0.0061 
  true mean 0.4409 0.4350 0.4389 0.1768 0.0438 0.0009 
  % 100.00 98.68 99.55 40.10 9.93 0.21 
                
V168A Abs 0.2397 0.2064 0.2208 0.1698 0.1244 0.1195 
  (400 nm) 0.2354 0.2529 0.2102 0.1891 0.1358 0.1282 
    0.2214 0.2233 0.2398 0.1742 0.1267 0.1136 
  mean 0.2322 0.2275 0.2236 0.1777 0.1290 0.1204 
  SD 0.0096 0.0235 0.0150 0.0101 0.0060 0.0073 
  true mean 0.1179 0.1155 0.1123 0.0651 0.0163 0.0076 
  % 100.01 97.92 95.23 55.21 13.79 6.42 
                
M172F Abs 0.2213 0.2238 0.2301 0.1639 0.1236 0.1080 
  (400 nm) 0.2338 0.2483 0.2393 0.1848 0.1381 0.1286 
    0.2183 0.2385 0.2107 0.1636 0.1205 0.1179 
  mean 0.2245 0.2369 0.2267 0.1708 0.1274 0.1182 
  SD 0.0082 0.0123 0.0146 0.0122 0.0094 0.0103 
  true mean 0.1140 0.1253 0.1152 0.0590 0.0138 0.0053 
  % 90.85 99.83 91.75 46.98 10.99 4.25 
                
F334A Abs 0.2853 0.2916 0.2884 0.2734 0.1328 0.1175 
  (400 nm) 0.3059 0.3162 0.3186 0.2139 0.1480 0.1197 
    0.2869 0.2927 0.2947 0.2184 0.1342 0.1076 
  mean 0.2927 0.3002 0.3006 0.2352 0.1383 0.1149 
  SD 0.0115 0.0139 0.0159 0.0331 0.0084 0.0064 
  true mean 0.1818 0.1904 0.1896 0.1248 0.0261 0.0044 
  % 95.48 100.00 99.60 65.54 13.71 2.33 
                
V168A/ Abs 0.2213 0.2138 0.2301 0.1316 0.1050 0.1119 
M172F (400 nm) 0.2338 0.2283 0.2393 0.1533 0.1168 0.1173 
    0.2183 0.2385 0.2107 0.1438 0.1111 0.1024 
  mean 0.2245 0.2269 0.2267 0.1429 0.1110 0.1105 
  SD 0.0082 0.0124 0.0146 0.0109 0.0059 0.0075 
  true mean 0.1133 0.1147 0.1115 0.0318 0.0017 -0.0005 
  % 100.00 101.24 98.41 28.05 1.47 -0.47 
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V168A/ Abs 0.1935 0.1817 0.1851 0.1539 0.1236 0.1185 
F334A (400 nm) 0.1816 0.2287 0.1849 0.1448 0.1381 0.1229 
    0.1864 0.1714 0.1844 0.1636 0.1205 0.1135 
  mean 0.1872 0.1939 0.1848 0.1541 0.1274 0.1183 
  SD 0.0060 0.0305 0.0004 0.0094 0.0094 0.0047 
  true mean 0.0752 0.0744 0.0718 0.0440 0.0154 0.0066 
  % 100.0000 98.8918 95.5231 58.4663 20.4787 8.7323 
    100.00 101.24 98.41 28.05 1.47 -0.47 
                
M172F/ Abs 0.4243 0.4027 0.4197        - 0.1626 0.1113 
F334A (400 nm) 0.4295 0.3976 0.4218 0.2892 0.1596 0.1121 
    0.4104 0.4689 0.4235 0.2551 0.1561 0.1094 
  mean 0.4214 0.4231 0.4217 0.2722 0.1594 0.1109 
  SD 0.0099 0.0398 0.0019 0.0241 0.0033 0.0014 
  true mean 0.3120 0.3106 0.3110 0.1620 0.0490 0.0000 
  % 100.00 99.56 99.68 51.93 15.71 0.00 
                
V168A/ Abs 0.1532 0.1525 0.1436 0.1190 0.1095 0.1095 
M172F/ (400 nm) 0.1535 0.1536 0.1478 0.1377 0.1225 0.1132 
F334A   0.1421 0.1429 0.1587 0.1119 0.1033 0.1088 
  mean 0.1496 0.1497 0.1500 0.1229 0.1118 0.1105 
  SD 0.0065 0.0059 0.0078 0.0133 0.0098 0.0024 
  true mean 0.0385 0.0384 0.0376 0.0098 0.0000 0.0000 
  % 100.00 99.91 97.75 25.48 0.00 0.00 
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Appendix 8 : Data used to determine kinetic parameters for wild type hCβG and pNPGlc 
substrate. 
 
a) Wild type hCβG - End point assay 
 
      Mean absorbance (400 nm)     
Time 
(min) 20 mM 10 mM 5 mM 2 mM 1 mM 0.5 mM 0.2 mM 
0.5 0.0887 0.0858 0.0773 0.0886 0.0585 0.057 0.057 
1 0.1179 0.1174 0.1108 0.1177 0.0868 0.0681 0.065 
1.5 0.169 0.1567 0.1681 0.12 0.0956 0.089 0.08 
2 0.2412 0.2143 0.1651 0.1241 0.1205 0.1055 0.093 
2.5 0.3012 0.2582 0.2054 0.155 0.1536 0.1234 0.1 
3 0.3422 0.2918 0.2413 0.2115 0.1717 0.1426 0.1309 
3.5 0.3961 0.3488 0.2789 0.2365 0.1997 0.1818 0.15 
4 0.4501 0.4036 0.3207 0.2633 0.2271 0.1913 0.165 
4.5 0.5011 0.4637 0.3608 0.2964 0.2614 0.2113 0.17 
5 0.5219 0.4632 0.4153 0.3856 0.3316 0.2507 0.181 
 
b) Wild type hCβG – continuous assay 
 
      Mean absorbance (400 nm)     
Time 
(min) 20 mM 10 mM 5 mM 2 mM  1 mM 0.5 mM 0.2 mM 
0 0.1709 0.1163 0.0857 0.0683 0.0624 0.0560 0.0539 
0.5 0.1792 0.1256 0.0948 0.0797 0.0696 0.0631 0.0616 
1 0.1882 0.1359 0.1047 0.0858 0.0777 0.0703 0.0691 
1.5 0.1975 0.1462 0.1146 0.0937 0.0858 0.0779 0.0764 
2 0.2070 0.1567 0.1247 0.1031 0.0938 0.0856 0.0838 
2.5 0.2168 0.1671 0.1346 0.1123 0.1018 0.0934 0.0910 
3 0.2265 0.1776 0.1447 0.1214 0.1098 0.1012 0.0979 
3.5 0.2372 0.1879 0.1546 0.1312 0.1179 0.1087 0.1047 
4 0.2466 0.1984 0.1645 0.1399 0.1257 0.1162 0.1111 
4.5 0.2568 0.2086 0.1740 0.1488 0.1335 0.1240 0.1174 
5 0.2668 0.2187 0.1834 0.1577 0.1413 0.1316 0.1233 
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Appendix 9: Data used to determine kinetic parameters for mutant hCβGs and pNPGlc 
substrate. 
a) V168A 
      Mean absorbance (400 nm)     
Time 
(min) 20 mM 10 mM 5 mM 2 mM  1 mM 0.5 mM 0.2 mM 
0 0.1729 0.1201 0.0932 0.0808 0.0673 0.0639 0.0599 
0.5 0.1884 0.1384 0.114 0.0916 0.0842 0.0778 0.0731 
1 0.2041 0.1549 0.1323 0.107 0.1006 0.0906 0.0851 
1.5 0.2205 0.1723 0.1509 0.1225 0.1174 0.1044 0.0968 
2 0.2357 0.1886 0.1688 0.1381 0.1347 0.1169 0.1083 
2.5 0.252 0.205 0.1871 0.1531 0.1515 0.1309 0.1191 
3 0.2698 0.2226 0.2041 0.1684 0.1684 0.143 0.1295 
3.5 0.2864 0.2395 0.2215 0.1832 0.1847 0.1545 0.1392 
4 0.305 0.2539 0.2383 0.1988 0.2007 0.1653 0.1481 
4.5 0.3221 0.2724 0.2549 0.2126 0.2162 0.1759 0.1591 
5 0.3378 0.2852 0.2714 0.2267 0.2313 0.1852 0.1694 
 
b) M172F 
 
      Mean absorbance (400 nm)     
Time 
(min) 20 mM 10 mM 5 mM 2 mM  1 mM 0.5 mM 0.2 mM 
0 0.1509 0.1150 0.0934 0.0950 0.0673 0.0639 0.0599 
0.5 0.1720 0.1416 0.1206 0.1151 0.0842 0.0778 0.0731 
1 0.1931 0.1679 0.1463 0.1341 0.1006 0.0906 0.0851 
1.5 0.2138 0.1928 0.1720 0.1541 0.1174 0.1044 0.0968 
2 0.2349 0.2176 0.1974 0.1755 0.1347 0.1169 0.1083 
2.5 0.2567 0.2424 0.2226 0.1932 0.1515 0.1309 0.1191 
3 0.2777 0.2664 0.2472 0.2127 0.1684 0.1430 0.1295 
3.5 0.2994 0.2906 0.2716 0.2319 0.1847 0.1545 0.1392 
4 0.3213 0.3141 0.2955 0.2513 0.2007 0.1653 0.1481 
4.5 0.3435 0.3375 0.3188 0.2701 0.2162 0.1759 0.1561 
5 0.3656 0.3606 0.3417 0.2889 0.2313 0.1852 0.1634 
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c) F334A 
 
      Mean absorbance (400 nm)     
Time 
(min) 20 mM 10 mM 5 mM 2 mM  1 mM 0.5 mM 0.2 mM 
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
0.5 0.0385 0.0313 0.0282 0.0181 0.0165 0.0105 0.0110 
1 0.0748 0.0617 0.0557 0.0389 0.0337 0.0233 0.0214 
1.5 0.1090 0.0910 0.0825 0.0591 0.0504 0.0359 0.0316 
2 0.1419 0.1200 0.1080 0.0787 0.0668 0.0486 0.0413 
2.5 0.1731 0.1592 0.1330 0.0978 0.0829 0.0608 0.0504 
3 0.2036 0.1753 0.1580 0.1168 0.0981 0.0728 0.0590 
3.5 0.2330 0.2017 0.1810 0.1346 0.1132 0.0840 0.0666 
4 0.2615 0.2274 0.2040 0.1508 0.1277 0.0953 0.0738 
4.5 0.2893 0.2587 0.2260 0.1682 0.1417 0.1060 0.0797 
5 0.3161 0.2761 0.2470 0.1840 0.1552 0.1170 0.0847 
 
d) V168A/M172F 
 
      Mean absorbance (400 nm)     
Time 
(min) 20 mM 10 mM 5 mM 2 mM  1 mM 0.5 mM 0.2 mM 
0 0.1729 0.1201 0.0932 0.0808 0.0673 0.0639 0.0599 
0.5 0.1884 0.1380 0.1140 0.0916 0.0842 0.0778 0.0731 
1 0.2041 0.1549 0.1323 0.1070 0.1010 0.0906 0.0851 
1.5 0.2205 0.1723 0.1510 0.1230 0.1170 0.1040 0.0968 
2 0.2357 0.1886 0.1690 0.1381 0.1350 0.1170 0.1080 
2.5 0.2520 0.2050 0.1870 0.1530 0.1520 0.1310 0.1190 
3 0.2698 0.2226 0.2040 0.1680 0.1680 0.1430 0.1300 
3.5 0.2864 0.2395 0.2220 0.1830 0.1850 0.1550 0.1390 
4 0.3050 0.2539 0.2380 0.1990 0.2010 0.1650 0.1480 
4.5 0.3221 0.2724 0.2550 0.2130 0.2160 0.1760 0.1590 
5 0.3378 0.2852 0.2710 0.2270 0.2310 0.1850 0.1690 
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e) V168A/F334A 
 
      Mean absorbance (400 nm)     
Time 
(min) 20 mM 10 mM 5 mM 2 mM  1 mM 0.5 mM 0.2 mM 
0 0.1602 0.1165 0.0882 0.0731 0.0610 0.0571 0.0557 
0.5 0.1722 0.1300 0.1012 0.0843 0.0698 0.0635 0.0610 
1 0.1844 0.1436 0.1152 0.0965 0.0791 0.0707 0.0669 
1.5 0.1972 0.1581 0.1300 0.1090 0.0888 0.0775 0.0731 
2 0.2111 0.1726 0.1440 0.1216 0.0987 0.0849 0.0792 
2.5 0.2251 0.1874 0.1590 0.1340 0.1090 0.0921 0.0854 
3 0.2393 0.2018 0.1730 0.1470 0.1190 0.0995 0.0917 
3.5 0.2542 0.2163 0.1870 0.1590 0.1290 0.1070 0.0982 
4 0.2694 0.2307 0.2020 0.1710 0.1390 0.1140 0.1040 
4.5 0.2844 0.2449 0.2150 0.1840 0.1490 0.1220 0.1090 
5 0.3002 0.2592 0.2290 0.1960 0.1590 0.1280 0.1150 
 
f) M172F/F334A 
 
      Mean absorbance (400 nm)     
Time 
(min) 20 mM 10 mM 5 mM 2 mM  1 mM 0.5 mM 0.2 mM 
0 0.1602 0.1170 0.0882 0.0731 0.0673 0.0639 0.0599 
0.5 0.1722 0.1300 0.1010 0.0843 0.0842 0.0778 0.0731 
1 0.1844 0.1440 0.1150 0.0965 0.1010 0.0906 0.0851 
1.5 0.1972 0.1580 0.1300 0.1090 0.1170 0.1040 0.0968 
2 0.2111 0.1730 0.1440 0.1220 0.1350 0.1170 0.1080 
2.5 0.2251 0.1870 0.1590 0.1340 0.1520 0.1310 0.1190 
3 0.2393 0.2020 0.1730 0.1470 0.1680 0.1430 0.1300 
3.5 0.2542 0.2160 0.1870 0.1590 0.1850 0.1550 0.1390 
4 0.2694 0.2310 0.2020 0.1710 0.2010 0.1650 0.1480 
4.5 0.2844 0.2450 0.2150 0.1840 0.2160 0.1760 0.1590 
5 0.3002 0.2590 0.2290 0.1960 0.2310 0.1850 0.1690 
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g) V168A/M172F/F334A 
 
      Mean absorbance (400 nm)     
Time 
(min) 20 mM 10 mM 5 mM 2 mM  1 mM 0.5 mM 0.2 mM 
0 0.1690 0.1149 0.0861 0.0710 0.0594 0.0554 0.0543 
0.5 0.1766 0.1230 0.0940 0.0788 0.0654 0.0603 0.0597 
1 0.1860 0.1322 0.1028 0.0870 0.0725 0.0655 0.0646 
1.5 0.1917 0.1416 0.1120 0.0955 0.0794 0.0710 0.0699 
2 0.2007 0.1516 0.1220 0.1044 0.0863 0.0793 0.0754 
2.5 0.2106 0.1617 0.1320 0.1130 0.0939 0.0847 0.0812 
3 0.2200 0.1728 0.1420 0.1220 0.1010 0.0885 0.0870 
3.5 0.2310 0.1827 0.1520 0.1300 0.1090 0.0945 0.0927 
4 0.2413 0.1929 0.1610 0.1390 0.1170 0.1010 0.0985 
4.5 0.2523 0.2038 0.1710 0.1480 0.1250 0.1070 0.1040 
5 0.2616 0.2137 0.1810 0.1560 0.1320 0.1150 0.1100 
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Appendix 10: Data used to determine kinetic parameters for hCβG enzyme variants with 
linamarin (cyanogenesis). 
 
A )Wild type hCβG  
 
    Mean absorbance (562 nm)   
Time (hrs) 10 5 2 1 0.5 
1 0.0298 0.0229 0.021 0.0261 0.0253 
2 0.0542 0.0386 0.0249 0.0255 0.0263 
3 0.0932 0.0727 0.0476 0.0386 0.0294 
4 0.1321 0.1079 0.0688 0.0443 0.0325 
5 0.1404 0.1243 0.0828 0.056 0.0362 
6 0.1539 0.1312 0.0861 0.0645 0.0434 
7 0.1732 0.1339 0.0962 0.0691 0.0454 
8 0.1835 0.142 0.094 0.0739 0.0513 
9 0.1927 0.143 0.101 0.0772 0.0553 
10 0.1983 0.1518 0.1109 0.0855 0.0575 
 
b) V168A 
 
    Mean absorbance (562 nm)   
Time (hrs) 10 5 2 1 0.5 
1 0.1005 0.0780 0.1305 0.0340 0.0245 
2 1.4678 0.8455 0.3308 0.1960 0.0753 
3 2.4380 1.8375 0.9503 0.5962 0.2730 
4 2.9340 2.6815 1.4695 0.9463 0.4253 
5 3.2405 2.8590 1.6740 1.1265 0.8223 
6 3.8370 3.6583 2.1650 1.7840 1.2720 
7 4.4328 4.1890 2.6183 2.0478 1.4463 
8 4.4765 4.1078 2.8235 2.1990 1.5293 
9 4.7283 4.2613 2.6245 2.1305 1.4685 
10 4.8058 4.4653 2.8935 2.3883 1.5228 
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c) Plant Linamarase 
 
    Mean absorbance (562 nm)   
Time (hrs) 10 5 2 1 0.5 
1 4.9920 4.3275 2.1645 1.2450 1.0800 
2 15.2905 6.6825 3.2520 2.8165 2.2045 
3 25.0215 12.6105 6.6130 4.4095 3.7010 
4 32.0160 16.0455 8.2195 6.0550 4.7225 
5 34.5015 18.4170 10.7250 8.5914 6.0385 
6 37.7120 21.5510 14.4250 10.3775 6.7060 
7 43.1645 24.1955 16.9295 13.4740 8.5180 
8 45.0770 27.2240 21.8450 15.9580 10.2330 
9 41.9285 31.9010 23.5720 16.6310 12.3900 
10 42.5345 32.8625 24.4990 17.9865 13.4965 
 
Appendix 11: Data used to determine KCN standard. 
 
 [KCN] 
mM 0.30 0.25 0.20 0.15 0.10 0.05 
Abs 1.5910 1.2500 1.0590 0.8360 0.5720 0.3420 
(562 nm) 1.5860 1.2180 1.0780 0.8130 0.5410 0.3290 
  1.6050 1.2110 1.0670 0.8130 0.5600 0.2940 
mean 1.5940 1.2263 1.0680 0.8207 0.5577 0.3217 
neg. ctrl 0.0474 0.0474 0.0474 0.0474 0.0474 0.0474 
true 
mean 1.5466 1.1789 1.0206 0.7733 0.5103 0.2743 
SD 0.01 0.02 0.01 0.01 0.02 0.02 
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Appendix 12: Data used to determine in vitro cell cytotoxicity with U87, WI38(VA13) and SKOV3 cells. 
 
        Negative  control       
            
Experiment                                                           
         
Positive  control   
Cell 
line 
 
  Cell  Linamarin 
Wild 
type V168A BSA 
BSA(5 µg) 
+ 
Wild Type 
 (5 µg) + 
V168A 
(5 µg) +  KCN  
 
Linamarase 
(5 µg) + 
Linamarase 
(1 µg) + 
  
 
Blank only (10mM) (5 µg)  (5 µg) (5 µg) 
Linamarin 
(10mM) 
Linamarin 
 (10mM) 
Linamarin 
(10mM) 
(10 
mM) 
 Triton X-
100 
linamarin  
(10 mM) 
linamarin  
(10 mM) 
  Abs  0.1782 0.6406 0.6002 0.6360 0.6617 0.6253 0.5885 0.5857 0.4184 0.1913 0.1837 0.1885 0.1978 
  
(562 
nm) 0.1666 0.6098 0.6127 0.6420 0.6560 0.5903 0.6569 0.3202 0.1547 0.1702 0.1532 0.1785 0.1875 
    0.1803 0.6471 0.6019 0.6550 0.6467 0.6516 0.6494 0.3030 0.1360 0.1623 0.1671 0.1919 0.2075 
WI38    0.1665 0.6224 0.6194 0.6558 0.6467 0.6664 0.5226 0.4038 0.3041 0.1543 0.1794 0.1677 0.1979 
(VA13) mean 0.1729 0.6300 0.6086 0.6472 0.6528 0.6334 0.6044 0.4032 0.2533 0.1695 0.1709 0.1817 0.1977 
  
true 
mean 0.0074 0.4633 0.4419 0.4805 0.4861 0.4667 0.4377 0.2365 0.0866 0.0029 0.0042 0.0150 0.0310 
    
            
 
  Abs 0.1782 1.8741 1.7974 1.9312 2.2683 2.0928 1.7734 1.1210 0.1441 0.1507 0.0866 0.1274 0.1978 
  
(562 
nm) 0.1666 1.9460 1.5822 1.9262 1.8675 1.7726 1.5224 1.0506 0.1202 0.1436 0.1051 0.1173 0.2175 
U87   0.1803 2.0043 1.5986 1.8856 1.5894 1.7206 1.6963 0.9990 0.1370 0.1672 0.1177 0.1384 0.1875 
    0.1665 1.9491 1.5283 1.8462 1.7991 1.5658 1.6914 0.9821 0.1219 0.1592 0.1057 0.1259 0.2079 
  mean 0.1729 1.9434 1.6266 1.8973 1.8811 1.7880 1.6709 1.0382 0.1308 0.1552 0.1038 0.1273 0.2027 
  
true 
mean   1.7705 1.4537 1.7244 1.7082 1.6151 1.4980 0.8653 -0.0421 -0.0177 -0.0691 -0.0457 
0.0298 
    
               Abs 0.1643 1.5140 1.3091 1.3622 1.5492 1.1235 1.0390 0.9864 0.6948 0.1544 0.1457 0.1306 0.1978 
  
(562 
nm) 0.1666 1.5410 1.5293 1.4434 1.4232 1.2104 1.2330 1.0041 0.3830 0.1587 0.1536 0.1490 0.2175 
SKOV3   0.1670 1.5878 1.4820 1.5181 1.4677 1.3576 1.1552 1.0683 0.6656 0.1584 0.1621 0.1418 0.1875 
    0.1688 1.5778 1.3232 1.3715 1.5983 1.3873 1.3032 1.0597 1.0700 0.1779 0.1426 0.1896 0.2079 
  mean 0.1667 1.5552 1.4109 1.4238 1.5096 1.2697 1.1826 1.0296 0.7034 0.1624 0.1510 0.1528 0.2027 
  
True 
mean 0.0003 1.4211 1.3153 1.3514 1.3010 1.1909 0.9885 0.9016 0.4989 -0.0083 -0.0046 -0.0249 0.0208 
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Appendix 13: Data used to determine in vitro cell cytotoxicity with U87 cells (enzyme variant). 
 
      Negative control         Positive control 
                    Linamarase 
              BSA (5ug)     (5 µg ) + 
    cell Linamarin WT V168A BSA 
 + 
Linamarin KCN 
Triton X-
100  Linamarin 
  Blank suspension  (10 mM)  (5 µg)  (5 µg) (5 µg)   10 mM 
(10 
mM) -0.20% 10 mM 
Abs 0.1491 1.5694 1.7749 1.7118 1.6794 1.9590 1.6916 0.2662 0.0883 0.2512 
(562 
nm) 0.1602 1.7671 1.7748 1.6985 1.7096 1.9218 1.7304 0.2354 0.1040 0.2043 
  0.1483 1.8777 1.7284 1.7596 1.7193 1.8015 1.6432 0.2121 0.0929 0.2417 
mean 0.1525 1.7381 1.7594 1.7233 1.7028 1.8941 1.6884 0.2379 0.0951 0.2324 
True  0.0000 1.5855 1.6068 1.5708 1.5502 1.7416 1.5359 0.0854 -0.0575 0.0799 
mean                     
 
                 Experiment       
        V168A V168A V168A 
  WT (1 µg) +  WT (5 µg ) +  WT (10 µg) +   (1 µg) +   (5 µg) +   (10 µg) +  
   Linamarin   Linamarin   Linamarin   Linamarin   Linamarin   Linamarin  
  (10 mM) (10 mM) (10 mM) (10 mM) (10 mM) (10 mM) 
Abs 1.4940 0.9686 0.9229 0.9673 0.2907 0.2584 
(562 nm) 1.3046 0.9530 0.9265 0.8023 0.2453 0.2541 
  1.3190 0.9448 0.9659 0.8881 0.3469 0.2169 
mean 1.3725 0.9555 0.9384 0.8859 0.2943 0.2431 
True  1.2200 0.8029 0.7859 0.7334 0.1418 0.0906 
mean             
 
 
257 
 
Appendix 14: Data used to determine in vitro cell cytotoxicity with U87 cells (substrate variant). 
 
      Negative control         Positive control 
                    Linamarase 
              BSA (5ug)     (5 µg ) + 
    cell Linamarin WT V168A BSA 
 + 
Linamarin KCN 
Triton X-
100  Linamarin 
  Blank suspension  (10 mM)  (5 µg)  (5 µg) (5 µg)   10 mM 
(10 
mM) -0.20% 10 mM 
Abs 0.1491 1.5694 1.7749 1.7118 1.6794 1.9590 1.6916 0.2662 0.0883 0.2512 
(562 
nm) 0.1602 1.7671 1.7748 1.6985 1.7096 1.9218 1.7304 0.2354 0.1040 0.2043 
  0.1483 1.8777 1.7284 1.7596 1.7193 1.8015 1.6432 0.2121 0.0929 0.2417 
mean 0.1525 1.7381 1.7594 1.7233 1.7028 1.8941 1.6884 0.2379 0.0951 0.2324 
True  0.0000 1.5855 1.6068 1.5708 1.5502 1.7416 1.5359 0.0854 -0.0575 0.0799 
mean                     
 
 
 
 
 
 
 
 
 
                                                        Experiment 
 
      
  
Linamarin    
(2 mM) + 
Linamarin     
(5 mM) +  
Linamarin      
(10 mM) + 
Linamarin      
(20 mM) +  
Linamarin           
(2 mM) + 
Linamarin                  
(5 mM) + 
Linamarin            
(10 mM)+ 
Linamarin     
(20 mM)+ 
   WT (5 µg)    WT (5 µg)   WT (5 µg)  WT (5 µg)  V168A (5 µg) V168A (5 µg) V168A (5 µg) V168A (5 µg) 
Absorbance 1.4481 1.5525 0.9686 0.9391 1.4991 1.5728 0.2907 0.2313 
(562 nm) 1.5183 1.5546 0.9530 0.9181 1.5821 1.3370 0.2453 0.3781 
  1.7141 1.5096 0.9448 0.9294 1.5189 1.2216 0.3469 0.2616 
mean 1.5602 1.5389 0.9555 0.9289 1.5334 1.3771 0.2943 0.2903 
True mean 1.4076 1.3864 0.8029 0.7763 1.3808 1.2246 0.1418 0.1378 
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Appendix 15: Annotated sequence of fusion gene construct in pHEN2 vector. 
 
 
 
 
 
 
 
10        20        30        40        50        60  
atgaaatacctattgcctacggcagccgctggattgttattactcgcggcccagccggcc 
tactttatggataacggatgccgtcggcgacctaacaataatgagcgccgggtcggccgg 
 M  K  Y  L  L  P  T  A  A  A  G  L  L  L  L  A  A  Q  P  A  
 
        70        80        90        100       110       120  
atggccgaggtgcagctggtgcagtctggggctgacgtgaagaagcctggggcctcagtg 
taccggctccacgtcgaccacgtcagaccccgactgcacttcttcggaccccggagtcac 
 M  A  E  V  Q  L  V  Q  S  G  A  D  V  K  K  P  G  A  S  V  
 
        130       140       150       160       170       180 
aaggtctcctgcaaggcttctggatacaccttcaccaactacgtaatgcactgggtgcga 
ttccagaggacgttccgaagacctatgtggaagtggttgatgcattacgtgacccacgct  
K  V  S  C  K  A  S  G  Y  T  F  T  N  Y  V  M  H  W  V  R  
 
        190       200       210       220       230       240 
caggcccctggacaagggcttgagtggctgggatatattaatccttacaatgatggtact 
gtccggggacctgttcccgaactcaccgaccctatataattaggaatgttactaccatga 
 Q  A  P  G  Q  G  L  E  W  L  G  Y  I  N  P  Y  N  D  G  T  
 
        250       260       270       280       290       300 
cagtacaatgagaggttcaaaggcagggtcaccatgaccggggacacgtccatcagtaca 
gtcatgttactctccaagtttccgtcccagtggtactggcccctgtgcaggtagtcatgt 
 Q  Y  N  E  R  F  K  G  R  V  T  M  T  G  D  T  S  I  S  T  
 
        310       320       330       340       350       360 
gcctatatggagctgagcaggctgacttctgacgacaccgcggtgtattactgtgcgaga 
cggatatacctcgactcgtccgactgaagactgctgtggcgccacataatgacacgctct 
 A  Y  M  E  L  S  R  L  T  S  D  D  T  A  V  Y  Y  C  A  R  
 
        370       380       390       400       410       420 
gaggtctatggtaactacatctggggcaactggggccagggaaccctggtctccgtctcg 
ctccagataccattgatgtagaccccgttgaccccggtcccttgggaccagaggcagagc 
 E  V  Y  G  N  Y  I  W  G  N  W  G  Q  G  T  L  V  S  V  S  
 
        430       440       450       460       470       480 
agtggtggaggcggttcaggcggaggtggctctggcggtagtgcacttgaaattgtgttg 
tcaccacctccgccaagtccgcctccaccgagaccgccatcacgtgaactttaacacaac 
 S  G  G  G  G  S  G  G  G  G  S  G  G  S  A  L  E  I  V  L  
 
        490       500       510       520       530       540 
acgcagtctccaggcaccctgtctttgtctccaggggaaagagccaccctctcctgcagt 
tgcgtcagaggtccgtgggacagaaacagaggtcccctttctcggtgggagaggacgtca 
 T  Q  S  P  G  T  L  S  L  S  P  G  E  R  A  T  L  S  C  S  
 
        550       560       570       580       590       600 
gccagttcaagtataagttccaattacttgcattggtaccagcagaaacctggccaggct 
cggtcaagttcatattcaaggttaatgaacgtaaccatggtcgtctttggaccggtccga 
 A  S  S  S  I  S  S  N  Y  L  H  W  Y  Q  Q  K  P  G  Q  A  
 
 
NcoI 
XhoI 
ApaLI 
The pelB leader sequence is shown in purple, followed by the huBC-1 gene (blue), hCβG gene (green) 
His6- and myc- tags for purification and detection purposes are shown in orange and pink respectively 
and the amber stop codon is marked with an asterisk. Restriction sites used for cloning are underlined in 
the nucleotide sequence. The fusion site linker (Ala-Ala-Ala, from the Not I fusion point) is marked in 
yellow. 
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        610       620       630       640       650       660 
cccaggctcctcatctataggacgtccaatctggcttctggcatcccagacaggttcagt 
gggtccgaggagtagatatcctgcaggttagaccgaagaccgtagggtctgtccaagtca 
 P  R  L  L  I  Y  R  T  S  N  L  A  S  G  I  P  D  R  F  S  
 
        670       680       690       700       710       720 
ggcagtgggtctgggacagacttcactctcaccatcagcagactggagcctgaagatttt 
ccgtcacccagaccctgtctgaagtgagagtggtagtcgtctgacctcggacttctaaaa 
 G  S  G  S  G  T  D  F  T  L  T  I  S  R  L  E  P  E  D  F 
  
        730       740       750       760       770       780 
gcagtgtattactgtcagcagggtagtagtataccattcacgtttggccaggggaccaag 
cgtcacataatgacagtcgtcccatcatcatatggtaagtgcaaaccggtcccctggttc 
 A  V  Y  Y  C  Q  Q  G  S  S  I  P  F  T  F  G  Q  G  T  K  
 
        790       800       810       820       830       840 
ctggagatcaatggtgcggccgcagctttccctgcaggatttggatgggcggcagccact 
     gacctctagttaccacgccggcgtcgaaagggacgtcctaaacctacccgccgtcggtga 
 
  L  E  I  N  G  A  A  A  A  F  P  A  G  F  G  W  A  A  A  T   
 
       850       860       870       880       890       900  
     gcagcttatcaagtagaaggaggctgggatgcagatggaaaaggcccttgtgtctgggac 
     cgtcgaatagttcatcttcctccgaccctacgtctaccttttccgggaacacagaccctg 
      A  A  Y  Q  V  E  G  G  W  D  A  D  G  K  G  P  C  V  W  D   
 
       910       920       930       940       950       960  
     acatttactcatcagggaggagagagagttttcaagaaccagactggcgatgtagcttgt 
     tgtaaatgagtagtccctcctctctctcaaaagttcttggtctgaccgctacatcgaaca 
T  F  T  H  Q  G  G  E  R  V  F  K  N  Q  T  G  D  V  A  C   
 
       970       980       990       1000      1010      1020 
     ggcagctacactctgtgggaggaagatttgaaatgtatcaaacagcttggattgactcat 
     ccgtcgatgtgagacaccctccttctaaactttacatagtttgtcgaacctaactgagta 
G  S  Y  T  L  W  E  E  D  L  K  C  I  K  Q  L  G  L  T  H     
 
       1030      1040      1050      1060      1070      1080 
     taccgcttctctctttcctggtcacgtctgttacctgatgggacgacaggtttcatcaac 
     atggcgaagagagaaaggaccagtgcagacaatggactaccctgctgtccaaagtagttg 
Y  R  F  S  L  S  W  S  R  L  L  P  D  G  T  T  G  F  I  N   
 
       1090      1100      1110      1120      1130      1140 
     cagaaaggaattgattattacaacaagatcatcgatgatttgttaaaaaatggggttact 
     gtctttccttaactaataatgttgttctagtagctactaaacaattttttaccccaatga 
Q  K  G  I  D  Y  Y  N  K  I  I  D  D  L  L  K  N  G  V  T   
 
       1150      1160      1170      1180      1190      1200 
     cccattgtgaaccctctaccactttgatttgcctcagactttagaagaccaaggaggttg 
     gggtaacacttgggagatggtgaaactaaacggagtctgaaatcttctggttcctccaac 
 P  I  V T  L  Y  H  F  D  L  P  Q  T  L  E  D  Q  G  G  W   
 
       1210      1220      1230      1240      1250      1260 
     gttgtcagaggcaatcattgaatcctttgacaaatatgctcagttttgcttcagtacctt 
     caacagtctccgttagtaacttaggaaactgtttatacgagtcaaaacgaagtcatggaa 
L  S  E  A  I  I  E  S  F  D  K  Y  A  Q  F  C  F  S  T  F   
 
 
 
 
 
 
Not I 
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       1270       1280     1290      1300      1310      1320 
     tggggatcgtgtcaagcagtggatcaccataaatgaagctaatgttctttctgtgatgtc 
     acccctagcacagttcgtcacctagtggtatttacttcgattacaagaaagacactacag 
G  D  R  V  K  Q  W  I  T  I  N  E  A  N  V  L  S  V  M  S   
 
 
       1330       1340     1350      1360      1370      1380 
ggtatgtttcctccgggtatccctcactttgggactggaggttatcaggcagctcataat 
ccatacaaaggaggcccatagggagtgaaaccctgacctccaatagtccgtcgagtatta 
 G  M  F  P  P  G  I  P  H  F  G  T  G  G  Y  Q  A  A  H  N  
 
 
       1390       1400      1410      1420     1430      1440 
ttgattaaggctcatgccagatcctggcacagctatgattccttatttcgaaaaaagcag 
aactaattccgagtacggtctaggaccgtgtcgatactaaggaataaagcttttttcgtc 
 L  I  K  A  H  A  R  S  W  H  S  Y  D  S  L  F  R  K  K  Q  
 
       1450       1460      1470      1480     1490      1500 
aaaggtatggtgtctctatcactttttgcggtctggttggaaccagcagatcccaactca 
tttccataccacagagatagtgaaaaacgccagaccaaccttggtcgtctagggttgagt 
 K  G  M  V  S  L  S  L  F  A  V  W  L  E  P  A  D  P  N  S  
 
       1510       1520      1530      1540     1550      1560 
gtgtctgaccaggaagctgctaaaagagccatcactttccatctggatttatttgctaaa 
cacagactggtccttcgacgattttctcggtagtgaaaggtagacctaaataaacgattt 
 V  S  D  Q  E  A  A  K  R  A  I  T  F  H  L  D  L  F  A  K  
 
       1570       1580      1590      1600     1610       1620 
cccatattcatcgatggtgattatcctgaagttgtcaagtctcagattgcctccatgagt 
gggtataagtagctaccactaataggacttcaacagttcagagtctaacggaggtactca 
 P  I  F  I  D  G  D  Y  P  E  V  V  K  S  Q  I  A  S  M  S  
 
       1630       1640      1650      1660     1670       1680 
caaaagcaaggctatccatcatcgaggcttccagaattcactgaagaagagaagaaaatg 
gttttcgttccgataggtagtagctccgaaggtcttaagtgacttcttctcttcttttac 
 Q  K  Q  G  Y  P  S  S  R  L  P  E  F  T  E  E  E  K  K  M  
 
       1690       1700      1710      1720     1730     1740 
atcaaaggcactgctgatttttttgctgtgcaatattatacaactcgcttaatcaagtac 
tagtttccgtgacgactaaaaaaacgacacgttataatatgttgagcgaattagttcatg 
 I  K  G  T  A  D  F  F  A  V  Q  Y  Y  T  T  R  L  I  K  Y  
 
       1750      1760      1770      1780      1790      1800 
caggagaacaagaaaggagaactaggtattctccaggatgcggaaattgaattttttcca 
gtcctcttgttctttcctcttgatccataagaggtcctacgcctttaacttaaaaaaggt 
 Q  E  N  K  K  G  E  L  G  I  L  Q  D  A  E  I  E  F  F  P  
 
       1810      1820      1830      1840      1850      1860 
gatccatcttggaaaaatgtggattggatctacgtggtaccttggggagtatgtaaacta 
ctaggtagaacctttttacacctaacctagatgcaccatggaacccctcatacatttgat 
 D  P  S  W  K  N  V  D  W  I  Y  V  V  P  W  G  V  C  K  L  
 
       1870      1880      1890      1900      1910      1920 
ctgaaatatattaaggatacatataataaccctgtaatttacatcactgagaatgggttt 
gactttatataattcctatgtatattattgggacattaaatgtagtgactcttacccaaa 
 L  K  Y  I  K  D  T  Y  N  N  P  V  I  Y  I  T  E  N  G  F  
 
 
 
 
 
NCOs 
I 
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       1930      1940      1950      1960      1970      1980 
ccccagagtgacccagcgcctcttgatgacactcaacgctgggagtatttcagacaaaca 
ggggtctcactgggtcgcggagaactactgtgagttgcgaccctcataaagtctgtttgt 
 P  Q  S  D  P  A  P  L  D  D  T  Q  R  W  E  Y  F  R  Q  T  
 
       1990      2000      2010      2020      2030      2040 
tttcaggaactgttcaaagctatccaacttgataaagtcaatcttcaagtatattgtgca 
aaagtccttgacaagtttcgataggttgaactatttcagttagaagttcatataacacgt 
 F  Q  E  L  F  K  A  I  Q  L  D  K  V  N  L  Q  V  Y  C  A  
 
 
       2050      2060      2070      2080      2090      2100 
tggtctcttctggataactttgagtggaaccagggatacagcagccggtttggtctcttc 
accagagaagacctattgaaactcaccttggtccctatgtcgtcggccaaaccagagaag 
 W  S  L  L  D  N  F  E  W  N  Q  G  Y  S  S  R  F  G  L  F  
 
       2110      2120      2130      2140      2150      2160 
cacgttgattttgaagacccagctagaccccgagtcccttacacatcggccaaggaatat 
gtgcaactaaaacttctgggtcgatctggggctcagggaatgtgtagccggttccttata 
 H  V  D  F  E  D  P  A  R  P  R  V  P  Y  T  S  A  K  E  Y  
 
       2170      2180      2190      2200      2210      2220 
gccaagatcatccgaaacaatggccttgaagcacatctcgaggcggccgcacatcatcat 
cggttctagtaggctttgttaccggaacttcgtgtagagctccgccggcgtgtagtagta 
 A  K  I  I  R  N  N  G  L  E  A  H  L  E  A  A  A  H  H  H   
 
 
        2230      2240      2250      2260      2270      2280 
 caccatcacggggccgcagaacaaaaactcatctcagaagaggatctgaatggggccgca 
 gtggtagtgccccggcgtcttgtttttgagtagagtcttctcctagacttaccccggcgt 
  H  H  H  G  A  A  E  Q  K  L  I  S  E  E  D  L  N  G  A  A   
 
         
 tag 
 atc 
  * 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xho I Not I 
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Appendix 16: Annotated sequence of fusion gene construct in pET23b vector. 
 
Plasmid DNA sequence between the initiation codon and NheI cloning site is shown in red, followed by the 
huBC-1 scFv (blue) and hCβG (green). The His6-tag for purification and detection purposes is shown in orange 
and the amber stop codon is marked with an asterisk. Restriction sites used for cloning are underlined and the 
deleted Nco I restriction site is shown in italics in the nucleotide sequence. The fusion site linker (Ala-Ala-Ala, 
from the Not I fusion point) is marked in yellow. 
         
 
          10        20        30        40       50        60  
atggctagcgaggtgcagctggtgcagtctggggctgacgtgaagaagcctggggcctca 
taccgatcgctccacgtcgaccacgtcagaccccgactgcacttcttcggaccccggagt 
  M  A  S  E  V  Q  L  V  Q  S  G  A  D  V  K  K  P  G  A  S   
 
         70        80        90        100       110       120 
 gtgaaggtctcctgcaaggcttctggatacaccttcaccaactacgtaatgcactgggtg 
 cacttccagaggacgttccgaagacctatgtggaagtggttgatgcattacgtgacccac  
  V  K  V  S  C  K  A  S  G  Y  T  F  T  N  Y  V  M  H  W  V   
 
         130       140       150       160       170       180 
 cgacaggcccctggacaagggcttgagtggctgggatatattaatccttacaatgatggt 
 gctgtccggggacctgttcccgaactcaccgaccctatataattaggaatgttactacca 
  R  Q  A  P  G  Q  G  L  E  W  L  G  Y  I  N  P  Y  N  D  G   
 
        190       200       210       220       230       240 
 actcagtacaatgagaggttcaaaggcagggtcaccatgaccggggacacgtccatcagt 
 tgagtcatgttactctccaagtttccgtcccagtggtactggcccctgtgcaggtagtca 
  T  Q  Y  N  E  R  F  K  G  R  V  T  M  T  G  D  T  S  I  S   
 
        250       260       270       280       290       300 
 acagcctatatggagctgagcaggctgacttctgacgacaccgcggtgtattactgtgcg 
 tgtcggatatacctcgactcgtccgactgaagactgctgtggcgccacataatgacacgc 
  T  A  Y  M  E  L  S  R  L  T  S  D  D  T  A  V  Y  Y  C  A   
 
        310       320       330       340       350       360 
 agagaggtctatggtaactacatctggggcaactggggccagggaaccctggtctccgtc 
 tctctccagataccattgatgtagaccccgttgaccccggtcccttgggaccagaggcag 
  R  E  V  Y  G  N  Y  I  W  G  N  W  G  Q  G  T  L  V  S  V   
 
        370       380       390       400       410       420 
 tcgagtggtggaggcggttcaggcggaggtggctctggcggtagtgcacttgaaattgtg 
 agctcaccacctccgccaagtccgcctccaccgagaccgccatcacgtgaactttaacac 
  S  S  G  G  G  G  S  G  G  G  G  S  G  G  S  A  L  E  I  V   
 
        430       440       450       460       470       480 
 ttgacgcagtctccaggcaccctgtctttgtctccaggggaaagagccaccctctcctgc 
 aactgcgtcagaggtccgtgggacagaaacagaggtcccctttctcggtgggagaggacg 
  L  T  Q  S  P  G  T  L  S  L  S  P  G  E  R  A  T  L  S  C   
 
        490       500       510       520       530       540 
 agtgccagttcaagtataagttccaattacttgcattggtaccagcagaaacctggccag 
 tcacggtcaagttcatattcaaggttaatgaacgtaaccatggtcgtctttggaccggtc 
  S  A  S  S  S  I  S  S  N  Y  L  H  W  Y  Q  Q  K  P  G  Q   
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        550      560       570       580       590       600 
gctcccaggctcctcatctataggacgtccaatctggcttctggcatcccagacaggttc 
cgagggtccgaggagtagatatcctgcaggttagaccgaagaccgtagggtctgtccaag 
 A  P  R  L  L  I  Y  R  T  S  N  L  A  S  G  I  P  D  R  F   
 
        610       620       630       640       650       660 
agtggcagtgggtctgggacagacttcactctcaccatcagcagactggagcctgaagat 
tcaccgtcacccagaccctgtctgaagtgagagtggtagtcgtctgacctcggacttcta 
 S  G  S  G  S  G  T  D  F  T  L  T  I  S  R  L  E  P  E  D   
  
        670       680       690       700       710       720 
tttgcagtgtattactgtcagcagggtagtagtataccattcacgtttggccaggggacc 
aaacgtcacataatgacagtcgtcccatcatcatatggtaagtgcaaaccggtcccctgg 
 F  A  V  Y  Y  C  Q  Q  G  S  S  I  P  F  T  F  G  Q  G  T   
 
        730       740       750       760       770       780 
     aagctggagatcaatggtgcggccgcatgctttccctgcaggatttggatgggcggcagc 
     ttcgacctctagttaccacgccggcgtacgaaagggacgtcctaaacctacccgccgtcg 
      K  L  E  I  N  G  A  A  A  A  F  P  A  G  F  G  W  A  A  A     
 
       790       800       810        820      830       840  
     cactgcagcttatcaagtagaaggaggctgggatgcagatggaaaaggcccttgtgtctg 
     gtgacgtcgaatagttcatcttcctccgaccctacgtctaccttttccgggaacacagac 
      T  A  A  Y  Q  V  E  G  G  W  D  A  D  G  K  G  P  C  V  W  
 
        850       860       870        880      890       900  
     ggacacatttactcatcagggaggagagagagttttcaagaaccagactggcgatgtagc 
     cctgtgtaaatgagtagtccctcctctctctcaaaagttcttggtctgaccgctacatcg 
      D  T  F  T  H  Q  G  G  E  R  V  F  K  N  Q  T  G  D  V  A 
        
 910       920      930        940       950       960  
     ttgtggcagctacactctgtgggaggaagatttgaaatgtatcaaacagcttggattgac 
     aacaccgtcgatgtgagacaccctccttctaaactttacatagtttgtcgaacctaactg 
      C  G  S  Y  T  L  W  E  E  D  L  K  C  I  K  Q  L  G  L  T   
 
       970       980       990       1000      1010      1020 
     tcattaccgcttctctctttcctggtcacgtctgttacctgatgggacgacaggtttcat 
     agtaatggcgaagagagaaaggaccagtgcagacaatggactaccctgctgtccaaagta 
H  Y  R  F  S  L  S  W  S  R  L  L  P  D  G  T  T  G  F  I   
 
       1030      1040      1050      1060      1070       1080 
caaccagaaaggaattgattattacaacaagatcatcgatgatttgttaaaaaatggggt 
gttggtctttccttaactaataatgttgttctagtagctactaaacaattttttacccca 
 N  Q  K  G  I  D  Y  Y  N  K  I  I  D  D  L  L  K  N  G   
 
       1090       1100     1110      1120      1130       1140 
tactcccattgtgaccctctaccactttgatttgcctcagactttagaagaccaaggagg 
atgagggtaacactgggagatggtgaaactaaacggagtctgaaatcttctggttcctcc 
 T  P  I  V  T  L  Y  H  F  D  L  P  Q  T  L  E  D  Q  G  V 
 
       1150      1160      1170      1180      1190       1200 
ttggttgtcagaggcaatcattgaatcctttgacaaatatgctcagttttgcttcagtac 
aaccaacagtctccgttagtaacttaggaaactgtttatacgagtcaaaacgaagtcatg 
 G  W  L  S  E  A  I  I  E  S  F  D  K  Y  A  Q  F  C  F  S 
 
       1210      1220      1230      1240      1250       1260 
ctttggggatcgtgtcaagcagtggatcaccataaatgaagctaatgttctttctgtgat 
gaaacccctagcacagttcgtcacctagtggtatttacttcgattacaagaaagacacta 
 T  F  G  D  R  V  K  Q  W  I  T  I  N  E  A  N  V  L  S  V   
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        1270      1280      1290      1300     1310      1320 
gtcatatgacttaggtatgtttcctccgggtatccctcactttgggactggaggttatca 
cagtatactgaatccatacaaaggaggcccatagggagtgaaaccctgacctccaatagt 
 M  S  Y  D  L G  M  F  P  P  G  I  P  H  F  G  T  G  G  Y  Q   
 
 
       1330       1340      1350      1360      1370      1380 
ggcagctcataatttgattaaggctcatgccagatcctggcacagctatgattccttatt 
ccgtcgagtattaaactaattccgagtacggtctaggaccgtgtcgatactaaggaataa 
 A  A  H  N  L  I  K  A  H  A  R  S  W  H  S  Y  D  S  L  F   
 
       1390       1400      1410      1420      1430      1440 
tcgaaaaaagcagaaaggtatggtgtctctatcactttttgcggtctggttggaaccagc 
agcttttttcgtctttccataccacagagatagtgaaaaacgccagaccaaccttggtcg 
 R  K  K  Q  K  G  M  V  S  L  S  L  F  A  V  W  L  E  P  A 
 
       1450      1460      1470       1480      1490      1500 
agatcccaactcagtgtctgaccaggaagctgctaaaagagccatcactttccatctgga 
tctagggttgagtcacagactggtccttcgacgattttctcggtagtgaaaggtagacct 
 D  P  N  S  V  S  D  Q  E  A  A  K  R  A  I  T  F  H  L  D   
 
       1510       1520     1530       1540      1550      1560 
tttatttgctaaacccatattcatcgatggtgattatcctgaagttgtcaagtctcagat 
aaataaacgatttgggtataagtagctaccactaataggacttcaacagttcagagtcta 
 L  F  A  K  P  I  F  I  D  G  D  Y  P  E  V  V  K  S  Q  I 
 
       1570       1580     1590       1600      1610      1620 
tgcctccatgagtcaaaagcaaggctatccatcatcgaggcttccagaattcactgaaga 
acggaggtactcagttttcgttccgataggtagtagctccgaaggtcttaagtgacttct 
 A  S  M  S  Q  K  Q  G  Y  P  S  S  R  L  P  E  F  T  E  E  
 
       1630       1640     1650       1660      1670      1680 
agagaagaaaatgatcaaaggcactgctgatttttttgctgtgcaatattatacaactcg 
tctcttcttttactagtttccgtgacgactaaaaaaacgacacgttataatatgttgagc 
 E  K  K  M  I  K  G  T  A  D  F  F  A  V  Q  Y  Y  T  T  R 
 
       1690       1700      1710      1720      1730      1740 
cttaatcaagtaccaggagaacaagaaaggagaactaggtattctccaggatgcggaaat 
gaattagttcatggtcctcttgttctttcctcttgatccataagaggtcctacgccttta 
 L  I  K  Y  Q  E  N  K  K  G  E  L  G  I  L  Q  D  A  E  I  
 
       1750      1760      1770      1780      1790      1800 
tgaattttttccagatccatcttggaaaaatgtggattggatctacgtggtaccttgggg 
acttaaaaaaggtctaggtagaacctttttacacctaacctagatgcaccatggaacccc 
 E  F  F  P  D  P  S  W  K  N  V  D  W  I  Y  V  V  P  W  G 
 
       1810      1820      1830      1840      1850      1860 
agtatgtaaactactgaaatatattaaggatacatataataaccctgtaatttacatcac 
tcatacatttgatgactttatataattcctatgtatattattgggacattaaatgtagtg 
 V  C  K  L  L  K  Y  I  K  D  T  Y  N  N  P  V  I  Y  I  T     
 
       1870      1880      1890      1900      1910      1920 
tgagaatgggtttccccagagtgacccagcgcctcttgatgacactcaacgctgggagta 
actcttacccaaaggggtctcactgggtcgcggagaactactgtgagttgcgaccctcat 
 E  N  G  F  P  Q  S  D  P  A  P  L  D  D  T  Q  R  W  E  Y  
 
       1930      1940      1950      1960      1970      1980 
tttcagacaaacatttcaggaactgttcaaagctatccaacttgataaagtcaatcttca 
aaagtctgtttgtaaagtccttgacaagtttcgataggttgaactatttcagttagaagt 
 F  R  Q  T  F  Q  E  L  F  K  A  I  Q  L  D  K  V  N  L  Q  
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       1990      2000      2010      2020      2030      2040 
agtatattgtgcatggtctcttctggataactttgagtggaaccagggatacagcagccg 
tcatataacacgtaccagagaagacctattgaaactcaccttggtccctatgtcgtcggc 
 V  Y  C  A  W  S  L  L  D  N  F  E  W  N  Q  G  Y  S  S  R  
 
 
       2050      2060      2070      2080      2090      2100 
gtttggtctcttccacgttgattttgaagacccagctagaccccgagtcccttacacatc 
caaaccagagaaggtgcaactaaaacttctgggtcgatctggggctcagggaatgtgtag 
 F  G  L  F  H  V  D  F  E  D  P  A  R  P  R  V  P  Y  T  S 
 
       2110      2120      2130      2140      2150      2160 
ggccaaggaatatgccaagatcatccgaaacaatggccttgaagcacatctcgagcacca 
ccggttccttatacggttctagtaggctttgttaccggaacttcgtgtagagctcgtggt 
 T  S  A  K  E  Y  A  K  I  I  R  N  N  G  L  E  A  H  L  E   
 
       2170 
ccaccaccaccaccaccatga 
ggtggtggtggtggtggtact 
  H  H  H  H  H  H  * 
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